Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy

ABSTRACT

Provided herein are therapeutic compositions and methods that keep cellular immunotherapies in the circulation or at the site of injection for extended periods of time without resorting to the use of cytotoxic preconditioning. For example, the compositions and methods herein lymphodeplete and reduce or ablate sites in the secondary lymphatics where the cellular immunotherapy is bound and sequestered, without the use of cytotoxic preconditioning.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No.15/976,630, filed May 10, 2018, which is a continuation of InternationalPatent Application No. PCT/US2018/025517, filed Mar. 30, 2018, whichclaims priority to U.S. Provisional Application No. 62/480,414, filedApr. 1, 2017, to U.S. Provisional Application No. 62/613,697, filed Jan.4, 2018, and to U.S. Provisional Application No. 62/624,454, filed Jan.31, 2018, each of which is incorporated herein by reference in itsentirety

FIELD OF THE INVENTION

The field of the invention pertains to compositions and methods,including novel dosing regimens, that enhance the short and long termtumor and pathogen killing by cellular immunotherapies, by keeping thecellular immunotherapy in the circulation or at the site of injectionfor extended periods of time without resorting to the use of cytotoxicpreconditioning. The field of invention additionally enhances long termengraftment of the cellular immunotherapy.

BACKGROUND OF THE INVENTION

Cellular immunotherapies need to remain in the circulation or at thesite of injection for extended periods of time in order to effectivelyfind and participate in killing cancer or autoimmune activated cells orinfectious agents. Unfortunately, the cellular immunotherapies arerapidly, typically within one hour after injection, cleared from thecirculation or site of injection unless cytotoxic chemotherapy orradiation preconditioning has been done (Muranski Nat Clin Pract Oncol.2006 December; 3(12): 668-681.; Kalos M et al. Sci Transl Med. Aug 10;3(95) (2011); Rosenberg et al., Clin. Cancer. Res. (2011)). Theprevailing thought has been that preconditioning enhanced adoptive celltransfer or therapy (ACT) effectiveness by eliminating Tregs andcompeting elements of the immune system called ‘cytokine sinks’ thatwould use up cytokines needed for optimal activation of ACT (MuranskiNat Clin Pract Oncol. 2006 December; 3(12): 668-681 page 2 paragraph 3,page 4 paragraph 4; U.S. Pat. No. 9,855,298 B2 January/2018, Bot page 29Detailed Description of the Invention first paragraph). Severalinvestigators have observed that the cellular immunotherapies rapidlybind and accumulate in the lung, liver, spleen, and secondary lymphatics(Kershaw M H et al. Clin Cancer Res. October 15; 12(20 Pt 1):6106-15(2006)); (Ritchie D S et al. Mol Ther. November; 21(11):2122-9 (2013);(Cheadle J Immunol Apr. 15, 2014, 192 (8) 3654-3665). Kershaw concludedthat the cellular immunotherapy signal in the lung and spleen was due tothe cells being sticky and non-selectively trapped (page 6114, paragraph3), while Cheadle concluded that the spleen accumulation observed inmice was a chronic toxicity manifested as a granuloma formation (page3654, abstract).

Because of the toxicities associated with chemotherapy or radiation andthe contribution of the chemotherapy to neuroedema and cytokine releasesyndrome after ACT, there is a need to develop safer and less cytotoxicmethods to precondition patients to allow cellular immunotherapies toremain in the circulation or at the site of injection for extendedperiods of time.

While chemotherapy and radiotherapy have often been used to preconditionpatients prior to ACT, most leaders in the field teach that steroids orother immunosuppressive medications are specifically excluded for atleast 3 days prior to NK administration (Klingemann H, Transfusion. 2013February; 53(2):412-8 page 3 Study Design, paragraph 3), and in adoptivecell therapy clinical trials steroid use is commonly an exclusioncriteria for patient enrollment. For instance see the ACTIVATE clinicaltrial exclusion criteria #2 which specifically excludes systemic steroidor other immunosuppressant therapy within 7 days of ACT which in thisclinical trial is autologous tumor-infiltrating lymphocytes that havebeen culture expanded (clinical trial identifier: NCT03158935—currentonline address: clinicaltrials.gov/ct2/show/NCT03158935). Also see U.S.Pat. No. 9,855,298 January 2018 (Bot et al) which in Example 3 exclusioncriteria p Column 54 specifically excludes patients from ACT treatmentif they have a current or expected need for systemic corticosteroidtherapy. This demonstrates that the field believed corticosteroids weredetrimental prior to ACT, and would not have conceived ofpreconditioning just prior to ACT with glucocorticoids as described inthe present patent application. While US2013/0287748 A1 October 2013(June et al) paragraph 0227 does disclose “In further embodiments, the Tcells of the invention [claimed in US2013/0287748 A1] may be used incombination with chemotherapy, radiation, immunosuppressive agents, suchas cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506,antibodies, or other immunoablative agents such as CAMPATH, anti-CD3antibodies or other antibody therapies, cytoxin, fludaribine,cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228,cytokines, and irradiation. These drugs inhibit either the calciumdependent phosphatase calcineurin (cyclosporine and FK506) or inhibitthe p70S6 kinase that is important for growth factor induced signaling(rapamycin) (Liu et al., Cell 66:807-815, 1991; Henderson et al., Immun.73:316-321, 1991; Bierer et al., Curr. Opin. Immun. 5:763-773, 1993)”,June does not explain whether the use of the listed agents “incombination” with the disclosed T cell therapy relates to prior,concurrent or subsequent use, e.g. to manage symptoms. Preconditioningis not suggested.

June references Liu who used cyclosporine, FK506 and rapamycin at 300 nMconcentrations and Henderson who used about 100 nM concentrations, whichtranslate to low in vivo doses, of below 0.05 mg/kg.

Prior studies into the use of steroids to precondition a patient priorto ACT had shown this approach to be ineffective. Hinrichs (JImmunother. 2005 November-December; 28(6):517-24.) had evaluateddexamethasone as a preconditioning treatment prior to ACT. In comparisonto total body irradiation (TBI), Hinrichs demonstrated that an HED of0.8 mg/kg administered on day −6, day −4, and day −2 lymphodepletedequivalently to 5 Gy TBI. Hinrichs demonstrate that pretreatment withsystemic intraperitoneal dexamethasone at 10 mg/kg (HED 0.81 mg/kg) onday −6, −4, and −2 before ACT induced equivalent lymphodepletioncompared to radiation, but this pretreatment did not enhance ACT tumorkilling. In contrast, Hinrichs discloses that pretreatment withradiation did enhance ACT tumor killing. In the Hinrichs paper, thedexamethasone reportedly caused lymphodepletion as demonstrated by 99%reduced spleen cellularity. However, while Hinrichs reported 99%lymphodepletion, no enhancement of ACT tumor killing was observed. Incontrast, Hinrichs observed that radiation does enhance ACT tumorkilling. Experiments to repeat Hinrichs reported lymphodepletion,however, demonstrate that the Hinrichs doses of intraperitonealdexamethasone at 10 mg/kg (HED 0.81 mg/kg) on day −6, day −4, and day−2, do not effectively lymphodeplete peripheral blood lymphocytes. WithHinrichs dosing, only B lymphocytes in the peripheral blood weresignificantly lymphodepleted, from 10680 (vehicle control) to 3733 liveevents measured by flow cytometry of CD3−CD19+ cells, a 65% reduction.In contrast, CD3+ T lymphocytes were reduced from 3370 to 2441 liveevents, only a non-significant 33% reduction. CD3+CD4+ T lymphocyteswere reduced from 1779 to 902 live events, only a non-significant 50%reduction. CD3+CD8_T lymphocytes were reduced from 1318 to 1277 liveevents, only a non-significant 3% reduction. CD3+CD4+CD25+FoxP3+ Tregswere reduced from 198 to 70 live events, only a non-significant 65%reduction. And natural killer (NK) cells were reduced from 1153 to 958live events, only a non-significant 17% reduction.

Some studies have preconditioned patients with a chemotherapeutic agent,which was administered in combination with dexamethasone. For instance,Shi et al (Br J Haematol. 2008 December; 143(5):641-53.) preconditionedrelapsed multiple myeloma patients with fludarabine (Flu, 25 mg/m² onday −5 to day −2), and dexamethasone (Dex, 40 mg/d on days −5 to −2).This dose of dexamethasone corresponds to approximately 1.14 to 1.6mg/kg within 72 hours prior to administration of ACT. Lymphodepletionwas complete as shown in FIG. 5 of Shi et al with absolute WBC reducedfrom 10.9e9/L to 0.7e9/L a 94% reduction. Shi et al did not suggestusing higher dexamethasone doses. Cell Therapy Catapult haspreconditioned patients with fludarabine×5 days 30 mg/m² intravenous(i.v.) and methylprednisolone×1 day 500 mg i.v. for their A Phase I/IIStudy of Gene-modified WT1 TCR Therapy in MDS & AML Patients(clinicaltrials.gov/ct2/show/NCT02550535). This dose ofmethylprednisolone corresponds to a 100 mg dose of Dexamethasone whichtranslates to about 1.4 mg/kg to 2 mg/kg. Additionally, both the Shipublication and the Cell Therapy Catapult trial preconditioned withrepetitive doses of chemotherapy. Furthermore, methylprednisoneincreases Tregs, an undesirable response in the cancer patient whereTregs limit T cell tumor killing (Braitch Acta Neurol Scand. 2009 April;119(4): 239-245; Mathian PLoS One. 2015; 10(12): e0143689).

Because of the toxicities associated with chemotherapy or radiation andthe contribution of the cytotoxic preconditioning to neuroedema andcytokine release syndrome after ACT, there is a need to develop saferand less cytotoxic methods to precondition patients to allow cellularimmunotherapies to remain in the circulation or at the site of injectionfor extended periods of time.

SUMMARY OF THE INVENTION

The present inventors have shown the spleen accumulation of cellularimmunotherapies to be a specific binding event, in contrast to the priorbelief, discussed above, that spleen accumulation was due non-selectivesequestration. The present inventors believe that prior artchemotherapy- and radiatiotherapy-based methods non-selectively destroythe cellularity of the spleen, to keep the administered cellularimmunotherapies in circulation or at the site of injection for extendeddurations of time and enhancing patient outcome.

The present patent application shows that non-chemotherapeutic agents,such as glucorticoids and other non-toxic lymphodepleting agents(NTLAs), can be used to make cellular immunotherapies more effectivewithout the need for chemotherapy (or at least, can reduce the need forchemotherapy to just one day of chemotherapy treatment). For instance,the present application shows that acute doses of dexamethasone,typically about 300 to about 840 mgs, can be highly effective. Inparticular, the present invention discloses the benefit to cancerpatients of pretreating the patient with a steroid such as dexamethasoneshortly before cellular immunotherapy administration.

Thus, the present invention fills the need to replace chemo- andradiotherapy preconditioning by providing for methods and compositionsfor inhibiting binding of cellular immunotherapies to lymphoid tissuecomprising administering cellular immunotherapies to an individual inconjunction with a therapeutic agent or agents that inhibit binding ofcellular immunotherapies to lymphoid tissue, in particular to germinalcenters and marginal zones in lymph nodes and germinal centers andmarginal zones in the spleen. The therapeutic agent or agents alsolymphodepletes peripheral blood lymphocytes via a biologic rather than acytotoxic mechanism. The term “in conjunction with” can mean before,and/or together with, and/or after the cellular immunotherapies.

Accordingly, in a first aspect, this invention provides a method ofenhancing adoptive cellular therapy (ACT) in a patient, by administeringto the patient a non-toxic lymphodepleting agent (NTLA) at a dose thatis effective to cause substantial lymphodepletion and/or cause ablationof secondary lymphatic germinal centers, wherein the method does notinclude the administration of radiotherapy nor a chemotherapeutic agentfor a duration of more than 1 day within about 2 weeks preceding thestart of ACT.

In a second aspect, this invention provides an NTLA for use in a methodof enhancing adoptive cellular therapy (ACT) in a patient, the methodcomprising administering to the patient a dose of the NTLA that iseffective to cause substantial lymphodepletion and/or cause ablation ofsecondary lymphatic germinal centers, wherein the method does notinclude the administration of a chemotherapeutic agent for a duration of1 day or more.

In a third aspect, this invention provides a method of performingadoptive cellular therapy (ACT) in a patient in need thereof, saidmethod comprising performing a method of enhancing ACT by pretreatingthe patient according to the invention; and then performing the ACT byadministering therapeutic cells to the patient. In some embodiments, theNTLA is a steroid. The steroid may be a glucocorticoid. In someembodiments, the steroid is selected from the group consisting ofdexamethasone, dexamethasone base, prednisone, methylprednisone, anddexamethasone analogues. In other embodiments, the NTLA is a selectedfrom the group consisting of tacrolimus and cyclosporine.

In some embodiments, the dose of the NTLA achieves at least 60% CD3+lymphodepletion. Preferably, the dose achieves at least 70%, at least80% or at least 90% lymphodepletion. In preferred embodiments, the ACTinvolves administration of either a cell used to enhance the immunesystem in treating a disease in said patient or a cell derived from animmune lineage which directly treats said disease.

In embodiments in which the NTLA is dexamethasone, the dexamethasone maybe administered at a dose of at least about 3 mg/kg, at least about 4mg/kg, at least about 5 mg/kg, at least about 6 mg/kg, at least about 7mg/kg, at least about 8 mg/kg, at least about 9 mg/kg, at least about 10mg/kg, at least about 11 mg/kg, at least about 12 mg/kg, at least about13 mg/kg, at least about 14 mg/kg, at least about 15 mg/kg, at leastabout 16 mg/kg, at least about 17 mg/kg, at least about 18 mg/kg, atleast about 19 mg/kg, at least about 20 mg/kg, at least about 21 mg/kg,at least about 22 mg/kg, at least about 23 mg/kg, at least about 24mg/kg, at least about 25 mg/kg, or at least about 26 mg/kg. The NTLAdexamethasone dose may be chosen from a range delimited by dexamethasonedosage values as disclosed herein, e.g. in the present paragraph. Forinstance the NTLA dexamethasone may be expressed as being administeredat a dose chosen from a range of between about 9 mg/kg to about 12mg/kg. In some embodiments, the dexamethasone may be administered at adose of up to about 26 mg/kg.

Preferably, the NTLA is administered before ACT commences. The NTLA maybe administered at least 12 hours before ACT commences. The NTLA may beadministered at one or more time points between about 72 to about 12hours prior to commencement of ACT.

In a fourth aspect, this invention provides a method of ameliorating thebinding and accumulation of a cellular immunotherapy in secondarylymphatic binding sites comprising: identifying a patient suffering fromcancer; administering to said patient a cellular immunotherapycomprising either a cell used to enhance the immune system in treatingsaid cancer or a cell derived from an immune lineage which directlytreats said cancer; and administering a non-toxic lymphodepleting agent(NTLA), which lymphodepletes and ablates the secondary lymphatic bindingsites where said cellular immunotherapy binds and accumulates, and isselected from the group consisting of: Tacrolimus delivered as aninjection or oral dose of 0.48 mg/kg to about 10 mg/kg for about 1-4weeks, Cyclosporine administered at about 15-100 mgs/kg/daily or about7.5-50 mgs/kg/twice-daily for about 7-28 days, Dexamethasone base, or anequivalent dose of another glucocorticoid, between about 3-26 mg/kg fora single acute dose about 12-72 hours, and a TNF inhibitor administeredfor about 3 to about 4 weeks; wherein the administration of the NTLAoccurs before administration said cellular immunotherapy, such as toameliorate the binding and accumulation of said cellular immunotherapyin secondary lymphatic binding sites.

In preferred embodiments of the aspects described herein, the patient isa human. The NTLA may be administered at least 12 hours before ACTcommences. In some embodiments, NTLA is administered within about 72hours preceding commencement of ACT. In some embodiments, the ACTcomprises administration of anticancer T cells and/or anticancer NKcells to the patient. In preferred embodiments, the cells administeredfor ACT include T cells. The ACT may be adoptive T cell therapy.Preferably, the method does not include the administration ofradiotherapy or a chemotherapeutic agent for a duration of more than 1day within about 2 weeks preceding the start of ACT. In someembodiments, no radiotherapy or chemotherapeutic agents are administeredto the patient. In some embodiments, the NTLA induces an elevation ofone or more plasma cytokine in the patient, selected from the groupconsisting of IL-2, IL-7, IL-12, and IL-15 to levels preferably of 20pg/ml or greater. Levels of IL-6 may be unaffected by the NTLA.

The enhancement of ACT may comprise enhanced cancer killing in a cancerpatient, or reduced autoimmune causing cell count in a patient with anautoimmune disorder, or reduced infectious agent load, in a patient withan infectious disease.

Preferably the NTLA is administered before ACT commences. For instance,NTLA may be administered at least 12 hours before ACT commences, or atanother interval in advance of ACT, as described herein. In someembodiments, the NTLA is administered at one or more time points betweenabout 12 to about 72 hours prior to commencement of ACT.

In some embodiments of this invention, the method according to any ofthe preceding claims, wherein the ACT is an adoptive T cell therapy, forinstance based on the transfusion of CAR T cells. In some embodiments,the patient is a cancer patient and the ACT comprises administration ofanticancer T cells and/or anticancer NK cells.

The ACT may be based on autologous cells (i.e. cells that have beenharvested from the patient, before being optionally modified orstimulated prior to transfer/readministration) or heterologous (i.e.cells or cell lines originating from another donor).

In some embodiments of this invention, no chemotherapeutic agents areadministered to the patient.

A non-toxic lympodepleting therapeutic agent is an agent that induceslymphodepletion and inhibits germinal centers in the spleen withoutkilling other rapidly dividing cells such as hair cells, mucosal cells,intestinal cells, and which does not induce sepsis, organ dysfunction,capillary leak, myocarditis, lethal inflammatory syndrome, fatalinfusion reactions or subsequent new cancers.

The non-toxic lymphodepleting therapeutic agent can be administeredwithout cytotoxic preconditioning or in combination with cytotoxicpreconditioning. “In combination with” means administered before, and/ortogether with and/or after cytotoxic lymphodepleting chemotherapy,preferably with only one day of cytotoxic chemotherapy dosing. Additionof non-toxic lymphodepleting therapy can reduce the total dose or neededduration of cytotoxic lymphodepleting chemotherapy for lower adverseevents and toxicities to the patient. The non-toxic lymphodepletingtherapeutic agent can also be administered in combination with othercytotoxic preconditioning agents that include rituximab and similarmolecules that bind lymphocytes and induce antibody-dependent cellularcytotoxicity (ADCC) and complement mediated cytotoxicity (CMC), incombination with temodar, in combination with interleukins or toll-likereceptor agonists that can activate endogenous cytotoxic pathways, incombination with radiolabeled antibodies that trigger immune celldestruction (immunotoxins) such as antibodies to CD45, for instanceIomab-B, or in combination with total body radiation (TBI).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Acute high dose Dex eliminates ACT binding niches in the mousespleen and secondary lymphatics. Black and white scale immunofluorescentpictures of fresh thick spleen sections stained with FITC-PNA toquantitate germinal centers from IP administered placebo control andmice IP administered HED 9.3 mg kg dexamethasone base 96 hours beforespleen harvest is shown. The graph shows column plots of averagegerminal cell count per spleen area plus standard area of the mean(SEM).

FIG. 2: Acute high dose Dex dose-dependently eliminates ACT bindingniches in the mouse spleen. A graph of column plots of average GerminalCenter staining intensity measured using immunofluorescent staining offresh tichk spleen sections stained with FITC-PNA is shown.Immunofluorescent intensity was calculated using thresholding andMetaMorph Image Analysis. Columns are average plus SEM. The mice wereadministered placebo, 3 mg/kg HED dexamethasone base, 6 mg/kg HEDdexamethasone base, 9 mg/kg HED dexamethasone base or 12 mg/kg HEDdexamethasone base 48 hours before spleen harvest.

FIG. 3: Acute high dose Dex eliminates ACT binding niches in the ratspleen (MZ: marginal zone). A graph of column plots of marginal zonewidths measured on 5 micron spleen sections from rats treated IV or POwith placebo, 20 mg/kg (HED 3.23 mg/kg), 40 mg/kg (HED 6.45) or 80 mg/kg(HED 12.9 mg/kg) dexamethasone base 48 hours before spleen harvest isshown.

FIG. 4: Acute high dose Dex eliminates ACT binding niches in the ratspleen. A graph of column plots of the area per spleen are of BCL-6staining of 5 micron fixed spleen sections as a measure of germinalcenter numbers given as average per section is shown. The rats treatedIV or PO with placebo, 20 mg/kg (HED 3.23 mg/kg), 40 mg/kg (HED 6.45) or80 mg/kg (HED 12.9 mg/kg) dexamethasone base 48 hours before spleenharvest.

FIG. 5: Acute high dose Dex reduces rat lymphocyte number. Graphs ofindividual absolute lymphocyte numbers and averages measured by completeblood chemistries 48 hours after rats were treated IV or PO withplacebo, 20 mg/kg (HED 3.23 mg/kg), 40 mg/kg (HED 6.45) or 80 mg/kg (HED12.9 mg/kg) dexamethasone base are shown.

FIG. 6: Acute high dose Dex does not reduce rat neutrophil number.Graphs of individual absolute neutrophil numbers and averages measuredby complete blood chemistries 48 hours after rats were treated IV or POwith placebo, 20 mg/kg (HED 3.23 mg/kg), 40 mg/kg (HED 6.45) or 80 mg/kg(HED 12.9 mg/kg) dexamethasone base are shown. Data in FIGS. 3, 4, 5 and6 are from the same rats.

FIG. 7: Acute high dose Dex reduces mouse CD3 and CD4 positivelymphocytes (Dexamethasone (AVM0703) doses are shown as HED). Graphs ofindividual CD3+ and CD4+ lymphocytes and averages measured by flowcytometry as relative counts and normalized to relative absolute countsusing complete blood chemistries 48 hours after mice were treated POwith placebo, HED 3 mg/kg, HED 6 mg/kg, HED 9 mg/kg or HED 12 mg/kgdexamethasone base.

FIG. 8: Acute high dose Dex reduces mouse CD8 positive lymphocytes andTregs (Dexamethasone (AVM0703) doses are shown as HED). Graphs ofindividual CD8+ and Treg lymphocytes and averages measured by flowcytometry as relative counts and normalized to relative absolute countsusing complete blood chemistries 48 hours after mice were treated POwith placebo, HED 3 mg/kg, HED 6 mg/kg, HED 9 mg/kg or HED 12 mg/kgdexamethasone base. Treg lymphocytes were identified by beingCD3+CD4+CD25+FoxP3+.

FIG. 9: Acute high dose Dex reduces mouse NK cells and B lymphocytes(Dexamethasone (AVM0703) doses are shown as HED). Graphs of individualnatural killer (NK) cells and B lymphocytes and averages measured byflow cytometry as relative counts and normalized to relative absolutecounts using complete blood chemistries 48 hours after mice were treatedPO with placebo, HED 3 mg/kg, HED 6 mg/kg, HED 9 mg/kg or HED 12 mg/kgdexamethasone base. NK cells were identified by being CD3−CD49b+. Blymphocytes were identified by being CD3−B220+.

FIG. 10: Acute high dose Dex reduces mouse absolute lymphocyte numberswhile sparing neutrophils (Dexamethasone (AVM0703) doses are shown asHED). Graphs of individual absolute neutrophils and total lymphocytesand averages measured by complete blood chemistries 48 hours after micewere treated PO with placebo, HED 3 mg/kg, HED 6 mg/kg, HED 9 mg/kg orHED 12 mg/kg dexamethasone base.

FIG. 11: Acute high dose Dex spares mouse RBCs and Platelets(Dexamethasone (AVM0703) doses are shown as HED). Graphs of individualabsolute RBC and platelet and averages measured by complete bloodchemistries 48 hours after mice were treated PO with placebo, HED 3mg/kg, HED 6 mg/kg, HED 9 mg/kg or HED 12 mg/kg dexamethasone base. Datain FIG. 8, FIG. 9, FIG. 10, FIG. 11 are from the same cohorts of mice.

FIG. 12: Fifty percent (2 of 4) of human patients treated with 3 mg/kgdexamethasone base depleted CD3, CD4 and CD8 positive lymphocytes.Individual pre- and post-treatment, 48 hours after oral administrationof 3 mg/kg dexamethasone base to four human patients, values and lineplots of CD3+, CD4+, and CD8+ lymphocytes measured by flow cytometry.Each patients pre-treatment values are connected to post-treatmentvalues by a connecting line. CD4+ cells are also CD3+. CD8+ cells arealso CD3+.

FIG. 13: Twenty-five percent (1 of 4) of human patients treated with 3mg/kg dexamethasone base depleted Tregs and B lymphocytes. Line areindividual pre- and post-, 48 hours after oral administration of 3 mg/kgdexamethasone base to four human patients, values and line plots of Tregand B lymphocytes measured by flow cytometry. Each patient'spre-treatment values are connected to post-treatment values by aconnecting line. Tregs are identified by being CD3+CD4+CD25+FoxP3+. Blymphocytes are identified by being CD3−CD19+.

FIG. 14: Seventy-five percent (3 of 4) of human patients treated with 3mg/kg dexamethasone base depleted NK cells while hematopoietic stemcells were spared. Line are individual pre- and post-treatment, 48 hoursafter oral administration of 3 mg/kg dexamethasone base to four humanpatients, values and line plots of NK cells and Hematopoietic Stem Cells(HSCs) measured by flow cytometry. Each patient's pre-treatment valuesare connected to post-treatment values by a connecting line. NK cellsare identified by being CD3−CD16/56+. HSCs are identified by beingCD34+CD38−.

FIG. 15: 100% of human patients treated with 3 mg/kg dexamethasone baseshowed increased serum IL-2 and/or IL-15 levels, but no elevation inIL-6. Column plots of each patients pre- and post-treatment, 48 hoursafter oral administration of 3 mg/kg dexamethasone base to four humanpatients, plasma levels of interleukin 2 and interleukin 15 measured byProCartaPlex-9 plx Luminex assay. (FIG. 12, FIG. 13, FIG. 14 and FIG. 15show data from the same four human patients.)

FIG. 16: Oral administration of 3 mg/kg dexamethasone base increasedbone marrow MSC number 48 hours later. Column plots of data from 31historical naïve control humans plus standard deviation, and two humanpatients treated with 3 mg/kg dexamethasone base 48 hours beforeaspiration of concentrated bone marrow from the ileac crest using aMarrowCellution™ needle. Bone marrow was added to directly to colonyforming unit assay fibroblast (CFU-F) media without further manipulation24 hours after harvest and shipment at controlled room temperature.CFU-F colony number is a measure of mesenchymal stem cell (MSC) numberin the starting material. 48 hours after oral administration of 3 mg/kgdexamethasone base, ileac crest bone marrow MSC numbers appear abouttwice as high as 31 historical controls.

FIG. 17: Comparison of a 12 mg/kg Dex base oral dose on day −2 to asingle dose of Cyclophosphamide 166 mg/kg (HED 500 mg/m2) andFludarabine 10 mg/kg on day −5 combined with 12 mg/kg Dex base on day−2, and to 2 days of repeat Cyclophosphamide 166 mg/kg on day −5 and −4and 4 days of Fludarabine 10 mg/kg (HED 30 mg/m2) on days −5, −4, −3,−2. FIG. 17 is a representation of the dosing schedules in mice of 2days Cy plus 4 days Flu (light grey), compared to 1 day Cy plus 1 dayFlu plus Dexamethasone base HED 12 mg/kg on day −2 (dark grey) or toDexamethasone base HED 12 mg/kg on day −2 alone (black). Below thedosing schedule are columns indicating the percent change compared tovehicle controls in body weights, CD3+ lymphocytes, CD4+ lymphocytes,CD8+ lymphocytes, Tregs, B lymphocytes, NK cells, neutrophils, absolutelymphocytes, platelets, and RBCs.

FIG. 18: A single dose of Cyclophosphamide 166 mg/kg (HED 500 mg/m2) andFludarabine 10 mg/kg on day −5 combined with 12 mg/kg Dex base on day −2equivalently lymphodepleted CD3+ and CD4+ lymphocytes compared to 2 daysof repeat Cyclophosphamide 166 mg/kg on day −5 and −4 and 4 days ofFludarabine 10 mg/kg (HED 30 mg/m2) on days −5, −4, −3, −2. FIG. 18shows graphs of individual CD3+ and CD4+ lymphocytes and averagesmeasured by flow cytometry as relative counts and normalized to relativeabsolute counts using complete blood chemistries 48 hours after micewere treated IP with PBS (Vehicle 1), or with repeat IP Cyclophosphamide166 mg/kg on day −5 and −4 and 4 days of IP Fludarabine 10 mg/kg (HED 30mg/m²) on days −5, −4, −3, −2 (Flu+Cy), or with a single IP dose ofCyclophosphamide 166 mg/kg (HED 500 mg/m²) and IP Fludarabine 10 mg/kgboth on day −5 and then with oral 12 mg/kg Dex base on day −2(Flu+Cy+AVM0703), or with oral placebo (Vehicle 2), or with oral 12mg/kg dexamethasone base.

FIG. 19: A single dose of Cyclophosphamide 166 mg/kg (HED 500 mg/m2) andFludarabine 10 mg/kg on day −5 combined with 12 mg/kg Dex base on day −2equivalently lymphodepleted CD8+ lymphocytes and Tregs compared to 2days of repeat Cyclophosphamide 166 mg/kg on day −5 and −4 and 4 days ofFludarabine 10 mg/kg (HED 30 mg/m2) on days −5, −4, −3, −2. FIG. 19shows graphs of individual Treg and CD8+ lymphocytes and averagesmeasured by flow cytometry as relative counts and normalized to relativeabsolute counts using complete blood chemistries 48 hours after micewere treated IP with PBS (Vehicle 1), or with repeat IP Cyclophosphamide166 mg/kg on day −5 and −4 and 4 days of IP Fludarabine 10 mg/kg (HED 30mg/m²) on days −5, −4, −3, −2 (Flu+Cy), or with a single IP dose ofCyclophosphamide 166 mg/kg (HED 500 mg/m²) and IP Fludarabine 10 mg/kgboth on day −5 and then with oral 12 mg/kg Dex base on day −2(Flu+Cy+AVM0703), or with oral placebo (Vehicle 2), or with oral 12mg/kg dexamethasone base.

FIG. 20: A single dose of Cyclophosphamide 166 mg/kg (HED 500 mg/m2) andFludarabine 10 mg/kg on day −5 combined with 12 mg/kg Dex base on day −2equivalently lymphodepleted NK cells and B lymphocytes compared to 2days of repeat Cyclophosphamide 166 mg/kg on day −5 and −4 and 4 days ofFludarabine 10 mg/kg (HED 30 mg/m2) on days −5, −4, −3, −2. FIG. 20graphs of individual B lymphocytes and NK cell lymphocytes and averagesmeasured by flow cytometry as relative counts and normalized to relativeabsolute counts using complete blood chemistries 48 hours after micewere treated IP with PBS (Vehicle 1), or with repeat IP Cyclophosphamide166 mg/kg on day −5 and −4 and 4 days of IP Fludarabine 10 mg/kg (HED 30mg/m²) on days −5, −4, −3, −2 (Flu+Cy), or with a single IP dose ofCyclophosphamide 166 mg/kg (HED 500 mg/m²) and IP Fludarabine 10 mg/kgboth on day −5 and then with oral 12 mg/kg Dex base on day −2(Flu+Cy+AVM0703), or with oral placebo (Vehicle 2), or with oral 12mg/kg dexamethasone base.

FIG. 21: A single dose of Cyclophosphamide 166 mg/kg (HED 500 mg/m2) andFludarabine 10 mg/kg on day −5 combined with 12 mg/kg Dex base on day −2equivalently lymphodepleted absolute lymphocytes, but sparedneutrophils, compared to 2 days of repeat Cyclophosphamide 166 mg/kg onday −5 and −4 and 4 days of Fludarabine 10 mg/kg (HED 30 mg/m2) on days−5, −4, −3, −2. FIG. 21 shows graphs of individual absolute neutrophilsand absolute lymphocytes and averages measured by complete bloodchemistries 48 hours after mice were treated IP with PBS (Vehicle 1), orwith repeat IP Cyclophosphamide 166 mg/kg on day −5 and −4 and 4 days ofIP Fludarabine 10 mg/kg (HED 30 mg/m²) on days −5, −4, −3, −2 (Flu+Cy),or with a single IP dose of Cyclophosphamide 166 mg/kg (HED 500 mg/m²)and IP Fludarabine 10 mg/kg both on day −5 and then with oral 12 mg/kgDex base on day −2 (Flu+Cy+AVM0703), or with oral placebo (Vehicle 2),or with oral 12 mg/kg dexamethasone base.

FIG. 22: A single dose of Cyclophosphamide 166 mg/kg (500 mg/m2) andFludarabine 10 mg/kg (HED 30 mg/m2) on day −5 combined with 12 mg/kg Dexbase on day −2 spared RBCs and platelets. FIG. 22 shows graphs ofindividual absolute platelet and absolute RBCs and averages measured bycomplete blood chemistries 48 hours after mice were treated IP with PBS(Vehicle 1), or with repeat IP Cyclophosphamide 166 mg/kg on day −5 and−4 and 4 days of IP Fludarabine 10 mg/kg (HED 30 mg/m²) on days −5, −4,−3, −2 (Flu+Cy), or with a single IP dose of Cyclophosphamide 166 mg/kg(HED 500 mg/m²) and IP Fludarabine 10 mg/kg both on day −5 and then withoral 12 mg/kg Dex base on day −2 (Flu+Cy+AVM0703), or with oral placebo(Vehicle 2), or with oral 12 mg/kg dexamethasone base.

FIG. 23: A single dose of Cyclophosphamide 166 mg/kg (500 mg/m2) andFludarabine 10 mg/kg on day −5 combined with 12 mg/kg Dex base on day −2spared body weight, a measure of toxicity, compared to 2 days of repeatCyclophosphamide 166 mg/kg on day −5 and −4 and 4 days of Fludarabine 10mg/kg on days −5, −4, −3, −2. FIG. 23 shows graphs of individual bodyweight differences and averages calculated by subtracting body weight 48hours after mice were treated IP with PBS (Vehicle 1), or with repeat IPCyclophosphamide 166 mg/kg on day −5 and −4 and 4 days of IP Fludarabine10 mg/kg (HED 30 mg/m²) on days −5, −4, −3, −2 (Flu+Cy), or with asingle IP dose of Cyclophosphamide 166 mg/kg (HED 500 mg/m²) and IPFludarabine 10 mg/kg both on day −5 and then with oral 12 mg/kg Dex baseon day −2 (Flu+Cy+AVM0703), or with oral placebo (Vehicle 2), or withoral 12 mg/kg dexamethasone base from pretreatment body weights.

DESCRIPTION OF THE INVENTION Overview

Provided herein are novel therapeutic compositions and methods that keepcellular immunotherapies in the circulation or at the site of injectionfor extended periods of time without resorting to the use of cytotoxicpreconditioning. More specifically the compositions and methods hereinlymphodeplete and reduce or ablate sites in the secondary lymphaticswhere the cellular immunotherapy is bound and sequestered, without theuse of cytotoxic preconditioning.

Cytotoxic chemotherapeutic preconditioning agents trigger cell death viamechanisms or means that are not receptor mediated. Cytotoxicchemotherapeutic agents trigger cell death by interfering with functionsthat are necessary for cell division, metabolism, or cell survival.Because of this mechanism of action, cells that are growing rapidly(which means proliferating or dividing) or are active metabolically willbe killed preferentially over cells that are not. The status of thedifferent cells in the body as dividing or as using energy (which ismetabolic activity to support function of the cell) determines the doseof the chemotherapeutic agent that triggers cell death. The skilledperson will appreciate that the NTLA that is utilized in this inventionis not a cytotoxic chemotherapeutic. Cytotoxic chemotherapeutic agentsnon-exclusively relates to alkylating agents, anti-metabolites, plantalkaloids, topoisomerase inhibitors, antineoplastics and arsenictrioxide, carmustine, fludarabine, IDA ara-C, myalotang, GO, mustargen,cyclophosphamide, gemcitabine, bendamustine, total body irradiation,cytarabine, etoposide, melphalan, pentostatin and radiation.

Examples of alkylating agents non-exclusively relates to cisplatin andcarboplatin, as well as oxaliplatin. TEMODAR® (temozolomide) is analkylating agent. ACNU is also an alkylating agent. They impair cellfunction by forming covalent bonds with the amino, carboxyl, sulfhydryl,and phosphate groups in biologically important molecules.

Examples of antimetabolites non-exclusively relates to azathioprine,mercaptopurine, capecitabine, fluorouracil-which become the buildingblocks of DNA. They prevent these substances from becoming incorporatedin to DNA during the “S” phase (of the cell cycle), stopping normaldevelopment and division. They also affect RNA synthesis. Due to theirefficiency, these drugs are the most widely used cytostatics.

Alkaloids non-exclusively relates to the vinca alkaloids and taxanes.Vinca alkaloids non-exclusively relates to vincristin, vinblastin,vinorelbine, and vindesine. Taxanes non-exclusively relates totaxol,paclitaxel and docetaxel.

Topoisomerases are essential enzymes that maintain the topology of DNA.Inhibition of type I or type II topoisomerases interferes with bothtranscription and replication of DNA by upsetting proper DNAsupercoiling. Some type I topoisomerase inhibitors non-exclusivelyrelates to camptothecins: irinotecan and topotecan. Examples of type IIinhibitors non-exclusively relates to amsacrine, etoposide, etoposidephosphate, and teniposide.

Antineoplastic non-exclusively relates to dactinomycin, doxorubicin,epirubicin, and bleomycin.

Other cytotoxic preconditioning agents non-exclusively relate to;rituximab and similar antibody molecules which activateantibody-dependent cellular cytotoxicity and complement mediatedcytotoxicity upon binding their target cells; radiolabeled antibodiesthat trigger immune cell destruction (immunotoxins) such as antibodiesto CD45, for instance Iomab-B; immunotoxins such as MYLOTARG®(gemtuzumab ozogamicin), Denileukin diftitox (ONTAK®), BL22 and 8H9; andpharmacologic doses of interleukins such as IL-2, IL12, or IL15 whichactivate cytotoxic T lymphocytes.

Agents which lymphodeplete and ablate the secondary lymphatic bindingsites where cellular immunotherapies bind and accumulate but are notcytotoxic preconditioning agents are considered non-toxiclymphodepleting agents (NTLA).

NTLAs that reduce cellular immunotherapies binding to the spleen andother lymphatics and lymphodeplete thus augment the numbers of cellularimmunotherapy cells at the site of injection or in the circulation thatcan thus find and participate in killing cancer or tumor cells orautoimmune causing cells or infectious agents. Therapeutic agents whichhave this affect via a biologic mechanism of action, rather than acytotoxic mechanism of action, are considered NTLAs.

NTLAs that inhibit the binding of cellular immunotherapies to lymphoidtissues, particularly to the germinal centers of lymphoid tissues andcause lymphodepletion via a biologic mechanism of action, which are notcytotoxic preconditioning agents, non-exclusively relates toimmunosuppressants, particularly agents that contain dexamethasone,glucocorticoid-receptor modulating agents, antagonists to CD40L or CD40,or antagonists to CD26. Thus, some of the NTLAs used in this inventionmay be termed NTLA immunosuppressants. NTLAs that inhibit the binding ofcellular immunotherapies to lymphoid tissues, particularly to thegerminal centers of lymphoid tissues and cause lymphodepletion via abiologic mechanism of action, which are not cytotoxic preconditioningagents, also non-exclusively relates to steroids, glucocorticoidsincluding but not limited to; dexamethasone, prednisone,methylprednisone, beclomethasone, betamethasone, budesonide, cortisone,hydrocortisone, prednisolone, mometasone furoate, TriamcinoloneAcetonide and methylprednisolone, and agents that enhance the expressionof or activate CCR7, an agent that inhibits the binding of CD40L to CD40(for example antagonistic antibodies to CD40 or to CD40L), antagonistsor inhibitors of signaling lymphocyte activation molecule-associatedprotein, and antagonists or inhibitors of the following list:Interleukin 1, interleukin 2, Interleukin 4, interleukin 5, interleukin6, Interleukin 12, Interleukin 13, interleukin 21, Interleukin 23, IgE,Vascular Adhesion Protein (VAP), Vascular Endothelial Growth Factor(VEGF), BAFF (BLyS), complement, CD2, CD23, CD25a, CD40, CD154 (CD40L),CD62L, CD147, LFA1, (CD11a), CD18, Adenosine deaminase, tumor necrosisfactor (TNF).

In administering a glucocorticoid or glucocorticoid receptor modulatingtherapeutic NTLA agent that inhibits the binding of cellularimmunotherapies to lymphatic tissues and causes lymphodepletion it ispreferred to administer the therapeutic agents about 1-14 days prior totreatment with cellular immunotherapies, more preferably about 1-7 daysprior to treatment with cellular immunotherapies, and most preferablyabout 36-48 hours prior to treatment with cellular immunotherapies.

Corticosteroids, which are NTLA immunosuppressants at certain doses,such as dexamethasone, prednisolone, methylprednisolone, dexamethasonesodium phosphate and betamethasone will cause lymphodepletion andprevent cellular immunotherapies from binding to the secondarylymphatics and thus keep the cellular immunotherapies in the circulationor retained at the site of injection so that they can find and killcancer, tumor or autoimmune causing cells or infectious agents. Longterm engraftment of the cellular immunotherapy will also be enhanced.

Glucocorticoids and glucocorticoid-receptor (GR) modulating agents exerttheir effects through both membrane glucocorticoid receptors andcytoplasmic GRs which activate or repress gene expression. Some of thedesirable lymphodepletion effects of the glucocorticoids and GRmodulating agents appear to be mediated via membrane GRs or othernon-genomic effects in addition to their genomic effects. Interestingly,co-treatment with dexamethasone has been shown to be able to reduceglucocorticoid resistance (Serafin Blood 2017 130:2750-2761).

The effects of glucocorticoids are complex and depend on each specificglucocorticoid's affinity for the GR and mineralocorticoid receptor(MR). Additionally, there are now 9 known isoforms of the cytosolic GRand additional membrane expressed GR receptors that have been identifiedbut which are not fully characterized. Glucocorticoids have beenreported to have varied effects on lymphocyte levels, depending on theconcentration of the glucocorticoid administered and the duration oftreatment. In general, at low doses typically used for chronic therapy,glucocorticoids have been reported to redistribute lymphocytes from theperipheral blood into the bone marrow, at medium doses glucocorticoidshave been reported to cause leukocytosis thought to be a redistributionof leukocytes from the bone marrow, spleen and thymus into theperipheral blood, and at high doses glucocorticoids have a lymphotoxicaction on lymphocytes by triggering apoptosis and necroptosis. Theduration of effect also depends on the dose level, for instance Fauci(Clin. exp. Immunol. (1976) 24, 54-62.) reports a single oral 0.24 mg/kgdexamethasone dose suppresses peripheral blood T and B lymphocytes 80%with recovery beginning at 12 hours and normal levels by 24 hours.However, the present invention demonstrates that acute oral doses of 3mg/kg or greater are necessary to reduce peripheral blood T and B cells48 hours after administration, with return to baseline levels occurringaround 5 to 14 days after dosing.

The desired in vivo effects of exemplary NTLAs would include reductionsin germinal center and marginal zones in secondary lymphatics, directtumor killing of some cancers particularly; multiple myeloma, renal cellcarcinoma, leukemia and lymphoma, non-small cell lung cancer (NSCLC),prostate and breast cancer; depletion of all peripheral blood lymphocytetypes, lack of lymphocyte redistribution to the BM or other organs, andelevation of plasma cytokines including IL-2, and/or IL-7, and/or IL-12,and/or IL-15 to levels preferably of 20 pg/ml or greater, among others.Exemplary NTLAs do not elevate plasma levels of IL-6, one of the majorcontributors to ACT induced cytokine release syndrome (CRS). Acute dosesof dexamethasone of about HED 6 mg/kg and above reduce germinal centersand marginal zones in secondary lymphatics; acute doses of dexamethasoneof about 1.6 mg/kg HED in a 48 hour period have about 50% direct tumorkilling against multiple myeloma and other cancer cell lines which ismaintained but not increased with doses up to about 12 mg/kg HED; acutedoses of dexamethasone of greater than about HED 3 mg/kg are requiredfor lymphodepletion demonstrated by the observation that 50% of patientstreated with 3 mg/kg HED showed lymphocytosis (FIG. 12); plasma IL-2 andIL-15 cytokine elevations are observed at doses of dexamethasone base ofabout HED 3 mg/kg or higher (FIG. 15). Based on the desired in vivoeffects in the indications disclosed in this application, the mostpreferred acute dexamethasone base doses, which can be converted to NTLAequivalent doses of other glucocorticoids based on known calculators oras disclosed in this description, will be most likely about HED 9 mg/kgand above.

NTLA dosing of Dexamethasone, or an equivalent dose of anotherglucocorticoid, should be between about 3 mg/kg and about 26 mg/kgsingle acute dose about 12 to about 72 hours prior to cellularimmunotherapy administration or total dose of about 3 mg/kg to about 26mg/kg given between about 12 to about 72 hours prior to cellularimmunotherapy administration. The single acute dose would mostpreferably be given about 36 to about 48 hours prior to cellimmunotherapy administration.

A single acute NTLA dose is an oral administration or about a one hourIV infusion. A total dose may be given as repetitive IV or oral doses inany quantity such that the total dose reaches about 3 mg/kg to about 26mg/kg between about 12 to about 72 hours prior to cell immunotherapyadministration.

Equivalent doses of another glucorticoid or glucocorticoid receptormodulating agent can be readily and easily calculated using publiclyavailable corticoid conversion algorithms. For example, a 12 mg/kg doseof dexamethasone corresponds to 1) a 75 mg/kg dose of prednisolone thatwould require repeat dosing of about two to about three doses withinabout 48 hours before administration of ACT because of its shorterpharmacologic half life, 2) a 10 mg/kg dose of betamethasone that has apharmacodynamic (biologic) half-life similar to dexamethasone. However,Betamethasone reduces RBC at doses of about 24 mg/50 kg (Gaur 2017).

An NTLA agent containing dexamethasone is preferably administeredintravenously or orally about 36 to about 48 hours before administrationof the cellular immunotherapy at a dose between about 3.0 to about 12.0mgs dexamethasone base per kg of the patient's body weight. The mostpreferable dose in young children is between about 3.0 and about 12.0mg/kg dexamethasone base and in adolescents and adults is between about6.0 and about 12.0 mg/kg, with about 9.0 mg/kg to about 12.0 mg/kgdexamethasone base being most preferred. Dexamethasone, like the otherglucocorticoid steroids at equivalent doses, inhibits the formation andproliferation of germinal centers in the lymph tissues andlymphodepletes peripheral blood.

An NTLA agent containing hydrocortisone is administered intravenously ororally about every 12 hours at a dose of about 75 to about 300 mg/kgbetween about 12 to about 72 hours before administration of the cellularimmunotherapy. An NTLA agent containing cortisone is administeredintravenously or orally about every 12 hours at a dose of about 93 toabout 375 mg/kg between about 12 to about 72 hours before administrationof the cellular immunotherapy. An NTLA agent containing prednisolone isadministered intravenously or orally about every 24 hours at a dose ofabout 19 to about 75 mg/kg between about 12 to about 60 hours beforeadministration of the cellular immunotherapy. An NTLA agent containingmethylprednisolone is administered intravenously or orally about every24 hours at a dose of about 15 to about 60 mg/kg between about 12 toabout 60 hours before administration of the cellular immunotherapy. AnNTLA agent containing triamcinolone is administered intravenously ororally about every 24 hours at a dose of about 15 to about 60 mg/kgbetween about 12 to about 60 hours before administration of the cellularimmunotherapy. An NTLA agent containing paramethasone is administered ineither a single acute dose or cumulative doses of about 7.5 to about 30mg/kg, given between about 12-72 hours prior to cellular immunotherapy.An NTLA agent containing betamethasone is administered in either asingle acute dose or cumulative doses of about 2.5 to 10 mg/kg, givenbetween about 12-72 hours prior to cellular immunotherapy.

Clinically effective doses of NTLA, particularly Dexamethasone, achievegreater than 60% CD3+ lymphodepletion. More preferable clinicallyeffective doses of NTLA, particularly Dexamethasone, achieve greaterthan 70% CD3+ lymphodepletion. The most preferable clinically effectivedoses of NTLA, particularly Dexamethasone, achieve greater than 80% CD3+lymphodepletion. The skilled person will understand that CD3+lymphodepletion can be measured readily by measuring complete bloodcounts (CBCs) with differentials and/or the percent of cells that arepositive for CD3 by flow cytometry. Flow cytometry is a technology thatis used to analyse the physical and chemical characteristics ofparticles in a fluid as it passes through at least one laser. Cellcomponents are fluorescently labelled and then excited by the laser toemit light at varying wavelengths. Flow cytometry enables theidentification and characterization of distinct subsets of cells withina heterogeneous sample.

Clinically effective doses of NTLA, particularly Dexamethasone, achievegreater than 60% Treg lymphodepletion. More preferable clinicallyeffective doses of NTLA, particularly Dexamethasone, achieve greaterthan 70% Treg lymphodepletion. The most preferable clinically effectivedoses of NTLA, particularly Dexamethasone, achieve greater than 80% Treglymphodepletion. Clinically effective doses of Dexamethasone and otherpreferred agents for NTLA spare neutrophils and do not inhibitneutrophil function (Schleimer R P, J Pharmacol Exp Ther 1989;250:598-605), and spare red blood cells (RBCs), platelets, mesenchymalstem cells (MSC) and hematopoietic stem cells (HSC). Neutrophil sparingin humans is an absolute neutrophil count (ANC) greater than 500 permm³. By sparing neutrophils, RBCs and platelets, preferred NTLA,particularly NTLA Dexamethasone, would reduce or eliminate the need fortransfusions. NTLA Dexamethasone also spares bone marrow mesenchymalstem cells (MSCs) and does not affect the capacity of bone marrow MSCsto differentiate towards chondrocytes, osteocytes or adipocytes. NTLADexamethasone also increases the endogenous number of BM MSCs or theirex vivo survival in both humans and horses. Preferred NTLA, particularlyNTLA Dexamethasone, increase plasma IL-2, IL-7, IL-12 and IL-15 levels,but not IL-6 levels.

Dexamethasone is approved for use with an initial dosage ofdexamethasone sodium phosphate injection that varies from 0.5 to 9 mg aday depending on the disease being treated, which is a daily dose of0.01 to 0.18 mg/kg based on a 50 kg BW. In less severe diseases doseslower than 0.5 mg may suffice, while in severe diseases doses higherthan 9 mg may be required. There is a tendency in current medicalpractice to use high (pharmacologic) doses of corticosteroids for thetreatment of unresponsive shock. For cerebral edema Dexamethasone sodiumphosphate injection is generally administered initially in a dosage of10 mg intravenously followed by four mg every six hours intramuscularlyuntil the symptoms of cerebral edema subside. This total dose wouldcorrespond to a total 24 hour dose of about 0.34 to 0.48 mg/kg and atotal 72 hour dose of 0.8 to 1.12 mg/kg in 72 hours, which is not anNTLA dose as disclosed in the present application, which are total dosesbetween about 3 mg/kg and about 26 mg/kg given between about 12 to about72 hours before ACT.

For acute allergic disorders Dexamethasone sodium phosphate injection,USP 4 mg/mL; is recommended: first day, 1 or 2 mL (4 or 8 mg),intramuscularly, then Dexamethasone sodium phosphate tablets, 0.75 mg;second and third days, 4 tablets in two divided doses each day; fourthday, 2 tablets in two divided doses; fifth and sixth days, 1 tablet eachday; seventh day, no treatment; eighth day, follow-up visit.Dexamethasone has been used in the emergency room for severe acutepediatric asthma at 2 mg/kg, a dose which is below the NTLA doses asdefined in this invention.

The human CD26 gene contains 26 exons and is located on chromosome2q.24.3. The gene spans a region of circa 70 kb.vFlanking to the 5′ end,a sequence of 300 base pairs is located that consists for not less than72% of cytosine and guanine residues, implying that the sequence holdspotential-binding sites for growth factors such as the nuclear factorkappa-light-chain enhancer of activated B cells (NF-κB) and hepatocytenuclear transcription factor 1 (HNF-1). Absence of a TATA box and a highCG content, which characterize the CD26 gene, are typical features of apromotor region of a house keeping gene. As it results to the presentinvention, antagonists to CD26 do not effect the DPPIV activity of themolecule. The coding glycoprotein, as a monomer, has a size of 110 kDaand is multifunctional. CD26 exists both as a soluble molecule as wellas in a membrane-bound form and functions as a serine protease, as areceptor, as an adhesion molecule for collagen and fibronectin, as acostimulatory signal for T lymphocytes, and is involved in apoptosis.Conditions of hypoxia promote CD26 expression and hypoxia-inducibleprotein-1α (HIP-1α) is a strong inducing factor for CD26 gene expressionand protein production. Several cytokines including IFNs and IL-1β,retinoic acid, and HNF-1 can also stimulate activation of CD26 onfibroblasts, epithelial cells, endothelial cells, and leukocytes.Membrane-bound CD26 contains a transmembrane domain that is located 28residues from the NH2-terminus and is a leukocyte surface marker. Theprotein shows catalytic proteolytic activity only as a dimer and can befound on the surface of T and B cells, NK cells, some types ofmacrophages, and hematopoietic stem and progenitor cells. In addition,fibroblasts, endothelial, acinar, and epithelial cells of differenttissues like kidney and liver do also express CD26. Both termini of theprotein contribute to the formation of a so called β-propeller domain(amino acids 55-497). The β-propeller structure holds seven sheets andcontains only hydrophobic bonds and salt bridges, implying that theregion is extremely flexible. Furthermore, the protein contains an a/Phydroxylase domain (amino acid 39-51 and amino acid 506-766) that iscovalently bound to the β-propeller domain. All together, theseproperties imply that the catalytic pocket is situated in a locked hole.The other side of the β-propeller domain faces the extracellularenvironment. It cannot be excluded that the flexibility of theβ-propeller domain plays a role in facilitating the passage ofsubstrates toward the catalytic pocket of CD26. However, only entranceof substrates through a side opening of the enzyme is supported byexperimental data at the moment. In addition to functional homodimericCD26, active heterodimers with FAPα have also been described.

CD26 contains multiple regions that can be subjected to N-glycosylation.Research, however, suggests that glycosylation of these sequences doesnot have implications for dimerization of the protein, binding toadenosine deaminase (ADA), or the catalytic activity.

CD26, also called DPP4, is a multi-functional protein involved in T cellactivation by co-stimulation via its association with adenosinedeaminase (ADA), caveolin-1, CARMA-1, CD45, mannose-6-phosphate/insulingrowth factor-II receptor (M6P/IGFII-R) and C-X-C motif receptor 4(CXC-R4). CD26 is a T-cell activation antigen. Antagonists to CD26 wouldprevent CD26 co-stimulation of T cells. Without T cell activation, Bcells cannot be activated and germinal center formation cannot occur.

CD26 is expressed in all organs, primarily on apical surfaces ofepithelial and acinar cells and at lower levels on lymphocytes andcapillary endothelial cells. Immunohistochemical analysis has detectedCD26 in human tissue sections of the gastrointestinal tract, biliarytract, exocrine pancreas, kidney, uterus, placenta, prostate andepidermis, the adrenal, parotid, sweat, salivary and mammary glands andon endothelia of all organs examined including liver, spleen, lungs andbrain. Similar studies of rat tissues produced identical data byimmunohistochemistry and showed that endothelial cells of capillaries inall organs including lymphoid organs, muscle and brain express CD26.

CD26 in addition to its DPPIV enzymatic activity can directly bindadenosine deaminase, fibronectin, collagen and other extracellularmatrix proteins, gp120, fibroblast activation protein alpha, CARD11,gelatin, CAV1, BCL10, GPC3, CXRC4, TAT, coronavirus-EMC spike protein,IGF2R, and PTPRC and CD45. CD26 also has signal transduction activity(uniprot.org/uniprot/P27487). Residues of Leucine_<340>, Valine_<341>,Alanine_<342> and Arginine_<343> on the CD26 molecule were essentialamino acids for ADA binding. These interactions were specified toinvolve fibronectin and collagen: collagen binds to a region in thecysteine domain14 between residues 238 and 495, whereas fibronectinbinds residues 469 to 479. The residues 340-343 on the CD26 moleculeproved to be essential for ADA binding21. GP120 bocks ADA binding toCD26. The receptor-binding subdomain of MERS-CoV RBD binds to the DPP4b-propeller, contacting blades four and five and a small bulged helix inthe blade-linker. Structural analysis and mutational analysis haveidentified Y499, L506, W533, and E513 in the RBD to be critical forreceptor binding and viral entry, and mutations of these significantlyabrogate its interaction with DPP4.

In certain embodiments of the invention it would be desirable to have anantagonist to CD26 that prevented cellular immunotherapies from bindingto the secondary lymphatics but that did not affect or impact the DPPIVproteolytic activity of CD26.

The complete cDNA and derived amino acid sequence for human CD26 wasfirst published in 1992. The CD26 gene5 encodes a type II transmembraneprotein of 766 amino acids, which is anchored to the lipid bilayer by asingle hydrophobic segment located at the N-terminus, and has a shortcytoplasmic tail of six amino acids. A flexible stalk links the membraneanchor to a large glycosylated region, a cysteine-rich region and aC-terminal catalytic domain. Alignment of the amino acid sequencesreveals a high degree of conservation between different species, withthe C-terminal segment showing the highest level of identity.

The present invention also provides a means to achieve adequatelymphodepletion by combining NTLA, particularly NTLA Dexamethasone, withreduced intensity cytotoxic preconditioning administered as only one dayof dosing to reduce the toxicities of the cytotoxic preconditioning orby significantly reducing an acute dose of cytotoxic preconditioning.Standard chemotherapy preconditioning regimens include cyclophosphamide(about 200 to about 2100 mg/m2/day from about day −14 to about day-2)with or without fludarabine (about 10 mg/m2/day to about 9000 mg/m2/dayfrom about day −14 to about day −2) in various combinations and dailyduration of dosing. A single treatment of cyclophosphamide (Cy) 167mg/kg (equivalent to a HED of about 500 mg/m2) for mice on day −5 andfludarabine (Flu) 10 mg/kg (equivalent to a HED of about 30 mg/m2) formice on day −5 plus 12 mg/kg HED dose of Dexamethasone base on day −2was equally effective for lymphodepletion compared to more standardcyclophosphamide 167 mg/kg dose on day −5 and −4 and fludarabine 10mg/kg on day −5, −4, −3, −2, however, toxicity of the preconditioningwas reduced as evidenced by lower BW reductions in the Dexamethasoneplus single CyFlu compared to standard CyFlu repeat dosing. A reduceddose of cytotoxic preconditioning would be a single dose of a standardchemotherapy preconditioning regime dose used in repetitive dosing or acumulative dose of a cytotoxic preconditioning agent below cumulativestandard chemotherapy preconditioning regimens. For example a reduceddose of cyclophosphamide would be a single dose of cyclophosphamidebetween about 200 to about 3000 mg/m² or a cumulative dose below about200 mg/m2.

To reduce the toxicity of preconditioning, a single dose of anystandardly used preconditioning therapy or combination preconditioningtherapy can be given between about day 0 and about day −9, followed by adose of NTLA, particularly NTLA Dexamethasone. NTLA Dexamethasone shouldbe administered between about 3 mg/kg and about 26 mg/kg single acutedose about 12 to about 72 hours prior to cell immunotherapyadministration or total dose of about 3 mg/kg to about 26 mg/kg givenbetween about 12 to about 72 hours before cell therapy administration.Preconditioning agents that can be used in lower doses in combinationwith NTLA Dexamethasone between about 3 mg/kg and about 26 mg/kg singleacute dose about 12 to about 72 hours prior to cell immunotherapyadministration or total dose of about 3 mg/kg to about 26 mg/kg givenbetween about 12 to about 72 hours before cell therapy administrationnon-exclusively relate to Abiraterone, Alemtuzumab, Anastrozole,Aprepitant, Aranose, Arsenic trioxide, Atezolizumab, Azacitidine,Bevacizumab, Bleomycin, Bortezomib, Cabazitaxel, Capecitabine,Carboplatin, Cetuximab, Cisplatin, Crizotinib, Cyclophosphamide,Cytarabine, Chlorozotocin, Chlorambucil, Denosumab, Docetaxel,Doxorubicin, Eribulin, Erlotinib, Etoposide, Everolimus, Exemestane,Filgrastim, Fluorouracil, Fotemustine, Fulvestrant, Gemcitabine, HPVVaccine, Imatinib, Imiquimod, Ipilimumab, Ixabepilone, Lapatinib,Lenalidomide, Letrozole, Leuprolide, Mesna, Melphalan, Methotrexate,Mechlorethamine, Nivolumab, Oxaliplatin, Paclitaxel, Palonosetron,Pembrolizumab, Pemetrexed, Radium-223, Rituximab, Sipuleucel-T,Sorafenib, Sunitinib, Talc Intrapleural, Tamoxifen, Temozolomide,Temsirolimus, Thalidomide, Trastuzumab, Vinorelbine, Zoledronic acid,Abitrexate (Methotrexate Injection), Abraxane® (Paclitaxel Injection),Adcetris® (Brentuximab Vedotin Injection), Adriamycin® (Doxorubicin),Adrucil® Injection (5-FU (fluorouracil)), Afinitor® (Everolimus),Afinitor® Disperz (Everolimus), Alimta® (PEMETREXED), Alkeran® Injection(Melphalan Injection), Alkeran® Tablets (Melphalan), Aredia®(Pamidronate), Arimidex® (Anastrozole), Aromasin® (Exemestane), Arranon®(Nelarabine), Arzerra® (Ofatumumab Injection), Avastin® (Bevacizumab),Beleodaq® (Belinostat Injection), Bexxar (Tositumomab), BiCNU®(Carmustine), Blenoxane® (Bleomycin), Blincyto® (BlinatumomabInjection), Bosulif® (Bosutinib), Busulfex® Injection (BusulfanInjection), Campath® (Alemtuzumab), Camptosar® (Irinotecan), Caprelsa®(Vandetanib), Casodex® (Bicalutamide), CeeNU® (Lomustine), CeeNU® DosePack (Lomustine), Cerubidine® (Daunorubicin), Clolar® (ClofarabineInjection), Cometriq® (Cabozantinib), Cosmegen® (Dactinomycin),Cotellic® (Cobimetinib), Cyramza® (Ramucirumab Injection), CytosarU®(Cytarabine), Cytoxan® (Cytoxan), Cytoxan® Injection (CyclophosphamideInjection), Dacogen® (Decitabine), DaunoXome® (Daunorubicin LipidComplex Injection), DepoCyt® (Cytarabine Lipid Complex Injection),Docefrez® (Docetaxel), Doxil® (Doxorubicin Lipid Complex Injection),Droxia® (Hydroxyurea), DTIC® (Decarbazine), Eligard® (Leuprolide),Ellence® (Ellence (epirubicin)), Eloxatin® (oxaliplatin), Elspar®(Asparaginase), Emcyt® (Estramustine), Erbitux® (Cetuximab), Erivedge®(Vismodegib), Erwinaze® (Asparaginase Erwinia chrysanthemi), Ethyol®(Amifostine), Etopophos® (Etoposide Injection), Eulexin® (Flutamide),Fareston® (Toremifene), Farydak® (Panobinostat), Faslodex®(Fulvestrant), Femara® (Letrozole), Firmagon® (Degarelix Injection),Fludara® (Fludarabine), Folex® (Methotrexate Injection), Folotyn®(Pralatrexate Injection), FUDR® (floxuridine), Gazyva® (ObinutuzumabInjection), Gemzar® (Gemcitabine), Gilotrif® (Afatinib), Gleevec®(Imatinib Mesylate), Gliadel® Wafer (Carmustine wafer), Halaven®(Eribulin Injection), Herceptin® (Trastuzumab), Hexalen® (Altretamine),Hycamtin® (Topotecan), Hydrea® (Hydroxyurea), Ibrance® (Palbociclib),Iclusig® (Ponatinib), Idamycin® PFS (Idarubicin), Ifex® (Ifosfamide),Imbruvica® (Ibrutinib), Inlyta® (Axitinib), Intron® A alfab (Interferonalfa-2a), Iressa® (Gefitinib), Istodax (Romidepsin Injection), Ixempra®(Ixabepilone Injection), Jakafi® (Ruxolitinib), Jevtana® (CabazitaxelInjection), Kadcyla® (Ado-trastuzumab Emtansine), Keytruda®(Pembrolizumab Injection), Kyprolis® (Carfilzomib), Lanvima®(Lenvatinib), Leukeran® (Chlorambucil), Leukine® (Sargramostim),Leustatin® (Cladribine), Lonsurf® (Trifluridine and Tipiracil), Lupron®(Leuprolide), Lupron® Depot (Leuprolide), Lupron® DepotPED (Leuprolide),Lynparza® (Olaparib), Lysodren® (Mitotane), Marqibo® Kit (VincristineLipid Complex Injection), Matulane® (Procarbazine), Megace® (Megestrol),Mekinist® (Trametinib), Mesnex® (Mesna), Mesnex® (Mesna Injection),Metastron® (Strontium-89 Chloride), Mexate® (Methotrexate Injection),Mustargen® (Mechlorethamine), Mutamycin® (Mitomycin), Myleran®(Busulfan), Mylotarg® (Gemtuzumab Ozogamicin), Navelbine® (Vinorelbine),Neosar® Injection (Cyclophosphamide Injection), Neulasta® (filgrastim),Neulasta® (pegfilgrastim), Neupogen® (filgrastim), Nexavar® (Sorafenib),Nilandron® (nilutamide), Nipent® (Pentostatin), Nolvadex® (Tamoxifen),Novantrone® (Mitoxantrone), Odomzo® (Sonidegib), Oncaspar®(Pegaspargase), Oncovin® (Vincristine), Ontak® (Denileukin Diftitox),Onxol® (Paclitaxel Injection), Opdivo® (Nivolumab Injection), Panretin®(Alitretinoin), Paraplatin® (Carboplatin), Perjeta® (PertuzumabInjection), Platinol® (Cisplatin), Platinol® (Cisplatin Injection),Platinol® AQ (Cisplatin), Platinol® AQ (Cisplatin Injection), Pomalyst®(Pomalidomide), Proleukin® (Aldesleukin), Purinethol® (Mercaptopurine),Reclast® (Zoledronic acid), Revlimid® (Lenalidomide), Rheumatrex®(Methotrexate), Rituxan® (Rituximab), Roferon® A alfaa (Interferonalfa-2a), Rubex® (Doxorubicin), Sandostatin® (Octreotide), Sandostatin®LAR Depot (Octreotide), Soltamox® (Tamoxifen), Sprycel® (Dasatinib),Stivarga® (Regorafenib), Supprelin® LA (Histrelin Implant), Sutent®(Sunitinib), Sylatron® (Peginterferon Alfa-2b Injection), Sylvant®(Siltuximab Injection), Synribo® (Omacetaxine Injection), Tabloid®(Thioguanine), Taflinar® (Dabrafenib), Tarceva® (Erlotinib), Targretin®Capsules (Bexarotene), Tasigna® (Decarbazine), Taxol® (PaclitaxelInjection), Taxotere® (Docetaxel), Temodar® (Temozolomide), Temodar®(Temozolomide Injection), Tepadina® (Thiotepa), Thalomid® (Thalidomide),TheraCys® BCG (BCG), Thioplex® (Thiotepa), TICE® BCG (BCG), Toposar®(Etoposide Injection), Torisel® (Temsirolimus), Treanda® (Bendamustinehydrochloride), Trelstar® (Triptorelin Injection), Trexall®(Methotrexate), Trisenox® (Arsenic trioxide), Tykerb® (lapatinib),Unituxin® (Dinutuximab Injection), Valstar® (Valrubicin Intravesical),Vantas® (Histrelin Implant), Vectibix (Panitumumab), Velban®(Vinblastine), Velcade (Bortezomib), Vepesid® (Etoposide), Vepesid®(Etoposide Injection), Vesanoid® (Tretinoin), Vidaza® (Azacitidine),Vincasar® PFS (Vincristine), Vincrex® (Vincristine), Votrient®(Pazopanib), Vumon® (Teniposide), Wellcovorin® IV (LeucovorinInjection), Xalkori® (Crizotinib), Xeloda® (Capecitabine), Xtandi®(Enzalutamide), Yervoy® (Ipilimumab Injection), Yondelis® (TrabectedinInjection), Zaltrap® (Ziv-aflibercept Injection), Zanosar®(Streptozocin), Zelboraf® (Vemurafenib), Zevalin® (IbritumomabTiuxetan), Zoladex® (Goserelin), Zolinza® (Vorinostat), Zometa®(Zoledronic acid), Zortress® (Everolimus), Zydelig® (Idelalisib),Zykadia® (Ceritinib), Zytiga® (Abiraterone), ABVD (combination ofdoxorubicin (Adriamycin®), bleomycin, vinblastine, and dacarbazine(DTIC)), AC (combination of Adriamycin® (doxorubicin) andcyclophosphamide), ACE (combination of Adriamycin® (doxorubicin),cyclophosphamide, and etoposide (Eposin, Etopophos, Vepesid)),Abiraterone (Zytiga®), Abraxane® (Nab-paclitaxel), Abstral® (fentanyl),Actinomycin D, Actiq®, Adriamycin, Afatinib (Giotrif®), Afinitor®(Everolimus), Aflibercept (Zaltrap®), Aldara® imiquimod cream),Aldesleukin (IL-2, Proleukin® or interleukin 2), Alemtuzumab(MabCampath®), Alkeran® (melphalan), Amsacrine (Amsidine®, m-AMSA),Amsidine®, Anastrozole (Arimidex®), Ara C (cytarabine), Aredia®,Arimidex®, Aromasin®, Arsenic trioxide (Trisenox™, ATO), Asparaginase(Crisantaspase, Erwinase®), Axitinib (Inlyta®), Azacitidine (Vidaza®),BEACOPP, BEAM, Bendamustine (Levact®), Bevacizumab (Avastin®),Bexarotene (Targretin®), Bicalutamide (Casodex®), Bleomycin, [Bleomycin,etoposide and platinum (BEP)], Bortezomib (Velcade®), Bosulif®,Bosutinib (Bosulif®), Brentuximab (Adcetris®), Brufen, Buserelin(Suprefact®), Busilvex®, Busulfan (Myleran®, Busilvex®), CAPE-OX(oxaliplatin and capecitabine (XELOX)), CAPOX (oxaliplatin andcapecitabine (XELOX)), CAV (cyclophosphamide, doxorubicin (Adriamycin®),vincristine), CAVE (cyclophosphamide, doxorubicin (Adriamycin®),vincristine, etoposide), CCNU (Lomustine), CHO (combination ofcyclophosphamide, doxorubicin hydrochloride (Adriamycin®), vincristine(Oncovin®), CMF (combination of cyclophosphamide, methotrexate, andfluorouracil (5FU)), CMV (combination of cisplatin, methotrexate, andvinblastine), CT (combination of cyclophosphamide, thalidomide), CV (acombination of cyclophosphamide, vincristine (Oncovin®), Cabazitaxel(Jevtana®), Cabozantinib (Cometriq®), Caelyx®, Calpol®, Campto®,Capecitabine (Xeloda®), Caprelsa®, Carbo® MV (combination ofcarboplatin, methotrexate, and vinblastine), CarboTaxol®, Carboplatin®,Carboplatin® and etoposide, Carboplatin® and paclitaxel, Carmustine(BCNU, Gliadel®), Casodex®, Celebrex®, Celecoxib (Celebrex®), Ceritinib(Zykadia®), Cerubidin®, Cetuximab (Erbitux®), ChlVPP, Chlorambucil(Leukeran®), Cisplatin®, Cisplatin® and Teysuno®, Cisplatin® andcapecitabine (CX), Cisplatin®, etoposide and ifosfamide (PEI),Cisplatin®, fluorouracil (5-FU) and trastuzumab, Cladribine (Leustat,LITAK®), Clasteon®, Clofarabine (Evoltra®), Co-codamol (Kapake®,Solpadol®, Tylex®), Cometriq®, Cosmegen®, Crisantaspase®, Crizotinib(Xalkori®), Cyclophosphamide, Cyprostat®, Cyproterone acetate(Cyprostat®), Cytarabine (Ara C, cytosine arabinoside), Cytarabine intospinal fluid, Cytosine arabinoside, HAP (combination of HA (high doseAra C, also known as cytarabine), and cisplatin), DTIC (dacarbazine),Dabrafenib (Tafinlar®), Dacarbazine (DTIC), Dacogen®, Dactinomycin(actinomycin D, Cosmegen®), Dasatinib (Sprycel®), Daunorubicin, DeGramont, Decapeptyl® SR, Decitabine (Dacogen®), Degarelix (Firmagon®),Denosumab (Prolia®, Xgeva®), Depocyte®, Diamorphine, Disodiumpamidronate, Disprol, Docetaxel (Taxotere®), Docetaxel, cisplatin andfluorouracil (TPF), Doxifos®, Doxil®, Doxorubicin (Adriamycin®),Doxorubicin and ifosfamide (Doxifos®), Drogenil®, Durogesic®, E-CMF(Epi-CMF), EC, ECF, EOF, EOX, EP, ESHAP, Effentora®, Efudix®, Eldisine®,Eloxatin®, Enzalutamide (Xtandi®), Epirubicin (Pharmorubicin®),Epirubicin, carboplatin and capecitabine (ECarboX), Epirubicin,cisplatin and capecitabine (ECX), Eposin®, Erbitux®, Eribulin(Halaven®), Erlotinib (Tarceva®), Erwinase®, Estracyt, Estramustine(Estracyt®), Etopophos®, Etoposide (Eposin, Etopophos®, Vepesid),Etoposide, leucovorin and fluorouracil (ELF), Everolimus (Afinitor®),Evoltra, Exemestane (Aromasin®), FAD, FC, FEC, FEC-T chemotherapy, FMD,FOLFIRINOX, Faslodex®, Femara®, Fentanyl, Firmagon®, Fludara®,Fludarabine (Fludara®), [Fludarabine, cyclophosphamide and rituximab(FCR)], Fluorouracil (5FU), Flutamide, [Folinic acid, fluorouracil andirinotecan (FOLFIRI)], [Folinic acid, fluorouracil and oxaliplatin(FOL.,FOX)], Fulvestrant (Faslodex®), G-CSF, Gefitinib (Iressa®),GemCarbo (gemcitabine and carboplatin), GemTaxol, Gemcitabine (Gemzar®),Gemcitabine and capecitabine (GemCap), Gemcitabine and cisplatin (GC),Gemcitabine and paclitaxel (GemTaxol), Gemzar®, Giotrif®, Gliadel®,Glivec®, Gonapeptyl® Depot, Goserelin (Zoladex®), Goserelin (Zoladex®,Novgos®), Granulocyte colony stimulating factor (G-CSF), Halaven®,Herceptin®, Hycamtin®, Hydrea, Hydroxycarbamide (Hydrea®), Hydroxyurea,I-DEX, ICE, IL-2, IPE, Ibandronic acid, Ibritumomab (Zevalin®),Ibuprofen (Brufen®, Nurofen®), Iclusig, Idarubicin (Zavedos®),Idelalisib (Zydelig®), Ifosfamide (Mitoxana®), Imatinib (Glivec®),Imiquimod cream (Aldara®), Imnovid®, Instanyl®, Interferon (Intron A®),Interleukin, Intron A®, Ipilimumab (Yervoy®), Iressa®, Irinotecan(Campto®), Irinotecan and capecitabine (XELIRI®), Irinotecan de Gramont,Irinotecan modified de Gramont, Javlor™, Jevtana®, Kadcyla®, Kapake®,Keytruda®, Lanvis™, Lapatinib (Tyverb®), Lenalidomide (Revlimid®),Letrozole (Femara®), Leukeran®, Leuprorelin (Prostap®, Lutrate®),Leustat®, Levact®, Liposomal doxorubicin, Litak®, Lomustine (CCNU,Gleostine®), Lynparza®, Lysodren®, MIC, MM, MMVAM, MST Continus, MVAC,MVP, MabCampath®, Mabthera®, Maxtrex®, Medroxyprogesterone acetate(Provera®), Megace®, Megestrol acetate (Megace®), Melphalan (Alkeran®),Melphalan, thalidomide, Mepact®, Mercaptopurine (Xaluprine®),Methotrexate (Maxtrex®), Mifamurtide (Mepact®), Mitomycin C, Mitotane,Mitoxana®, Mitoxantrone (Mitozantrone®), Morphgesic® SR, Morphine,Myleran®, Myocet®, Nab-paclitaxel, Nab-paclitaxel (Abraxane®),Navelbine®, Nelarabine (Atriance®), Nexavar®, Nilotinib (Tasigna®),Nintedanib (Vargatef®), Nipent™ Nivolumab (Opdivo®), Novgos®, Nurofen®,Ofatumumab (Arzerra®), Olaparib (Lynparza®), Oncovin®, Onkotrone®,Opdivo®, Oramorph®, Oxaliplatin (Eloxatin®), Oxaliplatin andcapecitabine (XELOX), PAD, PC (paclitaxel and carboplatin, CarboTaxol®),PCV, PE, PMitCEBO, POMB/ACE, Paclitaxel (Taxol®), Paclitaxel andcarboplatin, Pamidronate, Panadol®, Panitumumab (Vectibix®),Paracetamol, Pazopanib (Votrient®), Pembrolizumab (Keytruda®),Pemetrexed (Alimta®), Pemetrexed and carboplatin, Pemetrexed andcisplatin, Pentostatin (Nipent®), Perjeta®, Pertuzumab (Perjeta®),Pixantrone (Pixuvri®), Pixuvri®, Pomalidomide (Imnovid®), Ponatinib(Iclusig®), Potactasol, Procarbazine, Proleukin®, Prolia®, Prostap®,Provera®, Purinethol, R-CHOP, R-CVP, R-DHAP, R-ESHAP, R-GCVP, RICE,Raloxifene, Raltitrexed (Tomudex®), Regorafenib (Stivarga®), Revlimid,Rituximab (Mabthera®), Sevredol®, Sodium clodronate (Bonefos®,Clasteon®), Solpadol®, Sorafenib (Nexavar®), Stanford V, Streptozocin(Zanosar®), Sunitinib (Sutent®), Sutent®, TAC, TIP, Tafinlar®,Tamoxifen, Tarceva®, Targretin®, Tasigna®, Taxol®, Taxotere®, Taxotere®and cyclophosphamide (TC), Temodal®, Temozolomide (Temodal®),Temsirolimus (Torisel®), Tepadina®, Teysuno®, Thalidomide, Thiotepa(Tepadina®), Tioguanine (thioguanine, 6-TG, 6-tioguanine), Tomudex®,Topotecan (Hycamtin®, Potactasol®), Torisel®, Trabectedin (Yondelis®),Trastuzumab (Herceptin®), Trastuzumab emtansine (Kadcyla®), Treosulfan®,Tretinoin (Vesanoid®, ATRA), Triptorelin (Decapeptyl® SR, Gonapeptyl®Depot), Trisenox®, Tylex®, Tyverb®, VIDE, Vandetanib (Caprelsa®),Vargatef®, VeIP, Vectibix®, Velbe®, Velcade®, Vemurafenib (Zelboraf®),Vepesid®, Vesanoid®, Vidaza®, Vinblastine (Velbe®), Vincristine,[Vincristine, actinomycin D (dactinomycin) and cyclophosphamide (VAC)],[Vincristine, actinomycin and ifosfamide (VAI)], [Vincristine,doxorubicin (VA)], Vindesine (Eldisine®), Vinflunine (Javlor®),Vinorelbine (Navelbine®), Vismodegib (Erivedge®), Votrient®, XELOX®,Xalkori®, Xeloda®, Xgeva®, Xtandi®, Yervoy®, Yondelis, Z-DEX, Zaltrap®,Zanosar®, Zavedos®, Zelboraf®, Zevalin®, Zoladex® (breast cancer),Zoladex® (prostate cancer), Zoledronic acid (Zometa®), Zometa®,Zomorph®, Zydelig®, Zytiga®, Abemaciclib, Abiraterone Acetate,Abitrexate (Methotrexate®), Abraxane® (Paclitaxel Albumin-stabilizedNanoparticle Formulation), ABVD, ABVE, ABVE-PC, AC, Acalabrutinib, AC-T,Adcetris® (Brentuximab Vedotin), ADE, Ado-Trastuzumab Emtansine,Adriamycin (Doxorubicin Hydrochloride), Afatinib Dimaleate, Afinitor(Everolimus®), Akynzeo® (Netupitant and Palonosetron Hydrochloride),Aldara® (Imiquimod), Aldesleukin, Alecensa® (Alectinib), Alectinib,Alemtuzumab, Alimta® (Pemetrexed Disodium), Aliqopa® (CopanlisibHydrochloride), Alkeran® for Injection (Melphalan Hydrochloride),Alkeran® Tablets (Melphalan), Aloxi® (Palonosetron Hydrochloride),Alunbrig® (Brigatinib), Ambochlorin (Chlorambucil), Amifostine,Aminolevulinic Acid, Anastrozole, Aprepitant, Aredia® (PamidronateDisodium), Arimidex® (Anastrozole), Aromasin® (Exemestane), Arranon®(Nelarabine), Arsenic Trioxide, Arzerra® (Ofatumumab), AsparaginaseErwinia chrysanthemi, Atezolizumab, Avastin® (Bevacizumab), Avelumab,Axicabtagene Ciloleucel, Axitinib, Azacitidine, Bavencio® (Avelumab),BEACOPP, Becenum (Carmustine™), Beleodaq (Belinostat™), Belinostat™,Bendamustine Hydrochloride, BEP, Besponsa™ (Inotuzumab Ozogamicin),Bevacizumab, Bexarotene, Bicalutamide, BiCNU (Carmustine™), Bleomycin,Blinatumomab, Blincyto® (Blinatumomab), Bortezomib, Bosulif®(Bosutinib), Bosutinib, Brentuximab Vedotin, Brigatinib, BuMel,Busulfan, Busulfex (Busulfan), Cabazitaxel, Cabometyx(Cabozantinib-S-Malate), Cabozantinib-S-Malate, CAF, Calquence(Acalabrutinib), Campath (Alemtuzumab), Camptosar (IrinotecanHydrochloride), Capecitabine, CAPOX, Carac (Fluorouracil—Topical),Carboplatin, CARBOPLATIN-TAXOL, Carfilzomib, Carmubris (Carmustine),Carmustine, Carmustine Implant, Casodex (Bicalutamide), CEM, Ceritinib,Cerubidine (Daunorubicin Hydrochloride), Cervarix (Recombinant HPVBivalent Vaccine), Cetuximab, CEV, Chlorambucil, Cisplatin, Cladribine,Clafen (Cyclophosphamide), Clofarabine, Clofarex (Clofarabine), Clolar(Clofarabine), CMF, Cobimetinib, Cometriq (Cabozantinib-S-Malate),Copanlisib Hydrochloride, COPDAC, COPP, COPP-ABV, Cosmegen(Dactinomycin), Cotellic (Cobimetinib), Crizotinib, CVP,Cyclophosphamide, Cyfos (Ifosfamide), Cyramza (Ramucirumab), Cytarabine,Cytarabine Liposome, Cytosar-U (Cytarabine), Cytoxan (Cyclophosphamide),Dabrafenib, Dacarbazine, Dacogen (Decitabine), Dactinomycin,Daratumumab, Darzalex (Daratumumab), Dasatinib, DaunorubicinHydrochloride, Daunorubicin Hydrochloride and Cytarabine Liposome,Decitabine, Defibrotide Sodium, Defitelio (Defibrotide Sodium),Degarelix, Denileukin Diftitox, Denosumab, DepoCyt (CytarabineLiposome), Dexrazoxane Hydrochloride, Dinutuximab, Docetaxel, Doxil(Doxorubicin Hydrochloride Liposome), Doxorubicin Hydrochloride,Doxorubicin Hydrochloride Liposome, Dox-SL (Doxorubicin HydrochlorideLiposome), DTIC-Dome (Dacarbazine), Durvalumab, Efudex(Fluorouracil—Topical), Elitek (Rasburicase), Ellence (EpirubicinHydrochloride), Elotuzumab, Eloxatin® (Oxaliplatin), EltrombopagOlamine, Emend® (Aprepitant), Empliciti® (Elotuzumab), EnasidenibMesylate, Enzalutamide, Epirubicin Hydrochloride, EPOCH, Erbitux®(Cetuximab), Eribulin Mesylate, Erivedge® (Vismodegib), ErlotinibHydrochloride, Erwinaze (Asparaginase Erwinia chrysanthemi), Ethyol®(Amifostine), Etopophos® (Etoposide Phosphate), Etoposide, EtoposidePhosphate, Evacet™ (Doxorubicin Hydrochloride Liposome), Everolimus,Evista® (Raloxifene Hydrochloride), Evomela® (Melphalan Hydrochloride),Exemestane, 5-FU (Fluorouracil Injection), 5-FU (Fluorouracil—Topical),Fareston® (Toremifene), Farydak® (Panobinostat), Faslodex®(Fulvestrant), FEC, Femara® (Letrozole), Filgrastim, Fludara®(Fludarabine Phosphate), Fludarabine Phosphate, Fluoroplex®(Fluorouracil—Topical), Fluorouracil Injection, Fluorouracil—Topical,Flutamide, Folex® (Methotrexate), Folex® PFS (Methotrexate), FOLFIRI®,FOLFIRI-BEVACIZUMAB, FOLFIRI-CETUXIMAB, FOLFIRINOX, FOLFOX, Folotyn®(Pralatrexate), FU-LV, Fulvestrant, Gardasil® (Recombinant HPVQuadrivalent Vaccine), Gardasil® 9 (Recombinant HPV Nonavalent Vaccine),Gazyva® (Obinutuzumab), Gefitinib, Gemcitabine Hydrochloride,GEMCITABINE-CISPLATIN, GEMCITABINE-OXALIPLATIN, Gemtuzumab Ozogamicin,Gemzar® (Gemcitabine Hydrochloride), Gilotrif® (Afatinib Dimaleate),Gleevec® (Imatinib Mesylate), Gliadel® (Carmustine Implant), Gliadel®wafer (Carmustine Implant), Glucarpidase, Goserelin Acetate, Halaven®(Eribulin Mesylate), Hemangeol® (Propranolol Hydrochloride), Herceptin®(Trastuzumab), [HPV Bivalent Vaccine, Recombinant], [HPV NonavalentVaccine, Recombinant], [HPV Quadrivalent Vaccine, Recombinant],Hycamtin® (Topotecan Hydrochloride), Hydrea® (Hydroxyurea), Hydroxyurea,Hyper-CVAD, Ibrance® (Palbociclib), Ibritumomab Tiuxetan, Ibrutinib,ICE, Iclusig® (Ponatinib Hydrochloride), Idamycin® (IdarubicinHydrochloride), Idarubicin Hydrochloride, Idelalisib, Idhifa®(Enasidenib Mesylate), Ifex® (Ifosfamide), Ifosfamide, Ifosfamidum®(Ifosfamide), IL-2 (Aldesleukin), Imatinib Mesylate, Imbruvica®(Ibrutinib), Imfinzi® (Durvalumab), Imiquimod, Imlygic® (TalimogeneLaherparepvec), Inlyta® (Axitinib), Inotuzumab Ozogamicin, [InterferonAlfa-2b, Recombinant], Interleukin-2 (Aldesleukin), Intron A(Recombinant Interferon Alfa-2b), Ipilimumab, Iressa® (Gefitinib),Irinotecan Hydrochloride, Irinotecan Hydrochloride Liposome, Istodax®(Romidepsin), Ixabepilone, Ixazomib Citrate, Ixempra® (Ixabepilone),Jakafi® (Ruxolitinib Phosphate), JEB, Jevtana® (Cabazitaxel), Kadcyla®(Ado-Trastuzumab Emtansine), Keoxifene® (Raloxifene Hydrochloride),Kepivance® (Palifermin), Keytruda® (Pembrolizumab), Kisqali®(Ribociclib), Kymriah® (Tisagenlecleucel), Kyprolis® (Carfilzomib),Lanreotide Acetate, Lapatinib Ditosylate, Lartruvo® (Olaratumab),Lenalidomide, Lenvatinib Mesylate, Lenvima® (Lenvatinib Mesylate),Letrozole, Leucovorin Calcium, Leukeran® (Chlorambucil), LeuprolideAcetate, Leustatin® (Cladribine), Levulan® (Aminolevulinic Acid),Linfolizin® (Chlorambucil), LipoDox® (Doxorubicin HydrochlorideLiposome), Lomustine, Lonsurf® (Trifluridine and TipiracilHydrochloride), Lupron® (Leuprolide Acetate), Lupron® Depot (LeuprolideAcetate), Lupron® Depot-Ped (Leuprolide Acetate), Lynparza® (Olaparib),Marqibo® (Vincristine Sulfate Liposome), Matulane® (ProcarbazineHydrochloride), Mechlorethamine Hydrochloride, Megestrol Acetate,Mekinist® (Trametinib), Melphalan, Melphalan Hydrochloride,Mercaptopurine, Mesna, Mesnex® (Mesna), Methazolastone® (Temozolomide),Methotrexate, Methotrexate LPF (Methotrexate), Methylnaltrexone Bromide,Mexate (Methotrexate), Mexate-AQ (Methotrexate), Midostaurin, MitomycinC, Mitoxantrone Hydrochloride, Mitozytrex® (Mitomycin C), MOPP, Mozobil®(Plerixafor), Mustargen® (Mechlorethamine Hydrochloride), Mutamycin®(Mitomycin C), Myleran® (Busulfan), Mylosar® (Azacitidine), Mylotarg®(Gemtuzumab Ozogamicin), Nanoparticle Paclitaxel (PaclitaxelAlbumin-stabilized Nanoparticle Formulation), Navelbine® (VinorelbineTartrate), Necitumumab, Nelarabine, Neosar® (Cyclophosphamide),Neratinib Maleate, Nerlynx® (Neratinib Maleate), Netupitant andPalonosetron Hydrochloride, Neulasta® (Pegfilgrastim), Neupogen®(Filgrastim), Nexavar® (Sorafenib Tosylate), Nilandron® (Nilutamide),Nilotinib, Nilutamide, Ninlaro® (Ixazomib Citrate), Niraparib TosylateMonohydrate, Nivolumab, Nolvadex® (Tamoxifen Citrate), Nplate®(Romiplostim), Obinutuzumab, Odomzo® (Sonidegib), OEPA, Ofatumumab, OFF,Olaparib, Olaratumab, Omacetaxine Mepesuccinate, Oncaspar®(Pegaspargase), Ondansetron Hydrochloride, Onivyde® (IrinotecanHydrochloride Liposome), Ontak® (Denileukin Diftitox), Opdivo®(Nivolumab), OPPA, Osimertinib, Oxaliplatin, Paclitaxel, PaclitaxelAlbumin-stabilized Nanoparticle Formulation, PAD, Palbociclib,Palifermin, Palonosetron Hydrochloride, Palonosetron Hydrochloride andNetupitant, Pamidronate Disodium, Panitumumab, Panobinostat, Paraplat®(Carboplatin), Paraplatin® (Carboplatin), Pazopanib Hydrochloride, PCV,PEB, Pegaspargase, Pegfilgrastim, Peginterferon Alfa-2b, PEG-Intron(Peginterferon Alfa-2b), Pembrolizumab, Pemetrexed Disodium, Perjeta®(Pertuzumab), Pertuzumab, Platinol® (Cisplatin), Platinol®-AQ(Cisplatin), Plerixafor, Pomalidomide, Pomalyst® (Pomalidomide),Ponatinib Hydrochloride, Portrazza® (Necitumumab), Pralatrexate,Procarbazine Hydrochloride, Proleukin® (Aldesleukin), Prolia®(Denosumab), Promacta® (Eltrombopag Olamine), Propranolol Hydrochloride,Provenge® (Sipuleucel-T), Purinethol® (Mercaptopurine), Purixan®(Mercaptopurine), Radium 223 Dichloride, Raloxifene Hydrochloride,Ramucirumab, Rasburicase, R-CHOP, R-CVP, Recombinant HumanPapillomavirus (HPV) Bivalent Vaccine, Recombinant Human Papillomavirus(HPV) Nonavalent Vaccine, Recombinant Human Papillomavirus (HPV)Quadrivalent Vaccine, Recombinant Interferon Alfa-2b, Regorafenib,Relistor® (Methylnaltrexone Bromide), R-EPOCH, Revlimid® (Lenalidomide),Rheumatrex® (Methotrexate), Ribociclib, R-ICE, Rituxan® (Rituximab),Rituxan® Hycela (Rituximab and Hyaluronidase Human), Rituximab,Rituximab and Hyaluronidase Human, Rolapitant Hydrochloride, Romidepsin,Romiplostim, Rubidomycin (Daunorubicin Hydrochloride), Rubraca®(Rucaparib Camsylate), Rucaparib Camsylate, Ruxolitinib Phosphate,Rydapt® (Midostaurin), Sclerosol® Intrapleural Aerosol (Talc),Siltuximab, Sipuleucel-T, Somatuline® Depot (Lanreotide Acetate),Sonidegib, Sorafenib Tosylate, Sprycel® (Dasatinib), STANFORD V, SterileTalc Powder (Talc), Steritalc® (Talc), Stivarga® (Regorafenib),Sunitinib Malate, Sutent® (Sunitinib Malate), Sylatron® (PeginterferonAlfa-2b), Sylvant® (Siltuximab), Synribo® (Omacetaxine Mepesuccinate),Tabloid® (Thioguanine), TAC, Tafinlar (Dabrafenib), Tagrisso®(Osimertinib), Talc, Talimogene Laherparepvec, Tamoxifen Citrate,Tarabine® PFS (Cytarabine), Tarceva® (Erlotinib Hydrochloride),Targretin® (Bexarotene), Tasigna® (Nilotinib), Taxol® (Paclitaxel),Taxotere® (Docetaxel), Tecentriq® (Atezolizumab), Temodar®(Temozolomide), Temozolomide, Temsirolimus, Thalidomide, Thalomid®(Thalidomide), Thioguanine, Thiotepa, Tisagenlecleucel, Tolak®(Fluorouracil—Topical), Topotecan Hydrochloride, Toremifene, Torisel®(Temsirolimus), Totect® (Dexrazoxane Hydrochloride), TPF, Trabectedin,Trametinib, Trastuzumab, Treanda® (Bendamustine Hydrochloride),Trifluridine and Tipiracil Hydrochloride, Trisenox® (Arsenic Trioxide),Tykerb® (Lapatinib Ditosylate), Unituxin® (Dinutuximab), UridineTriacetate, VAC, Valrubicin, Valstar® (Valrubicin), Vandetanib, VAMP,Varubi® (Rolapitant Hydrochloride), Vectibix® (Panitumumab), VeTP,Velban® (Vinblastine Sulfate), Velcade® (Bortezomib), Velsar®(Vinblastine Sulfate), Vemurafenib, Venclexta® (Venetoclax), Venetoclax,Verzenio® (Abemaciclib), Viadur® (Leuprolide Acetate), Vidaza®(Azacitidine), Vinblastine Sulfate, Vincasar® PFS (Vincristine Sulfate),Vincristine Sulfate, Vincristine Sulfate Liposome, Vinorelbine Tartrate,VIP, Vismodegib, Vistogard® (Uridine Triacetate), Voraxaze®(Glucarpidase), Vorinostat, Votrient® (Pazopanib Hydrochloride), Vyxeos®(Daunorubicin Hydrochloride and Cytarabine Liposome), Wellcovorin®(Leucovorin Calcium), Xalkori® (Crizotinib), Xeloda® (Capecitabine),XELIRI, XELOX, Xgeva® (Denosumab), Xofigo® (Radium 223 Dichloride),Xtandi® (Enzalutamide), Yervoy® (Ipilimumab), Yescarta® (AxicabtageneCiloleucel), Yondelis® (Trabectedin), Zaltrap® (Ziv-Aflibercept),Zarxio® (Filgrastim), Zejula® (Niraparib Tosylate Monohydrate),Zelboraf® (Vemurafenib), Zevalin® (Ibritumomab Tiuxetan), Zinecard®(Dexrazoxane Hydrochloride), Ziv-Aflibercept, Zofran® (OndansetronHydrochloride), Zoladex® (Goserelin Acetate), Zoledronic Acid, Zolinza®(Vorinostat), Zometa® (Zoledronic Acid), Zydelig® (Idelalisib), Zykadia®(Ceritinib), Zytiga® (Abiraterone Acetate), Monoclonalantibodies—approved by FDA abciximab (Reopro), adalimumab (Humira®,Amjevita®), ado-trastuzumab emtansine (Kadcyla®), alefacept (Amevive®),alemtuzumab (Campath®, Lemtrada®), Alirocumab (Praluent®), Atezolizumab(Tecentriq®), Avelumab (Bavencio®), basiliximab (Simulect®), belimumab(Benlysta®), blinatumomab (Blincyto®), Brentuximab vedotin (Adcentris),Bevacizumab (Avastin®), bezlotoxumab (Zinplava®), Brodalumab (Siliz®),Canakinumab (Ilaris®), Capromab pendetide (Prostascint®), Catumaxomab(Removab®), canakinumab (Ilaris®), certolizumab pegol (Cimzia®),cetuximab (Erbitux®), cixutumumab, daclizumab (Zenapax®, Zinbryta®),daratumumab (Darzalex®), denosumab (Prolia®, Xgeva®), dinutuximab(Unituxin®), dupilumab (Dupixent®), durvalumab (Imfinzi®), eculizumab(Soliris®), elotuzumab (Repatha®), efalizumab (Raptiva®), emicizumab(Hemlibra®), ertumaxomab (Rexomun®), etaracizumab (Abegrin®), evolocumab(Repatha®), gemtuzumab ozogamicin (Mylotarg®), girentuximab (Rencarex®),golimumab (Simponi®, Simponi® Aria), Guselkumab, ibritumomab tiuxetan(Zevalin®), idarucizumab (Praxbind®), imciromab (Myoscint®),infliximab/inflectra (Remicade®), ipilimumab (Yervoy®), ixekizumab(Taltz®), mepolizumab (Bosatria®), natalizumab (Tysabri®), necitumumab(Portrazza®), nivolumab (Opdivo®), obiltoxaximab, obinutuzumab(Gazyva®), ocrelizumab (Ocrevus®), ofatumumab (Arzerra®), olaratumab(Lartruvo®), omalizumab (Xolair®), palivizumab (Synagis®, Abbosynagis®),panitumumab (Vectibix®), pembrolizumab (Keytruda®), pertuzumab(Omnitarg®), ramucirumab (Cyramza®), ranibizumab (Lucentis®),raxibacumab, reslizumab, rituximab (Rituxan®, MabThera®), rovelizumab(LeukArrest®), Ruplizumab (Antova®), secukinumab (Cosentyx®), siltuximab(Sylvant®), tocilizumab (Actemra®, RoActemra®), tositumomab (Bexxar®),trastuzumab (Herceptin®), trastuzumab emtansine (Kadcyla®), ustekinumab(Stelara®), vedolizumab (Entyvio®), Pertuzumab, alpha interferon,Galiximab, humanized SMART Anti-IL-12 Antibody, Dinutuximab, Oregovomab,Epratuzumab, anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox,CAT-5001 (formerly SS1P), Labetuzumab, anti-alpha5Beta1-integrinantibody, NVS antibody, Efmoroctocog alfa, 3f8 (CAS #339169-93-6), SH9MAb, Abagovomab, Abituzumab, Abrilumab, Actoxumab, Adecatumumab,Aducanumab, Afasevikumab, Afelimomab, Afutuzumab, Alacizumab pegol,Altumomab pentetate, Amatuximab, Anatumomab mafenatox, Anetumabravtansine, Anifrolumab, Anrukinzumab, Apolizumab, Arcitumomab,Ascrinvacumab, Aselizumab, Atinumab, Atorolimumab, Bapineuzumab,Bavituximab, Bectumomab, Begelomab, Benralizumab, Bertilimumab,Besilesomab (Scintimun®), Biciromab (FibriScint®), Bimagrumab,Bimekizumab, Bivatuzumab Mertansine, Bleselumab, Blontuvemab(Blontress®), Blosozumab, Bococizumab, Brazikumab, Briakinumab,Brolucizumab, Brontictuzumab, Burosumab, Cabiralizumab, Cantuzumabmertansine, Cantuzumab ravtansine, Caplacizumab, Carlumab, Carotuximab,eBR96-doxorubicinimmunoconjugate, Cedelizumab, Cergutuzumab amunaleukin,Citatuzumab bogatox, Clazakizumab, Clenoliximab, Clivatuzumab tetraxetan(hPAM4-cide), Codrituzumab, Coltuximab ravtansine, Conatumumab,Concizumab, Crenezumab, Crotedumab, CR6261, Dacetuzumab, Dalotuzumab,Dapriolizumab pegol, Dectrekumab, Demcizumab, Denintuzumab mafodotin,Depatuxizumab mafodotin, Derlotuximab biotin, detumomab, diridavumab,domagrozumab, dorlimomab aritox, drozitumab, duligotumab, dusigitumab,ecromeximab, edobacomab, edrecolomlab, efalizumab, efungumab, eldelumab,elgentumab, elsiliomab, emactuzumab, emibetuzumab, enavatuzumab,enfortumabvedotin, enlimomabpegol, enoblituzumab, enokizumab,enoticumab, ensituximab, epitumomabcituxetan, epratuzumab, erenumab,erlizumab, etrolizumab, evinacumab, exbivirumab, fanolesomab(NeutroSpec), faraliimomab, farletuzumab, Fasinumab, FBTA05(Lymnphomun), Felvizumab, Fezakinumab, Fibatuzumab, Ficlatuzumab,Figitumumab, Firivumab, Flanvotumab, Fletikumab, Fontolizumab (HuZAF),Foralumab, Foravirumab, Fresolimumab, Fulranumab, Futuximab,Galcanezumab, Galiximab, Gianitumab, Giantenerumab, Giavilimomab,Gevokizumab, Glembatum umab vedotin, Gomiliximab, ibalizumab, icrucumab,igovomab (Indimacis-125™), IMAB362, Imalumab, Imgatuzumab, INTLAcumab,indatuximab ravtansine, indusatumab vedotin, inebilizumab, intetumumab,inolimomab, inotuzumab ozogamicin, iratumumab, isatuximab, itolizumab,keliximab, labetuzumab (CLA-cide), lampalizumab, lanadelumab,landogrozumab, laprituximab emtansine, lebrikizumab, lemalesomab,lendalizumab, lenzilumab, lerdelimumab, lexatumumab, libivirumab,lifastuzumab vedotin, liglizumab, lilotomab satetraxetan, lintuzumab,lirilumab, lodelcizumab, lorvotuzumab mertansine, lucatumumab, lulizumabpegol, lurniliximab, lumretuzumab, MABpI (Xilonix™), mapatumumab,margetuximab, maslimomab, mapatumumab, margetuximab, maslimomab,mavrilimumab, matuzumab, metelimumab, milatuzumab, minretumomab,mirvetuximab soravtansine, Mitumomab, mogamulizumab, monalizumab,morolimumab, motavizumab (Numax™), Moxetunomab pasudotox, Muromonab-CD3(orthoclone OKT3), nacolomab tafenatox, namilumab, naptumomabestafenatox, naratuximab erntansine, narnatumab, navicixizumab,navivumab, nebacumab, nemolizumab, nerelimomab, nesvacumab, nimotuzumab(Theracim®, Theraloc®), nofetumomab merpentan (Verlunia®),ocaratuzuniab, odulimomab, olokizumab, onartuzumab, ontuxizumab,opicinumab, oportuzumab monatox, oregovomab, orticumab, otelixizumab,otlertuzumab, oxelumab, ozanezumab, ozoralizumab, pagibaximab,pamrevlumab, pankomab, panobacumab, parsatuzumab, pascolizumab,pasotuxizumab, pateclizumab, patritumab, pemtumomab, perakizumab,pexelizumab, pidilizumab, pinatuzumab vedotin, pintumomab, placulumab,plozalizumab, pogalizumab, polatuzumab vedotin, ponezumab, prezalizumab,priliximab, pritoxaximab, pritumumab, PRO 140, Quilizumab, Racotumomab,radretumab, rafivirumab, ralpancizumab, refanezumab, regavirumab,rilotumumab, rinucumab, resankizumab, rivabazumab pego, robatumumab,roledumab, romosozumab, rontalizumab, rovalpituzumab tesirine,sacituzumab govitecan, samalizumab, sapelizumab, sarilumab, satumomabpendetide, seribanturmab, setoxaximab, sevirumab, sibrotluzumab,SGN-CD19A, SGN-CD33A, sifalinumab, sittuzumab, siplizumab, sirukumab,softuzumab vedotin, solanezumab, solitomab, sonepcizumab, sontuzumab,stamulumab, sulesomab (LeukoScan®), suvizumab, tabalumab, tacatuzumabtetraxetan, tadocizumab, talizumab, tamtuvetiab, tanezumab, taplitumomabpaptox, tarextumab, tefibazumab (Aurexis), telimomab aritox,tenatumomab, teneliximab, teplizumab, teprotumumab, tesidolumab,tetulomab, tezepelumab, TGN1412, ticilimumab, tildrakizumab,tigatuzumab, timolumab, tisotumab vedotin, TNX-650, Toralizumab,tosatoxumab, tovetumab, tralokinumab, TRBS07 (Ektomab), tregalizumab,tremelimumab, trevogrumab, tucotuzumab celmoleukin, tuvirumab,ublituximab, ulocuplumab, urelumab, urtoxazumab, utomilumab,vadastuximab talirine, vandortuzumab vedotin, vantictumab, vanucizuiab,vapaliximab, varlilumab, vatelizuiab, veltuzumab, vepalimomab,vesencumab, visilizumab (Nuvion), vobarilizumab, volociximab,vorsetuzumab mafodotin, votumumab (HumaSPECT®), xentuzurmab, zalutumumab(HuMax-EGFr), Zanolimumab (HuMax-CD4), Zatuximab, Ziralimumab, zolimomabaritox, Digoxin Immune Fab (Ovine), Recombinant Cholera Toxin B Subunit,Denileukin diftitox, Ranimustine (approved in Japan), Resimmune(A-dmDT390-bisFv(UCHT1), MOC31PE, BL22, Anti-CD22 RecombinantImmunotoxin BL22 (CAT-3888), and immunotoxin CMD-193.

NTLA, particularly NTLA Dexamethasone dosed between about 3 mg/kg andabout 26 mg/kg single acute dose about 12 to about 72 hours prior tocell immunotherapy administration or total dose of about 3 mg/kg toabout 26 mg/kg given between about 12 to about 72 hours of cell therapyadministration increases plasma IL-2 and IL-15 levels.

NTLA, particularly NTLA Dexamethasone dosed between about 3 mg/kg andabout 26 mg/kg single acute dose or total dose of about 3 mg/kg to about26 mg/kg given over about a 72 hour period, either alone, or incombination with reduced intensity cytotoxic preconditioning can beuseful for the treatment of autoimmune diseases. For the treatment ofautoimmune disease an ACT could be targeted to the immune cells drivingthe disease in an effort to eradicate the autoimmune recognizing cells.Additionally, for autoimmune diseases the ACT could be a Treg targetedby a CAR or TCR or expressed antibody for an antigen expressedspecifically or selectively by the region or organ of the body where theautoimmune attack goes on. The Tregs could non-exclusively relate toCD4+ Tregs, CD4+CD45RA+ Tregs, CD4+CD25+CD45RA+Tregs, FoxP3+ Tregs,CD4+CD25+FoxP3+CD152+ Tregs, CD4+CD25+CD152+ Tregs, CD8+Tregs, CD8+CD28−Tregs, CD4+CD25int/high, CD127low, CTLA4+, GITR+, FoxP3+, CD127low,CD4+CD25−⁻ induced Tregs, or Type I T regs.

“Natural” regulatory T cells originally recognised by their constitutiveexpression of CD4 and CD25 can be further defined by expression of thetranscription factor foxP3 and surface CD152. Their generation and someof their suppressive activity is dependent on TGF-beta, and it has beenshown that they can induce IDO in appropriate DCs by CD152 mediatedligation of CD80/86. Anergic CD4+ T cells generated by antigenstimulation in the absence of costimulation seem to be characterised byan intrinsic raising of their threshold for antigen stimulation, thatmay be maintained by expression of E3 ubiquitin ligases such as GRAIL,c-cbl and Itch. Anergic cells can act as regulatory T cells by competingat the sites of antigen presentation and adsorbing out stimulatorycytokines such as IL-2. Tr1 cells represent an induced subset of CD4helper T cells that are dependent on IL-10 for their differentiation andfor some of their regulatory properties. They do not express foxP3 butmay express markers associated with Th2 cells and repressor of GATA(ROG). Like natural Tregs, they express high levels of surface CD152 andcan induce IDO and trypophan catabolism in appropriate DCs. CD8+CD28−suppressor T (Ts) cells were first characterised in human, but haverecently also been demonstrated in rodents. Like Tr cells, they areinduced in the presence of IL-10, and IL-10 may be involved in thedownregulation of dendritic cell costimulation and the upregulation ofILT-3 and ILT-4 (in human DC) that seem to play an important role inpresenting antigen to tolerise further cohorts of T cells.

Regulatory T cells (Tregs) play an important role in maintaining immunehomeostasis1. Tregs suppress the function of other T cells to limit theimmune response. Alterations in the number and function of Tregs hasbeen implicated in several autoimmune diseases including multiplesclerosis, active rheumatoid arthritis, and type 1 diabetes. High levelsof Tregs have been found in many malignant disorders including lung,pancreas, and breast cancers. Tregs may also prevent antitumor immuneresponses, leading to increased mortality.

Two major classes of Tregs have been identified to date: CD4 and CD8Tregs. CD4 Tregs consist of two types, “natural” Tregs (nTregs) thatconstitutively express CD25 and FoxP3, and so-called adaptive orinducible Tregs (iTregs).

Natural Tregs originate from the thymus as CD4⁺ cells expressing highlevels of CD25 together with the transcription factor (and lineagemarker) FoxP3. nTregs represent approximately 5-10% of the total CD4⁺ Tcell population, and can first be seen at the single-positive stage of Tlymphocyte development.²They are positively selected thymocytes with arelatively high avidity for self-antigens. (Fehérvari Z, Sakaguchi S.Development and function of CD25⁺CD4⁺ regulatory T cells. Curr OpinImmunol. 2004; 16:203-208.)

The signal to develop into Treg cells is thought to come frominteractions between the T cell receptor and the complex of MHC II withself peptide expressed on the thymic stroma. nTregs are essentiallycytokine independent.

Adaptive or inducible Tregs originate from the thymus as single-positiveCD4 cells. They differentiate into CD25 and FoxP3 expressing Tregs(iTregs) following adequate antigenic stimulation in the presence ofcognate antigen and specialized immunoregulatory cytokines such asTGF-β, IL-10, and IL-4. (Chatenoud L, Bach J F. Adaptive humanregulatory T cells: myth or reality? J Clin Invest. 2006;116:2325-2327.)

FoxP3 is currently the most accepted marker for Tregs, although therehave been reports of small populations of FoxP3⁻ Tregs. The discovery oftranscription factor FoxP3 as a marker for Tregs has allowed scientiststo better define Treg populations leading to the discovery of additionalTreg markers including CD127.

NTLA, particularly NTLA Dexamethasone dosed between about 3 mg/kg andabout 26 mg/kg single acute dose or total dose of about 3 mg/kg to about26 mg/kg given over about a 72 hour period, either alone or incombination with reduced intensity cytotoxic preconditioning can beuseful for the treatment of residual HIV disease, and for the treatmentof germinal center lymphomas such as Burkitt's Lymphoma.

Follicular helper CD4 T cells, T_(FH), residing in B-cell follicleswithin secondary lymphoid tissues, are readily infected by AIDS virusesand are a major source of persistent virus despite relative control ofviral replication. This persistence is due at least in part to arelative exclusion of effective antiviral CD8 T cells from B-cellfollicles. AIDS virus persistence in individuals under effective drugtherapy or those who spontaneously control viremia remains an obstacleto definitive treatment. Infected follicular helper CD4 T cells, T_(FH),present inside B-cell follicles represent a major source of thisresidual virus. While effective CD8 T-cell responses can control viralreplication in conjunction with drug therapy or in rare casesspontaneously, most antiviral CD8 T cells do not enter B-cell follicles,and those that do fail to robustly control viral replication in theT_(FH) population. Thus, these sites are a sanctuary and a reservoir forreplicating AIDS viruses. Here, we demonstrate that engineeringunselected CD8 T cells to express CXCR5, a chemokine receptor on T_(FH)associated with B-cell follicle localization, redirects them into B-cellfollicles. Lymphodepletion and reduction of germinal centers andmarginal zones in the spleen would force residual HIV infected cellsinto the blood stream where they could be killed by existing therapies.Latently infected resting CD4 T cells have been detected in theperipheral blood, gastrointestinal (GI) tract, and lymph nodes ofHIV-1-infected individuals and are also likely to exist in other organscontaining lymphoid tissue.

Highly active antiretroviral therapy (HAART) enables long-termsuppression of plasma HIV-1 loads in infected persons, but low-levelvirus persists and rebounds following cessation of therapy. DuringHAART, this virus resides in latently infected cells, such as restingCD4 T cells, and in other cell types that may support residual virusreplication. Therapeutic eradication will require elimination of virusfrom all reservoirs.

Burkitt's Lymphoma is a germinal center lymphoma originating and growingwithin the secondary lymphatic system, always associated with a c-Mycactivating chromosomal translocation. It is one of the fastest growingcancers and can double in size every 14-18 hours.

Clinical observations on the ability of a Bruton's Tyrosine Kinaseinhibitor ibrutinib for treatment of chronic lymphocytic leukemia hasdemonstrated that redistribution of CLL cells from the lymphatics intothe bloodstream is a contributing mechanism of action to its benefit inCLL. Circulating CLL cells are not proliferative, with proliferation ofthe clone limited to the lymphatic microenvironment. Therefore,redistribution into the blood stream reduces cancerous proliferation.Similarly, redistribution of ALL from the bone marrow to thebloodstream, has also been reported to enhance sensitivity to standardchemotherapy (Chang B Y, Blood 2013 122: 2412-24;).

Among B-cell malignancies, CLL is the most responsive to ibrutinib, andthus unfortunately ibrutinib is not likely to significantly benefitpeople afflicted with Burkitt's Lymphoma and other germinal centerlymphomas. However, the same result to redistribute B-cell cancers intothe circulation where they are more susceptible to chemotherapy and lessproliferative can be achieved for germinal center lymphomas such asBurkitt's lymphoma with the use of agents that ablate secondarylymphatic germinal centers.

Glucocorticoids have been reported to have multiple and contradictoryactions on lymphocytes, depending on the dose, the duration of dosingand the species investigated. Glucocorticoids have been investigated aslymphocytosis inducing agents, agents which increase circulatinglymphocyte numbers, since 1943 (for review see Burger J A, Blood 2013121: 1501-9), typically with the use of prednisone between 0.5 and 1mg/kg, which would be an equivalent 0.1-0.2 mg/kg dexamethasone dose.High dose methylprednisone (HDMP) used for refractory CLL, in contrast,does not appear to induce lymphocytosis at the methylprednisoneequivalent to the 0.5-1.0 mg/kg dose at which prednisone did.Lymphotoxic high-dose steroids are typically considered to beapproximately 100 mg daily of prednisone equivalent, which would be adexamethasone equivalent dose of 16 mg which is approximately 0.23 to0.32 mg/kg, and which we have demonstrated is not an NTLA dose. NTLADexamethasone does not reduce germinal centers in mice until an HED of 3mg/kg is administered. Prednisone does not significantly impact spleenweights or germinal centers until used at doses in mice over 2.5 mg/kgpo daily for 13 weeks (Yan S X¹, Acta Pharmacol Sin. 2015 November;36(11):1367-76.), a human dose which would have unacceptablemineralocorticoid activity as a dose of 30 mgs per day (˜0.48-0.72mg/kg) is considered a high dose in human lupus patients.

For Burkitt's lymphoma (BL) treatment with standard chemotherapyregimens such as COPADM, prednisone is included in various cyclestypically at 60 mg/m², which converts to 1.62 mg/kg prednisone and anequivalent 0.3 mg/kg dexamethasone dose, which is not an NTLA dose.Dexamethasone is also used clinically for the treatment of B-cellcancers, typically in an oral four-five day 40 mg daily regimen or 6mg/m² for 5 days. In some indications such as ALL, dexamethasone isgiven daily for weeks and can be associated with osteonecrosis,particularly in adolescent boys. Risk of osteonecrosis can besubstantially eliminated by alternate week dosing of dexamethasone andmay be particularly present in ALL because of the asparaginase regimenthat is part of the treatment for ALL (Chang B Y, Blood 2013 122:2412-24).

BL is an aggressive B-cell lymphoma found in germinal centers of thespleen and secondary lymphatics. Epstein-Barr virus (EBV) infection isfound in nearly all African BL patients, and chronic malaria is believedto reduce resistance to EBV, allowing it to take hold. The diseasecharacteristically involves the jaw or other facial bone, distal ileum,cecum, ovaries, kidney, or breast. Additionally, BL strikeimmunocompromised people, such as those with HIV.

BL is classified into three main clinical variants: Endemic, Sporadic,and the Immunodeficiency-associated variants, with the Endemic variant(also called the “African variant”) most commonly occurring in childrenliving in malaria endemic regions of the world.

The use of NTLA which ablate germinal centers to selectively drive BLand other germinal center cancer cells from the germinal centers intocirculation where they can be more easily killed with chemotherapy orother agents could dramatically, safely and cost-effectively advance BLtreatment outcomes.

NTLA, particularly NTLA Dexamethasone dosed between about 3 mg/kg andabout 26 mg/kg single acute dose or total dose of about 3 mg/kg to about26 mg/kg given over about a 72 hour period, either alone, or incombination with reduced intensity cytotoxic preconditioning, preferablyone day of cytotoxic preconditioning dosing, can be useful forpreconditioning prior to allogeneic or autologous bone marrow transplantor hematopoietic stem cell transplant (HSCT).

DEX (dexamethasone base) doses in the examples in the presentapplication are given as human equivalent doses (HED). AVM0703 (alsoreferred to as AugmenStem™ or PlenaStem™) in the examples given is Dex(dexamethasone base) as dexamethasone sodium phosphate in a proprietarybuffer.

The specific NTLA drugs listed below at standard or novel high doseswould prevent cellular immunotherapies from binding to and accumulatingin the secondary lymphatics and cause peripheral blood lymphodepletionbecause they are also immunosuppressants:

Tacrolimus is a calcineurin inhibitor delivered as an NTLA as aninjection or oral dose of about 0.48 mg/kg/day to about 10 mgs/kg/dayfor about 1 to about 4 weeks. The doses of tacrolimus needed for NTLAare higher than doses typically used for approved indications.Tacrolimus (Prograf™) is approved for adult kidney transplant Incombination with azathioprine at 0.2 mg/kg/day and in combination withMMF/IL-2 receptor antagonist 0.1 mg/kg/day, for adult liver transplantat 0.1 to 0.15 mg/kg/day, for pediatric liver transplant at 0.15-0.20mg/kg/day, and for adult heart transplant 0.075 mg/kg/day, much lowerdoses than disclosed in this invention for NTLA. Tacrolimus suppressedinterleukin 2. Tacrolimus Sandoz® is approved for: Primaryimmunosuppression in liver, kidney, pancreas, lung or heart allograftrecipients LIVER: Administration should start approximately 6 hoursafter the completion of surgery. When commencing oral therapy, aninitial dose of 0.10-0.20 mg/kg/day should be administered in twodivided doses. KIDNEY, PANCREAS or KIDNEY-PANCREAS: Administrationshould start approximately 6 hours after the completion of surgery. Whencommencing oral therapy, an initial dose of 0.15-0.30 mg/kg/day shouldbe administered in two divided doses. HEART: Administration should startno sooner than 6 hours after the completion of surgery. When commencingoral therapy, an initial dose of 0.075 mg/kg/day should be administeredin two divided doses. LUNG: Administration should start no sooner than 6hours after the completion of surgery. When commencing oral therapy, aninitial dose of 0.10-0.30 mg/kg/day should be administered in twodivided doses. Tacrolimus is associated with an increased risk ofmalignancy, particularly lymphomas. Tacrolimus inhibits neutrophilfunction (Suzuki 1993). Ulrich et al (Toxicol Lett 149, 123-31, 2004)showed that 1 to 4 weeks of daily FK506 (tacrolimus) dosing at about0.48 mg/kg/day to about 10 mgs/kg/day is required to reduce germinalcenters.

Cyclosporine is a cyclic polypeptide immunosuppressant agent orallyadministered as an NTLA at about 20 to about 100 mgs/kg/daily for about7 to about 28 days. The daily dose is divided by two and administeredevery 12 hours. The doses of cyclosporine needed for NTLA are in generalhigher than doses typically used for approved indications. Sandimmune®(cyclosporine) is approved for an initial single oral dose of 15 mg/kgand should be given 4 to 12 hours prior to transplantation. Although adaily single dose of 14 to 18 mg/kg was used in most clinical trials,few centers continue to use the highest dose, most favoring the lowerend of the scale. There is a trend towards use of even lower initialdoses for renal transplantation in the ranges of 10 to 14 mg/kg/day. Theinitial single daily dose is continued postoperatively for 1 to 2 weeksand then tapered by 5% per week to a maintenance dose of 5 to 10mg/kg/day. Some centers have successfully tapered the maintenance doseto as low as 3 mg/kg/day in selected renal transplant patients withoutan apparent rise in rejection rate. Cyclosporine inhibits neutrophilfunction (Suzuki 1993). If cyclosporine trough blood concentrations areused, the target range is the same for Neoral® as for Sandimmune®.Cyclosporine causes significant nephrotoxicity. Moriyama et al (J VetMed Sci 74, 1487-1491 2012) showed that 7 to 28 days of 20 to 100 mg/kgcyclosporine dosing is required to reduce germinal centers.

Anakinra (trade name KINERET®, BIOVITRUM, Stockholm, Sweden) is arecombinant, non-glycosylated version of human IL-1RA (RA for receptorantagonist) delivered as injection concentrate containing about 100 mgeach single dose, weekly preferably for 3-4 weeks prior to theadministration of the cellular immunotherapies.

Infliximab (trade name REMICADE®, CENTOCOR ORTHO BIOTECH, Horsham, Pa.)is a monoclonal antibody against tumour necrosis factor alpha (TNFα).administered by intravenous infusion at a dose of from about 3 mg/kg upto about 10 mg/kg, weekly preferably for 3-4 weeks prior to theadministration of the cellular immunotherapies.

Golimumab (CNTO 148) is a human monoclonal antibody and is marketedunder the brand name SIMPONI®, CENTOCOR ORTHO BIOTECH, Horsham, Pa.Golimumab targets TNF-alpha. administered by intravenous infusion, aonce monthly subcutaneous injection preferably for 3-6 months prior toadministration of the cellular immunotherapy.

Adalimumab (HUMIRA®, ABBOTT LABORATORIES, North Chicago, Ill.) is a TNFinhibitor, adalimumab binds to TNFα, preventing it from activating TNFreceptors; adalimumab was constructed from a fully human monoclonalantibody, marketed in both preloaded 0.8 mL syringes and also inpreloaded pen devices each containing 40 mg of adalimumab. Todown-regulate the germinal centers prior to stem cell administration ofat least 40 mg of adalimumab should be administered weekly preferablyfor 3-4 weeks prior to the administration of the cellularimmunotherapies.

Certolizumab pegol (trade name CIMZIA®, UCB Inc., Atlanta, Ga.) is amonoclonal antibody directed against tumor necrosis factor alpha. Moreprecisely, it is a PEGylated Fab′ fragment of a humanized TNF inhibitormonoclonal antibody. It is administered as two subcutaneous injectionsof 200 mg, injections, weekly preferably for 3-4 weeks prior to theadministration of the cellular immunotherapies.

Eculizumab (trade name SOLIRIS®, ALEXION PHARMACEUTICALS, Cheshire,Conn.) is a monoclonal antibody directed against the complement proteinC5. This antibody blocks the clea CIMZIA® age of C5 and halts theprocess of complement-mediated cell destruction. Soliris® isadministered as an IV infusion administered in 600-mg doses or 900-mgdoses, weekly preferably for 3-4 weeks prior to the administration ofthe cellular immunotherapies.

Mepolizumab (proposed trade name BOSATRIA, GLAXO SMITH KLINE, King ofPrussia, Pa.) is a humanized monoclonal antibody that recognizesinterleukin-5 (IL-5) administered in subcutaneously (SC) at 750 mg everyfour weeks, preferably for 1 to 6 months prior to the administration ofthe cellular immunotherapies.

Omalizumab (trade name XOLAIR®, GENENTECH/NOVARTIS) is a humanizedantibody Omalizumab is a recombinant DNA-derived humanized IgG1kmonoclonal antibody that selectively binds to human immunoglobulin E(IgE). XOLAIR® (Omalizumab) 150 to 375 mg is administered SC every 2 to4 weeks, preferably for 4 to 12 weeks prior to the administration of thecellular immunotherapies.

Nerelimomab (BAYX®) is a mouse anti-TNF antibody, and can beadministered at 10 mg/kg sc weekly, preferably for 1 to 3 months priorto the administration of the cellular immunotherapies.

Faralimomab is a mouse anti-TNF antibody, and can be administered at 10mg/kg weekly preferably for 3-4 weeks prior to the administration of thecellular immunotherapies.

Elsilimomab (also known as B-E8) is a mouse monoclonal antibody and animmunosuppressive drug that blocks interleukin 6. According to thepresent invention, it can be administered at a dose of 10 mg/kg weeklypreferably for 3-4 weeks prior to the administration of the cellularimmunotherapies.

Lebrikizumab (GENENTECH, South San Francisco, Calif.) is a humanizedmonoclonal antibody that is designed to bind specifically to IL-13 andcan be administered at 10 mg/kg weekly preferably for 3-4 weeks prior tothe administration of the cellular immunotherapies.

Ustekinumab (experimental name CNTO 1275, proprietary commercial nameSTELARA®, CENTOCOR) is a human monoclonal antibody. It is directedagainst interleukin 12 and interleukin 23, naturally occurring proteinsthat regulate the immune system and immune-mediated inflammatorydisorders. 2 injections, one-month apart, of either 90 or 45 milligrams,preferably given for 2 months before administration of the cellularimmunotherapy.

Efalizumab (trade name RAPTIVA®, GENENTECH, MERCK SERONO) is arecombinant humanized monoclonal antibody. Efalizumab binds to the CD11asubunit of lymphocyte function-associated antigen 1. According to thepresent invention, it can be administered once weekly by subcutaneousinjection at a dose of 20 mg/kg, weekly preferably for 3-4 weeks priorto the administration of the cellular immunotherapies.

Erlizumab, also known as rhuMAb, is a recombinant humanized monoclonalantibody developed by GENENTECH under a partnership with ROCHE.According to the present invention, it can be administered once weeklyby subcutaneous injection at a dose of 20 mg/kg, weekly preferably for3-4 weeks prior to the administration of the cellular immunotherapies.The drug works by blocking a growth factor in blood vessels.Specifically, erlizumab targets CD18 and an LFA-1 integrin.

Pascolizumab is an anti-IL-4 humanized monoclonal antibody. According tothe present invention, it can be administered once weekly bysubcutaneous injection at a dose of 20 mg/kg, weekly preferably for 3-4weeks prior to the administration of the cellular immunotherapies.

Lumiliximab (BIOGEN IDEC) is a monoclonal antibody that targets CD23.According to the present invention, it can be dosed at 50 mg/m2, to 450mg/m2, to 500 mg/m2 weekly preferably for 3-4 weeks prior to theadministration of the cellular immunotherapies. The drug is a chimericantibody from Macaca irus and Homo sapiens.

Teneliximab is a chimeric monoclonal antibody binding to the immunestimulatory protein CD40. According to the present invention, it can beadministered once weekly by subcutaneous injection at a dose of 20mg/kg, weekly preferably for 3-4 weeks prior to the administration ofthe cellular immunotherapies.

Toralizumab (IDEC 131, IDEC Pharmaceuticals Corporation) is a humanizedmonoclonal antibody to IL-6. According to the present invention, it canbe administered once weekly by subcutaneous injection at a dose of 20mg/kg, weekly preferably for 3-4 weeks prior to the administration ofthe cellular immunotherapies.

Aselizumab is an anti-CD62L administered by I.V. infusion at dosesranging from 0.5-mg/kg, 1.0-mg/kg, and 2.0-mg/kg weekly preferably for3-4 weeks prior to the administration of the cellular immunotherapies.

Gavilimomab is a mouse monoclonal antibody (also known as ABX-CBL,developed by ABGENIX. It binds to the antigen CD147. According to thepresent invention it can be administered by I.V. infusion at a dose of20 mg/kg weekly preferably for 3-4 weeks prior to the administration ofthe cellular immunotherapies.

BG9588, a humanized anti-CD40L administered at 20 mg/kg weeklypreferably for 3-4 weeks prior to the administration of the cellularimmunotherapies. Administration of antibodies to CD154, also called CD40ligand or CD40L, is a protein that is primarily expressed on activated Tcells and is a member of the TNF superfamily of molecules. It binds toCD40 on antigen-presenting cells (APC), which leads to many effectsdepending on the target cell type. In general, CD40L plays the role of acostimulatory molecule and induces activation in APC in association withT cell receptor stimulation by MHC molecules on the APC. In total CD40Lhas three binding partners: CD40, α5β1 integrin and αIIbβ3.

(Hu5c8) 5c8, a monoclonal antibody that binds CD154 (CD40 ligand), thusblocking the interaction between CD40 and CD154, administered at 20mg/kg weekly preferably for 3-4 weeks prior to the administration of thecellular immunotherapies.

Belimumab (registered name BENLYSTA® previously known as LymphoStat-B),is a fully human monoclonal antibody that specifically recognizes andinhibits the biological activity of B-Lymphocyte stimulator (BLyS), alsoknown as B cell activation factor of the TNF family (BAFF) HUMAN GENOMESCIENCES. According to the present invention, it can be administered ata dose of 10 mg/kg weekly preferably for 3-4 weeks prior to theadministration of the cellular immunotherapies.

Bertilimumab is a human monoclonal antibody that binds to eotaxin-1.(iCo Therapeutics Inc. Vancouver, B.C.) According to the presentinvention, it is administered at a dose of 10 mg/kg weekly preferablyfor 3-4 weeks prior to the administration of the cellularimmunotherapies.

Natalizumab is a humanized monoclonal antibody against the cellularadhesion molecule α4-integrin. It is co-marketed by Biogen Idec and Elanas TYSABRI®, and was previously named Antegren. Natalizumab isadministered at a dose of 300 mg infused intravenously overapproximately one hour every 4 weeks preferably for 1 to 6 months priorto the administration of the cellular immunotherapies.

Tocilizumab or atlizumab, developed by Hoffmann-La Roche and Chugaiunder the trade names ACTEMRA® and ROACTEMRA®, is a humanized monoclonalantibody against the interleukin-6 receptor (IL-6R). According to thepresent invention, it can be administered by intravenous infusions at 8mg/kg, weekly preferably for 3-4 weeks prior to the administration ofthe cellular immunotherapies.

Odulimomab is a mouse monoclonal antibody directed against the alphachain of the protein lymphocyte function-associated antigen 1 which isinvolved in immune reactions. It is administered 10 mg/kg active drugweekly preferably for 3-4 weeks prior to the administration of thecellular immunotherapies.

Atorolimumab is mouse monoclonal antibody directed against the Rhesusfactor. According to the present invention, it can be administered at adose of 10 mg/kg weekly preferably for 3-4 weeks prior to theadministration of the cellular immunotherapies.

Fontolizumab (trade name HuZAF®, PDL Biopharma) is anti-interferon gammahumanized monoclonal antibody. According to the present invention, itcan be administered at an I.V. dose of fontolizumab given as 4.0 mg/kgor 10.0 mg/kg weekly preferably for 3-4 weeks prior to theadministration of the cellular immunotherapies.

Gantenerumab is anti-beta amyloid monoclonal antibody (ROCHE). It isadministered at a dose of 10 mg/kg of active drug weekly preferably for3-4 weeks prior to the administration of the cellular immunotherapies.

Gomiliximab is a monoclonal antibody that targets the low affinity IgEreceptor (FcεRII or CD23). According to the present invention, it can beadministered at a dose of 10 mg/kg weekly preferably for 3-4 weeks priorto the administration of the cellular immunotherapies.

Morolimumab is a human monoclonal antibody against the human Rhesusfactor. According to the present invention, it can be administered at adose of 10 mg/kg weekly preferably for 3-4 weeks prior to theadministration of the cellular immunotherapies.

Pexelizumab is a single chain variable fragment of a monoclonal antibodytargeted against component 5 of the complement system. According to thepresent invention, it can be administered at a dose of 10 mg/kg weeklypreferably for 3-4 weeks prior to the administration of the cellularimmunotherapies.

Reslizumab (CEPTION THERAPEUTICS Inc) is an anti-IL-5 humanizedmonoclonal antibody. According to the present invention, It canadministered as an infusion at a preferred dose of reslizumab 3.0 mg/kgweekly preferably for 3-4 weeks prior to the administration of thecellular immunotherapies.

Rovelizumab, also known as LEUKARREST® and Hu23F2G, is an anti-CD11/CD18 humanized monoclonal antibody that suppresses white blood cells.According to the present invention, it can be administered at a dose of10 mg/kg weekly preferably for 3-4 weeks prior to the administration ofthe cellular immunotherapies.

Talizumab (TNX-901) is a humanized monoclonal antibody being developedby TANOX in Houston, Tex. It was designed to target immunoglobulin E (orIgE) and IgE-expressing B lymphocytes specifically, without binding toIgE already bound by the IgE receptors on mast cells and basophils.According to the present invention, it can be administered at a dose of10 mg/kg weekly preferably for 3-4 weeks prior to the administration ofthe cellular immunotherapies.

Omalizumab is an anti-IgE monoclonal antibody, developed by TANOX,NOVARTIS, and GENENTECH. According to the present invention, it can beadministered at a dose of 10 mg/kg preferably 3-4 weeks days prior tothe administration of the cellular immunotherapies.

Vapaliximab is an anti-VAP-1 chimeric monoclonal antibody. According tothe present invention, it can be administered at a dose of 10 mg/kgpreferably 3-4 weeks days prior to the administration of the cellularimmunotherapies.

Vepalimomab is an anti-VAP1 (vascular adhesion protein 1) mousemonoclonal antibody According to the present invention, it can beadministered at a dose of 10 mg/kg preferably 3-4 weeks days prior tothe administration of the cellular immunotherapies.

Etanercept (trade name ENBREL®, AMGEN, Thousand Oaks, Calif.) is a drugthat treats autoimmune diseases by interfering with the tumor necrosisfactor (TNF, a part of the immune system) by acting as a TNF inhibitor.Etanercept can be administered subcutaneously (s.c.) at a dose 25 mg or50 mg one to three times weekly for preferably 3-4 weeks prior to theadministration of the cellular immunotherapies.

Pegsunercept is a pegylated soluble tumor necrosis factor receptor.According to the present invention, it can be administered at apreferable dose of 9 mg/kg s.c., preferably 3-4 weeks prior to theadministration of the cellular immunotherapies.

Aflibercept is protein comprised of segments of the extracellulardomains of human vascular endothelial growth factor receptors 1 (VEGFR1)and 2 (VEGFR2) fused to the constant region (Fc) of human IgG1 withpotential antiangiogenic activity and is being co-developed bySANOFI-AVENTIS and REGENERON Pharmaceuticals. Aflibercept (VEGF Trap),an antiangiogenic agent, is a fusion protein specifically designed tobind all forms of Vascular Endothelial Growth Factor-A (called VEGF-A).In addition, aflibercept binds Placental Growth Factor (PLGF), which hasalso been implicated in tumor angiogenesis. Aflibercept can beadministered by injection or IV infusion at preferable doses of 2milligrams per kilogram (mg/kg) or 4 mg/kg, preferably 3-4 weeks priorto the administration of the cellular immunotherapies.

Alefacept (trade name AMEVIVE®, ASTELLAS Pharma US, Inc. Deerfield, Ill.60015) is a fusion protein: it combines part of an antibody with aprotein that blocks the growth of some types of T cells. Alefacept is animmunosuppressive dimeric fusion protein that consists of theextracellular CD2-binding portion of the human leukocyte functionantigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portionof human IgG1. The preferred dosage is either 7.5 mg IV or 15 mg IMweekly preferably 3-4 weeks prior to the administration of the cellularimmunotherapies.

Rilonacept also known as IL-1 Trap (marketed under the trade nameARCALYST®), is a dimeric fusion protein consisting of the extracellulardomain of human interleukin-1 receptor and the FC domain of human IgG1that binds and neutralizes IL-1h. Treatment should be initiated with aloading dose of 320 mg delivered as two, 2 mL, subcutaneous injectionsof 160 mg each given on the same day at two different sites, weeklypreferably 3-4 weeks prior to the administration of the cellularimmunotherapies. Pediatric patients aged 12 to 17 years: Treatmentshould be initiated with a loading dose of 4.4 mg/kg, up to a maximum of320 mg, delivered as one or two subcutaneous injections with a maximumsingle-injection volume of 2 mL, preferably 3-4 days prior toadministration of the cellular immunotherapies. Produced by REGENERON.

Dacetuzumab (also known as SGN-40 or huS2C6, SEATTLE GENETICS, Inc.) isan anti-CD40 humanized monoclonal antibody. The CD40 antigen is highlyexpressed on most B-lineage hematologic malignancies including multiplemyeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. CD40 isalso found on many types of solid tumors, including bladder, renal andovarian cancer and on cells that play a role in immunologic disorders.It is administered at a preferred dose of 10 mg/kg of active drug weeklypreferably 3-4 weeks prior to the administration of the cellularimmunotherapies.

HCD122 is a fully human antagonist anti-CD40 monoclonal antibody. CD40is a cell-surface receptor that plays a pivotal role in immuneresponses, as well as cell growth and survival signaling, through itsactivation by CD40 ligand (CD40L). It is commonly overexpressed andactivated in B-cell malignancies. According to the present invention, itcan be administered at a dose of 10 mg/kg of active drug weeklypreferably 3-4 weeks prior to the administration of the cellularimmunotherapies. This is being developed by XOMA/NOVARTIS ONCOLOGY.

Adenosine deaminases deficiency will also lead to reduced activegerminal center formation and cause lymphodepletion as will agents whichtrigger the accumulation of deoxyATP (J Immunol 171: 5562-5570, 2003).Similarly, agents which enhance the expression of or activate CCR7 willlead to diminished active germinal center formation and causelymphodepletion.

Of all of the immune suppressant immunomodulators disclosed, an agentthat contains dexamethasone that can be given at a dose between about3.0 to about 12.0 mg dexamethasone base/kg body weight about 12 to about72 hours before cellular immunotherapy administration, most preferredgiven at a dose between about 6.0 to 12.0 mg/kg, is the most preferredmethod to lymphodeplete and prevent cellular immunotherapies binding tothe secondary lymphatics so that they remain in the circulation wherethey can find and participate in killing cancer, tumor or autoimmunecausing cells or infection because of dexamethasone's long biologicalhalf-life, short pharmacokinetic half-life and limited to no toxicity.

Definitions

Definitions used to describe the embodiments of the invention:

The antibody-dependent cell-mediated cytotoxicity (ADCC), also referredto as antibody-dependent cellular cytotoxicity, is a mechanism ofcell-mediated immune defense whereby an effector cell of the immunesystem actively lyses a target cell, whose membrane-surface antigenshave been bound by specific antibodies. A type of immune reaction inwhich a target cell or microbe is coated with antibodies and killed bycertain types of white blood cells. The white blood cells bind to theantibodies and release substances that kill the target cells ormicrobes. Also called antibody-dependent cell-mediated cytotoxicity andantibody-dependent cellular cytotoxicity. Antibody-dependentcell-mediated cytotoxicity (ADCC) is the killing of an antibody-coatedtarget cell by a cytotoxic effector cell through a nonphagocyticprocess, characterised by the release of the content of cytotoxicgranules or by the expression of cell death-inducing molecules. ADCC istriggered through interaction of target-bound antibodies (belonging toIgG or IgA or IgE classes) with certain Fc receptors (FcRs),glycoproteins present on the effector cell surface that bind the Fcregion of immunoglobulins (Ig). Effector cells that mediate ADCC includenatural killer (NK) cells, monocytes, macrophages, neutrophils,eosinophils and dendritic cells. ADCC is a rapid effector mechanismwhose efficacy is dependent on a number of parameters (density andstability of the antigen on the surface of the target cell; antibodyaffinity and FcR-binding affinity), ADCC involving human IgG1, the mostused IgG subclass for therapeutic antibodies, is highly dependent on theglycosylation profile of its Fc portion and on the polymorphism of Feyreceptors.

Complement-Mediated Cytotoxicity (CMC): CMC is the mechanism by whichantibody-coated target cells recruit and activate components of thecomplement cascade, leading to the formation of a Membrane AttackComplex (MAC) on the cell surface and subsequent cell lysis.

Biologic mechanism of lymphodepletion means induction of programmed celldeath via apoptosis or necroptosis or pyroptosis or autophagy oroncosis. Various stimuli can engage a non-apoptotic form of cell deathcalled necroptosis, which occurs when caspases required for apoptosisare inhibited. Pyroptosis is a caspase-dependent form of programmed celldeath that differs in many respects from apoptosis. Unlike apoptosis, itdepends on the activation of caspase-1 or caspase-11 (caspase-5 inhumans). Autophagy is a lysosome-dependent process.

Apoptosis: A form of cell death in which a programmed sequence of eventsleads to the elimination of cells without releasing harmful substancesinto the surrounding area. Apoptosis plays a crucial role in developingand maintaining the health of the body by eliminating old cells,unnecessary cells, and unhealthy cells.

The term “and/or” where used herein is to be taken as specificdisclosure of each of the two specified features or components with orwithout the other. Thus, the term “and/or” as used in a phrase such as“A and/or B” herein is intended to include “A and B,” “A or B,” “A”(alone), and “B” (alone). Likewise, the term “and/or” as used in aphrase such as “A, B, and/or C” is intended to encompass each of thefollowing aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; Aand C; A and B; Band C; A (alone); B (alone); and C (alone).

The term “about’ when referring to a measurable value such as an amountor a temporal duration and the like refers to variations of +/−20% or+/−10%.

Administering” refers to the physical introduction of an agent to asubject, using any of the various methods and delivery systems known tothose skilled in the art. Exemplary routes of administration for theformulations disclosed herein include intravenous, intramuscular,subcutaneous, intraperitoneal, spinal or other parenteral routes ofadministration, for example by injection or infusion. The phrase“parenteral administration” as used herein means modes of administrationother than enteral and topical administration, usually by injection, andincludes, without limitation, intravenous, intramuscular, intraarterial,intrathecal, intralymphatic, intralesional, intracapsular, intraorbital,intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous,subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal,epidural and intrasternal injection and infusion, as well as in vivoelectroporation. In some embodiments, the formulation is administeredvia a non-parenteral route, e.g., orally. Other non-parenteral routesinclude a topical, epidermal or mucosal route of administration, forexample, intranasally, vaginally, rectally, sublingually or topically.

A pharmacologic dose is a dose far in excess of normal levels in thebody.

An “anti-tumor effect” as used herein, refers to a biological effectthat can present as a decrease in tumor volume, a decrease in the numberof tumor cells, a decrease in tumor cell proliferation, a decrease inthe number of metastases, an increase in overall or progression-freesurvival, an increase in life expectancy, or amelioration of variousphysiological symptoms associated with the tumor. An anti-tumor effectcan also refer to the prevention of the occurrence of a tumor, e.g., avaccine.

A therapeutic agent is an agent that enhances the efficacy of cellularimmunotherapies compared to the cellular immunotherapies without saidtherapeutic agent.

The term “autologous” refers to any material derived from the sameindividual to which it is later to be re-introduced, whether theindividual is a human or other animal.

The term “allogeneic” refers to any material derived from one individualwhich is then introduced to another individual of the same species,whether the individual is a human or other animal.

The term dexamethasone (also referred to as Dex) non-exclusively relatesto any formulation whether a liquid solution, liquid suspension, oralsolution, tablet form, tablet form dissolved in a liquid containing theactive ingredient of dexamethasone, injectable form, gel formulation,patch formulation or any formulation containing the active ingredientdexamethasone.

The term glucocorticoid-receptor modulating agents non-exclusivelyrelates to glucocorticoid receptor agonists or glucocorticoid receptormodulators including but not limited to: compound A [CpdA;(2-((4-acetophenyl)-2-chloro-N-methyl)ethylammonium-chloride)] andN-(4-methyl-1-oxo-1H-2,3-benzoxazine-6-yl)-4-(2,3-dihydrobenzofuran-7-yl)-2-hydroxy-2-(trifluoromethyl)-4-methylpentanamide(ZK216348), AL-438, Mapracorat, LGD-5552, RU-24858, Fosdagrocorat,PF-802, Compound 10, MK5932, C108297, LGD5552, and ORG 214007-0.

Immunotoxins are proteins that contain a toxin along with an antibody orgrowth factor that binds specifically to target cells. Immunotoxins arecreated by chemically conjugating an antibody to a whole protein toxin,devoid of its natural binding domain. Immunologic proteins that aresmaller than monoclonal antibodies (MoAbs), like growth factors andcytokines, have also been chemically conjugated and genetically fused toprotein toxins. Toxins used in immunotoxin constructs are derived frombacteria, fungi, and plants, and most function by inhibiting proteinsynthesis. Bacterial toxins commonly used in immunotoxins includeDiphtheria toxin (DT) and the toxin from Pseudomonas exotoxin (PE).Plant toxins utilized in immunotoxins include the A chain of ricin(RTA), and the ribosome inactivating proteins (RIPs) gelonin, pokeweedantiviral protein, and dodecandron. Because it is an enzyme, one toxinmolecule can work on many substrate molecules, having a devastatingeffect on the cell. Toxins such as diphtheria toxin (DT) and Pseudomonasexotoxin (PE) prevent protein synthesis by an effect on elongationfactor 2 (EF-2).

The term systemic injection as used herein non-exclusively relates to aroute of administration that rapidly, within seconds or a few hours,leads to circulating levels of cellular immunotherapies, andnon-exclusively relates to intravenous, intraperitoneally, subcutaneous,via nasal submucosa, lingual, via bronchoscopy, intravenous,intra-arterial, intra-muscular, intro-ocular, intra-striatal,subcutaneous, intradermal, by dermal patch, by skin patch, by patch,into the cerebrospinal fluid, into the portal vein, into the brain, intothe lymphatic system, intra-pleural, retro-orbital, intra-dermal, intothe spleen, intra-lymphatic, among others.

The term ‘site of injection’ as used herein non-exclusively relates tointra-tumor, or intra-organ such as the kidney or liver or pancreas orheart or lung or brain or spleen or eye, intra-muscular, intro-ocular,intra-striatal, intradermal, by dermal patch, by skin patch, by patch,into the cerebrospinal fluid, into the brain, among others.

The term ‘chimeric antigen receptor(s)’ (CAR) as used hereinnon-exclusively relates to constructs that contain an antigen-bindingdomain of an antibody fused to a strong T-cell activator domain. T-cellsmodified with the CAR construct can bind to the antigen and bestimulated to attack the bound cells. Artificial T cell receptors (alsoknown as chimeric T cell receptors, chimeric immunoreceptors, chimericantigen receptors (CARs)) are engineered receptors, which graft anarbitrary specificity onto an immune effector cell. The receptors arecalled chimeric because they are composed of parts from differentsources.

The term lymphodepletion as used herein non-exclusively relates to thereduction of lymphocyte number in the peripheral blood without causingredistribution of lymphocytes to another organ such as the bone marrow,thymus, lymph nodes, lung or spleen or another organ.

The term cytotoxic lymphodepletion as used herein relates to thereduction of lymphocyte number in the peripheral blood by a mechanism ofADCC, CMC or direct lysis or cytotoxic elimination of lymphocyte.

The term ‘cellular immunotherapy’, ‘adoptive cellular immunotherapy’,‘adoptive cellular therapy’ (ACT) or cell immunotherapy or cell therapyas used herein non-exclusively relates to treatments that contain a cellused to help the immune system fight diseases or a cell from the immunelineage which directly fights diseases such as cancer, autoimmunediseases and infections with certain viruses. The cellular immunotherapycan be from either an autologous or allogeneic source. In preferredembodiments, the adoptive immunotherapy used in the methods disclosedherein may be an adoptive T cell immunotherapy, i.e. ‘T cell therapy’.

The term preconditioning as used herein relates to the preparation of apatient with a cytotoxic lymphodepleting agent or a NTLA prior to ACT.

The term immunotherapy, also called biologic therapy, as used hereinnon-exclusively relates to a type of treatment for cancer, autoimmunedisease or infection treatment designed to boost the body's naturaldefenses to fight the cancer, autoimmune disease or infection. It usessubstances either made by the body or in a laboratory to improve orrestore immune system function. The term “immunotherapy” refers to thetreatment of a subject afflicted with, or at risk of contracting orsuffering a recurrence of, a disease by a method comprising inducing,enhancing, suppressing or otherwise modifying an immune response.Examples of immunotherapy include, but are not limited to, T celltherapies. T cell therapy can include adoptive T cell therapy,tumor-infiltrating lymphocyte (TIL) immunotherapy, autologous celltherapy, engineered autologous cell therapy (eACT), and allogeneic Tcell transplantation. However, one of skill in the art would recognizethat the conditioning methods disclosed herein would enhance theeffectiveness of any transplanted T cell therapy. Examples of T celltherapies are described in U.S. Patent Publication Nos. 2014/0154228 and2002/0006409, U.S. Pat. No. 5,728,388, and International Publication No.WO 2008/081035.

The term ‘immune modulation’ as used herein non-exclusively relates to,in cancer, autoimmune disease or infection, a range of treatments aimedat harnessing a patient's immune system to achieve tumour, autoimmunecausing cell or viral control, stabilization, and potential eradicationof disease.

The term immunomodulator as used herein non-exclusively relates to achemical agent (such as dexamethasone) or biologic agent (such asHUMIRA® and rituximab) that modifies the immune response or thefunctioning of the immune system (as by the stimulation of antibodyformation or the inhibition of white blood cell activity). Traditionalimmune modulating drugs that are immunosuppressants non-exclusivelyrelates to glucocorticoids, calcineurin inhibitors, antimetabolites, andalkylating agents. Antimetabolites non-exclusively relates topurineanalogues (e.g., azathioprine and mycophenolate mofetil), and folateantagonists (e.g., methotrexate and dapsone).

Immunosuppressants (also termed immunosuppressants) can be chemical orbiologic agents that can suppress or prevent the immune response. Forinstance, antagonists to CD26 and dexamethasone are immunosuppressants.The NTLAs used in this invention may be NTLA immunosuppressants.

The term ‘T cell therapy’ as used herein non-exclusively relates toimmune cells or antibodies that can be produced in the laboratory undertightly controlled conditions and then given to patients to treatdiseases such as cancer, autoimmunity or infection. T cell therapy is atype of immunotherapy, and it involves taking a patient's own immunecells—specifically, white blood cells called T-cells—and reprogrammingthem to attack tumours.

The T cells of the immunotherapy can come from any source known in theart. For example, T cells can be differentiated in vitro from ahematopoietic stem cell population, or T cells can be obtained from asubject. T cells can be obtained from, e.g., peripheral bloodmononuclear cells, bone marrow, lymph node tissue, cord blood, thymustissue, tissue from a site of infection, ascites, pleural effusion,spleen tissue, and tumors. In addition, the T cells can be derived fromone or more T cell lines available in the art. T cells can also beobtained from a unit of blood collected from a subject using any numberof techniques known to the skilled artisan, such as FI COLL™ separationand/or apheresis. Additional methods of isolating T cells for a T celltherapy are disclosed in U.S. Patent Publication No. 2013/0287748, whichis herein incorporated by references in its entirety.

The term “engineered Autologous Cell Therapy,” which can be abbreviatedas “eACT™,” also known as adoptive cell transfer, is a process by whicha patient's own T cells are collected and subsequently geneticallyaltered to recognize and target one or more antigens expressed on thecell surface of one or more specific tumor cells or malignancies. Tcells can be engineered to express, for example, chimeric antigenreceptors (CAR) or T cell receptor (TCR). CAR positive (+) T cells areengineered to express an extracellular single chain variable fragment(scFv) with specificity for a particular tumor antigen linked to anintracellular signaling part comprising a costimulatory domain and anactivating domain. The costimulatory domain can be derived from, e.g.,CD28, and the activating domain can be derived from, e.g., CD3-zeta. Incertain embodiments, the CAR is designed to have two, three, four, ormore costimulatory domains. The CAR scFv can be designed to target, forexample, CD19, which is a transmembrane protein expressed by cells inthe B cell lineage, including all normal B cells and B cell malignances,including but not limited to NHL, CLL, and non-T cell ALL. Example CAR+T cell therapies and constructs are described in U.S. Patent PublicationNos. 2013/0287748, 2014/0227237, 2014/0099309, and 2014/0050708, andthese references are incorporated by reference in their entirety.

The terms “conditioning” and “pre-conditioning” are used interchangeablyherein and indicate preparing a patient or animal in need of a T celltherapy for a suitable condition. Conditioning as used herein includes,but is not limited to, reducing the number of germinal centers andmarginal zones, reducing the number of endogenous lymphocytes, removinga cytokine sink, increasing a serum level of one or more homeostaticcytokines or pro-inflammatory factors, enhancing an effector function ofT cells administered after the conditioning, enhancing antigenpresenting cell activation and/or availability, or any combinationthereof prior to a T cell therapy.

The term ‘adoptive immunotherapy’ or ‘cellular adoptive immunotherapy’as used herein non-exclusively relates to immune cells that arecollected from a patient (autologous or autogenic) or a donor(allogeneic), either related or unrelated, and grown in the laboratory.This increases the number of immune cells that are able to kill cancercells, autoimmune causing cells or fight infections. These immune cellsare given back to the patient to help the immune system fight disease.This is also called cellular adoptive immunotherapy. The immune cell canbe a T cell and/or other cell of the immune system non-exclusivelyrelating to macrophages, monocytes, dendritic cells, neutrophils,granulocytes, phagocytes, mast cells, basophils, thymocytes, or innatelymphoid cells, or any combination thereof.

The term agonist as used herein non-exclusively relates to any entitythat activates a specific receptor or downstream signaling pathwayessential to mediate the receptor's effect(s). Agonists maynon-exclusively relates to but are not limited to antibodies, antibodyfragments, soluble ligands, small molecules, cyclic peptides,cross-linking agents.

The term antagonist as used herein non-exclusively relates to any entitythat interferes with the binding of a receptor's counter structure(s),or with the activation of a specific receptor or downstream signalingpathway essential to mediate the receptor's effect(s). Antagonists maynon-exclusively relates to but are not limited to antibodies, antibodyfragments, soluble ligands, Fc fusion receptors, chimeric receptors,small molecules, cyclic peptides, peptides.

The term inhibitor as used herein non-exclusively relates to any entitythat diminishes the target effect of a specific receptor. Inhibitors maybe small molecules, antisense agents, nucleic acids including siRNA andmicroRNA.

The term “lymphocyte” as used herein includes natural killer (NK) cells,T cells, or B cells. NK cells are a type of cytotoxic (cell toxic)lymphocyte that represent a major component of the inherent immunesystem. NK cells reject tumors and cells infected by viruses. It worksthrough the process of apoptosis or programmed cell death. They weretermed “natural killers” because they do not require activation in orderto kill cells. T-cells play a major role in cell-mediated-immunity (noantibody involvement). Its T-cell receptors (TCR) differentiatethemselves from other lymphocyte types. The thymus, a specialized organof the immune system, is primarily responsible for the T cell'smaturation. There are six types of T-cells, namely: Helper T-cells(e.g., CD4+ cells), Cytotoxic T-cells (also known as TC, cytotoxic Tlymphocyte, CTL, T-killer cell, cytolytic T cell, CDS+ T-cells or killerT cell), Memory T-cells ((i) stem memory T scM cells, like naive cells,are CD45RO−, CCR 7+, CD45RA+, CD62L+(L-selectin), CD27+, CD28+ andIL-7Ra+, but they also express large amounts of CD95, IL-2R˜, CXCR3, andLFA-1, and show numerous functional attributes distinctive of memorycells); (ii) central memory TcM cells express L-selectin and the CCR7,they secrete IL-2, but not IFNy or IL-4, and (iii) effector memory T EMcells, however, do not express L-selectin or CCR 7 but produce effectorcytokines like IFNy and IL-4), Regulatory T-cells (Tregs, suppressor Tcells, or CD4+CD25+ regulatory T cells), Natural Killer T-cells (NKT)and Gamma Delta T-cells. B-cells, on the other hand, play a principalrole in humoral immunity (with antibody involvement). It makesantibodies and antigens and performs the role of antigen presentingcells (APCs) and turns into memory B-cells after activation by antigeninteraction. In manmials, immatureB-cells are formed in the bone marrow,where its name is derived from.

The term “autologous” refers to any material derived from the sameindividual to whom it is later to be re-introduced into the individual.

The term “allogeneic” refers to any material derived from a differentanimal of the same species as the individual to whom the material isintroduced. Two or more individuals are said to be allogeneic to oneanother when the genes at one or more loci are not identical. In someaspects, allogeneic material from individuals of the same species may besufficiently unlike genetically to interact antigenically.

The term “cancer” refers to a disease characterized by the uncontrolledgrowth of aberrant cells. Cancer cells can spread locally or through thebloodstream and lymphatic system to other parts of the body. Examples ofvarious cancers are described herein and include but are not limited to,breast cancer, prostate cancer, ovarian cancer, cervical cancer, skincancer, pancreatic cancer, colorectal cancer, renal cancer, livercancer, brain cancer, lymphoma, leukemia, lung cancer and the like. Theterms “tumor” and “cancer” are used interchangeably herein, e.g., bothterms encompass solid and liquid, e.g., diffuse or circulating, tumors.As used herein, the term “cancer” or “tumor” includes premalignant, aswell as malignant cancers and tumors.

The particular cancer can be responsive to chemo- or radiation therapyor the cancer can be refractory. A refractory cancer refers to a cancerthat is not amendable to surgical intervention and the cancer is eitherinitially unresponsive to chemo- or radiation therapy or the cancerbecomes unresponsive over time.

An “anti-tumor effect” as used herein, refers to a biological effectthat can present as a decrease in tumor volume, a decrease in the numberof tumor cells, a decrease in tumor cell proliferation, a decrease inthe number of metastases, an increase in overall or progression-freesurvival, an increase in life expectancy, or amelioration of variousphysiological symptoms associated with the tumor. An anti-tumor effectcan also refer to the prevention of the occurrence of a tumor, e.g., avaccine.

The term “progression-free survival,” which can be abbreviated as PFS,as used herein refers to the time from the treatment date to the date ofdisease progression per the revised IWG Response Criteria for MalignantLymphoma or death from any cause.

“Disease progression” is assessed by measurement of malignant lesions onradiographs or other methods should not be reported as adverse events.Death due to disease progression in the absence of signs and symptomsshould be reported as the primary tumor type (e.g., DLBCL).

The “duration of response,” which can be abbreviated as DOR, as usedherein refers to the period of time between a subject's first objectiveresponse to the date of confirmed disease progression, per the revisedIWG Response Criteria for Malignant Lymphoma, or death.

The term “overall survival,” which can be abbreviated as OS, is definedas the time from the date of treatment to the date of death.

Doses described herein can be presented as a “weight based dose” or as a“body surface area (BSA) based dose.” A weight based dose is a dose thatis administered to a patient that is calculated based on the weight ofthe patient, e.g., mg/kg. A BSA based dose is a dose that isadministered to a patient that is calculated based on the surface areaof the patient, e.g., mg/m2. The two forms of dose measurement can beconverted for human dosing by multiplying the weight based dose by 37 ordividing the BSA based dose by 37.

The terms “subject” and “patient” are used interchangeably herein, andrefer to a human or animal.

The terms “reducing” and “decreasing” are used interchangeably hereinand indicate any change that is less than the original. “Reducing” and“decreasing” are relative terms, requiring a comparison between pre- andpost-measurements. “Reducing” and “decreasing” include completedepletions.

“Treatment” or “treating” of a subject refers to any type ofintervention or process performed on, or the administration of an activeagent to, the subject with the objective of reversing, alleviating,ameliorating, inhibiting, slowing down or preventing the onset,progression, development, severity or recurrence of a symptom,complication or condition, or biochemical indicia associated with adisease. In one embodiment, “treatment” or “treating” includes a partialremission. In another embodiment, “treatment” or “treating” includes acomplete remission.

The use of the alternative (e.g., “or”) should be understood to meaneither one, both, or any combination thereof of the alternatives. Asused herein, the indefinite articles “a” or “an” should be understood torefer to “one or more” of any recited or enumerated component.

The terms “about” or “comprising essentially of’ refer to a value orcomposition that is within an acceptable error range for the particularvalue or composition as determined by one of ordinary skill in the art,which will depend in part on how the value or composition is measured ordetermined, i.e., the limitations of the measurement system. Forexample, “about” or “comprising essentially of’ can mean within 1 ormore than 1 standard deviation per the practice in the art.Alternatively, “about” or “comprising essentially of’ can mean a rangeof up to 20% (i.e., ±20%). For example, about 3 mg can include anynumber between 2.3 mg and 3.6 mg (for 20%). Furthermore, particularlywith respect to biological systems or processes, the terms can mean upto an order of magnitude or up to 5-fold of a value. When particularvalues or compositions are provided in the application and claims,unless otherwise stated, the meaning of “about” or “comprisingessentially of’ should be assumed to be within an acceptable error rangefor that particular value or composition.

As described herein, any concentration range, percentage range, ratiorange or integer range is to be understood to include the value of anyinteger within the recited range and, when appropriate, fractionsthereof (such as one-tenth and one-hundredth of an integer), unlessotherwise indicated.

Ranges. Various aspects of the invention are presented in range format.The description in range format is for convenience and brevity andshould not be construed as an inflexible limitation on the scope of theinvention. Accordingly, the description of a range should be consideredto have specifically disclosed all the possible subranges as well asindividual numerical values within that range. For example, a range from3 to 12 includes 3.1, 3.2, 3.3 etc.

The spleen contains both a white pulp and a red pulp. The red pulp ofthe spleen holds macrophages that normally filter and remove senescentor defective red blood cells (RBCs) and antibody-coated bacteria or redblood cells from the circulation. The white pulp of the spleen containsthe lymphoid compartments and is crucial for immune surveillance andresponse. it synthesizes antibodies against invading pathogens andreleases platelets and neutrophils in response to bleeding or infection.During development the spleen is believed to have multiple rolesincluding being the first site of hematopoiesis (at six weeks ofgestation). Preclinical and clinical trials have demonstrated thatwithout cytotoxic chemotherapy preconditioning, cellular immunotherapiesare cleared from the circulation, largely within one hour afteradministration, and accumulate in the spleen. The cytotoxic chemotherapypreconditioning must be immediate to administration of the cellularimmunotherapies in order to maintain the cellular immunotherapies in thecirculation, typically 48 hours before administration of the cellularimmunotherapies. When cytotoxic chemotherapy preconditioning is given 4weeks before or at a pretreatment time which allows bone marrowrecovery, it is not effective to keep the cellular immunotherapies inthe circulation Ritchie D S et al. Mol Ther. November; 21(11):2122-9(2013).

The periarterial lymphoid sheaths (PALS) of the white pulp of the spleenare populated mainly by T cells, while the lymphoid portions arepopulated mainly by B cells. Germinal centers (GC) are sites withinlymph nodes or lymph nodules in peripheral lymph tissues, and in thewhite pulp of the spleen where intense mature B lymphocytes, otherwiseknown as Centrocytes rapidly proliferate, differentiate, mutate throughsomatic hypermutation and class switch during antibody responses.Germinal centers are an important part of the B-cell humoral immuneresponse. They develop dynamically after the activation of B-cells byT-dependent antigen. Histologically, the GCs describe microscopicallydistinguishable parts in lymphoid tissues. Activated B-cells migratefrom the primary focus into the primary follicles follicular system andbegin monoclonal expansion in the environment of follicular dendriticcells (FDC).

After several days of expansion the B cells mutate theirantibody-encoding DNA and thus generate a diversity of clones in thegerminal center. This involves random substitutions, deletions andinsertions due to somatic hypermutation. Upon some unidentified stimulusfrom the FDC, the maturing B cells (Centroblasts) migrate from the darkzone to the light zone and start to expose their antibody to theirsurface and in this stage are referred to as Centrocytes. TheCentrocytes are in a state of activated apoptosis and compete forsurvival signals from FDCs that present the antigen. This rescue processis believed to be dependent on the affinity of the antibody to theantigen. The functional B-cells have then to interact with helper Tcells to get final differentiation signals. This also involves isotypeswitching for example from IgM to IgG. The interaction with T cells isbelieved to prevent the generation of autoreactive antibodies. The Bcells become either a plasma cell spreading antibodies or a memory Bcell that will be activated in subsequent contacts with the sameantigen. They may also restart the whole process of proliferation,mutation and selection according to the recycling hypothesis.

The B cells contained within the white pulp region of the spleen can befurther divided into specific areas, identified by staining withspecific molecular markers. The marginal zone of the spleen containsnoncirculating mature B cells that border on the white pulp creating aseparation between the white and the red pulp and express high levels ofCD21 and IgM and CD24 and CD79a, and measurable levels of CD9 and CD22.The mantle zone surrounds normal germinal center follicles and expressesCD21, CD23 and CD38. The follicular zone is contained within thegerminal centers and expresses high levels of IgD and CD23, intermediatelevels of CD21 and CD24, and can also be identified by PNA staining. Thegerminal center is best distinguished by PNA binding and expresseshigher levels of CD54 than the follicular zone. Germinal centers have aspecial population of helper T cells that seem to distribute evenly inall germinal centers. Germinal centers are traditionally associated withimmune responses that require T helper cells, although this is notabsolute. Germinal centers are where hypervariable gene mutation occursand high affinity IgG producing B cells are generated. Active germinalcenters have tangible macrophages and CD21 expressing dendritic cells.Follicular centers can also be identified by the expression of CD45R(B220) (Cytotoxicologic Pathology, 35:366-375, 2007). CD45R follicularcenters are found surrounding germinal centers expressing Bcl6 and Bcl2.BioEssays 29:166-177, 2007; Cytotoxicol Pathol 34(5): 648-655, (2006)]

Cells of the Immune System

The response to pathogens or cancer cells is orchestrated by the complexinteractions and activities of the large number of diverse cell typesinvolved in the immune response. The innate immune response is the firstline of defense and occurs soon after pathogen exposure. It is carriedout by phagocytic cells such as neutrophils and macrophages,cytocytotoxic natural killer (NK) cells, and granulocytes. Thesubsequent adaptive immune response elicits antigen-specific defensemechanisms and may take days to develop. Cell types with critical rolesin adaptive immunity are antigen-presenting cells including macrophagesand dendritic cells. Antigen-dependent stimulation of various cell typesincluding T cell subsets, B cells, and macrophages all play criticalroles in host defense. Immune cells non-exclusively relates to: B Cells,Dendritic Cells, Granulocytes, Innate Lymphoid Cells (TLCs),Megakaryocytes, Monocytes/Macrophages, Myeloid-derived Suppressor Cells(MDSC), Natural Killer (NK) Cells, Platelets, Red Blood Cells (RBCs), TCells, Thymocytes.

Cell Types for Cellular Immunotherapy

In certain embodiments of the invention the cellular immunotherapy canbe either autologous or allogeneic, endogenous or exogenous. The celltypes used for cellular immunotherapy may non-exclusively, as single orcombination cell therapies, be any of the following cell types:macrophages, phagocytes, toleragenic dendritic cells, tumor infiltratinglymphocytes, adoptive cell transfer, adoptive cell therapy, adoptive Tcell therapy, chimeric antigen receptor cells, genetically engineeredTCR cells, genetically engineered TCR-modified T cells, CAR T cells,regulatory T cell transfer, cellular adoptive immunotherapy, cellularimmunotherapy, cellular immune-oncology, in vivo complex (IL-2C)consisting of IL-2 and anti-IL-2 monoclonal antibody (JES6-1) expandedTregs, T-Cell receptor (TCR) immunogenicity for T-cell vaccinations,autological polyclonal T-cell vaccines (TCVs), adoptive transfer ofTreg-of-B cells (B cells induced a particular subset of regulatory T),adoptive transfer of GC-induced or ATF3-deficient G-MDSCs (myeloidderived suppressor cells), genetically engineered lymphocytes, RNAredirected autologous T cells, T-cell Natural Killer cells, ReceptorNKG2D cells, CD4+ cells, CD8+ cells, CD4+ T cells, CD8+ T cells,mixtures of CD4+ and CD8 T cells, MDSCs, CTLs, EBV-CTLs, virus specificcytocytotoxic T lymphocytes (CTLs), cytokine-induced killer cells,antigen pulsed dendritic cells, CMV-CTLs, natural dendritic cells,dendritic cells, third party donor derived CTL's, autologous γδ Tlymphocyte therapy, CD45RA Depleted T-cell Infusion, Laboratory-treatedT Cells, HER2Bi-armed activated T cells, autologous tumor DC vaccine,Dendritic Cell (DC)-Based Vaccines Loaded with Allogeneic Prostate CellLines, Dendritic Cell/AML Vaccine, Dendritic Cell vaccines,gene-modified lymphocytes, dendritic cell therapy, ESO-1 Lymphocytes,Tumor-Pulsed Dendritic Cells, Autologous Tumor Lysate-pulsed DendriticCell, gene-modified immune cells, Marrow Infiltrating Lymphocytes,Alpha-galactosylceramide-pulsed Dendritic Cells,Alpha-galactosylceramide-pulsed Natural Killer T (NKT) Cells,Alpha-galactosylceramide-pulsed Dendritic Cells and Natural Killer T(NKT) Cells, Autologous gamma/Delta T Cells, Activated Self-lymphocytes,Epstein-Barr Virus Immune T-Lymphocytes Derived From a NormalHLA-Compatible Or Partially-Matched Third-Party Donor, granulocytemacrophage colony-stimulating factor plus bi-shRNAi furin vectortransfected autologous tumor cells, Alpha-galactosylceramide PulsedDendritic Cells (Chiba-NKT), P53-Pulsed Dendritic Cells, PrimaryTransplant Donor Derived CMVpp65 Specific T-cells, mixed T- and naturalkiller (NK) cell-like phenotype (CIK Cells), Antigen Pulsed DendriticCells (APDC), DC-CTK, Alpha-galcer Pulsed APC, Zoledronate-ActivatedAutologous Killer Lymphocytes (Zak Cells), Chiba NKT cells, AutologousDendritic Cells Loaded with Autologous Tumor Lysate or Homogenate, ThirdParty Donor Derived CMVpp65 Specific T-cells, Autologous TumorLysate-pulsed D-CIK, Multi-epitope TARP Peptide Autologous DendriticCells, T-reg Adoptive Cell Transfer (TRACT), Modified DLI (Donor DoubleNegative T Cells), Type-1 Polarized Dendritic Cells (AlphaDC1),Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells, Peptide PulsedDendritic Cells, Dendritic Cytocytotoxic Lymphocyte (DC-CTL) Cells,MTCR-transduced Autologous Peripheral Blood Lymphocytes, CytokineInduced Memory-like NK Cells, LMP-specific T-cells, Modified DLI(Related-donor Double Negative T Cells), Autologous Dendritic CellsLoaded with Autologous Tumour Homogenate, Vigil® Engineered AutologousTumor Cell (EATC) therapy, New Antigen Reactive Immune Cell Therapy(NRT), Autologous Cytokine-induced Killer Cells, Fused AutologousDendritic Cells, Peptide Specific CTL, Allogeneic Cell ImmunotherapyACIT-1, PD-1 Knockout Engineered T Cells, DC/AML Fusion Cells, (DC/PC3),Laboratory-treated T Cells, Dendritic Cell Tumor Fusions, LethallyIrradiated, Autologous Breast Cancer Cells, CD4-ZETA Gene Modified TCells, EBV-specific Immune Effector Cell (EBV-IE), Herpes Virus (HHV)Specific Immune Effector (IE) Cell, mRNA-transfected Dendritic Cells,Allogeneic Dendritic Cell Therapy, Cytomegalovirus (CMV) Pp65-specificLyphocytes, Alpha-Galactosylceramide-Pulsed IL-2/GM-CSF-CulturedPeripheral Blood Mononuclear Cells, Depleted T Cells, Donor CellsDendritic Vaccination, DCs Vaccine Combined with Cytokine-induced KillerCells, DC Vaccine Combined with CIK Cells, HB-vac Activated-DCs,Haploidentical NK-cell Infusion, ZNK cell, WT1 and MUC1 Peptide-PulsedDendritic Cells, ONETreg1 cells, Alpha DC1, Autologous T Lymphocyteswith ADCC, Memory T-cell Infusion, HER-2/Neu Pulsed DC1, StimulatedAutologous CD4+ T Cells, Gamma delta T cell, irradiated allogeneic lungadenocarcinoma cells, CD40LGVAX, irradiated allogeneic lungadenocarcinoma cells combined with a bystander cell line transfectedwith hCD40L and hGM-CSF, EGFRBi-armed Autologous T Cells, MiHA-loadedPD-L-silenced DC, MyDC/pDC, ROR-1.taNK, PDL1.taNK, Adjuvant DendriticCell-immunotherapy, D-CIK, DOT-Cells, Autologous Tumor Lysate (TL) plusYeast Cell Wall Particles (YCWP) plus Dendritic Cells, AutologousEBV-specific Cytocytotoxic T Cells, Autologous TLPLDC vaccine (tumorlysate, particle loaded, dendritic cells), Regulatory T Cells,Personalized Cellular Vaccine (PERCELLVAC), CAR-pNK Cell, HER2.taNK,MUC16.taNK, DC1s-CTLs, (PERCELLVAC2), (PERCELLVAC3), MASCT, CAR-pNKCells, CD33.taNK, Post Cord Blood HCT Dendritic Cells, Umbilical CordBlood Regulatory T Cells, High-activity Natural Killer cells, PD-1Knockout EBV-CTLs, DC-CTL Combined with CIK, Antigen-Bearing DendriticCells, Dendritic Cell/Tumor Fusions, Transfected Dendritic Cell, Her2and TGFBeta CTLs, Blood T-cells and EBV Specific CTLs, Autologous BreastCancer Cells Engineered to Secrete Granulocyte-macrophageColony-Stimulating Factor (GM-CSF), Gene-modified White Blood Cells,Epitope-enhanced TARP Peptide and TARP Peptide-pulsed Dendritic Cells,Laboratory-treated Autologous Lymphocytes, Multi-virus CTLs,Cytomegalovirus-specific T-cell Adoptive Transfer (ERaDICATe), GM-K562Cells, Kappa-CD28 T Lymphocytes, TGFB2-Antisense-GMCSF Gene ModifiedAutologous Tumor Cell, Bi-shRNA-furin and Granulocyte Macrophage ColonyStimulating Factor (GMCSF) Augmented Autologous Tumor Cells, Donor TCells Sensitized with Pentadecapeptides of the CMV-PP65 Protein,Peptide-pulsed Monocyte-derived Dendritic Cell Vaccination to ExpandAdoptively Transferred CMV-specific Cytocytotoxic T Lymphocytes, CMVSpecific DLIs From 3-6/6 HLA Matched Family Member, CMV Specific DLIs,Autologous T-cells Combined With Autologous OC-DC, TAA-Specific CTLs,Autologous Lymphocytes, Autologous Tolerogenic Dendritic Cells,Langerhans-type Dendritic Cells, Langerhans-type Dendritic CellsElectroporated with mRNA Encoding a Tumor-associated Antigen, AutologousT Cells, Multi-virus Cytocytotoxic T-cells, Autologous TL2 and CD40Ligand-Expressing Tumor Cells, Multiple Antigen-Engineered DC. WT1And/Or Tumor Lysates-pulsed Dendritic Cells, Autologous HumanCytomegalovirus (HCMV)-specific T cell Therapy, Ad/HER2/Neu DendriticCell, WT1 Peptide (Peptivator)-pulsed Dendritic Cell, Donor Derived,Multi-virus-specific, Cytocytotoxic T-Lymphocytes, Ex-vivo ExpandedDonor Regulatory T Cells, Alpha-GalCer-Pulsed Antigen Presenting Cells(APCs), Cytokine-induced Memory-like NK Cells, “Re-stimulated”Tumor-infiltrating Lymphocytes, Autologous Langerhans-type DendriticCells, Memory Enriched T Cells, Expanded Multi-antigen SpecificallyOriented Lymphocytes, TAA-Specific CTLs, Regulatory Dendritic Cells,Closely Matched Third Party Rapidly Generated LMP, BARF1 and EBNA1Specific CTL, Activated Marrow Infiltrating Lymphocytes, AutologousTumor Lysate-loaded Dendritic Cells, Multi-Epitope TARP PeptideAutologous Dendritic Cells, HPV-16/18 E6/E7-specific T Lymphocytes,Autologous Epstein-barr Virus-specific T Cells, Activated T-cells, DonorMultitaa-specific T Cells, Multitaa-specific T Cells, Type I-PolarizedAutologous Dendritic Cells, Vaccine Enriched Autologous ActivatedT-cells, Multivirus-specific Cytocytotoxic T Lymphocytes (mCTL),Allogeneic Virus-specific T Cell Lines (VSTs), Donor Regulatory T Cells,TCR-modified T cells (TCRs), MIC Cell, Adoptive T Cell Therapy withActivated P53 Specific T Cells, MUC1-DC-CTL, T cell receptor-modified Tcells, “Negative” Dendritic Cell-based Vaccine, tolDC, CD22 RedirectedAutologous T Cells, Dendristim, Primary NK Cells, Lentiviral-basedCART-EGFRvIII Gene-modified Cellular Therapy Products, AutologousDendritic Cells Pulsed with Lysated Allegenic Tumor Lines, ExpandedMulti-antigen Specific Lymphocytes, PD-1 Knockout Engineered T Cells,GSC-loaded Dendritic Cells, Treg Adoptive Cell Transfer (TRACT), E7 TCRT Cells, PD-1 Knockout Engineered T Cells, CAR-Treg (ENTX-DN), ChimericSwitch Receptor Modified T Cells, Neoantigen-primed Dendritic Cells(DC), Pre-activated T (PreT) Cells, TSA-CTL (Tumor SpecificAntigen-induced Cytocytotoxic T Lymphocytes), Allogeneic CellImmunotherapy (ACIT-1), Autologous OC-DC, Mature Dendritic Cells,CD8+NKG2D+ AKT Cell, Natural Killer (NK) cells—oNKord®, antigenpresenting cells—sDCord®, Allogenic GM-CSF Transfected Pancreatic TumorVaccine.

The cellular immunotherapy can be genetically modified. The cellularimmunotherapy can be CRISPR/Cas9, TALEN, piggy-bac transposon,transposase, Sleeping Beauty, serine recombinase, CRE-lox recombinase,RheoSwitch®, recombinase, lipofection, nucleofection, Zinc fingernuclease, chemically, plasmid, biologically, ARCUS, homing endonucleaseor virally modified. The cellular immunotherapy cells can be engineeredwith a plasmid carrying the gene vector for shRNA Furin and GMCSF(VIGIL®).

In certain embodiments of the invention one would want to exclude andavoid using certain cell types for cellular immunotherapy including:

Macrophages, phagocytic cells, toleragenic dendritic cells, tumorinfiltrating lymphocytes, adoptive cell transfer, adoptive cell therapy,chimeric antigen receptor cells, genetically engineered TCR cells,regulatory T cell transfer, cellular adoptive immunotherapy, cellularimmunotherapy, cellular immune-oncology, in vivo complex (IL-2C)consisting of IL-2 and anti-IL-2 monoclonal antibody (JES6-1) expandedTregs, T-Cell receptor (TCR) immunogenicity for T-cell vaccinations,autological polyclonal T-cell vaccines (TCVs), adoptive transfer ofTreg-of-B cells (B cells induced a particular subset of regulatory T),adoptive transfer of GC-induced or ATF3-deficient G-MDSCs (myeloidderived suppressor cells), genetically engineered lymphocytes, RNAredirected autologous T cells, T-cell Natural Killer cells, ReceptorNKG2D cells, CD4+ cells, CD8+ cells, CD4+ T cells, CD8+ T cells,mixtures of CD4+ and CD8 T cells, MDSCs, CTLs, EBV-CTLs, virus specificcytocytotoxic T lymphocytes (CTLs), cytokine-induced killer cells,antigen pulsed dendritic cells, CMV-CTLs, natural dendritic cells,dendritic cells, third party donor derived CTL's, autologous γδ Tlymphocyte therapy, CD45RA Depleted T-cell Infusion, Laboratory-treatedT Cells, HER2Bi-armed activated T cells, autologous tumor DC vaccine,Dendritic Cell (DC)-Based Vaccines Loaded with Allogeneic Prostate CellLines, Dendritic Cell/AML Vaccine, Dendritic Cell vaccines,gene-modified lymphocytes, dendritic cell therapy, ESO-1 Lymphocytes,Tumor-Pulsed Dendritic Cells, Autologous Tumor Lysate-pulsed DendriticCell, gene-modified immune cells, Marrow Infiltrating Lymphocytes,Alpha-galactosylceramide-pulsed Dendritic Cells,Alpha-galactosylceramide-pulsed Natural Killer T (NKT) Cells,Alpha-galactosylceramide-pulsed Dendritic Cells and Natural Killer T(NKT) Cells, Autologous gamma/Delta T Cells, Activated Self-lymphocytes,Epstein-Barr Virus Immune T-Lymphocytes Derived From a NormalHLA-Compatible Or Partially-Matched Third-Party Donor, granulocytemacrophage colony-stimulating factor plus bi-shRNAi furin vectortransfected autologous tumor cells, Alpha-galactosylceramide PulsedDendritic Cells (Chiba-NKT), P53-Pulsed Dendritic Cells, PrimaryTransplant Donor Derived CMVpp65 Specific T-cells, mixed T- and naturalkiller (NK) cell-like phenotype (CIK Cells), Antigen Pulsed DendriticCells (APDC), DC-CIK, Alpha-galcer Pulsed APC, Zoledronate-ActivatedAutologous Killer Lymphocytes (Zak Cells), Chiba NKT cells, AutologousDendritic Cells Loaded with Autologous Tumor Lysate or Homogenate, ThirdParty Donor Derived CMVpp65 Specific T-cells, Autologous TumorLysate-pulsed D-CIK, Multi-epitope TARP Peptide Autologous DendriticCells, T-reg Adoptive Cell Transfer (TRACT), Modified DLI (Donor DoubleNegative T Cells), Type-1 Polarized Dendritic Cells (AlphaDC1),Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells, Peptide PulsedDendritic Cells, Dendritic Cytocytotoxic Lymphocyte (DC-CTL) Cells,MTCR-transduced Autologous Peripheral Blood Lymphocytes, CytokineInduced Memory-like NK Cells, LMP-specific T-cells, Modified DLI(Related-donor Double Negative T Cells), Autologous Dendritic CellsLoaded with Autologous Tumour Homogenate, VIGIL® Engineered AutologousTumor Cell (EATC) therapy, New Antigen Reactive Immune Cell Therapy(NRT), Autologous Cytokine-induced Killer Cells, Fused AutologousDendritic Cells, Peptide Specific CTL, Allogeneic Cell ImmunotherapyACIT-1, PD-1 Knockout Engineered T Cells, DC/AML Fusion Cells, (DC/PC3),Laboratory-treated T Cells, Dendritic Cell Tumor Fusions, LethallyIrradiated, Autologous Breast Cancer Cells, CD4-ZETA Gene Modified TCells, EBV-specific Immune Effector Cell (EBV-IE), Herpes Virus (HHV)Specific Immune Effector (IE) Cell, mRNA-transfected Dendritic Cells,Allogeneic Dendritic Cell Therapy, Cytomegalovirus (CMV) Pp65-specificLyphocytes, Alpha-Galactosylceramide-Pulsed IL-2/GM-CSF-CulturedPeripheral Blood Mononuclear Cells, Depleted T Cells, Donor CellsDendritic Vaccination, DCs Vaccine Combined with Cytokine-induced KillerCells, DC Vaccine Combined with CIK Cells, HB-vac Activated-DCs,Haploidentical NK-cell Infusion, ZNK cell, WT1 and MUC1 Peptide-PulsedDendritic Cells, ONETreg1 cells, Alpha DC1, Autologous T Lymphocyteswith ADCC, Memory T-cell Infusion, HER-2/Neu Pulsed DC1, StimulatedAutologous CD4+ T Cells, Gamma delta T cell, irradiated allogeneic lungadenocarcinoma cells, CD40LGVAX, irradiated allogeneic lungadenocarcinoma cells combined with a bystander cell line transfectedwith hCD40L and hGM-CSF, EGFRBi-armed Autologous T Cells, MiHA-loadedPD-L-silenced DC, MyDC/pDC, ROR-1.taNK, PDL1.taNK, Adjuvant DendriticCell-immunotherapy, D-CIK, DOT-Cells, Autologous Tumor Lysate (TL) plusYeast Cell Wall Particles (YCWP) plus Dendritic Cells, AutologousEBV-specific Cytocytotoxic T Cells, Autologous TLPLDC vaccine (tumorlysate, particle loaded, dendritic cells), Regulatory T Cells,Personalized Cellular Vaccine (PERCELLVAC), CAR-pNK Cell, HER2.taNK,MUC16.taNK, DC1s-CTLs, (PERCELLVAC2), (PERCELLVAC3), MASCT, CAR-pNKCells, CD33.taNK, Post Cord Blood HCT Dendritic Cells, Umbilical CordBlood Regulatory T Cells, High-activity Natural Killer cells, PD-1Knockout EBV-CTLs, DC-CTL Combined with CIK, Antigen-Bearing DendriticCells, Dendritic Cell/Tumor Fusions, Transfected Dendritic Cell, Her2and TGFBeta CTLs, Blood T-cells and EBV Specific CTLs, Autologous BreastCancer Cells Engineered to Secrete Granulocyte-macrophageColony-Stimulating Factor (GM-CSF), Gene-modified White Blood Cells,Epitope-enhanced TARP Peptide and TARP Peptide-pulsed Dendritic Cells,Laboratory-treated Autologous Lymphocytes, Multi-virus CTLs,Cytomegalovirus-specific T-cell Adoptive Transfer (ERaDICATe), GM-K562Cells, Kappa-CD28 T Lymphocytes, TGFB2-Antisense-GMCSF Gene ModifiedAutologous Tumor Cell, Bi-shRNA-furin and Granulocyte Macrophage ColonyStimulating Factor (GMCSF) Augmented Autologous Tumor Cells, Donor TCells Sensitized with Pentadecapeptides of the CMV-PP65 Protein,Peptide-pulsed Monocyte-derived Dendritic Cell Vaccination to ExpandAdoptively Transferred CMV-specific Cytocytotoxic T Lymphocytes, CMVSpecific DLIs From 3-6/6 HLA Matched Family Member, CMV Specific DLIs,Autologous T-cells Combined With Autologous OC-DC, TAA-Specific CTLs,Autologous Lymphocytes, Autologous Tolerogenic Dendritic Cells,Langerhans-type Dendritic Cells, Langerhans-type Dendritic CellsElectroporated with mRNA Encoding a Tumor-associated Antigen, AutologousT Cells, Multi-virus Cytocytotoxic T-cells, Autologous IL2 and CD40Ligand-Expressing Tumor Cells, Multiple Antigen-Engineered DC. WT1And/Or Tumor Lysates-pulsed Dendritic Cells, Autologous HumanCytomegalovirus (HCMV)-specific T cell Therapy, Ad/HER2/Neu DendriticCell, WT1 Peptide (Peptivator)-pulsed Dendritic Cell, Donor Derived,Multi-virus-specific, Cytocytotoxic T-Lymphocytes, Ex-vivo ExpandedDonor Regulatory T Cells, Alpha-GalCer-Pulsed Antigen Presenting Cells(APCs), Cytokine-induced Memory-like NK Cells, “Re-stimulated”Tumor-infiltrating Lymphocytes, Autologous Langerhans-type DendriticCells, Memory Enriched T Cells, Expanded Multi-antigen SpecificallyOriented Lymphocytes, TAA-Specific CTLs, Regulatory Dendritic Cells,Closely Matched Third Party Rapidly Generated LMP, BARF1 and EBNA1Specific CTL, Activated Marrow Infiltrating Lymphocytes, AutologousTumor Lysate-loaded Dendritic Cells, Multi-Epitope TARP PeptideAutologous Dendritic Cells, HPV-16/18 E6/E7-specific T Lymphocytes,Autologous Epstein-barr Virus-specific T Cells, Activated T-cells, DonorMultitaa-specific T Cells, Multitaa-specific T Cells, Type I-PolarizedAutologous Dendritic Cells, Vaccine Enriched Autologous ActivatedT-cells, Multivirus-specific Cytocytotoxic T Lymphocytes (mCTL),Allogeneic Virus-specific T Cell Lines (VSTs), Donor Regulatory T Cells,TCR-modified T cells (TCRs), MIC Cell, Adoptive T Cell Therapy withActivated P53 Specific T Cells, MUC1-DC-CTL, T cell receptor-modified Tcells, “Negative” Dendritic Cell-based Vaccine, tolDC, CD22 RedirectedAutologous T Cells, Dendristim, Primary NK Cells, Lentiviral-basedCART-EGFRvIII Gene-modified Cellular Therapy Products, AutologousDendritic Cells Pulsed with Lysated Allegenic Tumor Lines, ExpandedMulti-antigen Specific Lymphocytes, PD-1 Knockout Engineered T Cells,GSC-loaded Dendritic Cells, Treg Adoptive Cell Transfer (TRACT), E7 TCRT Cells, PD-1 Knockout Engineered T Cells, CAR-Treg (ENTX-DN), ChimericSwitch Receptor Modified T Cells, Neoantigen-primed Dendritic Cells(DC), Pre-activated T (PreT) Cells, TSA-CTL (Tumor SpecificAntigen-induced Cytocytotoxic T Lymphocytes), Allogeneic CellImmunotherapy (ACIT-1), Autologous OC-DC, Mature Dendritic Cells,CD8+NKG2D+ AKT Cell, Natural Killer (NK) cells—oNKord®, antigenpresenting cells—sDCord®, Allogenic GM-CSF Transfected Pancreatic TumorVaccine.

Chimeric Antigen Receptor Targets

In some embodiments of the invention the chimeric antigen receptor (CAR)T cells or genetically modified cellular immunotherapy may be to asingle target or target multiple combinations of any of the targetslisted below. The receptor/ligand or antibody expressed by the chimericantigen receptor T cells or cellular immunotherapy can be mono- orbi-specific or multi-specific. In some embodiments of the invention thecellular immunotherapy may not be genetically modified to any specifictarget. In some embodiments of the present invention the cellularimmunotherapy will be primed or activated in the laboratory to enhancethe immune activity of the cellular immunotherapy prior to administeringthe cellular immunotherapy to a patient.

The expressed receptor/ligand or the antibody target or the cellularimmunotherapy target may be chosen from the following list ofreceptors/ligands or targets including but not limited to;Proto-oncogene tyrosine-protein kinase ABL1, Citrullinated Antigen,ErbB2/HER2, CD16, WT-1, KRAS, glypican 3, CD3, CD20, CD226, CD155,CD123, HPV-16 E6, Melan-A/MART-1, TRAIL Bound to the DR4 Receptor, LMP,MTCR, ESO, NY-ESO-1, gp100, 4SCAR-GD2/CD56, Mesothelin (CAK1 Antigen orPre Pro Megakaryocyte Potentiating Factor or MSLN); DNA SynthesisInhibitor; Histamine H1 Receptor (HRH1) Antagonist; Prostaglandin G/HSynthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin EndoperoxideSynthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC1.14.99.1) Inhibitor, CD19 (B Lymphocyte Surface Antigen B4 orDifferentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19),Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or MeconiumAntigen 100 or CD66e or CEACAM5); Interleukin 2 Receptor (IL2R) Agonist,Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or ReceptorTyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1);DNA Ligase (EC 6.5.1.) Inhibitor; DNA Ligase (EC 6.5.1.), DNA PolymeraseAlpha (POLA or EC 2.7.7.7) Inhibitor; DNA Primase (EC 2.7.7.6)Inhibitor; Ribonucleoside Diphosphate Reductase (RibonucleotideReductase or RRM or EC 1.17.4.1) Inhibitor; RNA Polymerase II (RNAP IIor Pol II or EC 2.7.7.6) Inhibitor, DNA Polymerase (EC 2.7.7.7)Inhibitor; DNA Topoisomerase II (EC 5.99.1.3) Inhibitor; CD22, meso, DNAPrimase (EC 2.7.7.6); Programmed Cell Death 1 Ligand 1 (PD L1 or B7Homolog 1 or CD274) Inhibitor; RNA Polymerase II (RNAP II or Pol II orEC 2.7.7.6), Histone Lysine N Methyltransferase EZH2 (ENX 1 or EnhancerOf Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC2.1.1.43) Inhibitor; Programmed Cell Death 1 Ligand 1 (PD L1 or B7Homolog 1 or CD274), C-X—C Chemokine Receptor Type 4 (FB22 or Fusin orHM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor orLipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1Receptor or NPYRL or CD184 or CXCR4) Antagonist; Granulocyte ColonyStimulating Factor Receptor (CD114 or GCSFR or CSF3R) Agonist, AdenosineDeaminase (Adenosine Aminohydrolase or ADA or EC 3.5.4.4) Inhibitor;Tumor Necrosis Factor Receptor Superfamily Member 17 (B Cell MaturationAntigen or CD269 or TNFRSF17), Cytocytotoxic To Cells ExpressingInactive Tyrosine Protein Kinase Transmembrane Receptor ROR1(Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC2.7.10.1); T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell SurfaceAntigen T3/Leu 4 Epsilon Chain or CD3E); Dihydrofolate Reductase (DHFRor EC 1.5.1.3) Inhibitor; Ephrin Type A Receptor 2 (Epithelial CellKinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1)Inhibitor; Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3Group C Member 1 or NR3C1) Agonist; Mast/Stem Cell Growth FactorReceptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or vKit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or PiebaldTrait Protein or p145 c Kit or CD117 or KIT or EC 2.7.10.1) Inhibitor;Platelet Derived Growth Factor Receptor Beta (Beta Type Platelet DerivedGrowth Factor Receptor or CD140 Antigen Like Family Member B or PlateletDerived Growth Factor Receptor 1 or CD140b or PDGFRB or EC 2.7.10.1)Inhibitor; Tubulin Inhibitor; Tyrosine Protein Kinase CSK (C Src Kinaseor Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Inhibitor;Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fynor Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Inhibitor; TyrosineProtein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 orProto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase orLymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC2.7.10.2) Inhibitor; Tyrosine Protein Kinase Yes (Proto Oncogene c Yesor p61 Yes or YES1 or EC 2.7.10.2) Inhibitor, Tumor Necrosis Factor(Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand SuperfamilyMember 2 or TNF a or TNF) Inhibitor, Signal Transducer And Activator OfTranscription 3 (Acute Phase Response Factor or DNA Binding Protein APRFor STAT3) Inhibitor, Bcr-Abl Tyrosine Kinase (EC 2.7.10.2) Inhibitor;Dihydrofolate Reductase (DHFR or EC 1.5.1.3); Ephrin Type A Receptor 2(Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2or EC 2.7.10.1); Mast/Stem Cell Growth Factor Receptor Kit (ProtoOncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or p145 cKit or CD117 or KIT or EC 2.7.10.1); Platelet Derived Growth FactorReceptor Beta (Beta Type Platelet Derived Growth Factor Receptor orCD140 Antigen Like Family Member B or Platelet Derived Growth FactorReceptor 1 or CD140b or PDGFRB or EC 2.7.10.1); Tubulin; TyrosineProtein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSKor EC 2.7.10.2) Inhibitor; Tyrosine Protein Kinase Fyn (Proto OncogeneSyn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC2.7.10.2) Inhibitor; Tyrosine Protein Kinase Lck (Leukocyte C TerminalSrc Kinase or Protein YT16 or Proto Oncogene Lck or T Cell SpecificProtein Tyrosine Kinase or Lymphocyte Cell Specific Protein TyrosineKinase or p56 LCK or LCK or EC 2.7.10.2) Inhibitor; Tyrosine ProteinKinase Yes (Proto Oncogene c Yes or p61 Yes or YES1 or EC 2.7.10.2)Inhibitor, Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic ProteaseActivating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC3.4.22.62) Activator; Prostate Stem Cell Antigen (PSCA), MelanomaAntigen Preferentially Expressed In Tumors (Cancer/Testis Antigen 130 orOpa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen OfMelanoma or PRAME), Signal Transducer And Activator Of Transcription 3(Acute Phase Response Factor or DNA Binding Protein APRF or STAT3)Inhibitor, CD44 Antigen (CDw44 or Epican or Extracellular MatrixReceptor III or GP90 Lymphocyte Homing/Adhesion Receptor or HUTCH I orHeparan Sulfate Proteoglycan or Hermes Antigen or Hyaluronate Receptoror Phagocytic Glycoprotein 1 or CD44), AXL (anexelekto) receptortyrosine kinase, GAS6, TAM receptor tyrosine kinases, TYRO-3 (also knownas Brt, Dtk, Rse, Sky and Tif), AXL (also known as Ark, Tyro7 and Ufo),and MER (also known as Eyk, Nym and Tyro12), CTLA4, Tumor NecrosisFactor Receptor Superfamily Member 8 (CD30L Receptor or Ki 1 Antigen orLymphocyte Activation Antigen CD30 or CD30 or TNFRSF8), Caspase 9(Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 orICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) Activator;Cytocytotoxic To Cells Expressing Ganglioside GD2; Prostaglandin G/HSynthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin EndoperoxideSynthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1)Inhibitor; cytokines, interleukins, Claudin 6 (Skullin or CLDN6), NKG2D,MICA, MICB and ULBP 1-6, NKp30, B7H6 (NCR3LG1), Bag6, B7 family, CD40Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or TumorNecrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)Activator; Interleukin 12 (IL12) Activator, Interleukin 3 ReceptorSubunit Alpha (IL3RAMast/Stem Cell Growth F), actor Receptor Kit (ProtoOncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or p145 cKit or CD117 or KIT or EC 2.7.10.1) Antagonist; Proto Oncogene TyrosineProtein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogenec Ret or RET or EC 2.7.10.1) Inhibitor; Receptor Type Tyrosine ProteinKinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or StemCell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC2.7.10.1) Antagonist; Vascular Endothelial Growth Factor Receptor 1 (FmsLike Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT orTyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor orVEGFR1 or FLT1 or EC 2.7.10.1) Antagonist; Vascular Endothelial GrowthFactor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptoror Protein Tyrosine Kinase Receptor fik 1 or VEGFR2 or CD309 or KDR orEC 2.7.10.1) Antagonist; Vascular Endothelial Growth Factor Receptor 3(Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 orVEGFR3 or FLT4 or EC 2.7.10.1) Antagonist, Caspase 9 (Apoptotic ProteaseMch 6 or Apoptotic Protease Activating Factor 3 or ICE Like ApoptoticProtease 6 or CASP9 or EC 3.4.22.62) Activator, Cytocytotoxic TLymphocyte Protein 4 (Cytocytotoxic T Lymphocyte Associated Antigen 4 orCD152 or CTLA4) Antagonist, Myeloid Cell Surface Antigen CD33 (SialicAcid Binding Ig Like Lectin 3 or gp67 or CD33), Hepatocyte Growth FactorReceptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF/SFReceptor or Scatter Factor Receptor or MET or EC 2.7.10.1), EpithelialCell Adhesion Molecule (Adenocarcinoma Associated Antigen or CellSurface Glycoprotein Trop 1 or Epithelial Cell Surface Antigen orEpithelial Glycoprotein 314 or KS 1/4 Antigen or KSA or Tumor AssociatedCalcium Signal Transducer 1 or CD326 or EPCAM), Ganglioside GD2, Lewis YAntigen (CD174), Latent Membrane Protein 1 (Protein p63 or LMP1), Mucin1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG orKrebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin orPolymorphic Epithelial Mucin or Tumor Associated Epithelial MembraneAntigen or Tumor Associated Mucin or CD227 or MUC1), T Cell ReceptorBeta 1 Chain C Region (TRBC1), Vascular Endothelial Growth FactorReceptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor orProtein Tyrosine Kinase Receptor fik 1 or VEGFR2 or CD309 or KDR or EC2.7.10.1), BCMA, PD-1, interleukin-6 receptor, NKR2, CX-072, TLymphocyte Protein 4 (Cytocytotoxic T Lymphocyte Associated Antigen 4 orCD152 or CTLA4) Antagonist; Serine/Threonine Protein Kinase B Raf (p94or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene HomologB1 or BRAF or EC 2.7.11.1) Inhibitor, Mucin 16 (Ovarian Cancer RelatedTumor Marker CA125 or Ovarian Carcinoma Antigen CA125 or MUC16); Bcr-AblTyrosine Kinase (EC 2.7.10.2) Inhibitor; Tyrosine Protein Kinase CSK (CSrc Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)Inhibitor; Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or ProtoOncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)Inhibitor; Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinaseor Protein YT16 or Proto Oncogene Lck or T Cell Specific ProteinTyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase orp56 LCK or LCK or EC 2.7.10.2) Inhibitor; Tyrosine Protein Kinase Yes(Proto Oncogene c Yes or p61 Yes or YES1 or EC 2.7.10.2) Inhibitor,Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division ProteinKinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC2.7.11.22 or EC 2.7.11.23) Inhibitor; Cyclin Dependent Kinase 2 (p33Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC2.7.11.22) Inhibitor; Granulocyte Macrophage Colony Stimulating FactorReceptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Agonist, EGFRVIII,Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK orEC 2.7.10.2) Inhibitor, Alpha Fetoprotein (Alpha 1 Fetoprotein or AlphaFetoglobulin or AFP), Cancer/Testis Antigen 1 (AutoimmunogenicCancer/Testis Antigen or Cancer/Testis Antigen 6.1 or L Antigen FamilyMember 2 or CTAG1A or CTAG1B); HBV antigen, EGFR Family Member, Herin,Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell ProgenitorKinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)Inhibitor, CD4, Epithelial Cell Adhesion Molecule (AdenocarcinomaAssociated Antigen or Cell Surface Glycoprotein Trop 1 or EpithelialCell Surface Antigen or Epithelial Glycoprotein 314 or KS 1/4 Antigen orKSA or Tumor Associated Calcium Signal Transducer 1 or CD326 or EPCAM),Prolyl Endopeptidase FAP (170 kDa Melanoma Membrane Bound Gelatinase orDipeptidyl Peptidase FAP or Integral Membrane Serine Protease orFibroblast Activation Protein Alpha or Gelatine Degradation Protease FAPor Seprase or FAP or EC 3.4.21.26 or EC 3.4.14.5), Neural Cell AdhesionMolecule 1 (Antigen Recognized By Monoclonal Antibody 5.1H11 or CD56 orNCAM1); Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 orReceptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC2.7.10.1) Antagonist, Tyrosine Protein Kinase Transmembrane ReceptorROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC2.7.10.1); Wilms Tumor Protein (WT33 or WT1); Interleukin 13 ReceptorSubunit Alpha 2 (Interleukin 13 Binding Protein or CD213a2 or IL13RA2),Trophoblast Glycoprotein (M6P1 or 5T4 Oncofetal Antigen or 5T4 OncofetalTrophoblast Glycoprotein or Wnt Activated Inhibitory Factor 1 or TPBG),SLAM Family Member 7 (CD319 or Membrane Protein FOAP 12 or CD2 LikeReceptor Activating Cytocytotoxic Cells or Novel Ly9 or Protein 19A orCD2 Subset 1 or CS1 or SLAMF7), B Cell Lymphoma 2 (Bcl 2) Inhibitor; DNA(Cytosine 5) Methyltransferase 1 (CXXC Type Zinc Finger Protein 9 or DNAMethyltransferase HsaI or MCMT or DNMT1 or EC 2.1.1.37) Inhibitor, ROR1,CD19 & CD40L, avidin (EGFRiiiv), a folate receptor, CD30, pmel CD*8 T,CD33, NKR2, Epithelial tumor antigen (ETA), Tyrosinase,Melanoma-associated antigen, abnormal products of ras, p53,Alphafetoprotein (AFP), CA-125, CA15-3, CA27-29, CA19-9, Calcitonin,Calretinin, CD34, CD99MIC 2, CD117, Chromogranin, Cytokeratin (varioustypes: TPA, TPS, Cyfra21-1), Desmin, Epithelial membrane antigen (EMA),Factor VIII, CD31 FL1, Glial fibrillary acidic protein (GFAP), Grosscystic disease fluid protein (GCDFP-15), HM1B-45, Human chorionicgonadotropin (hCG), immunoglobulin, inhibin, keratin (various types),lymphocyte marker (various types), BCR-ABL, Myo D1, muscle-specificactin (MSA), neurofilament, neuron-specific enolase (NSE), placentalalkaline phosphatase (PLAP), prostate-specific antigen (PSA), PTPRC(CD45), S100 protein, smooth muscle actin (SMA), synaptophysin,thymidine kinase, thyroglobulin (Tg), thyroid transcription factor-1(TTF-1), Tumor M2-PK, vimentin, SV40, Adenovirus Elb-58kd, IGF2B3,ubiquitous (low level), Kallikrein 4, KIF20A, Lengsin, Meloe, MUC5AC,Immature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4,Calcium-activated chloride channel 2, Cyclin-B1, 9D7, Ep-CAM, EphA3,Telomerase, SAP-1, BAGE family, CAGE family, GAGE family, MAGE family,SAGE family, XAGE family, LAGE-1, PRAME, SSX-2, pmel17, Tyrosinase,TRP-1/-2, P.polypeptide, MC1R, β-catenin, Prostate-pecific antigen,BRCA1, BRCA2, CDK4, CML66, Fibronectin, MART-2, Ras, TGF-beta receptorII, T cell receptor (TCR), BLOC1S6, CD10/Neprilysin, CD24, CD248,CD5/Cluster of Differentiation 5, CD63/Tspan-30/Tetraspanin-30,CEACAM5/CD66e, CT45A3, CTAG1A, CXORF61, DSE, GPA33, HPSE, KLK3, LCP1,LRIG3, LRRC15, megakaryocyte potentiating factor, MOK, MUC4, NDNL2,OCIAD1, PMPCB, PTOV1, RCAS1/EBAG9, RNF43, ROPN1, RPLP1, SARNP,SBEM/MUCL1, TRP1/TYRP1, CA19-9, Inactive Tyrosine Protein KinaseTransmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase ReceptorRelated 1 or ROR1 or EC 2.7.10.1), ALK Tyrosine Kinase Receptor(Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1), ProstateStem Cell Antigen (PSCA), Melanoma Antigen Preferentially Expressed InTumors (Cancer/Testis Antigen 130 or Opa Interacting Protein 4 or OIP4or Preferentially Expressed Antigen Of Melanoma or PRAME), SignalTransducer And Activator Of Transcription 3 (Acute Phase Response Factoror DNA Binding Protein APRF or STAT3) Inhibitor, CD44 Antigen (CDw44 orEpican or Extracellular Matrix Receptor III or GP90 LymphocyteHoming/Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan orHermes Antigen or Hyaluronate Receptor or Phagocytic Glycoprotein 1 orCD44), CD40 Ligand (T Cell Antigen Gp39 or TNF Related ActivationProtein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 orCD40LG) Activator; Tumor Necrosis Factor Receptor Superfamily Member 13B(Transmembrane Activator And CAML Interactor or CD267 or TACI orTNFRSF13B); Cytocytotoxic To Cells Expressing Tumor Necrosis FactorReceptor Superfamily Member 17 (B Cell Maturation Antigen or CD269 orTNFRSF17), CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or CostimulatoryMolecule or CD276), Myeloid Cell Surface Antigen CD33 (Sialic AcidBinding Ig Like Lectin 3 or gp67 or CD33), ADP Ribosyl Cyclase/CyclicADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2′Phospho ADP Ribosyl Cyclase/2′ Phospho Cyclic ADP Ribose Transferase orADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20), C TypeLectin Domain Family 14 Member A (Epidermal Growth Factor Receptor 5 orEGFR5 or CLEC14A), Hepatocyte Growth Factor Receptor (Proto Oncogene cMet or Tyrosine Protein Kinase Met or HGF/SF Receptor or Scatter FactorReceptor or MET or EC 2.7.10.1), Epithelial Cell Adhesion Molecule(Adenocarcinoma Associated Antigen or Cell Surface Glycoprotein Trop 1or Epithelial Cell Surface Antigen or Epithelial Glycoprotein 314 or KS1/4 Antigen or KSA or Tumor Associated Calcium Signal Transducer 1 orCD326 or EPCAM), Ganglioside GD3, Interleukin 13 Receptor Subunit Alpha2 (Interleukin 13 Binding Protein or CD213a2 or IL13RA2); Kappa MyelomaAntigen (KMA), Lambda Myeloma Antigen (LMA), Latent Membrane Protein 1(Protein p63 or LMP1), Melanoma Associated Antigen, Cytocytotoxic ToCells Expressing T Lymphocyte Activation Antigen CD80 (Activation B7-1Antigen or CTLA 4 Counter Receptor B7.1 or CD80); Cytocytotoxic To CellsExpressing T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigenor CTLA 4 Counter Receptor B7.2 or CD86), Inactive Tyrosine ProteinKinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine KinaseReceptor Related 1 or ROR1 or EC 2.7.10.1), Fas Apoptotic InhibitoryMolecule 3 (IgM Fc Fragment Receptor or Regulator Of Fas InducedApoptosis Toso or TOSO or FAIM3 or FCMR), T Cell Receptor Beta 1 Chain CRegion (TRBC1), Vascular Endothelial Growth Factor Receptor 2 (FetalLiver Kinase 1 or Kinase Insert Domain Receptor or Protein TyrosineKinase Receptor fik 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1), AlphaFetoprotein (Alpha 1 Fetoprotein or Alpha Fetoglobulin or AFP),Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A orCTAG1B), T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1/Leu 1 orCD5), Prolyl Endopeptidase FAP (170 kDa Melanoma Membrane BoundGelatinase or Dipeptidyl Peptidase FAP or Integral Membrane SerineProtease or Fibroblast Activation Protein Alpha or Gelatine DegradationProtease FAP or Seprase or FAP or EC 3.4.21.26 or EC 3.4.14.5), NeuralCell Adhesion Molecule 1 (Antigen Recognized By Monoclonal Antibody5.1H11 or CD56 or NCAM1), C Type Lectin Domain Family 12 Member A(Myeloid Inhibitory C Type Lectin Like Receptor or Dendritic CellAssociated Lectin 2 or C Type Lectin Like Molecule 1 or CLEC12A),Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV);Cytocytotoxic To Cells Expressing Integrin Beta 6 (ITGB6), Interleukin13 Receptor Subunit Alpha 2 (Interleukin 13 Binding Protein or CD213a2or IL13RA2), Trophoblast Glycoprotein (M6P1 or 5T4 Oncofetal Antigen or5T4 Oncofetal Trophoblast Glycoprotein or Wnt Activated InhibitoryFactor 1 or TPBG), Trophoblast Glycoprotein (M6P1 or 5T4 OncofetalAntigen or 5T4 Oncofetal Trophoblast Glycoprotein or Wnt ActivatedInhibitory Factor 1 or TPBG), C Type Lectin Domain Family 12 Member A(Myeloid Inhibitory C Type Lectin Like Receptor or Dendritic CellAssociated Lectin 2 or C Type Lectin Like Molecule 1 or CLEC12A), SLAMFamily Member 7 (CD319 or Membrane Protein FOAP 12 or CD2 Like ReceptorActivating Cytocytotoxic Cells or Novel Ly9 or Protein 19A or CD2 Subset1 or CS1 or SLAMF7), SLAM Family Member 7 (CD319 or Membrane ProteinFOAP 12 or CD2 Like Receptor Activating Cytocytotoxic Cells or Novel Ly9or Protein 19A or CD2 Subset 1 or CS1 or SLAMF7), immunoglobulin,Multidrug resistance-associated protein 3 (MRP3), Proto-oncogenetyrosine-protein kinase ABL1, Prostatic acid phosphatase, OY-TES-1,ACSM2A, Alpha-actinin-4, Perilipin-2, Alphafetoprotein, Lymphoid blastcrisis oncogene (Lbc) oncoproptein, aldehyde dehydrogenase 1 familymember A1 (ALDH1A1), AML, ANKRD17, NY-BR-1, Annexin II, ARHGAP17,ARHGAP30, ARID1B, Endoplasmic reticulum-resident protein,5′-aminoimidazole-4-carboxamide-1-beta-d-ribonucleotidetransfolmylase/inosinicase (AICRT/I), ATR, ATXN2, ATXN2L, BAGEl, BCL11A,Bcl-xL, Breakpoint cluster region, Survivin, Livin/ML-IAP, HM1.24, BTBdomain containing 2 (BTBD2), C60RF89, Carbonic anhydrase IX, CLCA2,CRT2, CAMEL, CAN protein, Caspase-5, Caspase-8, KM-HN-1, CCDC88B, cyclinB1, Cyclin D1, CCNI, CDC2, CDC25A, CDC27, CDK12, intestinalcarboxylesterase, CEP95, CHAF1A, Coactosin-like 1, CPSF, CRYBA1, TRAG-3,Macrophage colony stimulating factor, CSNK1A1, Melanoma-associatedchondroitin sulfate proteoglycan (MCSP), Cathepsin H, Kita-kyushu lungcancer antigen 1, P450 1B1 or CYP1B1, DDR1, DEK oncogene, DEK-CAN,Dickkopf-1 (DKK1), DNAJC8, DSCAML1, EEF2, Elongation factor Tu GTPbinding domain containing or SNRP116, EIF4EBP1, Human Mena protein,EP300, ETV5, TEL1 or ETV6, Polycomb group protein enhancer of zestehomolog 2 (EZH2), F2R, F4.2, FAM53C, Fibroblast g, rowth factor 5 orFGF5, Formin-related protein in leukocytes 1 (FMNL1), Fibromodulin(FMOD), FNDC3B, FKHR, GDP-L-fucose, GAS7, GFI1, GIGYF2, GPNMB, O, A1,GPSM3, GRK2, GRM5, H3F3A, HAUS3, HERC1, HERV-K-MEL, HIVEP2, HMGN, HMHA1,heme oxygenase-1 (HO-1), HNRPL, Heparanase, HMSD-v-encoded mHA, HSPA1A,Hsp70, HSPB1, immediate early response gene X-1 (IEX-1), insulin-likegrowth factor (IGF)-II mRNA binding protein 3 (IMP-3), IP6K1, IRS2,ITGB8, JUP, RU2AS, KANSL3, KLF10, KLF2, KLK4, KMT2A, K-ras, Low densitylipid receptor (LDLR), LDLR-FUT, Mac-2-binding protein, KIAA0205, LPP,LRP1, LRRC41, LSP1, LUZP1, lymphocyte antigen 6 complex locus K (LY6K),MACF1, MAP1A, MAP3K11, MAP7D1, Matrilin-2, Mcl-1, MDM2, Malic enzyme,MEF2D, MEFV, Milk fat globule membrane protein BA46 (lactadherin),Melanotransferrin, GNT-V or N-acetylglucosaminytransferase V, MIIP, MMP14, Matrix metalloproteinase-2, MORC2, Melanoma antigen p15, MUC2, MUM,MYC, MYL9, Unconventional myosin class I gene, N4BP2, NCBP3, NCOA1,NCOR2, NFATC2, NFYC, NIFK, Ninein, NPM, NPM1-ALK1, N-ras, OAS3, Ppolypeptide, OGT, OS-9, ErbB3-binding protein 1, PAGE-4, P21-activatedserine kinase 2 (PAK2), neo-PAP, PARP12, PAX3, PAX3-FKHR, PCBP2,phosphoglycerate kinase 1 (PKG1), PLEKHM2, promyelocytic leukemia orPML, PML-RARA, POLR2A, Cyclophilin B, PPP1CA, PPP1R3B, Peroxiredoxin 5,Proteinase 3, Parathyroid hormone-related protein (PTHrP), Receptor-likeprotein tyrosine phosphatase kappa, MG50, NY-MEL-1 or RAB38, RAGE,RALGAPB, RAR alpha, RBM, RCSD1, Recoverin, RERE, RGS5, RHAMM/CD168,RPA1, Ribosomal protein L10a, Ribosomal protein S2, RREB1, RSRP1, RTCB,SART, SCAP, Mammaglobin A, Secernin 1, SDCBP, SETD2, SF3B1, Renalubiquitous protein 1, SIK1, SIRT2, SKI, hairpin-binding protein,SLC35A4, Prostein, SLC46A1, SNRPD1, SOGA1, SON, SOX10, SOX11, SOX2,SOX-4, Sperm protein 17, SPEN, SRRM2, SRSF7, SRSF8, SSX1, SSX2 orHOM-MEL-40, SSX4, STAT1, STEAP, STRAP, ART-1, SVIL, HOM-TES-14/SCP1,CD138, SYNM, SYNPO, SYT, SYT15, SYT-SSX1, SYT-SSX2, SZT2, TAPBP,TBC1D10C, TBC1D9B, hTERT, THNSL2, THOC6, TLK1, TNS3, TOP2A, TOP2B,ATP-dependent interferon-responsive (ADIR), TP53, Triosephosphateisomerase or TPI1, Tropomyosin-4, TPX2, TRG, T-cell receptor gammaalternate reading frame protein (TARP), TRIM68, Prostate-specificprotein transient receptor potential-p8 (trp-p8), TSC22D4, TTK proteinkinase (TTK), Thymidylate synthase (TYMS), UBE2A, Ubiquitin-conjugatingenzyme variant Kua, COA-1, USB1, NA88-A, VPS13D, BING4, WHSCIL1, WHSC2,WNK2, WT1, XBP1, XPO1, ZC3H14, ZNF106, ZNF219, Papillomavirus bindingfactor (PBF), E3 ubiquitin-protein ligase UBR4.

In certain embodiments of the invention one would want to exclude andavoid using certain expressed receptor/ligand or antibody target orcellular immunotherapy targets including but not limited to;Proto-oncogene tyrosine-protein kinase ABL1, Citrullinated Antigen,ErbB2/HER2, CD16, WT-1, KRAS, glypican 3, CD3, CD20, CD226, CD155,CD123, HPV-16 E6, Melan-A/MART-1, TRAIL Bound to the DR4 Receptor, LMP,MTCR, ESO, NY-ESO-1, gp100, 4SCAR-GD2/CD56, Mesothelin (CAK1 Antigen orPre Pro Megakaryocyte Potentiating Factor or MSLN); DNA SynthesisInhibitor; Histamine H1 Receptor (HRH1) Antagonist; Prostaglandin G/HSynthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin EndoperoxideSynthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC1.14.99.1) Inhibitor, CD19 (B Lymphocyte Surface Antigen B4 orDifferentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19),Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or MeconiumAntigen 100 or CD66e or CEACAM5); Interleukin 2 Receptor (IL2R) Agonist,Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or ReceptorTyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1);DNA Ligase (EC 6.5.1.) Inhibitor; DNA Ligase (EC 6.5.1.), DNA PolymeraseAlpha (POLA or EC 2.7.7.7) Inhibitor; DNA Primase (EC 2.7.7.6)Inhibitor; Ribonucleoside Diphosphate Reductase (RibonucleotideReductase or RRM or EC 1.17.4.1) Inhibitor; RNA Polymerase II (RNAP IIor Pol II or EC 2.7.7.6) Inhibitor, DNA Polymerase (EC 2.7.7.7)Inhibitor; DNA Topoisomerase II (EC 5.99.1.3) Inhibitor; CD22, meso, DNAPrimase (EC 2.7.7.6); Programmed Cell Death 1 Ligand 1 (PD L1 or B7Homolog 1 or CD274) Inhibitor; RNA Polymerase II (RNAP II or Pol II orEC 2.7.7.6), Histone Lysine N Methyltransferase EZH2 (ENX 1 or EnhancerOf Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC2.1.1.43) Inhibitor; Programmed Cell Death 1 Ligand 1 (PD L1 or B7Homolog 1 or CD274), C-X—C Chemokine Receptor Type 4 (FB22 or Fusin orHM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor orLipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1Receptor or NPYRL or CD184 or CXCR4) Antagonist; Granulocyte ColonyStimulating Factor Receptor (CD114 or GCSFR or CSF3R) Agonist, AdenosineDeaminase (Adenosine Aminohydrolase or ADA or EC 3.5.4.4) Inhibitor;Tumor Necrosis Factor Receptor Superfamily Member 17 (B Cell MaturationAntigen or CD269 or TNFRSF17), Cytocytotoxic To Cells ExpressingInactive Tyrosine Protein Kinase Transmembrane Receptor ROR1(Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC2.7.10.1); T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell SurfaceAntigen T3/Leu 4 Epsilon Chain or CD3E); Dihydrofolate Reductase (DHFRor EC 1.5.1.3) Inhibitor; Ephrin Type A Receptor 2 (Epithelial CellKinase or Tyrosine Protein Kinase Receptor ECK or EPHA2 or EC 2.7.10.1)Inhibitor; Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3Group C Member 1 or NR3C1) Agonist; Mast/Stem Cell Growth FactorReceptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or vKit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or PiebaldTrait Protein or p145 c Kit or CD117 or KIT or EC 2.7.10.1) Inhibitor;Platelet Derived Growth Factor Receptor Beta (Beta Type Platelet DerivedGrowth Factor Receptor or CD140 Antigen Like Family Member B or PlateletDerived Growth Factor Receptor 1 or CD140b or PDGFRB or EC 2.7.10.1)Inhibitor; Tubulin Inhibitor; Tyrosine Protein Kinase CSK (C Src Kinaseor Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) Inhibitor;Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fynor Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) Inhibitor; TyrosineProtein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 orProto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase orLymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC2.7.10.2) Inhibitor; Tyrosine Protein Kinase Yes (Proto Oncogene c Yesor p61 Yes or YES1 or EC 2.7.10.2) Inhibitor, Tumor Necrosis Factor(Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand SuperfamilyMember 2 or TNF a or TNF) Inhibitor, Signal Transducer And Activator OfTranscription 3 (Acute Phase Response Factor or DNA Binding Protein APRFor STAT3) Inhibitor, Bcr-Abl Tyrosine Kinase (EC 2.7.10.2) Inhibitor;Dihydrofolate Reductase (DHFR or EC 1.5.1.3); Ephrin Type A Receptor 2(Epithelial Cell Kinase or Tyrosine Protein Kinase Receptor ECK or EPHA2or EC 2.7.10.1); Mast/Stem Cell Growth Factor Receptor Kit (ProtoOncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or p145 cKit or CD117 or KIT or EC 2.7.10.1); Platelet Derived Growth FactorReceptor Beta (Beta Type Platelet Derived Growth Factor Receptor orCD140 Antigen Like Family Member B or Platelet Derived Growth FactorReceptor 1 or CD140b or PDGFRB or EC 2.7.10.1); Tubulin; TyrosineProtein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSKor EC 2.7.10.2) Inhibitor; Tyrosine Protein Kinase Fyn (Proto OncogeneSyn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC2.7.10.2) Inhibitor; Tyrosine Protein Kinase Lck (Leukocyte C TerminalSrc Kinase or Protein YT16 or Proto Oncogene Lck or T Cell SpecificProtein Tyrosine Kinase or Lymphocyte Cell Specific Protein TyrosineKinase or p56 LCK or LCK or EC 2.7.10.2) Inhibitor; Tyrosine ProteinKinase Yes (Proto Oncogene c Yes or p61 Yes or YES1 or EC 2.7.10.2)Inhibitor, Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic ProteaseActivating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC3.4.22.62) Activator; Prostate Stem Cell Antigen (PSCA), MelanomaAntigen Preferentially Expressed In Tumors (Cancer/Testis Antigen 130 orOpa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen OfMelanoma or PRAME), Signal Transducer And Activator Of Transcription 3(Acute Phase Response Factor or DNA Binding Protein APRF or STAT3)Inhibitor, CD44 Antigen (CDw44 or Epican or Extracellular MatrixReceptor III or GP90 Lymphocyte Homing/Adhesion Receptor or HUTCH I orHeparan Sulfate Proteoglycan or Hermes Antigen or Hyaluronate Receptoror Phagocytic Glycoprotein 1 or CD44), AXL (anexelekto) receptortyrosine kinase, GAS6, TAM receptor tyrosine kinases, TYRO-3 (also knownas Brt, Dtk, Rse, Sky and Tif), AXL (also known as Ark, Tyro7 and Ufo),and MER (also known as Eyk, Nym and Tyro12), CTLA4, Tumor NecrosisFactor Receptor Superfamily Member 8 (CD30L Receptor or Ki 1 Antigen orLymphocyte Activation Antigen CD30 or CD30 or TNFRSF8), Caspase 9(Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 orICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) Activator;Cytocytotoxic To Cells Expressing Ganglioside GD2; Prostaglandin G/HSynthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin EndoperoxideSynthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1)Inhibitor; cytokines, interleukins, Claudin 6 (Skullin or CLDN6), NKG2D,MICA, MICB and ULBP 1-6, NKp30, B7H6 (NCR3LG1), Bag6, B7 family, CD40Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or TumorNecrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)Activator; Interleukin 12 (IL12) Activator, Interleukin 3 ReceptorSubunit Alpha (IL3RAMast/Stem Cell Growth F), actor Receptor Kit (ProtoOncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or p145 cKit or CD117 or KIT or EC 2.7.10.1) Antagonist; Proto Oncogene TyrosineProtein Kinase Receptor Ret (Cadherin Family Member 12 or Proto Oncogenec Ret or RET or EC 2.7.10.1) Inhibitor; Receptor Type Tyrosine ProteinKinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or StemCell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC2.7.10.1) Antagonist; Vascular Endothelial Growth Factor Receptor 1 (FmsLike Tyrosine Kinase 1 or Tyrosine Protein Kinase Receptor FLT orTyrosine Protein Kinase FRT or Vascular Permeability Factor Receptor orVEGFR1 or FLT1 or EC 2.7.10.1) Antagonist; Vascular Endothelial GrowthFactor Receptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptoror Protein Tyrosine Kinase Receptor fik 1 or VEGFR2 or CD309 or KDR orEC 2.7.10.1) Antagonist; Vascular Endothelial Growth Factor Receptor 3(Fms Like Tyrosine Kinase 4 or Tyrosine Protein Kinase Receptor FLT4 orVEGFR3 or FLT4 or EC 2.7.10.1) Antagonist, Caspase 9 (Apoptotic ProteaseMch 6 or Apoptotic Protease Activating Factor 3 or ICE Like ApoptoticProtease 6 or CASP9 or EC 3.4.22.62) Activator, Cytocytotoxic TLymphocyte Protein 4 (Cytocytotoxic T Lymphocyte Associated Antigen 4 orCD152 or CTLA4) Antagonist, Myeloid Cell Surface Antigen CD33 (SialicAcid Binding Ig Like Lectin 3 or gp67 or CD33), Hepatocyte Growth FactorReceptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF/SFReceptor or Scatter Factor Receptor or MET or EC 2.7.10.1), EpithelialCell Adhesion Molecule (Adenocarcinoma Associated Antigen or CellSurface Glycoprotein Trop 1 or Epithelial Cell Surface Antigen orEpithelial Glycoprotein 314 or KS 1/4 Antigen or KSA or Tumor AssociatedCalcium Signal Transducer 1 or CD326 or EPCAM), Ganglioside GD2, Lewis YAntigen (CD174), Latent Membrane Protein 1 (Protein p63 or LMP1), Mucin1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG orKrebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin orPolymorphic Epithelial Mucin or Tumor Associated Epithelial MembraneAntigen or Tumor Associated Mucin or CD227 or MUC1), T Cell ReceptorBeta 1 Chain C Region (TRBC1), Vascular Endothelial Growth FactorReceptor 2 (Fetal Liver Kinase 1 or Kinase Insert Domain Receptor orProtein Tyrosine Kinase Receptor fik 1 or VEGFR2 or CD309 or KDR or EC2.7.10.1), BCMA, PD-1, interleukin-6 receptor, NKR2, CX-072, TLymphocyte Protein 4 (Cytocytotoxic T Lymphocyte Associated Antigen 4 orCD152 or CTLA4) Antagonist; Serine/Threonine Protein Kinase B Raf (p94or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene HomologB1 or BRAF or EC 2.7.11.1) Inhibitor, Mucin 16 (Ovarian Cancer RelatedTumor Marker CA125 or Ovarian Carcinoma Antigen CA125 or MUC16); Bcr-AblTyrosine Kinase (EC 2.7.10.2) Inhibitor; Tyrosine Protein Kinase CSK (CSrc Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)Inhibitor; Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or ProtoOncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)Inhibitor; Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinaseor Protein YT16 or Proto Oncogene Lck or T Cell Specific ProteinTyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase orp56 LCK or LCK or EC 2.7.10.2) Inhibitor; Tyrosine Protein Kinase Yes(Proto Oncogene c Yes or p61 Yes or YES1 or EC 2.7.10.2) Inhibitor,Cyclin Dependent Kinase 1 (p34 Protein Kinase or Cell Division ProteinKinase 1 or Cell Division Control Protein 2 Homolog or CDK1 or EC2.7.11.22 or EC 2.7.11.23) Inhibitor; Cyclin Dependent Kinase 2 (p33Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC2.7.11.22) Inhibitor; Granulocyte Macrophage Colony Stimulating FactorReceptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Agonist, EGFRVIII,Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK orEC 2.7.10.2) Inhibitor, Alpha Fetoprotein (Alpha 1 Fetoprotein or AlphaFetoglobulin or AFP), Cancer/Testis Antigen 1 (AutoimmunogenicCancer/Testis Antigen or Cancer/Testis Antigen 6.1 or L Antigen FamilyMember 2 or CTAG1A or CTAG1B); HBV antigen, EGFR Family Member, Herin,Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell ProgenitorKinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)Inhibitor, CD4, Epithelial Cell Adhesion Molecule (AdenocarcinomaAssociated Antigen or Cell Surface Glycoprotein Trop 1 or EpithelialCell Surface Antigen or Epithelial Glycoprotein 314 or KS 1/4 Antigen orKSA or Tumor Associated Calcium Signal Transducer 1 or CD326 or EPCAM),Prolyl Endopeptidase FAP (170 kDa Melanoma Membrane Bound Gelatinase orDipeptidyl Peptidase FAP or Integral Membrane Serine Protease orFibroblast Activation Protein Alpha or Gelatine Degradation Protease FAPor Seprase or FAP or EC 3.4.21.26 or EC 3.4.14.5), Neural Cell AdhesionMolecule 1 (Antigen Recognized By Monoclonal Antibody 5.1H11 or CD56 orNCAM1); Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 orReceptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC2.7.10.1) Antagonist, Tyrosine Protein Kinase Transmembrane ReceptorROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC2.7.10.1); Wilms Tumor Protein (WT33 or WT1); Interleukin 13 ReceptorSubunit Alpha 2 (Interleukin 13 Binding Protein or CD213a2 or IL13RA2),Trophoblast Glycoprotein (M6P1 or 5T4 Oncofetal Antigen or 5T4 OncofetalTrophoblast Glycoprotein or Wnt Activated Inhibitory Factor 1 or TPBG),SLAM Family Member 7 (CD319 or Membrane Protein FOAP 12 or CD2 LikeReceptor Activating Cytocytotoxic Cells or Novel Ly9 or Protein 19A orCD2 Subset 1 or CS1 or SLAMF7), B Cell Lymphoma 2 (Bcl 2) Inhibitor; DNA(Cytosine 5) Methyltransferase 1 (CXXC Type Zinc Finger Protein 9 or DNAMethyltransferase HsaI or MCMT or DNMT1 or EC 2.1.1.37) Inhibitor, ROR1,CD19 & CD40L, avidin (EGFRiiiv), a folate receptor, CD30, pmel CD*8 T,CD33, NKR2, Epithelial tumor antigen (ETA), Tyrosinase,Melanoma-associated antigen, abnormal products of ras, p53,Alphafetoprotein (AFP), CA-125, CA15-3, CA27-29, CA19-9, Calcitonin,Calretinin, CD34, CD99MIC 2, CD117, Chromogranin, Cytokeratin (varioustypes: TPA, TPS, Cyfra21-1), Desmin, Epithelial membrane antigen (EMA),Factor VIII, CD31 FL1, Glial fibrillary acidic protein (GFAP), Grosscystic disease fluid protein (GCDFP-15), HM1B-45, Human chorionicgonadotropin (hCG), immunoglobulin, inhibin, keratin (various types),lymphocyte marker (various types), BCR-ABL, Myo D1, muscle-specificactin (MSA), neurofilament, neuron-specific enolase (NSE), placentalalkaline phosphatase (PLAP), prostate-specific antigen (PSA), PTPRC(CD45), S100 protein, smooth muscle actin (SMA), synaptophysin,thymidine kinase, thyroglobulin (Tg), thyroid transcription factor-1(TTF-1), Tumor M2-PK, vimentin, SV40, Adenovirus Elb-58kd, IGF2B3,ubiquitous (low level), Kallikrein 4, KIF20A, Lengsin, Meloe, MUC5AC,Immature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4,Calcium-activated chloride channel 2, Cyclin-B1, 9D7, Ep-CAM, EphA3,Telomerase, SAP-1, BAGE family, CAGE family, GAGE family, MAGE family,SAGE family, XAGE family, LAGE-1, PRAME, SSX-2, pmel17, Tyrosinase,TRP-1/-2, P.polypeptide, MC1R, β-catenin, Prostate-specific antigen,BRCA1, BRCA2, CDK4, CML66, Fibronectin, MART-2, Ras, TGF-beta receptorII, T cell receptor (TCR), BLOC1S6, CD10/Neprilysin, CD24, CD248,CD5/Cluster of Differentiation 5, CD63/Tspan-30/Tetraspanin-30,CEACAM5/CD66e, CT45A3, CTAG1A, CXORF61, DSE, GPA33, HPSE, KLK3, LCP1,LRIG3, LRRC15, megakaryocyte potentiating factor, MOK, MUC4, NDNL2,OCIAD1, PMPCB, PTOV1, RCAS1/EBAG9, RNF43, ROPN1, RPLP1, SARNP,SBEM/MUCL1, TRP1/TYRP1, CA19-9, Inactive Tyrosine Protein KinaseTransmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase ReceptorRelated 1 or ROR1 or EC 2.7.10.1), ALK Tyrosine Kinase Receptor(Anaplastic Lymphoma Kinase or CD246 or ALK or EC 2.7.10.1), ProstateStem Cell Antigen (PSCA), Melanoma Antigen Preferentially Expressed InTumors (Cancer/Testis Antigen 130 or Opa Interacting Protein 4 or OIP4or Preferentially Expressed Antigen Of Melanoma or PRAME), SignalTransducer And Activator Of Transcription 3 (Acute Phase Response Factoror DNA Binding Protein APRF or STAT3) Inhibitor, CD44 Antigen (CDw44 orEpican or Extracellular Matrix Receptor III or GP90 LymphocyteHoming/Adhesion Receptor or HUTCH I or Heparan Sulfate Proteoglycan orHermes Antigen or Hyaluronate Receptor or Phagocytic Glycoprotein 1 orCD44), CD40 Ligand (T Cell Antigen Gp39 or TNF Related ActivationProtein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 orCD40LG) Activator; Tumor Necrosis Factor Receptor Superfamily Member 13B(Transmembrane Activator And CAML Interactor or CD267 or TACI orTNFRSF13B); Cytocytotoxic To Cells Expressing Tumor Necrosis FactorReceptor Superfamily Member 17 (B Cell Maturation Antigen or CD269 orTNFRSF17), CD276 Antigen (B7 Homolog 3 or 4Ig B7 H3 or CostimulatoryMolecule or CD276), Myeloid Cell Surface Antigen CD33 (Sialic AcidBinding Ig Like Lectin 3 or gp67 or CD33), ADP Ribosyl Cyclase/CyclicADP Ribose Hydrolase 1 (Cyclic ADP Ribose Hydrolase 1 or T10 or 2′Phospho ADP Ribosyl Cyclase/2′ Phospho Cyclic ADP Ribose Transferase orADP Ribosyl Cyclase 1 or CD38 or EC 3.2.2.6 or EC 2.4.99.20), C TypeLectin Domain Family 14 Member A (Epidermal Growth Factor Receptor 5 orEGFR5 or CLEC14A), Hepatocyte Growth Factor Receptor (Proto Oncogene cMet or Tyrosine Protein Kinase Met or HGF/SF Receptor or Scatter FactorReceptor or MET or EC 2.7.10.1), Epithelial Cell Adhesion Molecule(Adenocarcinoma Associated Antigen or Cell Surface Glycoprotein Trop 1or Epithelial Cell Surface Antigen or Epithelial Glycoprotein 314 or KS1/4 Antigen or KSA or Tumor Associated Calcium Signal Transducer 1 orCD326 or EPCAM), Ganglioside GD3, Interleukin 13 Receptor Subunit Alpha2 (Interleukin 13 Binding Protein or CD213a2 or IL13RA2); Kappa MyelomaAntigen (KMA), Lambda Myeloma Antigen (LMA), Latent Membrane Protein 1(Protein p63 or LMP1), Melanoma Associated Antigen, Cytocytotoxic ToCells Expressing T Lymphocyte Activation Antigen CD80 (Activation B7-1Antigen or CTLA 4 Counter Receptor B7.1 or CD80); Cytocytotoxic To CellsExpressing T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigenor CTLA 4 Counter Receptor B7.2 or CD86), Inactive Tyrosine ProteinKinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine KinaseReceptor Related 1 or ROR1 or EC 2.7.10.1), Fas Apoptotic InhibitoryMolecule 3 (IgM Fc Fragment Receptor or Regulator Of Fas InducedApoptosis Toso or TOSO or FAIM3 or FCMR), T Cell Receptor Beta 1 Chain CRegion (TRBC1), Vascular Endothelial Growth Factor Receptor 2 (FetalLiver Kinase 1 or Kinase Insert Domain Receptor or Protein TyrosineKinase Receptor fik 1 or VEGFR2 or CD309 or KDR or EC 2.7.10.1), AlphaFetoprotein (Alpha 1 Fetoprotein or Alpha Fetoglobulin or AFP),Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A orCTAG1B), T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1/Leu 1 orCD5), Prolyl Endopeptidase FAP (170 kDa Melanoma Membrane BoundGelatinase or Dipeptidyl Peptidase FAP or Integral Membrane SerineProtease or Fibroblast Activation Protein Alpha or Gelatine DegradationProtease FAP or Seprase or FAP or EC 3.4.21.26 or EC 3.4.14.5), NeuralCell Adhesion Molecule 1 (Antigen Recognized By Monoclonal Antibody5.1H11 or CD56 or NCAM1), C Type Lectin Domain Family 12 Member A(Myeloid Inhibitory C Type Lectin Like Receptor or Dendritic CellAssociated Lectin 2 or C Type Lectin Like Molecule 1 or CLEC12A),Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV);Cytocytotoxic To Cells Expressing Integrin Beta 6 (ITGB6), Interleukin13 Receptor Subunit Alpha 2 (Interleukin 13 Binding Protein or CD213a2or IL13RA2), Trophoblast Glycoprotein (M6P1 or 5T4 Oncofetal Antigen or5T4 Oncofetal Trophoblast Glycoprotein or Wnt Activated InhibitoryFactor 1 or TPBG), Trophoblast Glycoprotein (M6P1 or 5T4 OncofetalAntigen or 5T4 Oncofetal Trophoblast Glycoprotein or Wnt ActivatedInhibitory Factor 1 or TPBG), C Type Lectin Domain Family 12 Member A(Myeloid Inhibitory C Type Lectin Like Receptor or Dendritic CellAssociated Lectin 2 or C Type Lectin Like Molecule 1 or CLEC12A), SLAMFamily Member 7 (CD319 or Membrane Protein FOAP 12 or CD2 Like ReceptorActivating Cytocytotoxic Cells or Novel Ly9 or Protein 19A or CD2 Subset1 or CS1 or SLAMF7), SLAM Family Member 7 (CD319 or Membrane ProteinFOAP 12 or CD2 Like Receptor Activating Cytocytotoxic Cells or Novel Ly9or Protein 19A or CD2 Subset 1 or CS1 or SLAMF7), immunoglobulin,Multidrug resistance-associated protein 3 (MRP3), Proto-oncogenetyrosine-protein kinase ABL1, Prostatic acid phosphatase, OY-TES-1,ACSM2A, Alpha-actinin-4, Perilipin-2, Alphafetoprotein, Lymphoid blastcrisis oncogene (Lbc) oncoproptein, aldehyde dehydrogenase 1 familymember A1 (ALDH1A1), AML, ANKRD17, NY-BR-1, Annexin II, ARHGAP17,ARHGAP30, ARID1B, Endoplasmic reticulum-resident protein,5′-aminoimidazole-4-carboxamide-1-beta-d-ribonucleotidetransfolmylase/inosinicase (AICRT/I), ATR, ATXN2, ATXN2L, BAGEl, BCL11A,Bcl-xL, Breakpoint cluster region, Survivin, Livin/ML-IAP, HM1.24, BTBdomain containing 2 (BTBD2), C60RF89, Carbonic anhydrase IX, CLCA2,CRT2, CAMEL, CAN protein, Caspase-5, Caspase-8, KM-HN-1, CCDC88B, cyclinB1, Cyclin D1, CCNI, CDC2, CDC25A, CDC27, CDK12, intestinalcarboxylesterase, CEP95, CHAF1A, Coactosin-like 1, CPSF, CRYBA1, TRAG-3,Macrophage colony stimulating factor, CSNK1A1, Melanoma-associatedchondroitin sulfate proteoglycan (MCSP), Cathepsin H, Kita-kyushu lungcancer antigen 1, P450 1B1 or CYP1B1, DDR1, DEK oncogene, DEK-CAN,Dickkopf-1 (DKK1), DNAJC8, DSCAML1, EEF2, Elongation factor Tu GTPbinding domain containing or SNRP116, EIF4EBP1, Human Mena protein,EP300, ETV5, TEL1 or ETV6, Polycomb group protein enhancer of zestehomolog 2 (EZH2), F2R, F4.2, FAM53C, Fibroblast g, rowth factor 5 orFGF5, Formin-related protein in leukocytes 1 (FMNL1), Fibromodulin(FMOD), FNDC3B, FKHR, GDP-L-fucose, GAS7, GFI1, GIGYF2, GPNMB, O, A1,GPSM3, GRK2, GRM5, H3F3A, HAUS3, HERC1, HERV-K-MEL, HIVEP2, HMGN, HMHA1,heme oxygenase-1 (HO-1), HNRPL, Heparanase, HMSD-v-encoded mHA, HSPA1A,Hsp70, HSPB1, immediate early response gene X-1 (IEX-1), insulin-likegrowth factor (IGF)-II mRNA binding protein 3 (IMP-3), IP6K1, IRS2,ITGB8, JUP, RU2AS, KANSL3, KLF10, KLF2, KLK4, KMT2A, K-ras, Low densitylipid receptor (LDLR), LDLR-FUT, Mac-2-binding protein, KIAA0205, LPP,LRP1, LRRC41, LSP1, LUZP1, lymphocyte antigen 6 complex locus K (LY6K),MACF1, MAP1A, MAP3K11, MAP7D1, Matrilin-2, Mcl-1, MDM2, Malic enzyme,MEF2D, MEFV, Milk fat globule membrane protein BA46 (lactadherin),Melanotransferrin, GNT-V or N-acetylglucosaminytransferase V, MIIP, MMP14, Matrix metalloproteinase-2, MORC2, Melanoma antigen p15, MUC2, MUM,MYC, MYL9, Unconventional myosin class I gene, N4BP2, NCBP3, NCOA1,NCOR2, NFATC2, NFYC, NIFK, Ninein, NPM, NPM1-ALK1, N-ras, OAS3, Ppolypeptide, OGT, OS-9, ErbB3-binding protein 1, PAGE-4, P21-activatedserine kinase 2 (PAK2), neo-PAP, PARP12, PAX3, PAX3-FKHR, PCBP2,phosphoglycerate kinase 1 (PKG1), PLEKHM2, promyelocytic leukemia orPML, PML-RARA, POLR2A, Cyclophilin B, PPP1CA, PPP1R3B, Peroxiredoxin 5,Proteinase 3, Parathyroid hormone-related protein (PTHrP), Receptor-likeprotein tyrosine phosphatase kappa, MG50, NY-MEL-1 or RAB38, RAGE,RALGAPB, RAR alpha, RBM, RCSD1, Recoverin, RERE, RGS5, RHAMM/CD168,RPA1, Ribosomal protein L10a, Ribosomal protein S2, RREB1, RSRP1, RTCB,SART, SCAP, Mammaglobin A, Secernin 1, SDCBP, SETD2, SF3B1, Renalubiquitous protein 1, SIK1, SIRT2, SKI, hairpin-binding protein,SLC35A4, Prostein, SLC46A1, SNRPD1, SOGA1, SON, SOX10, SOX11, SOX2,SOX-4, Sperm protein 17, SPEN, SRRM2, SRSF7, SRSF8, SSX1, SSX2 orHOM-MEL-40, SSX4, STAT1, STEAP, STRAP, ART-1, SVIL, HOM-TES-14/SCP1,CD138, SYNM, SYNPO, SYT, SYT15, SYT-SSX1, SYT-SSX2, SZT2, TAPBP,TBC1D10C, TBC1D9B, hTERT, THNSL2, THOC6, TLK1, TNS3, TOP2A, TOP2B,ATP-dependent interferon-responsive (ADIR), TP53, Triosephosphateisomerase or TPI1, Tropomyosin-4, TPX2, TRG, T-cell receptor gammaalternate reading frame protein (TARP), TRIM68, Prostate-specificprotein transient receptor potential-p8 (trp-p8), TSC22D4, TTK proteinkinase (TTK), Thymidylate synthase (TYMS), UBE2A, Ubiquitin-conjugatingenzyme variant Kua, COA-1, USB1, NA88-A, VPS13D, BING4, WHSCIL1, WHSC2,WNK2, WT1, XBP1, XPO1, ZC3H14, ZNF106, ZNF219, Papillomavirus bindingfactor (PBF), E3 ubiquitin-protein ligase UBR4.

T Cell Activator Domains

The T cell activator domain of the CAR T or other targeted cellulartherapy can be 4-1BB, CD3, CD3 zeta, CD3 zeta cytoplasmic signallingdomain and uses the natural costimulatory molecule DAP10, or any otherappropriate T cell activator domain including but not limited to CD28,41BB, ICOS, CD3z-CD28-41BB, CD3z-CD28-OX40, CD27 or any combination.

Production of the Antibody or Receptor to be Expressed by the CellularImmunotherapeutic

Production of the expressed receptor/ligand or antibody may be throughany method including conditionally active biologics (CAB) technology.The antibody can be single chain or double chain. The antibody could bean Fc fusion protein, a Fab, F(ab′)₂, Fab′, single chain variablefragment, di-scFv, single domain antibody, tri-functional antibody,chemically linked, or bi-specific T cell engager.

Pretreatment of the Cellular Immunotherapy

In vitro or ex vivo pretreatment of the cellular immunotherapy can bedone and non-exclusively relates to interleukin-1, interleukin 2,interleukin-7, interleukin-15, allogeneic PBMC, anti-CD3, anti-CD28,anti-CD3 & 28, HA 512-520 peptide, IL2 & anti-CD3 & CD28, PBMCactivation, PMA/ionomycin, PHA, Con A, LPS, PWM, pokeweed mitogen, thecomitogenic monoclonal antibodies (mAbs) CD2/CD2R, the superantigenstaphylococcal enterotoxin B (SEB), and the specific antigen Candidaalbicans, SLAM, CD80 or CD86 crosslinking of CD28, dexamethasone oranother steroid, or any combination of the above pretreatments.

In certain embodiments of the invention in vitro or ex vivo pretreatmentof the cellular immunotherapy should exclude dexamethasone or othersteroid treatments, interleukin-1, interleukin 2, interleukin-7,interleukin-15, allogeneic PBMC, anti-CD3, anti-CD28, anti-CD3 & 28, HA512-520 peptide, IL2 & anti-CD3 & CD28, PBMC activation, PMA/ionomycin,PHA, Con A, LPS, PWM, pokeweed mitogen, the comitogenic monoclonalantibodies (mAbs) CD2/CD2R, the superantigen staphylococcal enterotoxinB (SEB), and the specific antigen Candida albicans, SLAM, CD80 or CD86crosslinking of CD28, dexamethasone or another steroid, or anycombination of the above pretreatments.

Diseases to be Treated Non-Exclusively Relates to all Cancers andAutoimmune Diseases and Infectious Diseases.

In certain embodiments of the invention a patient would be identifiedand/or selected who has one or more diseases of cancer or autoimmunityor infection. The following list and tables contains a list of diseasesthat may be used to identify and/or select a patient:

Hemophagocytic lymphohistiocytosis, multiple myeloma, allergen specificimmunotherapy, autosomal dominant haploinsufficiency, anteriorinterosseous nerve syndrome, Churg-Strauss syndrome, Systemicvasculitis, chronic graft versus host disease, Opsoclonus-MyoclonusSyndrome, Necrotising Autoimmune Myopathy (NAM), Pulmonary Sarcomatoidcarcinomas, Waldenstrom's macroglobulinaemia (WM), fertility, BehcetsDisease, Alopecia areata (AA), Acute-on-chronic Liver Failure, melanoma,‘organizing bronchiolitis syndrome’, encephalitis, minimal changedisease, or a patient receiving Tumor flare reaction therapy orSublingual immunotherapy (SLIT) or subcutaneous immunotherapy (SCIT), orhaving:

Disease (Source of Disease)

Acinetobacter infections (Acinetobacter baumannii), Actinomycosis(Actinomyces israelii, Actinomyces gerencseriae and Propionibacteriumpropionicus) African sleeping sickness or African trypanosomiasis(Trypanosoma brucei), AIDS (Acquired immunodeficiency syndrome) (Humanimmunodeficiency virus), Amebiasis (Entamoeba histolytica), Anaplasmosis(Anaplasma species), Angiostrongyliasis (Angiostrongylus), Anisakiasis(Anisakis), Anthrax (Bacillus anthracis), Arcanobacterium haemolyticuminfection (Arcanobacterium haemolyticum), Argentine hemorrhagic fever(Junin virus), Ascariasis (Ascaris lumbricoides), Aspergillosis(Aspergillus species), Astrovirus infection (Astroviridae family),Babesiosis (Babesia species), Bacillus cereus infection (Bacilluscereus), Bacterial pneumonia (multiple bacteria), Bacterial vaginosis(List of bacterial vaginosis microbiota), Bacteroides infection(Bacteroides species), Balantidiasis (Balantidium coli), Bartonellosis(Bartonella), Baylisascaris infection (Baylisascaris species), BK virusinfection (BK virus), Black piedra (Piedraia hortae), Blastocystosis(Blastocystis species), Blastomycosis (Blastomyces dermatitidis),Bolivian hemorrhagic fever (Machupo virus), Botulism (and Infantbotulism) (Clostridium botulinum; Note: Botulism is not an infection byClostridium botulinum but caused by the intake of botulinum toxin),Brazilian hemorrhagic fever (Sabia virus), Brucellosis (Brucellaspecies), Bubonic plague (the bacterial family Enterobacteriaceae),Burkholderia infection, usually Burkholderia cepacia and otherBurkholderia species, Buruli ulcer (Mycobacterium ulcerans), Calicivirusinfection (Norovirus and Sapovirus) (Caliciviridae family),Campylobacteriosis (Campylobacter species), Candidiasis (Moniliasis;Thrush) (usually Candida albicans and other Candida species),Capillariasis (Intestinal disease by Capillaria philippinensis, hepaticdisease by Capillaria hepatica and pulmonary disease by Capillariaaerophila), Carrion's disease (Bartonella bacilliformis), Cat-scratchdisease (Bartonella henselae), Cellulitis (usually Group A Streptococcusand Staphylococcus), Chagas Disease (American trypanosomiasis)(Trypanosoma cruzi), Chancroid (Haemophilus ducreyi), Chickenpox(Varicella zoster virus (VZV)), Chikungunya (Alphavirus), Chlamydia(Chlamydia trachomatis), Chlamydophila pneumoniae infection (Taiwanacute respiratory agent or TWAR) (Chlamydophila pneumoniae), Cholera(Vibrio cholerae), Chromoblastomycosis (usually Fonsecaea pedrosoi),Chytridiomycosis (Batrachochytrium dendrabatidis), Clonorchiasis(Clonorchis sinensis), Clostridium difficile colitis (Clostridiumdifficile), Coccidioidomycosis (Coccidioides immitis and Coccidioidesposadasii), Colorado tick fever (CTF) (Colorado tick fever virus(CTFV)), Common cold (Acute viral rhinopharyngitis; Acute coryza)(usually rhinoviruses and coronaviruses), Creutzfeldt-Jakob disease(CJD) (PRNP), Crimean-Congo hemorrhagic fever (CCHF) (Crimean-Congohemorrhagic fever virus), Cryptococcosis (Cryptococcus neoformans),Cryptosporidiosis (Cryptosporidium species), Cutaneous larva migrans(CLM) (usually Ancylostoma braziliense; multiple other parasites),Cyclosporiasis (Cyclospora cayetanensis), Cysticercosis (Taenia solium),Cytomegalovirus infection (Cytomegalovirus), Dengue fever (Dengueviruses (DEN-1, DEN-2, DEN-3 and DEN-4)—Flaviviruses), Desmodesmusinfection (Green algae Desmodesmus armatus), Dientamoebiasis(Dientamoeba fragilis), Diphtheria (Corynebacterium diphtheriae),Diphyllobothriasis (Diphyllobothrium), Dracunculiasis (Dracunculusmedinensis), Ebola hemorrhagic fever (Ebolavirus (EBOV)), Echinococcosis(Echinococcus species), Ehrlichiosis (Ehrlichia species), Enterobiasis(Pinworm infection) (Enterobius vermicularis), Enterococcus infection(Enterococcus species), Enterovirus infection (Enterovirus species),Epidemic typhus (Rickettsia prowazekii), Erythema infectiosum (Fifthdisease) (Parvovirus B19), Exanthem subitum (Sixth disease) (Humanherpesvirus 6 (HHV-6) and Human herpesvirus 7 (HHV-7)), Fasciolasis(Fasciola hepatica and Fasciola gigantica), Fasciolopsiasis(Fasciolopsis buski), Fatal familial insomnia (FFI) (PRNP), Filariasis(Filarioidea superfamily), Food poisoning by Clostridium perfringens(Clostridium perfringens), Free-living amebic infection (multiple),Fusobacterium infection (Fusobacterium species), Gas gangrene(Clostridial myonecrosis) (usually Clostridiumperfringens; otherClostridium species), Geotrichosis (Geotrichum candidum),Gerstmann-Straussler-Scheinker syndrome (GSS) (PRNP), Giardiasis(Giardia lamblia) Glanders (Burkholderia mallei), Gnathostomiasis(Gnathostoma spinigerum and Gnathostoma hispidum), Gonorrhea (Neisseriagonorrhoeae), Granuloma inguinale (Donovanosis) (Klebsiellagranulomatis), Group A streptococcal infection (Streptococcus pyogenes),Group B streptococcal infection (Streptococcus agalactiae), Haemophilusinfluenzae infection (Haemophilus influenzae) Hand, foot and mouthdisease (HFMD) (Enteroviruses, mainly Coxsackie A virus and Enterovirus71 (EV71)), Hantavirus Pulmonary Syndrome (HPS) (Sin Nombre virus),Heartland virus disease (Heartland virus), Helicobacter pylori infection(Helicobacter pylori), Hemolytic-uremic syndrome (HUS), Escherichia coliO157:H7, O111 and O104:H4, Hemorrhagic fever with renal syndrome (HFRS)(Bunyaviridae family), Hepatitis A (Hepatitis A virus), Hepatitis B(Hepatitis B virus), Hepatitis C (Hepatitis C virus), Hepatitis D(Hepatitis D Virus), Hepatitis E (Hepatitis E virus), Herpes simplex(Herpes simplex virus 1 and 2 (HSV-1 and HSV-2)), Histoplasmosis(Histoplasma capsulatum), Hookworm infection (Ancylostoma duodenale andNecator americanus), Human bocavirus infection (Human bocavirus (HBoV)),Human ewingii ehrlichiosis (Ehrlichia ewingii), Human granulocyticanaplasmosis (HGA) (Anaplasma phagocytophilum), Human metapneumovirusinfection, Human metapneumovirus (hMPV), Human monocytic ehrlichiosis(Ehrlichia chaffeensis), Human papillomavirus (HPV) infection (Humanpapillomavirus (HPV)), Human parainfluenza virus infection (Humanparainfluenza viruses (HPIV)), Hymenolepiasis (Hymenolepis nana andHymenolepis diminuta), Epstein-Barr virus infectious mononucleosis(Mono) (Epstein-Barr virus (EBV)), Influenza (flu) (Orthomyxoviridaefamily) Isosporiasis (Isospora belli), Kawasaki disease (unknown;evidence supports that it is infectious) Keratitis (multiple), Kingellakingae infection (Kingella kingae), Kuru (PRNP), Lassa fever (Lassavirus), Legionellosis (Legionnaires' disease) (Legionella pneumophila),Legionellosis (Pontiac fever) (Legionella pneumophila), Leishmaniasis(Leishmania species), Leprosy (Mycobacterium leprae and Mycobacteriumlepromatosis), Leptospirosis (Leptospira species), Listeriosis (Listeriamonocytogenes), Lyme disease (Lyme borreliosis) (Borrelia burgdorferi,Borrelia garinii, and Borrelia afzelii), Lymphatic filariasis(Elephantiasis) (Wuchereria bancrofti and Brugia malayi), Lymphocyticchoriomeningitis (Lymphocytic choriomeningitis virus (LCMV)), Malaria(Plasmodium species), Marburg hemorrhagic fever (MHF) (Marburg virus),Measles (Measles virus), Middle East respiratory syndrome (MERS) (MiddleEast respiratory syndrome coronavirus), Melioidosis (Whitmore's disease)(Burkholderia pseudomallei), Meningitis (multiple), Meningococcaldisease (Neisseria meningitidis), Metagonimiasis (usually Metagonimusyokagawai), Microsporidiosis (Microsporidia phylum), Molluscumcontagiosum (MC) (Molluscum contagiosum virus (MCV)), Monkeypox(Monkeypox virus), Mumps (Mumps virus), Murine typhus (Endemic typhus)(Rickettsia typhi), Mycoplasma pneumonia (Mycoplasma pneumoniae),Mycetoma (disambiguation) (numerous species of bacteria (Actinomycetoma)and fungi (Eumycetoma)), Myiasis (parasitic dipterous fly larvae),Neonatal conjunctivitis (Ophthalmia neonatorum) (most commonly Chlamydiatrachomatis and Neisseria gonorrhoeae), Norovirus (children and babies)((New) Variant Creutzfeldt-Jakob disease (vCJD, nvCJD), PRNP),Nocardiosis (usually Nocardia asteroides and other Nocardia species),Onchocerciasis (River blindness) (Onchocerca volvulus), Opisthorchiasis(Opisthorchis viverrini and Opisthorchis felineus),Paracoccidioidomycosis (South American blastomycosis) (Paracoccidioidesbrasiliensis), Paragonimiasis (usually Paragonimus westermani and otherParagonimus species), Pasteurellosis (Pasteurella species), Pediculosiscapitis (Head lice) (Pediculus humanus capitis), Pediculosis corporis(Body lice) (Pediculus humanus corporis), Pediculosis pubis (Pubic lice,Crab lice) (Phthirus pubis), Pelvic inflammatory disease (PID)(multiple), Pertussis (Whooping cough) (Bordetella pertussis), Plague(Yersinia pestis), Pneumococcal infection (Streptococcus pneumoniae),Pneumocystis pneumonia (PCP) (Pneumocystis jirovecii), Pneumonia(multiple), Poliomyelitis (Poliovirus), Prevotella infection (Prevotellaspecies), Primary amoebic meningoencephalitis (PAM) (usually Naegleriafowleri), Progressive multifocal leukoencephalopathy (JC virus),Psittacosis (Chlamydophila psittaci), Q fever (Coxiella burnetii),Rabies (Rabies virus), Relapsing fever (Borrelia hermsii, Borreliarecurrentis, and other Borrelia species), Respiratory syncytial virusinfection (Respiratory syncytial virus (RSV)), Rhinosporidiosis(Rhinosporidium seeberi), Rhinovirus infection (Rhinovirus), Rickettsialinfection (Rickettsia species), Rickettsialpox (Rickettsia akari), RiftValley fever (RVF) (Rift Valley fever virus), Rocky Mountain spottedfever (RMSF) (Rickettsia rickettsii), Rotavirus infection (Rotavirus),Rubella (Rubella virus), Salmonellosis (Salmonella species), SARS(Severe Acute Respiratory Syndrome) (SARS coronavirus), Scabies(Sarcoptes scabiei), Schistosomiasis (Schistosoma species), Sepsis(multiple), Shigellosis (Bacillary dysentery) (Shigella species),Shingles (Herpes zoster) (Varicella zoster virus (VZV)), Smallpox(Variola) (Variola major or Variola minor), Sporotrichosis (Sporothrixschenckii), Staphylococcal food poisoning (Staphylococcus species),Staphylococcal infection (Staphylococcus species), Strongyloidiasis(Strongyloides stercoralis), Subacute sclerosing panencephalitis(Measles virus), Syphilis (Treponema pallidum), Taeniasis (Taeniaspecies), Tetanus (Lockjaw) (Clostridium tetani), Tinea barbae (Barber'sitch) (usually Trichophyton species), Tinea capitis (Ringworm of theScalp) (usually Trichophyton tonsurans), Tinea corporis (Ringworm of theBody) (usually Trichophyton species), Tinea cruris (Jock itch) (usuallyEpidermophyton floccosum, Trichophyton rubrum, and Trichophytonmentagrophytes), Tinea manum (Ringworm of the Hand) (Trichophytonrubrum), Tinea nigra (usually Hortaea werneckii), Tinea pedis (Athlete'sfoot) (usually Trichophyton species), Tinea unguium (Onychomycosis)(usually Trichophyton species), Tinea versicolor (Pityriasis versicolor)(Malassezia species), Toxocariasis (Ocular Larva Migrans (OLM))(Toxocara canis or Toxocara cati), Toxocariasis (Visceral Larva Migrans(VLM)) (Toxocara canis or Toxocara cati), Trachoma (Chlamydiatrachomatis), Toxoplasmosis (Toxoplasma gondii), Trichinosis(Trichinella spiralis), Trichomoniasis (Trichomonas vaginalis),Trichuriasis (Whipworm infection) (Trichuris trichiura), Tuberculosis(usually Mycobacterium tuberculosis), Tularemia (Francisellatularensis), Typhoid fever (Salmonella enterica subsp. enterica, serovartyphi), Typhus fever (Rickettsia), Ureaplasma urealyticum infection(Ureaplasma urealyticum), Valley fever (Coccidioides immitis orCoccidioides posadasii), Venezuelan equine encephalitis (Venezuelanequine encephalitis virus), Venezuelan hemorrhagic fever (Guanaritovirus), Vibrio vulnificus infection (Vibrio vulnificus), Vibrioparahaemolyticus enteritis (Vibrio parahaemolyticus), Viral pneumonia(multiple viruses), West Nile Fever (West Nile virus), White piedra(Tinea blanca) (Trichosporon beigelii), Yersinia pseudotuberculosisinfection (Yersinia pseudotuberculosis), Yersiniosis (Yersiniaenterocolitica), Yellow fever (Yellow fever virus), Zygomycosis(Mucorales order (Mucormycosis) and Entomophthorales order(Entomophthoramycosis)) Human immunodeficiency virus [HIV] disease, HIVdisease with infectious and parasitic diseases, HIV disease withmycobacterial infection, HIV disease with cytomegaloviral disease, HIVdisease with other viral infections, HIV disease with candidiasis, HIVdisease with other mycoses, HIV disease with Pneumocystic cariniipneumonia, HIV disease with malignant neoplasms, HIV disease withKaposi's sarcoma, HIV disease with Burkitt's lymphoma, HIV disease withother type's of non-Hodgkin's lymphoma, HIV disease with other malignantneoplasms of lymphoid, hematopoietic and related tissue, HIV diseasewith multiple malignant neoplasms, HIV disease with other malignantneoplasms, HIV disease with unspecified malignant neoplasm, HIV diseasewith encephalopathy, HIV disease with lymphoid interstitial pneumonitis,HIV disease with wasting syndrome, HIV disease with multiple diseasesclassified elsewhere, HIV disease with other conditions, HIV diseaseAcute HIV infection syndrome, HIV disease with (persistent) generalizedlymphadenopathy, HIV disease with hematological and immunologicalabnormalities, not elsewhere classified, HIV disease with otherspecified conditions, Unspecified HIV disease, Malignant neoplasm oflip, Malignant neoplasm of tonsil, Malignant neoplasm of tongue,Malignant neoplasm of gum, Malignant neoplasm of mouth, Malignantneoplasm of parotid gland, Malignant neoplasm of salivary glands,Malignant neoplasm of pharynx, Malignant neoplasm of esophagus,Malignant neoplasm of stomach, Malignant neoplasm of small intestine,Malignant neoplasm of colon, Malignant neoplasm of recto sigmoidjunction, Malignant neoplasm of rectum, Malignant neoplasm of anus,Malignant neoplasm of liver, Malignant neoplasm of gallbladder,Malignant neoplasm of biliary tract, Malignant neoplasm of pancreas,Malignant neoplasm of intestinal tract, Malignant neoplasm of spleen,Malignant neoplasm of nasal cavity and middle ear, Malignant neoplasm ofaccessory sinuses, Malignant neoplasm of larynx, Malignant neoplasm oftrachea, Malignant neoplasm of bronchus and lung, Malignant neoplasm ofthymus, Malignant neoplasm of heart, mediastinum and pleura, Malignantneoplasm of sites in the respiratory system and intrathoracic organs,Malignant neoplasm of bone and articular cartilage of limbs, Malignantneoplasm of bones of skull and face, Malignant neoplasm of vertebralcolumn, Malignant neoplasm of ribs, sternum and clavicle, Malignantneoplasm of pelvic bones, sacrum and coccyx, Malignant melanoma of skin,Malignant melanoma of lip, Malignant melanoma of eyelid, includingcanthus, Malignant melanoma of ear and external auricular canal,Malignant melanoma of face, Malignant melanoma of anal skin, Malignantmelanoma of skin of breast, Malignant melanoma of limbs, includingshoulder, Merkel cell carcinoma, Basal cell carcinoma of skin of lip,Squamous cell carcinoma of skin of lip, Other and unspecified malignantneoplasm skin/eyelid, including canthus, Malignant neoplasm skin/ear andexternal auric canal, Other and unspecified malignant neoplasm skin/andunspecified parts of face, Basal cell carcinoma of skin of other andunspecified parts of face, Squamous cell carcinoma of skin of andunspecified parts of face, Basal cell carcinoma of skin of scalp andneck, Squamous cell carcinoma of skin of scalp and neck, Basal cellcarcinoma of skin of trunk, Basal cell carcinoma of anal skin, Basalcell carcinoma of skin of breast, Squamous cell carcinoma of skin oftrunk, Squamous cell carcinoma of anal skin, Squamous cell carcinoma ofskin of breast, Squamous cell carcinoma of skin of other part of trunk,Other and unspecified malignant neoplasm skin/limbs including shoulder,Basal cell carcinoma skin/limbs, including shoulder, Squamous cellcarcinoma skin/limbs, including shoulder, Basal cell carcinoma of skinof limbs, including hip, Squamous cell carcinoma of skin of limbs,including hip, Mesothelioma, Kaposi's sarcoma, Malignant neoplasm ofperipheral nerves and autonomic nervous sys, Malignant neoplasm ofretroperitoneum and peritoneum, Malignant neoplasm of other connectiveand soft tissue, Malignant neoplasm of connective and soft tissue ofthorax, Malignant neoplasm of connective and soft tissue of abdomen,Malignant neoplasm of connective and soft tissue of pelvis, Malignantneoplasm of conn and soft tissue of trunk, unspecified, Malignantneoplasm of overlapping sites of connective and soft tissue, Malignantneoplasm of connective and soft tissue, unspecified, Gastrointestinalstromal tumor, Malignant neoplasm of breast, Malignant neoplasm ofvulva, Malignant neoplasm of vagina, Malignant neoplasm of cervix uteri,Malignant neoplasm of corpus uteri, Malignant neoplasm of uterus, partunspecified, Malignant neoplasm of ovary, Malignant neoplasm of otherand unspecified female genital organs, Malignant neoplasm of placenta,Malignant neoplasm of penis, Malignant neoplasm of prostate, Malignantneoplasm of testis, Malignant neoplasm of other and unspecified malegenital organs, Malignant neoplasm of kidney, Malignant neoplasm ofrenal pelvis, Malignant neoplasm of ureter, Malignant neoplasm ofbladder, Malignant neoplasm of other and unspecified urinary organs,Malignant neoplasm of eye and adnexa, Malignant neoplasm of meninges,Malignant neoplasm of brain, Malignant neoplm of spinal cord, cranialnerves, Malignant neoplasm of optic nerve, Malignant neoplasm of otherand unspecified cranial nerves, Malignant neoplasm of central nervoussystem, unspecified, Malignant neoplasm of thyroid gland, Malignantneoplasm of adrenal gland, Malignant neoplasm of endo glands and relatedstructures, Malignant neuroendocrine tumors, Malignant carcinoid tumors,Secondary neuroendocrine tumors, Malignant neoplasm of head, face andneck, Malignant neoplasm of thorax, Malignant neoplasm of abdomen,Malignant neoplasm of pelvis, Malignant neoplasm of limbs, Malignantneoplasm of lower limb, Secondary and unspecified malignant neoplasm oflymph nodes, Secondary malignant neoplasm of respiratory and digestiveorgans, Secondary malignant neoplasm of kidney and renal pelvis,Secondary malignant neoplm of bladder and other and unspecified urinaryorgans, Secondary malignant neoplasm of skin, Secondary malignantneoplasm of brain and cerebral meninges, Secondary malignant neoplasm ofand unspecified parts of nervous sys, Secondary malignant neoplasm ofbone and bone marrow, Secondary malignant neoplasm of ovary, Secondarymalignant neoplasm of adrenal gland, Hodgkin lymphoma, Follicularlymphoma, Non-follicular lymphoma, Small cell B-cell lymphoma, Mantlecell lymphoma, Diffuse large B-cell lymphoma, Lymphoblastic (diffuse)lymphoma, Burkitt lymphoma, Other non-follicular lymphoma,Non-follicular (diffuse) lymphoma, unspecified, Mature T/NK-celllymphomas, Sezary disease, Peripheral T-cell lymphoma, not classified,Anaplastic large cell lymphoma, ALK-positive, Anaplastic large celllymphoma, ALK-negative, Cutaneous T-cell lymphoma, unspecified, Othermature T/NK-cell lymphomas, Mature T/NK-cell lymphomas, unspecified,Other and unspecified types of non-Hodgkin lymphoma, Malignantimmunoproliferative dis and certain other B-cell lymph, Multiple myelomaand malignant plasma cell neoplasms, Lymphoid leukemia, Acutelymphoblastic leukemia [ALL], Chronic lymphocytic leukemia of B-celltype, Prolymphocytic leukemia of B-cell type, Hairy cell leukemia, AdultT-cell lymphoma/leukemia (HTLV-1-associated), Prolymphocytic leukemia ofT-cell type, Mature B-cell leukemia Burkitt-type, Other lymphoidleukemia, Lymphoid leukemia, unspecified, Myeloid leukemia, Acutemyeloblastic leukemia, Chronic myeloid leukemia, BCR/ABL-positive,Atypical chronic myeloid leukemia, BCR/ABL-negative, Myeloid sarcoma,Acute promyelocytic leukemia, Acute myelomonocytic leukemia, Acutemyeloid leukemia with 11q23-abnormality, Other myeloid leukemia, Myeloidleukemia, unspecified, Monocytic leukemia, Chronic myelomonocyticleukemia, Juvenile myelomonocytic leukemia, Other monocytic leukemia,Monocytic leukemia, unspecified, Other leukemias of specified cell type,Acute erythroid leukemia, Acute megakaryoblastic leukemia, Mast cellleukemia, Acute panmyelosis with myelofibrosis, Myelodysplastic disease,not classified, Other specified leukemias, Leukemia of unspecified celltype, Chronic leukemia of unspecified cell type, Leukemia, unspecified,Other & unspecified malignant neoplasm of lymphoid, hematopoietictissue, Carcinoma in situ of oral cavity, esophagus and stomach,Carcinoma in situ of colon, Carcinoma in situ of recto sigmoid junction,Carcinoma in situ of rectum, Carcinoma in situ of anus and anal canal,Carcinoma in situ of other and unspecified parts of intestine, Carcinomain situ of unspecified part of intestine, Carcinoma in situ of otherparts of intestine, Carcinoma in situ of liver, gallbladder and bileducts, Carcinoma in situ of other specified digestive organs, Carcinomain situ of digestive organ, unspecified, Carcinoma in situ of middle earand respiratory system, Carcinoma in situ of larynx, Carcinoma in situof trachea, Carcinoma in situ of bronchus and lung, Carcinoma in situ ofother parts of respiratory system, Melanoma in situ, Melanoma in situ oflip, Melanoma in situ of eyelid, including canthus, Melanoma in situ ofear and external auricular canal, Melanoma in situ of unspecified partof face, Melanoma in situ of scalp and neck, Melanoma in situ of trunk,Melanoma in situ of anal skin, Melanoma in situ of breast (skin) (softtissue), Melanoma in situ of upper limb, including shoulder, Melanoma insitu of lower limb, including hip, Melanoma in situ of other sites,Carcinoma in situ of skin, Carcinoma in situ of skin of lip, Carcinomain situ of skin of eyelid, including canthus, Carcinoma in situ skin ofear and external auricular canal, Carcinoma in situ of skin of other andunspecified parts of face, Carcinoma in situ of skin of scalp and neck,Carcinoma in situ of skin of trunk, Carcinoma in situ of skin of upperlimb, including shoulder, Carcinoma in situ of skin of lower limb,including hip, Carcinoma in situ of skin of other sites, Carcinoma insitu of breast, Lobular carcinoma in situ of breast, Intraductalcarcinoma in situ of breast, Other specified type of carcinoma in situof breast, Unspecified type of carcinoma in situ of breast, Carcinoma insitu of cervix uteri, Carcinoma in situ of other parts of cervix,Carcinoma in situ of cervix, unspecified, Carcinoma in situ of other andunspecified genital organs, Carcinoma in situ of endometrium, Carcinomain situ of vulva, Carcinoma in situ of vagina, Carcinoma in situ ofother and unspecified female genital organs, Carcinoma in situ of penis,Carcinoma in situ of prostate, Carcinoma in situ of unspecified malegenital organs, Carcinoma in situ of scrotum, Carcinoma in situ of othermale genital organs, Carcinoma in situ of bladder, Carcinoma in situ ofother and unspecified urinary organs, Carcinoma in situ of eye,Carcinoma in situ of thyroid and other endocrine glands, Benign neoplasmof mouth and pharynx, Benign neoplasm of major salivary glands, Benignneoplasm of colon, rectum, anus and anal canal, Benign neoplasm of andill-defined parts of digestive system, Benign neoplasm of esophagus,Benign neoplasm of stomach, Benign neoplasm of duodenum, Benign neoplasmof other and unspecified parts of small intestine, Benign neoplasm ofliver, Benign neoplasm of extrahepatic bile ducts, Benign neoplasm ofpancreas, Benign neoplasm of endocrine pancreas, Benign neoplasm ofill-defined sites within the digestive system, Benign neoplasm of middleear and respiratory system, Benign neoplasm of respiratory system,unspecified, Benign neoplasm of other and unspecified intrathoracicorgans, Benign neoplasm of thymus, Benign neoplasm of heart, Benignneoplasm of mediastinum, Benign neoplasm of other specifiedintrathoracic organs, Benign neoplasm of intrathoracic organ,unspecified, Benign neoplasm of bone and articular cartilage, Benignneoplasm of short bones of upper limb, Benign neoplasm of long bones oflower limb, Benign neoplasm of short bones of lower limb, Benignneoplasm of bones of skull and face, Benign neoplasm of lower jaw bone,Benign neoplasm of vertebral column, Benign neoplasm of ribs, sternumand clavicle, Benign neoplasm of pelvic bones, sacrum and coccyx, Benignneoplasm of bone and articular cartilage, unspecified, Benign lipomatousneoplasm, Ben lipomatous neoplm of skin, subcutaneous of head, face andneck, Benign lipomatous neoplasm of intrathoracic organs, Benignlipomatous neoplasm of intra-abdominal organs, Benign lipomatousneoplasm of spermatic cord, Benign lipomatous neoplasm of other sites,Benign lipomatous neoplasm of kidney, Benign lipomatous neoplasm ofother genitourinary organ, Hemangioma and lymphangioma, any site,Hemangioma, Hemangioma unspecified site, Hemangioma of skin andsubcutaneous tissue, Hemangioma of intracranial structures, Hemangiomaof intra-abdominal structures, Hemangioma of other sites, Lymphangioma,any site, Benign neoplasm of mesothelial tissue, Benign neoplm of softtissue of retroperitoneum and peritoneum, Other benign neoplasms ofconnective and other soft tissue, Melanocytic nevi, Melanocytic nevi oflip, Melanocytic nevi of eyelid, including canthus, Melanocytic nevi ofunspecified eyelid, including canthus, Melanocytic nevi of ear andexternal auricular canal, Melanocytic nevi of other and unspecifiedparts of face, Melanocytic nevi of scalp and neck, Melanocytic nevi oftrunk, Melanocytic nevi of upper limb, including shoulder, Melanocyticnevi of lower limb, including hip, Melanocytic nevi, unspecified, Otherbenign neoplasm of skin of eyelid, including canthus, Other benignneoplasm skin/ear and external auricular canal, Other benign neoplasmskin/left ear and external auric canal, Other benign neoplasm of skin ofother and unspecified parts of face, Other benign neoplasm of skin ofother parts of face, Other benign neoplasm of skin of scalp and neck,Other benign neoplasm of skin of trunk, Other benign neoplasm skin/upperlimb, including shoulder, Other benign neoplasm of skin of lower limb,including hip, Other benign neoplasm of skin, unspecified, Benignneoplasm of breast, Benign neoplasm of unspecified breast, Leiomyoma ofuterus, Other benign neoplasms of uterus, Benign neoplasm of ovary,Benign neoplasm of other and unspecified female genital organs, Benignneoplasm of male genital organs, Benign neoplasm of urinary organs,Benign neoplasm of kidney, Benign neoplasm of renal pelvis, Benignneoplasm of ureter, Benign neoplasm of bladder, Benign neoplasm ofurethra, Benign neoplasm of other specified urinary organs, Benignneoplasm of urinary organ, unspecified, Benign neoplasm of eye andadnexa, Benign neoplasm of conjunctiva, Benign neoplasm of cornea,Benign neoplasm of retina, Benign neoplasm of choroid, Benign neoplasmof ciliary body, Benign neoplasm of lacrimal gland and duct, Benignneoplasm of unspecified site of orbit, Benign neoplasm of unspecifiedpart of eye, Benign neoplasm of meninges, Benign neoplasm of brain andcentral nervous system, Benign neoplasm of thyroid gland, Benignneoplasm of other and unspecified endocrine glands, Benign neoplasm ofother and unspecified sites, Benign neoplasm of lymph nodes, Benignneoplasm of peripheral nerves and autonomic nervous sys, Benign neoplasmof other specified sites, Benign neuroendocrine tumors, Other benignneuroendocrine tumors, Neoplasm of uncertain behavior of oral cavity anddigestive organs, Neoplasm of uncertain behavior of the major salivaryglands, Neoplasm of uncertain behavior of pharynx, Neoplasm of uncertainbehavior of sites of the oral cavity, Neoplasm of uncertain behavior ofstomach, Neoplasm of uncertain behavior of small intestine, Neoplasm ofuncertain behavior of appendix, Neoplasm of uncertain behavior of colon,Neoplasm of uncertain behavior of rectum, Neoplasm of uncertain behaviorof liver, GB & bile duct, Neoplasm of uncertain behavior of otherdigestive organs, Neoplasm of uncertain behavior of digestive organ,Neoplm of mid ear and intrathoracic organs, Neoplasm of uncertainbehavior of larynx, Neoplasm of uncertain behavior of trachea, bronchusand lung, Neoplasm of uncertain behavior of pleura, Neoplasm ofuncertain behavior of mediastinum, Neoplasm of uncertain behavior ofthymus, Neoplasm of uncertain behavior of other respiratory organs,Neoplasm of uncertain behavior of respiratory organ, unspecified,Neoplasm of uncertain behavior of female genital organs, Neoplasm ofuncertain behavior of uterus, Neoplasm of uncertain behavior of ovary,Neoplasm of uncertain behavior of unspecified ovary, Neoplasm ofuncertain behavior of placenta, Neoplasm of uncertain behavior of malegenital organs, Neoplasm of uncertain behavior of urinary organs,Neoplasm of uncertain behavior of kidney, Neoplasm of uncertain behaviorof unspecified kidney, Neoplasm of uncertain behavior of renal pelvis,Neoplasm of uncertain behavior of ureter, Neoplasm of uncertain behaviorof bladder, Neoplasm of uncertain behavior of other urinary organs,Neoplasm of uncertain behavior of unspecified urinary organ, Neoplasm ofuncertain behavior of meninges, Neoplasm of uncertain behavior ofcerebral meninges, Neoplasm of uncertain behavior of spinal meninges,Neoplasm of uncertain behavior of meninges, unspecified, Neoplasm ofuncertain behavior of brain, Neoplasm of uncertain behavior of brain,Neoplasm of uncertain behavior of brain, infratentorial, Neoplasm ofuncertain behavior of brain, unspecified, Neoplasm of uncertain behaviorof cranial nerves, Neoplasm of uncertain behavior of spinal cord,Neoplasm of uncertain behavior of central nervous system, Neoplasm ofuncertain behavior of endocrine glands, Neoplasm of uncertain behaviorof thyroid gland, Neoplasm of uncertain behavior of adrenal gland,Neoplasm of uncertain behavior of unspecified adrenal gland, Neoplasm ofuncertain behavior of parathyroid gland, Neoplasm of uncertain behaviorof pituitary gland, Neoplasm of uncertain behavior of craniopharyngealduct, Neoplasm of uncertain behavior of pineal gland, Neoplasm ofuncertain behavior of carotid body, Neoplasm of uncertain behavior ofaortic body and other paraganglia, Neoplasm of uncertain behavior ofunspecified endocrine gland, Polycythemia vera, Myelodysplasticsyndromes, Refractory anemia without ring sideroblasts, so stated,Refractory anemia with ring sideroblasts, Refractory anemia with excessof blasts [RAEB], Myelodysplastic syndrome, unspecified, Other neoplm ofuncertain behavior of lymphoid, hematopoietic tissue, Histiocytic andmast cell tumors of uncertain behavior, Chronic myeloproliferativedisease, Monoclonal gammopathy, Essential (hemorrhagic) thrombocythemia,Osteomyelofibrosis, Other neoplasm of uncertain behavior of lymphoid,hematopoietic tissue, Neoplasm of uncertain behavior of lymphoid,hematopoietic & unspecified, Neoplasm of uncertain behavior of other andunspecified sites, Neoplasm of uncertain behavior of bone/articcartilage, Neoplasm of uncertain behavior of connective/soft tissue,Neoplasm of uncertain behavior of peripheral nerves and autonomousnervous sys, Neoplasm of uncertain behavior of retroperitoneum, Neoplasmof uncertain behavior of peritoneum, Neoplasm of uncertain behavior ofskin, Neoplasm of uncertain behavior of breast, Neoplasm of unspecifiedbehavior of digestive system, Neoplasm of unspecified behavior ofrespiratory system, Neoplasm of unspecified behavior of bone, softtissue, and skin, Neoplasm of unspecified behavior of breast, Neoplasmof unspecified behavior of bladder, Neoplasm of unspecified behavior ofother genitourinary organs, Neoplasm of unspecified behavior of kidney,Neoplasm of unspecified behavior of other GU organ, Neoplasm ofunspecified behavior of brain, Neoplasm of unspecified behavior of endoglands and other parts of nervous sys, Neoplasm of unspecified behaviorof retina and choroid, Neoplasm of unspecified behavior of unspecifiedsite, Iron deficiency anemia, Vitamin B12 deficiency anemia, Folatedeficiency anemia, Protein deficiency anemia, Other megaloblasticanemias, not elsewhere classified, Scorbutic anemia, Other specifiednutritional anemias, Nutritional anemia, unspecified, Anemia due toenzyme disorders, Anemia, Thalassemia, Hereditary persistence of fetalhemoglobin [HPFH], Hemoglobin E-beta thalassemia, Other thalassemia's,Thalassemia, unspecified, Sickle-cell disorders, Other hereditaryhemolytic anemias, Acquired hemolytic anemia, Acquired pure red cellaplasia [erythroblastopenia], Acquired pure red cell aplasia,unspecified, Other aplastic anemias and other bone marrow failuresyndromes, Drug-induced aplastic anemia, Aplastic anemia due to otherexternal agents, Idiopathic aplastic anemia, Other aplastic anemias andother bone marrow failure syndromes, Aplastic anemia, unspecified, Acuteposthemorrhagic anemia, Anemia, Disseminated intravascular coagulation,Hereditary factor VIII deficiency, Hereditary factor IX deficiency,Other coagulation defects, Acquired coagulation factor deficiency,Primary thrombophilia, Other thrombophilia, Purpura and otherhemorrhagic conditions, Secondary thrombocytopenia, Thrombocytopenia,unspecified, Other specified hemorrhagic conditions, Hemorrhagiccondition, unspecified, Neutropenia, Congenital agranulocytosis,Agranulocytosis secondary to cancer chemotherapy, Other drug-inducedagranulocytosis, Neutropenia due to infection, Cyclic neutropenia, Otherneutropenia, Other disorders of white blood cells, Genetic anomalies ofleukocytes, Eosinophilia, Other specified disorders of white bloodcells, Decreased white blood cell count, Lymphocytosis (symptomatic),Diseases of spleen, Methemoglobinemia, Congenital methemoglobinemia,Other methemoglobinemias, Methemoglobinemia, unspecified, Other andunspecified diseases of blood and blood-forming organs, Familialerythrocytosis, Secondary polycythemia, Other specified diseases ofblood and blood-forming organs, Myelofibrosis, Heparin inducedthrombocytopenia (HIT), Other specified diseases of blood andblood-forming organs, Other dis with lymphoreticular andreticulohistiocytic tissue, Intraoperative and postproceduralcomplications of the spleen, Immunodeficiency with predominantlyantibody defects, Hereditary hypogammaglobulinemia, Nonfamilialhypogammaglobulinemia, Selective deficiency of immunoglobulin A [IgA],Selective deficiency of immunoglobulin G [IgG] subclasses, Selectivedeficiency of immunoglobulin M [IgM], Immunodeficiency with increasedimmunoglobulin M [IgM], Antibody deficiency w near-norm immunoglobulinor w hyperimmunoglobulin, Transient hypogammaglobulinemia of infancy,Other immunodeficiencies with predominantly antibody defects,Immunodeficiency with predominantly antibody defects, unspecified,Combined immunodeficiencies, Severe combined immunodeficiency withreticular dysgenesis, Severe combined immunodeficiency w low T- andB-cell numbers, Severe combined immunodeficiencies w low or normalB-cell numbers, Adenosine deaminase [ADA] deficiency, Nezelofs syndrome,Purine nucleoside phosphorylase [PNP] deficiency, Majorhistocompatibility complex class I deficiency, Major histocompatibilitycomplex class II deficiency, Other combined immunodeficiencies, Combinedimmunodeficiency, unspecified, Immunodeficiency associated with othermajor defects, Wiskott-Aldrich syndrome, Di George's syndrome,Immunodeficiency with short-limbed stature, Immunodeficiency followingresponse to Epstein-Barr virus, Hyperimmunoglobulin E [IgE] syndrome,Immunodeficiency associated with other major defects, Immunodeficiencyassociated with major defect, unspecified, Common variableimmunodeficiency, Other immunodeficiencies, Lymphocyte functionantigen-1 [LFA-1] defect, Defects in the complement system, Otherspecified immunodeficiencies, Sarcoidosis, Other disorders involving theimmune mechanism, NEC, Polyclonal hypergammaglobulinemia,Cryoglobulinemia, Hypergammaglobulinemia, unspecified, Immunereconstitution syndrome, Mast cell activation syndrome and relateddisorders, Mast cell activation, unspecified, Monoclonal mast cellactivation syndrome, Idiopathic mast cell activation syndrome, Secondarymast cell activation, Other mast cell activation disorder, Otherdisorders involving the immune mechanism, NEC, Graft-versus-hostdisease, Acute graft-versus-host disease, Chronic graft-versus-hostdisease, Acute on chronic graft-versus-host disease, Graft-versus-hostdisease, unspecified, Autoimmune lymphoproliferative syndrome [ALPS],Other disorders involving the immune mechanism, NEC, Disorder involvingthe immune mechanism, unspecified, Autoimmune thyroiditis, Type 1diabetes mellitus, Other diabetes mellitus with other specifiedcomplication, Primary adrenocortical insufficiency, Autoimmunepolyglandabular failure, Dementia in human immunodeficiency virus [HIV]disease (B22.0), Multiple sclerosis, Guillain-Barre syndrome, Myastheniagravis without (acute) exacerbation, Myasthenia gravis with (acute)exacerbation, Cytotoxic myoneural disorders, Congenital anddevelopmental myasthenia, Lambert-Eaton syndrome, unspecified,Lambert-Eaton syndrome in disease classified elsewhere, Other specifiedmyoneural disorders, Myoneural disorder, unspecified, Unspecified acuteand subacute iridocyclitis, Crohn's disease, Ulcerative (chronic)pancolitis, Inflammatory polyps of colon, Left sided colitis, Otherulcerative colitis without/with complications, Chronic persistenthepatitis, Chronic lobular hepatitis, Chronic active hepatitis, Otherchronic hepatitis, Chronic hepatitis, unspecified, Primary biliarycirrhosis, Autoimmune hepatitis, Celiac disease, Pemphigus, Bullouspemphigoid, Cicatricial pemphigoid, Chronic bullous disease ofchildhood, Acquired epidermolysis bullosa, unspecified, Other acquiredepidermolysis bullosa, Other pemphigoid, Psoriasis vulgaris, Otherpsoriatic arthropathy, Alopecia (capitis) totalis, Alopecia universalis,Ophiasis, Other alopecia areata, Alopecia areata, unspecified, Vitiligo,Felty's syndrome, Rheumatoid lung disease w rheumatoid arthritis,Rheumatoid vasculitis with rheumatoid arthritis of unspecified site,Rheumatoid vasculitis w rheumatoid arthritis, Rheumatoid heart disease wrheumatoid arthritis, Rheumatoid myopathy with rheumatoid arthritis,Rheumatoid polyneurop w rheumatoid arthritis, rheumatoid arthritis,Rheumatoid arthritis with/without rheumatoid factor, Adult-onset Still'sdisease, Rheumatoid bursitis, Rheumatoid nodule, Inflammatorypolyarthropathy, Other specified rheumatoid arthritis, Juvenilerheumatoid arthritis, Juvenile ankylosing spondylitis, Juvenilearthritis, Wegener's granulomatosis without renal involvement, Wegener'sgranulomatosis with renal involvement, Juvenile dermatopolymyositis,Polymyositis, Dermatopolymyositis, Giant cell arteritis with polymyalgiarheumatica, Systemic lupus erythematosus, Endocarditis in systemic lupuserythematosus, Pericarditis in systemic lupus erythematosus, Lunginvolvement in systemic lupus erythematosus, Glomerular disease insystemic lupus erythematosus, Tubulo-interstitial neuropath in sys lupuserythematosus, Progressive systemic sclerosis, CR(E)ST syndrome,Systemic sclerosis, Sicca syndrome, Polymyalgia rheumatica, Systemicinvolvement of connective tissue, Ankylosing spondylitis, Laboratoryevidence of human immunodeficiency virus [HIV].

In certain embodiments of the invention one would want to exclude andavoid treating certain patients who have one or more diseases of canceror autoimmunity or infection in the list and tables below:

Hemophagocytic lymphohistiocytosis, multiple myeloma, allergen specificimmunotherapy, autosomal dominant haploinsufficiency, anteriorinterosseous nerve syndrome, Churg-Strauss syndrome, Systemicvasculitis, chronic graft versus host disease, Opsoclonus-MyoclonusSyndrome, Necrotising Autoimmune Myopathy (NAM), Pulmonary Sarcomatoidcarcinomas, Waldenstrom's macroglobulinaemia (WM), fertility, BehcetsDisease, Alopecia areata (AA), Acute-on-chronic Liver Failure, melanoma,‘organizing bronchiolitis syndrome’, encephalitis, minimal changedisease, or a patient receiving Tumor flare reaction therapy orSublingual immunotherapy (SLIT) or subcutaneous immunotherapy (SCIT), orhaving:

Disease (Source of Disease)

Acinetobacter infections (Acinetobacter baumannii), Actinomycosis(Actinomyces israelii, Actinomyces gerencseriae and Propionibacteriumpropionicus) African sleeping sickness or African trypanosomiasis(Trypanosoma brucei), AIDS (Acquired immunodeficiency syndrome) (Humanimmunodeficiency virus), Amebiasis (Entamoeba histolytica), Anaplasmosis(Anaplasma species), Angiostrongyliasis (Angiostrongylus), Anisakiasis(Anisakis), Anthrax (Bacillus anthracis), Arcanobacterium haemolyticuminfection (Arcanobacterium haemolyticum), Argentine hemorrhagic fever(Junin virus), Ascariasis (Ascaris lumbricoides), Aspergillosis(Aspergillus species), Astrovirus infection (Astroviridae family),Babesiosis (Babesia species), Bacillus cereus infection (Bacilluscereus), Bacterial pneumonia (multiple bacteria), Bacterial vaginosis(List of bacterial vaginosis microbiota), Bacteroides infection(Bacteroides species), Balantidiasis (Balantidium coli), Bartonellosis(Bartonella), Baylisascaris infection (Baylisascaris species), BK virusinfection (BK virus), Black piedra (Piedraia hortae), Blastocystosis(Blastocystis species), Blastomycosis (Blastomyces dermatitidis),Bolivian hemorrhagic fever (Machupo virus), Botulism (and Infantbotulism) (Clostridium botulinum; Note: Botulism is not an infection byClostridium botulinum but caused by the intake of botulinum toxin),Brazilian hemorrhagic fever (Sabia virus), Brucellosis (Brucellaspecies), Bubonic plague (the bacterial family Enterobacteriaceae),Burkholderia infection, usually Burkholderia cepacia and otherBurkholderia species, Buruli ulcer (Mycobacterium ulcerans), Calicivirusinfection (Norovirus and Sapovirus) (Caliciviridae family),Campylobacteriosis (Campylobacter species), Candidiasis (Moniliasis;Thrush) (usually Candida albicans and other Candida species),Capillariasis (Intestinal disease by Capillaria philippinensis, hepaticdisease by Capillaria hepatica and pulmonary disease by Capillariaaerophila), Carrion's disease (Bartonella bacilliformis), Cat-scratchdisease (Bartonella henselae), Cellulitis (usually Group A Streptococcusand Staphylococcus), Chagas Disease (American trypanosomiasis)(Trypanosoma cruzi), Chancroid (Haemophilus ducreyi), Chickenpox(Varicella zoster virus (VZV)), Chikungunya (Alphavirus), Chlamydia(Chlamydia trachomatis), Chlamydophila pneumoniae infection (Taiwanacute respiratory agent or TWAR) (Chlamydophila pneumoniae), Cholera(Vibrio cholerae), Chromoblastomycosis (usually Fonsecaea pedrosoi),Chytridiomycosis (Batrachochytrium dendrabatidis), Clonorchiasis(Clonorchis sinensis), Clostridium difficile colitis (Clostridiumdifficile), Coccidioidomycosis (Coccidioides immitis and Coccidioidesposadasii), Colorado tick fever (CTF) (Colorado tick fever virus(CTFV)), Common cold (Acute viral rhinopharyngitis; Acute coryza)(usually rhinoviruses and coronaviruses), Creutzfeldt-Jakob disease(CJD) (PRNP), Crimean-Congo hemorrhagic fever (CCHF) (Crimean-Congohemorrhagic fever virus), Cryptococcosis (Cryptococcus neoformans),Cryptosporidiosis (Cryptosporidium species), Cutaneous larva migrans(CLM) (usually Ancylostoma braziliense; multiple other parasites),Cyclosporiasis (Cyclospora cayetanensis), Cysticercosis (Taenia solium),Cytomegalovirus infection (Cytomegalovirus), Dengue fever (Dengueviruses (DEN-1, DEN-2, DEN-3 and DEN-4)—Flaviviruses), Desmodesmusinfection (Green algae Desmodesmus armatus), Dientamoebiasis(Dientamoeba fragilis), Diphtheria (Corynebacterium diphtheriae),Diphyllobothriasis (Diphyllobothrium), Dracunculiasis (Dracunculusmedinensis), Ebola hemorrhagic fever (Ebolavirus (EBOV)), Echinococcosis(Echinococcus species), Ehrlichiosis (Ehrlichia species), Enterobiasis(Pinworm infection) (Enterobius vermicularis), Enterococcus infection(Enterococcus species), Enterovirus infection (Enterovirus species),Epidemic typhus (Rickettsia prowazekii), Erythema infectiosum (Fifthdisease) (Parvovirus B19), Exanthem subitum (Sixth disease) (Humanherpesvirus 6 (HHV-6) and Human herpesvirus 7 (HHV-7)), Fasciolasis(Fasciola hepatica and Fasciola gigantica), Fasciolopsiasis(Fasciolopsis buski), Fatal familial insomnia (FFI) (PRNP), Filariasis(Filarioidea superfamily), Food poisoning by Clostridium perfringens(Clostridium perfringens), Free-living amebic infection (multiple),Fusobacterium infection (Fusobacterium species), Gas gangrene(Clostridial myonecrosis) (usually Clostridiumperfringens; otherClostridium species), Geotrichosis (Geotrichum candidum),Gerstmann-Straussler-Scheinker syndrome (GSS) (PRNP), Giardiasis(Giardia lamblia) Glanders (Burkholderia mallei), Gnathostomiasis(Gnathostoma spinigerum and Gnathostoma hispidum), Gonorrhea (Neisseriagonorrhoeae), Granuloma inguinale (Donovanosis) (Klebsiellagranulomatis), Group A streptococcal infection (Streptococcus pyogenes),Group B streptococcal infection (Streptococcus agalactiae), Haemophilusinfluenzae infection (Haemophilus influenzae) Hand, foot and mouthdisease (HFMD) (Enteroviruses, mainly Coxsackie A virus and Enterovirus71 (EV71)), Hantavirus Pulmonary Syndrome (HPS) (Sin Nombre virus),Heartland virus disease (Heartland virus), Helicobacter pylori infection(Helicobacter pylori), Hemolytic-uremic syndrome (HUS), Escherichia coliO157:H7, O111 and O104:H4, Hemorrhagic fever with renal syndrome (HFRS)(Bunyaviridae family), Hepatitis A (Hepatitis A virus), Hepatitis B(Hepatitis B virus), Hepatitis C (Hepatitis C virus), Hepatitis D(Hepatitis D Virus), Hepatitis E (Hepatitis E virus), Herpes simplex(Herpes simplex virus 1 and 2 (HSV-1 and HSV-2)), Histoplasmosis(Histoplasma capsulatum), Hookworm infection (Ancylostoma duodenale andNecator americanus), Human bocavirus infection (Human bocavirus (HBoV)),Human ewingii ehrlichiosis (Ehrlichia ewingii), Human granulocyticanaplasmosis (HGA) (Anaplasma phagocytophilum), Human metapneumovirusinfection, Human metapneumovirus (hMPV), Human monocytic ehrlichiosis(Ehrlichia chaffeensis), Human papillomavirus (HPV) infection (Humanpapillomavirus (HPV)), Human parainfluenza virus infection (Humanparainfluenza viruses (HPIV)), Hymenolepiasis (Hymenolepis nana andHymenolepis diminuta), Epstein-Barr virus infectious mononucleosis(Mono) (Epstein-Barr virus (EBV)), Influenza (flu) (Orthomyxoviridaefamily) Isosporiasis (Isospora belli), Kawasaki disease (unknown;evidence supports that it is infectious) Keratitis (multiple), Kingellakingae infection (Kingella kingae), Kuru (PRNP), Lassa fever (Lassavirus), Legionellosis (Legionnaires' disease) (Legionella pneumophila),Legionellosis (Pontiac fever) (Legionella pneumophila), Leishmaniasis(Leishmania species), Leprosy (Mycobacterium leprae and Mycobacteriumlepromatosis), Leptospirosis (Leptospira species), Listeriosis (Listeriamonocytogenes), Lyme disease (Lyme borreliosis) (Borrelia burgdorferi,Borrelia garinii, and Borrelia afzelii), Lymphatic filariasis(Elephantiasis) (Wuchereria bancrofti and Brugia malayi), Lymphocyticchoriomeningitis (Lymphocytic choriomeningitis virus (LCMV)), Malaria(Plasmodium species), Marburg hemorrhagic fever (MHF) (Marburg virus),Measles (Measles virus), Middle East respiratory syndrome (MERS) (MiddleEast respiratory syndrome coronavirus), Melioidosis (Whitmore's disease)(Burkholderia pseudomallei), Meningitis (multiple), Meningococcaldisease (Neisseria meningitidis), Metagonimiasis (usually Metagonimusyokagawai), Microsporidiosis (Microsporidia phylum), Molluscumcontagiosum (MC) (Molluscum contagiosum virus (MCV)), Monkeypox(Monkeypox virus), Mumps (Mumps virus), Murine typhus (Endemic typhus)(Rickettsia typhi), Mycoplasma pneumonia (Mycoplasma pneumoniae),Mycetoma (disambiguation) (numerous species of bacteria (Actinomycetoma)and fungi (Eumycetoma)), Myiasis (parasitic dipterous fly larvae),Neonatal conjunctivitis (Ophthalmia neonatorum) (most commonly Chlamydiatrachomatis and Neisseria gonorrhoeae), Norovirus (children and babies)((New) Variant Creutzfeldt-Jakob disease (vCJD, nvCJD), PRNP),Nocardiosis (usually Nocardia asteroides and other Nocardia species),Onchocerciasis (River blindness) (Onchocerca volvulus), Opisthorchiasis(Opisthorchis viverrini and Opisthorchis felineus),Paracoccidioidomycosis (South American blastomycosis) (Paracoccidioidesbrasiliensis), Paragonimiasis (usually Paragonimus westermani and otherParagonimus species), Pasteurellosis (Pasteurella species), Pediculosiscapitis (Head lice) (Pediculus humanus capitis), Pediculosis corporis(Body lice) (Pediculus humanus corporis), Pediculosis pubis (Pubic lice,Crab lice) (Phthirus pubis), Pelvic inflammatory disease (PID)(multiple), Pertussis (Whooping cough) (Bordetella pertussis), Plague(Yersinia pestis), Pneumococcal infection (Streptococcus pneumoniae),Pneumocystis pneumonia (PCP) (Pneumocystis jirovecii), Pneumonia(multiple), Poliomyelitis (Poliovirus), Prevotella infection (Prevotellaspecies), Primary amoebic meningoencephalitis (PAM) (usually Naegleriafowleri), Progressive multifocal leukoencephalopathy (JC virus),Psittacosis (Chlamydophila psittaci), Q fever (Coxiella burnetii),Rabies (Rabies virus), Relapsing fever (Borrelia hermsii, Borreliarecurrentis, and other Borrelia species), Respiratory syncytial virusinfection (Respiratory syncytial virus (RSV)), Rhinosporidiosis(Rhinosporidium seeberi), Rhinovirus infection (Rhinovirus), Rickettsialinfection (Rickettsia species), Rickettsialpox (Rickettsia akari), RiftValley fever (RVF) (Rift Valley fever virus), Rocky Mountain spottedfever (RMSF) (Rickettsia rickettsii), Rotavirus infection (Rotavirus),Rubella (Rubella virus), Salmonellosis (Salmonella species), SARS(Severe Acute Respiratory Syndrome) (SARS coronavirus), Scabies(Sarcoptes scabiei), Schistosomiasis (Schistosoma species), Sepsis(multiple), Shigellosis (Bacillary dysentery) (Shigella species),Shingles (Herpes zoster) (Varicella zoster virus (VZV)), Smallpox(Variola) (Variola major or Variola minor), Sporotrichosis (Sporothrixschenckii), Staphylococcal food poisoning (Staphylococcus species),Staphylococcal infection (Staphylococcus species), Strongyloidiasis(Strongyloides stercoralis), Subacute sclerosing panencephalitis(Measles virus), Syphilis (Treponema pallidum), Taeniasis (Taeniaspecies), Tetanus (Lockjaw) (Clostridium tetani), Tinea barbae (Barber'sitch) (usually Trichophyton species), Tinea capitis (Ringworm of theScalp) (usually Trichophyton tonsurans), Tinea corporis (Ringworm of theBody) (usually Trichophyton species), Tinea cruris (Jock itch) (usuallyEpidermophyton floccosum, Trichophyton rubrum, and Trichophytonmentagrophytes), Tinea manum (Ringworm of the Hand) (Trichophytonrubrum), Tinea nigra (usually Hortaea werneckii), Tinea pedis (Athlete'sfoot) (usually Trichophyton species), Tinea unguium (Onychomycosis)(usually Trichophyton species), Tinea versicolor (Pityriasis versicolor)(Malassezia species), Toxocariasis (Ocular Larva Migrans (OLM))(Toxocara canis or Toxocara cati), Toxocariasis (Visceral Larva Migrans(VLM)) (Toxocara canis or Toxocara cati), Trachoma (Chlamydiatrachomatis), Toxoplasmosis (Toxoplasma gondii), Trichinosis(Trichinella spiralis), Trichomoniasis (Trichomonas vaginalis),Trichuriasis (Whipworm infection) (Trichuris trichiura),Tuberculosis(usually Mycobacterium tuberculosis), Tularemia (Francisellatularensis), Typhoid fever (Salmonella enterica subsp. enterica, serovartyphi), Typhus fever (Rickettsia), Ureaplasma urealyticum infection(Ureaplasma urealyticum), Valley fever (Coccidioides immitis orCoccidioides posadasii), Venezuelan equine encephalitis (Venezuelanequine encephalitis virus), Venezuelan hemorrhagic fever (Guanaritovirus), Vibrio vulnificus infection (Vibrio vulnificus), Vibrioparahaemolyticus enteritis (Vibrio parahaemolyticus), Viral pneumonia(multiple viruses), West Nile Fever (West Nile virus), White piedra(Tinea blanca) (Trichosporon beigelii), Yersinia pseudotuberculosisinfection (Yersinia pseudotuberculosis), Yersiniosis (Yersiniaenterocolitica), Yellow fever (Yellow fever virus), Zygomycosis(Mucorales order (Mucormycosis) and Entomophthorales order(Entomophthoramycosis)) Human immunodeficiency virus [HIV] disease, HIVdisease with infectious and parasitic diseases, HIV disease withmycobacterial infection, HIV disease with cytomegaloviral disease, HIVdisease with other viral infections, HIV disease with candidiasis, HIVdisease with other mycoses, HIV disease with Pneumocystic cariniipneumonia, HIV disease with malignant neoplasms, HIV disease withKaposi's sarcoma, HIV disease with Burkitt's lymphoma, HIV disease withother type's of non-Hodgkin's lymphoma, HIV disease with other malignantneoplasms of lymphoid, hematopoietic and related tissue, HIV diseasewith multiple malignant neoplasms, HIV disease with other malignantneoplasms, HIV disease with unspecified malignant neoplasm, HIV diseasewith encephalopathy, HIV disease with lymphoid interstitial pneumonitis,HIV disease with wasting syndrome, HIV disease with multiple diseasesclassified elsewhere, HIV disease with other conditions, HIV diseaseAcute HIV infection syndrome, HIV disease with (persistent) generalizedlymphadenopathy, HIV disease with hematological and immunologicalabnormalities, not elsewhere classified, HIV disease with otherspecified conditions, Unspecified HIV disease, Malignant neoplasm oflip, Malignant neoplasm of tonsil, Malignant neoplasm of tongue,Malignant neoplasm of gum, Malignant neoplasm of mouth, Malignantneoplasm of parotid gland, Malignant neoplasm of salivary glands,Malignant neoplasm of pharynx, Malignant neoplasm of esophagus,Malignant neoplasm of stomach, Malignant neoplasm of small intestine,Malignant neoplasm of colon, Malignant neoplasm of recto sigmoidjunction, Malignant neoplasm of rectum, Malignant neoplasm of anus,Malignant neoplasm of liver, Malignant neoplasm of gallbladder,Malignant neoplasm of biliary tract, Malignant neoplasm of pancreas,Malignant neoplasm of intestinal tract, Malignant neoplasm of spleen,Malignant neoplasm of nasal cavity and middle ear, Malignant neoplasm ofaccessory sinuses, Malignant neoplasm of larynx, Malignant neoplasm oftrachea, Malignant neoplasm of bronchus and lung, Malignant neoplasm ofthymus, Malignant neoplasm of heart, mediastinum and pleura, Malignantneoplasm of sites in the respiratory system and intrathoracic organs,Malignant neoplasm of bone and articular cartilage of limbs, Malignantneoplasm of bones of skull and face, Malignant neoplasm of vertebralcolumn, Malignant neoplasm of ribs, sternum and clavicle, Malignantneoplasm of pelvic bones, sacrum and coccyx, Malignant melanoma of skin,Malignant melanoma of lip, Malignant melanoma of eyelid, includingcanthus, Malignant melanoma of ear and external auricular canal,Malignant melanoma of face, Malignant melanoma of anal skin, Malignantmelanoma of skin of breast, Malignant melanoma of limbs, includingshoulder, Merkel cell carcinoma, Basal cell carcinoma of skin of lip,Squamous cell carcinoma of skin of lip, Other and unspecified malignantneoplasm skin/eyelid, including canthus, Malignant neoplasm skin/ear andexternal auric canal, Other and unspecified malignant neoplasm skin/andunspecified parts of face, Basal cell carcinoma of skin of other andunspecified parts of face, Squamous cell carcinoma of skin of andunspecified parts of face, Basal cell carcinoma of skin of scalp andneck, Squamous cell carcinoma of skin of scalp and neck, Basal cellcarcinoma of skin of trunk, Basal cell carcinoma of anal skin, Basalcell carcinoma of skin of breast, Squamous cell carcinoma of skin oftrunk, Squamous cell carcinoma of anal skin, Squamous cell carcinoma ofskin of breast, Squamous cell carcinoma of skin of other part of trunk,Other and unspecified malignant neoplasm skin/limbs including shoulder,Basal cell carcinoma skin/limbs, including shoulder, Squamous cellcarcinoma skin/limbs, including shoulder, Basal cell carcinoma of skinof limbs, including hip, Squamous cell carcinoma of skin of limbs,including hip, Mesothelioma, Kaposi's sarcoma, Malignant neoplasm ofperipheral nerves and autonomic nervous sys, Malignant neoplasm ofretroperitoneum and peritoneum, Malignant neoplasm of other connectiveand soft tissue, Malignant neoplasm of connective and soft tissue ofthorax, Malignant neoplasm of connective and soft tissue of abdomen,Malignant neoplasm of connective and soft tissue of pelvis, Malignantneoplasm of conn and soft tissue of trunk, unspecified, Malignantneoplasm of overlapping sites of connective and soft tissue, Malignantneoplasm of connective and soft tissue, unspecified, Gastrointestinalstromal tumor, Malignant neoplasm of breast, Malignant neoplasm ofvulva, Malignant neoplasm of vagina, Malignant neoplasm of cervix uteri,Malignant neoplasm of corpus uteri, Malignant neoplasm of uterus, partunspecified, Malignant neoplasm of ovary, Malignant neoplasm of otherand unspecified female genital organs, Malignant neoplasm of placenta,Malignant neoplasm of penis, Malignant neoplasm of prostate, Malignantneoplasm of testis, Malignant neoplasm of other and unspecified malegenital organs, Malignant neoplasm of kidney, Malignant neoplasm ofrenal pelvis, Malignant neoplasm of ureter, Malignant neoplasm ofbladder, Malignant neoplasm of other and unspecified urinary organs,Malignant neoplasm of eye and adnexa, Malignant neoplasm of meninges,Malignant neoplasm of brain, Malignant neoplm of spinal cord, cranialnerves, Malignant neoplasm of optic nerve, Malignant neoplasm of otherand unspecified cranial nerves, Malignant neoplasm of central nervoussystem, unspecified, Malignant neoplasm of thyroid gland, Malignantneoplasm of adrenal gland, Malignant neoplasm of endo glands and relatedstructures, Malignant neuroendocrine tumors, Malignant carcinoid tumors,Secondary neuroendocrine tumors, Malignant neoplasm of head, face andneck, Malignant neoplasm of thorax, Malignant neoplasm of abdomen,Malignant neoplasm of pelvis, Malignant neoplasm of limbs, Malignantneoplasm of lower limb, Secondary and unspecified malignant neoplasm oflymph nodes, Secondary malignant neoplasm of respiratory and digestiveorgans, Secondary malignant neoplasm of kidney and renal pelvis,Secondary malignant neoplm of bladder and other and unspecified urinaryorgans, Secondary malignant neoplasm of skin, Secondary malignantneoplasm of brain and cerebral meninges, Secondary malignant neoplasm ofand unspecified parts of nervous sys, Secondary malignant neoplasm ofbone and bone marrow, Secondary malignant neoplasm of ovary, Secondarymalignant neoplasm of adrenal gland, Hodgkin lymphoma, Follicularlymphoma, Non-follicular lymphoma, Small cell B-cell lymphoma, Mantlecell lymphoma, Diffuse large B-cell lymphoma, Lymphoblastic (diffuse)lymphoma, Burkitt lymphoma, Other non-follicular lymphoma,Non-follicular (diffuse) lymphoma, unspecified, Mature T/NK-celllymphomas, Sezary disease, Peripheral T-cell lymphoma, not classified,Anaplastic large cell lymphoma, ALK-positive, Anaplastic large celllymphoma, ALK-negative, Cutaneous T-cell lymphoma, unspecified, Othermature T/NK-cell lymphomas, Mature T/NK-cell lymphomas, unspecified,Other and unspecified types of non-Hodgkin lymphoma, Malignantimmunoproliferative dis and certain other B-cell lymph, Multiple myelomaand malignant plasma cell neoplasms, Lymphoid leukemia, Acutelymphoblastic leukemia [ALL], Chronic lymphocytic leukemia of B-celltype, Prolymphocytic leukemia of B-cell type, Hairy cell leukemia, AdultT-cell lymphoma/leukemia (HTLV-1-associated), Prolymphocytic leukemia ofT-cell type, Mature B-cell leukemia Burkitt-type, Other lymphoidleukemia, Lymphoid leukemia, unspecified, Myeloid leukemia, Acutemyeloblastic leukemia, Chronic myeloid leukemia, BCR/ABL-positive,Atypical chronic myeloid leukemia, BCR/ABL-negative, Myeloid sarcoma,Acute promyelocytic leukemia, Acute myelomonocytic leukemia, Acutemyeloid leukemia with 11q23-abnormality, Other myeloid leukemia, Myeloidleukemia, unspecified, Monocytic leukemia, Chronic myelomonocyticleukemia, Juvenile myelomonocytic leukemia, Other monocytic leukemia,Monocytic leukemia, unspecified, Other leukemias of specified cell type,Acute erythroid leukemia, Acute megakaryoblastic leukemia, Mast cellleukemia, Acute panmyelosis with myelofibrosis, Myelodysplastic disease,not classified, Other specified leukemias, Leukemia of unspecified celltype, Chronic leukemia of unspecified cell type, Leukemia, unspecified,Other & unspecified malignant neoplasm of lymphoid, hematopoietictissue, Carcinoma in situ of oral cavity, esophagus and stomach,Carcinoma in situ of colon, Carcinoma in situ of recto sigmoid junction,Carcinoma in situ of rectum, Carcinoma in situ of anus and anal canal,Carcinoma in situ of other and unspecified parts of intestine, Carcinomain situ of unspecified part of intestine, Carcinoma in situ of otherparts of intestine, Carcinoma in situ of liver, gallbladder and bileducts, Carcinoma in situ of other specified digestive organs, Carcinomain situ of digestive organ, unspecified, Carcinoma in situ of middle earand respiratory system, Carcinoma in situ of larynx, Carcinoma in situof trachea, Carcinoma in situ of bronchus and lung, Carcinoma in situ ofother parts of respiratory system, Melanoma in situ, Melanoma in situ oflip, Melanoma in situ of eyelid, including canthus, Melanoma in situ ofear and external auricular canal, Melanoma in situ of unspecified partof face, Melanoma in situ of scalp and neck, Melanoma in situ of trunk,Melanoma in situ of anal skin, Melanoma in situ of breast (skin) (softtissue), Melanoma in situ of upper limb, including shoulder, Melanoma insitu of lower limb, including hip, Melanoma in situ of other sites,Carcinoma in situ of skin, Carcinoma in situ of skin of lip, Carcinomain situ of skin of eyelid, including canthus, Carcinoma in situ skin ofear and external auricular canal, Carcinoma in situ of skin of other andunspecified parts of face, Carcinoma in situ of skin of scalp and neck,Carcinoma in situ of skin of trunk, Carcinoma in situ of skin of upperlimb, including shoulder, Carcinoma in situ of skin of lower limb,including hip, Carcinoma in situ of skin of other sites, Carcinoma insitu of breast, Lobular carcinoma in situ of breast, Intraductalcarcinoma in situ of breast, Other specified type of carcinoma in situof breast, Unspecified type of carcinoma in situ of breast, Carcinoma insitu of cervix uteri, Carcinoma in situ of other parts of cervix,Carcinoma in situ of cervix, unspecified, Carcinoma in situ of other andunspecified genital organs, Carcinoma in situ of endometrium, Carcinomain situ of vulva, Carcinoma in situ of vagina, Carcinoma in situ ofother and unspecified female genital organs, Carcinoma in situ of penis,Carcinoma in situ of prostate, Carcinoma in situ of unspecified malegenital organs, Carcinoma in situ of scrotum, Carcinoma in situ of othermale genital organs, Carcinoma in situ of bladder, Carcinoma in situ ofother and unspecified urinary organs, Carcinoma in situ of eye,Carcinoma in situ of thyroid and other endocrine glands, Benign neoplasmof mouth and pharynx, Benign neoplasm of major salivary glands, Benignneoplasm of colon, rectum, anus and anal canal, Benign neoplasm of andill-defined parts of digestive system, Benign neoplasm of esophagus,Benign neoplasm of stomach, Benign neoplasm of duodenum, Benign neoplasmof other and unspecified parts of small intestine, Benign neoplasm ofliver, Benign neoplasm of extrahepatic bile ducts, Benign neoplasm ofpancreas, Benign neoplasm of endocrine pancreas, Benign neoplasm ofill-defined sites within the digestive system, Benign neoplasm of middleear and respiratory system, Benign neoplasm of respiratory system,unspecified, Benign neoplasm of other and unspecified intrathoracicorgans, Benign neoplasm of thymus, Benign neoplasm of heart, Benignneoplasm of mediastinum, Benign neoplasm of other specifiedintrathoracic organs, Benign neoplasm of intrathoracic organ,unspecified, Benign neoplasm of bone and articular cartilage, Benignneoplasm of short bones of upper limb, Benign neoplasm of long bones oflower limb, Benign neoplasm of short bones of lower limb, Benignneoplasm of bones of skull and face, Benign neoplasm of lower jaw bone,Benign neoplasm of vertebral column, Benign neoplasm of ribs, sternumand clavicle, Benign neoplasm of pelvic bones, sacrum and coccyx, Benignneoplasm of bone and articular cartilage, unspecified, Benign lipomatousneoplasm, Ben lipomatous neoplm of skin, subcutaneous of head, face andneck, Benign lipomatous neoplasm of intrathoracic organs, Benignlipomatous neoplasm of intra-abdominal organs, Benign lipomatousneoplasm of spermatic cord, Benign lipomatous neoplasm of other sites,Benign lipomatous neoplasm of kidney, Benign lipomatous neoplasm ofother genitourinary organ, Hemangioma and lymphangioma, any site,Hemangioma, Hemangioma unspecified site, Hemangioma of skin andsubcutaneous tissue, Hemangioma of intracranial structures, Hemangiomaof intra-abdominal structures, Hemangioma of other sites, Lymphangioma,any site, Benign neoplasm of mesothelial tissue, Benign neoplm of softtissue of retroperitoneum and peritoneum, Other benign neoplasms ofconnective and other soft tissue, Melanocytic nevi, Melanocytic nevi oflip, Melanocytic nevi of eyelid, including canthus, Melanocytic nevi ofunspecified eyelid, including canthus, Melanocytic nevi of ear andexternal auricular canal, Melanocytic nevi of other and unspecifiedparts of face, Melanocytic nevi of scalp and neck, Melanocytic nevi oftrunk, Melanocytic nevi of upper limb, including shoulder, Melanocyticnevi of lower limb, including hip, Melanocytic nevi, unspecified, Otherbenign neoplasm of skin of eyelid, including canthus, Other benignneoplasm skin/ear and external auricular canal, Other benign neoplasmskin/left ear and external auric canal, Other benign neoplasm of skin ofother and unspecified parts of face, Other benign neoplasm of skin ofother parts of face, Other benign neoplasm of skin of scalp and neck,Other benign neoplasm of skin of trunk, Other benign neoplasm skin/upperlimb, including shoulder, Other benign neoplasm of skin of lower limb,including hip, Other benign neoplasm of skin, unspecified, Benignneoplasm of breast, Benign neoplasm of unspecified breast, Leiomyoma ofuterus, Other benign neoplasms of uterus, Benign neoplasm of ovary,Benign neoplasm of other and unspecified female genital organs, Benignneoplasm of male genital organs, Benign neoplasm of urinary organs,Benign neoplasm of kidney, Benign neoplasm of renal pelvis, Benignneoplasm of ureter, Benign neoplasm of bladder, Benign neoplasm ofurethra, Benign neoplasm of other specified urinary organs, Benignneoplasm of urinary organ, unspecified, Benign neoplasm of eye andadnexa, Benign neoplasm of conjunctiva, Benign neoplasm of cornea,Benign neoplasm of retina, Benign neoplasm of choroid, Benign neoplasmof ciliary body, Benign neoplasm of lacrimal gland and duct, Benignneoplasm of unspecified site of orbit, Benign neoplasm of unspecifiedpart of eye, Benign neoplasm of meninges, Benign neoplasm of brain andcentral nervous system, Benign neoplasm of thyroid gland, Benignneoplasm of other and unspecified endocrine glands, Benign neoplasm ofother and unspecified sites, Benign neoplasm of lymph nodes, Benignneoplasm of peripheral nerves and autonomic nervous sys, Benign neoplasmof other specified sites, Benign neuroendocrine tumors, Other benignneuroendocrine tumors, Neoplasm of uncertain behavior of oral cavity anddigestive organs, Neoplasm of uncertain behavior of the major salivaryglands, Neoplasm of uncertain behavior of pharynx, Neoplasm of uncertainbehavior of sites of the oral cavity, Neoplasm of uncertain behavior ofstomach, Neoplasm of uncertain behavior of small intestine, Neoplasm ofuncertain behavior of appendix, Neoplasm of uncertain behavior of colon,Neoplasm of uncertain behavior of rectum, Neoplasm of uncertain behaviorof liver, GB & bile duct, Neoplasm of uncertain behavior of otherdigestive organs, Neoplasm of uncertain behavior of digestive organ,Neoplm of mid ear and intrathoracic organs, Neoplasm of uncertainbehavior of larynx, Neoplasm of uncertain behavior of trachea, bronchusand lung, Neoplasm of uncertain behavior of pleura, Neoplasm ofuncertain behavior of mediastinum, Neoplasm of uncertain behavior ofthymus, Neoplasm of uncertain behavior of other respiratory organs,Neoplasm of uncertain behavior of respiratory organ, unspecified,Neoplasm of uncertain behavior of female genital organs, Neoplasm ofuncertain behavior of uterus, Neoplasm of uncertain behavior of ovary,Neoplasm of uncertain behavior of unspecified ovary, Neoplasm ofuncertain behavior of placenta, Neoplasm of uncertain behavior of malegenital organs, Neoplasm of uncertain behavior of urinary organs,Neoplasm of uncertain behavior of kidney, Neoplasm of uncertain behaviorof unspecified kidney, Neoplasm of uncertain behavior of renal pelvis,Neoplasm of uncertain behavior of ureter, Neoplasm of uncertain behaviorof bladder, Neoplasm of uncertain behavior of other urinary organs,Neoplasm of uncertain behavior of unspecified urinary organ, Neoplasm ofuncertain behavior of meninges, Neoplasm of uncertain behavior ofcerebral meninges, Neoplasm of uncertain behavior of spinal meninges,Neoplasm of uncertain behavior of meninges, unspecified, Neoplasm ofuncertain behavior of brain, Neoplasm of uncertain behavior of brain,Neoplasm of uncertain behavior of brain, infratentorial, Neoplasm ofuncertain behavior of brain, unspecified, Neoplasm of uncertain behaviorof cranial nerves, Neoplasm of uncertain behavior of spinal cord,Neoplasm of uncertain behavior of central nervous system, Neoplasm ofuncertain behavior of endocrine glands, Neoplasm of uncertain behaviorof thyroid gland, Neoplasm of uncertain behavior of adrenal gland,Neoplasm of uncertain behavior of unspecified adrenal gland, Neoplasm ofuncertain behavior of parathyroid gland, Neoplasm of uncertain behaviorof pituitary gland, Neoplasm of uncertain behavior of craniopharyngealduct, Neoplasm of uncertain behavior of pineal gland, Neoplasm ofuncertain behavior of carotid body, Neoplasm of uncertain behavior ofaortic body and other paraganglia, Neoplasm of uncertain behavior ofunspecified endocrine gland, Polycythemia vera, Myelodysplasticsyndromes, Refractory anemia without ring sideroblasts, so stated,Refractory anemia with ring sideroblasts, Refractory anemia with excessof blasts [RAEB], Myelodysplastic syndrome, unspecified, Other neoplm ofuncertain behavior of lymphoid, hematopoietic tissue, Histiocytic andmast cell tumors of uncertain behavior, Chronic myeloproliferativedisease, Monoclonal gammopathy, Essential (hemorrhagic) thrombocythemia,Osteomyelofibrosis, Other neoplasm of uncertain behavior of lymphoid,hematopoietic tissue, Neoplasm of uncertain behavior of lymphoid,hematopoietic & unspecified, Neoplasm of uncertain behavior of other andunspecified sites, Neoplasm of uncertain behavior of bone/articcartilage, Neoplasm of uncertain behavior of connective/soft tissue,Neoplasm of uncertain behavior of peripheral nerves and autonomousnervous sys, Neoplasm of uncertain behavior of retroperitoneum, Neoplasmof uncertain behavior of peritoneum, Neoplasm of uncertain behavior ofskin, Neoplasm of uncertain behavior of breast, Neoplasm of unspecifiedbehavior of digestive system, Neoplasm of unspecified behavior ofrespiratory system, Neoplasm of unspecified behavior of bone, softtissue, and skin, Neoplasm of unspecified behavior of breast, Neoplasmof unspecified behavior of bladder, Neoplasm of unspecified behavior ofother genitourinary organs, Neoplasm of unspecified behavior of kidney,Neoplasm of unspecified behavior of other GU organ, Neoplasm ofunspecified behavior of brain, Neoplasm of unspecified behavior of endoglands and other parts of nervous sys, Neoplasm of unspecified behaviorof retina and choroid, Neoplasm of unspecified behavior of unspecifiedsite, Iron deficiency anemia, Vitamin B12 deficiency anemia, Folatedeficiency anemia, Protein deficiency anemia, Other megaloblasticanemias, not elsewhere classified, Scorbutic anemia, Other specifiednutritional anemias, Nutritional anemia, unspecified, Anemia due toenzyme disorders, Anemia, Thalassemia, Hereditary persistence of fetalhemoglobin [HPFH], Hemoglobin E-beta thalassemia, Other thalassemia's,Thalassemia, unspecified, Sickle-cell disorders, Other hereditaryhemolytic anemias, Acquired hemolytic anemia, Acquired pure red cellaplasia [erythroblastopenia], Acquired pure red cell aplasia,unspecified, Other aplastic anemias and other bone marrow failuresyndromes, Drug-induced aplastic anemia, Aplastic anemia due to otherexternal agents, Idiopathic aplastic anemia, Other aplastic anemias andother bone marrow failure syndromes, Aplastic anemia, unspecified, Acuteposthemorrhagic anemia, Anemia, Disseminated intravascular coagulation,Hereditary factor VIII deficiency, Hereditary factor IX deficiency,Other coagulation defects, Acquired coagulation factor deficiency,Primary thrombophilia, Other thrombophilia, Purpura and otherhemorrhagic conditions, Secondary thrombocytopenia, Thrombocytopenia,unspecified, Other specified hemorrhagic conditions, Hemorrhagiccondition, unspecified, Neutropenia, Congenital agranulocytosis,Agranulocytosis secondary to cancer chemotherapy, Other drug-inducedagranulocytosis, Neutropenia due to infection, Cyclic neutropenia, Otherneutropenia, Other disorders of white blood cells, Genetic anomalies ofleukocytes, Eosinophilia, Other specified disorders of white bloodcells, Decreased white blood cell count, Lymphocytosis (symptomatic),Diseases of spleen, Methemoglobinemia, Congenital methemoglobinemia,Other methemoglobinemias, Methemoglobinemia, unspecified, Other andunspecified diseases of blood and blood-forming organs, Familialerythrocytosis, Secondary polycythemia, Other specified diseases ofblood and blood-forming organs, Myelofibrosis, Heparin inducedthrombocytopenia (HIT), Other specified diseases of blood andblood-forming organs, Other dis with lymphoreticular andreticulohistiocytic tissue, Intraoperative and postproceduralcomplications of the spleen, Immunodeficiency with predominantlyantibody defects, Hereditary hypogammaglobulinemia, Nonfamilialhypogammaglobulinemia, Selective deficiency of immunoglobulin A [IgA],Selective deficiency of immunoglobulin G [IgG] subclasses, Selectivedeficiency of immunoglobulin M [IgM], Immunodeficiency with increasedimmunoglobulin M [IgM], Antibody deficiency w near-norm immunoglobulinor w hyperimmunoglobulin, Transient hypogammaglobulinemia of infancy,Other immunodeficiencies with predominantly antibody defects,Immunodeficiency with predominantly antibody defects, unspecified,Combined immunodeficiencies, Severe combined immunodeficiency withreticular dysgenesis, Severe combined immunodeficiency w low T- andB-cell numbers, Severe combined immunodeficiencies w low or normalB-cell numbers, Adenosine deaminase [ADA] deficiency, Nezelofs syndrome,Purine nucleoside phosphorylase [PNP] deficiency, Majorhistocompatibility complex class I deficiency, Major histocompatibilitycomplex class II deficiency, Other combined immunodeficiencies, Combinedimmunodeficiency, unspecified, Immunodeficiency associated with othermajor defects, Wiskott-Aldrich syndrome, Di George's syndrome,Immunodeficiency with short-limbed stature, Immunodeficiency followingresponse to Epstein-Barr virus, Hyperimmunoglobulin E [IgE] syndrome,Immunodeficiency associated with other major defects, Immunodeficiencyassociated with major defect, unspecified, Common variableimmunodeficiency, Other immunodeficiencies, Lymphocyte functionantigen-1 [LFA-1] defect, Defects in the complement system, Otherspecified immunodeficiencies, Sarcoidosis, Other disorders involving theimmune mechanism, NEC, Polyclonal hypergammaglobulinemia,Cryoglobulinemia, Hypergammaglobulinemia, unspecified, Immunereconstitution syndrome, Mast cell activation syndrome and relateddisorders, Mast cell activation, unspecified, Monoclonal mast cellactivation syndrome, Idiopathic mast cell activation syndrome, Secondarymast cell activation, Other mast cell activation disorder, Otherdisorders involving the immune mechanism, NEC, Graft-versus-hostdisease, Acute graft-versus-host disease, Chronic graft-versus-hostdisease, Acute on chronic graft-versus-host disease, Graft-versus-hostdisease, unspecified, Autoimmune lymphoproliferative syndrome [ALPS],Other disorders involving the immune mechanism, NEC, Disorder involvingthe immune mechanism, unspecified, Autoimmune thyroiditis, Type 1diabetes mellitus, Other diabetes mellitus with other specifiedcomplication, Primary adrenocortical insufficiency, Autoimmunepolyglandabular failure, Dementia in human immunodeficiency virus [HIV]disease (B22.0), Multiple sclerosis, Guillain-Barre syndrome, Myastheniagravis without (acute) exacerbation, Myasthenia gravis with (acute)exacerbation, Cytotoxic myoneural disorders, Congenital anddevelopmental myasthenia, Lambert-Eaton syndrome, unspecified,Lambert-Eaton syndrome in disease classified elsewhere, Other specifiedmyoneural disorders, Myoneural disorder, unspecified, Unspecified acuteand subacute iridocyclitis, Crohn's disease, Ulcerative (chronic)pancolitis, Inflammatory polyps of colon, Left sided colitis, Otherulcerative colitis without/with complications, Chronic persistenthepatitis, Chronic lobular hepatitis, Chronic active hepatitis, Otherchronic hepatitis, Chronic hepatitis, unspecified, Primary biliarycirrhosis, Autoimmune hepatitis, Celiac disease, Pemphigus, Bullouspemphigoid, Cicatricial pemphigoid, Chronic bullous disease ofchildhood, Acquired epidermolysis bullosa, unspecified, Other acquiredepidermolysis bullosa, Other pemphigoid, Psoriasis vulgaris, Otherpsoriatic arthropathy, Alopecia (capitis) totalis, Alopecia universalis,Ophiasis, Other alopecia areata, Alopecia areata, unspecified, Vitiligo,Felty's syndrome, Rheumatoid lung disease w rheumatoid arthritis,Rheumatoid vasculitis with rheumatoid arthritis of unspecified site,Rheumatoid vasculitis w rheumatoid arthritis, Rheumatoid heart disease wrheumatoid arthritis, Rheumatoid myopathy with rheumatoid arthritis,Rheumatoid polyneurop w rheumatoid arthritis, rheumatoid arthritis,Rheumatoid arthritis with/without rheumatoid factor, Adult-onset Still'sdisease, Rheumatoid bursitis, Rheumatoid nodule, Inflammatorypolyarthropathy, Other specified rheumatoid arthritis, Juvenilerheumatoid arthritis, Juvenile ankylosing spondylitis, Juvenilearthritis, Wegener's granulomatosis without renal involvement, Wegener'sgranulomatosis with renal involvement, Juvenile dermatopolymyositis,Polymyositis, Dermatopolymyositis, Giant cell arteritis with polymyalgiarheumatica, Systemic lupus erythematosus, Endocarditis in systemic lupuserythematosus, Pericarditis in systemic lupus erythematosus, Lunginvolvement in systemic lupus erythematosus, Glomerular disease insystemic lupus erythematosus, Tubulo-interstitial neuropath in sys lupuserythematosus, Progressive systemic sclerosis, CR(E)ST syndrome,Systemic sclerosis, Sicca syndrome, Polymyalgia rheumatica, Systemicinvolvement of connective tissue, Ankylosing spondylitis, Laboratoryevidence of human immunodeficiency virus [HIV].

Route of Administration

In certain embodiments of the invention the cellular immunotherapy maybe administered to the patient by the following but not limiting routes:via nasal submucosa, lingual, via bronchoscopy, intravenous,intra-tumor, intra-arterial, intra-muscular, intro-ocular,intra-striatal, subcutaneous, intradermal, by dermal patch, by skinpatch, by patch, into the cerebrospinal fluid, intra-peritoneal, intothe portal vein, into the spleen, into the brain, into the lymphaticsystem, intra-pleural, retro-orbital, intralymphatic, intra-dermal, bysystemic among others. The cellular immunotherapy can be administered bysystemic injection or site of injection as defined previously.

In certain embodiments of the present invention applications to applythe cellular immunotherapies directly to an organ or tumornon-exclusively relates to collagen matrices, extracellular matrixcompositions, biopolymer microthreads made of fibrin or otherextracellular matrix material, patches containing extracellular matrixand biodegradable materials, fibrin patches, alginateor agarose basedpatches, scaffolds composed of extracellular matrix materials andbiodegradable physiologically inert material that could non-exclusivelyrelates tocomponents such as dextrans, coating stem cells with organspecific antigens or binding molecules, remnant extracellular matricesalso known as scaffolds or decellularized organs from ex vivo digestedorgan donors or cadaveric organs, and contact lenses among others.

Catheter based delivery systems that can be used to deliver cellularimmunotherapies non-exclusively relates to standard balloon angioplastyinfusion catheters, percutaneous coronary artery delivery catheters,stop flow inflations of over-the-wire balloon catheters, Swan Ganz typecatheters, Hickman type catheters, Foley type catheters, central venouscatheters, pigtail type catheters, SmartPort® systems, metal-tippedmagnet guided catheters such as the Gentle Touch™ Magnetic NavigationSystem developed by Stereotaxis Inc or Mitralign, the Accucinch System®,and by catheters that inject directly into an organ such as the HELIX™,the MyoCath™, NOGA R-guided Myostar™, the Stiletto™, or theintravascular ultrasound (IVUS) guided TransAccess Delivery System™, orcatheters that deliver via arterial routes such as the OpenSail™,Concerto™, Microsyringe infusion catheter from Mercator, and Maverick™,or via implantable device therapies such left ventricular assist devices(LVADs), biventricular assist devices (BiVADs), the Optimizer™,cell-delivery catheters such as described in US 2009/0299269.

In administering the antibody therapeutic agents that inhibit binding ofthe cellular immunotherapies to secondary lymphatic tissue it ispreferable to administer them systemically, repeatedly about three weeksbefore administering the cellular immunotherapy. In administering thesmall molecule therapeutic agents that inhibit binding of the cellularimmunotherapies to secondary lymphatic tissue it is preferable toadminister them systemically, repeatedly for about 1 to about 4 weeks.For dexamethasone containing agents it is preferable to administer themsystemically about 12 to about 72 hours before administering thecellular immunotherapy and most preferable to administer dexamethasonecontaining NTLA systemically about 36 to about 48 hours beforeadministering the cellular immunotherapy.

Example 1: T Cell Immunotherapies Bind to the Germinal Center andMarginal Zone Regions of the Spleen and Secondary Lymphatics and theBinding is Reduced by NTLA Dexamethasone Dosing

Mice are IV injected with NK cells isolated from syngeneic mice (usingcommercially available kits), with NK cell line KIL (from ATCC), withCD4+/CD8+ mixtures of T cells isolated from syngeneic mice (usingcommercially available kits) or with other ACTs, labeled with vital dyessuch as DiR and CTO. Mice are intravenously injected by tail vein withbetween about 1×10⁵ cells/kg to about 1×10⁷ cells/kg. Between 1 to 48hours later mice are sacrificed by exsanguination and then residualblood cells flushed out with 5 U heparin/ml PBS via retrograde flushinto the thoracic jugular vein. The spleens are removed, weighed wet,and then fixed in 10% formalin. Subsequently the spleens are sectionedvia proprietary methods that do not fix or later the temperature of thespleen, and then incubated with FITC-PNA to co-label germinal centers orFITC-anti-CD21 (10 ugs) to colabel marginal zones at 4 deg C. for 24hours, are washed, placed on slides and immunofluorescent images arecaptured. Metamorph software is used to quantify the immunofluorescentsignal. T cell, NK cell and KIL binding fluorescence co-localizes withFITC-PNA and FITC-anti-CD21 fluorescence, indicating the cells aresequestered in the marginal zones and germinal centers of the secondarylymphatics.

C57Bl/6 male mice weighing approximately 25 gms were treated orally onday −2 with Placebo or HED 12 mg/kg Dexamethasone. Naïve T cells wereisolated on day −1 from the spleens of donor C57Bl/6 mice using EasySep™Mouse Pan-Naïve T Cell Isolation Kits from Miltenyi. The resultingCD4+/CD8+ T cells were incubated overnight at 37 degree C. in 5% CO₂. Onday 0, fresh CMPTX dye solution was made for a concentration of 5 μM. Tcells isolated on day −1 were incubated with CMPTX dye solution for 40minutes at 37 degrees C. in 5% CO₂. Mice treated orally on day −2 wereeach tail vein injected with 5M labeled T cells in 80 uls volume. Threehours later the mice were euthanized by exsanguination, spleens wereweighed and then cut into thick sections to visual T cell bindingregions. The spleen sections were incubated overnight at 4 degrees withFITC-PNA to label germinal centers and anti-CD21/CD35 to label marginalzones. The next day the sections were rinsed, fixed with 4% PFA/PBS 5%sucrose and images were collected using an EVOS fluorescent microscope.

The labeled T cells were visualized bound in clusters on germinalcenters and marginal zone areas of the spleen sections. Compared toPlacebo treated mice, the spleens from Dexamethasone pretreated micewere significantly smaller and T cell total binding measured byfluorescence intensity was dramatically reduced.

C57Bl/6 male mice weighing approximately 25 gms were treated orally onday −2 with Placebo or HED 12 mg/kg Dexamethasone. Splenic NK cells wereisolated on day −1 from the spleens of donor C57Bl/6 mice usingMojoSort™ Mouse NK Cell Isolation Kit from BioLegend. The resulting NKcells were incubated overnight at 37 degree C. in 5% CO₂. On day 0,fresh CMPTX dye solution was made for a concentration of 5 μM. NK cellsisolated on day −1 were incubated with CMPTX dye solution for 40 minutesat 37 degrees C. in 5% CO₂. Mice treated orally on day −2 were each tailvein injected with 3M labeled NK cells in 80 uls volume. Three hourslater the mice were euthanized by exsanguination, spleens were weighedand then cut into thick sections to visual NK cell binding regions. Thesections were rinsed, fixed with 4% PFA/PBS 5% sucrose and images werecollected using an EVOS fluorescent microscope.

The labeled NK cells were visualized bound in clusters along marginalzone areas of the spleen sections. Compared to Placebo treated mice, thespleens from Dexamethasone pretreated mice were significantly smallerand NK cell total binding measured by fluorescence intensity wasdramatically reduced.

Example 2: Immunosuppressant Reduction of the Sites in the SecondaryLymphatics where Cellular Immunotherapies are Bound and Sequestered

For mice, male mice were intraperitoneally injected with dexamethasonesodium phosphate for 114.6 mg/kg dexamethasone base (HED 9.32 mg/kg) day0 and were sacrificed 96 hours after the dexamethasone injection. Acutehigh dose Dexamethasone is also referred to herein as Dex, AugmenStem™,PlenaStem™ or AVM0703. The mice were sacrificed by exsanguination andthen residual blood cells flushed out with 5 U heparin/ml PBS viaretrograde flush into the thoracic jugular vein. The spleens wereremoved, weighed wet, and then fixed in 10% formalin. Subsequently thespleens were sectioned via proprietary methods and then incubated withFITC-PNA at 4 deg C. for 24 hours, washed, placed on slides andimmunofluorescent images were captured. Metamorph software was used toquantify the immunofluorescent signal. Sample images and the results,normalized to spleen area, are shown in FIG. 1. Control mice havesignificant FITC-PNA immunofluorescence, while mice who were injectedwith dexamethasone sodium phosphate have almost no immunoflurescentsignal. FITC-PNA labels germinal centers, the site where cellularimmunotherapies bind in the secondary lymphatics, which non-exclusivelyrelates to the spleen and lymph nodes. This example demonstrates thatcellular immunotherapies cannot bind and sequester in the secondarylymphatics after being treated with an immunosuppressant at effectivedoses to eliminate germinal centers. When the cellular immunotherapiescannot bind to the secondary lymphatics they remain at the site ofinjection or in the circulation for extended periods of time where theyare able to locate and kill their cancer, autoimmune cell or pathogenictarget. Additionally, long term engraftment of the cellularimmunotherapy is enhanced.

FIG. 2 shows the dose response of acute high dose Dexamethasone (in HED)effect on germinal center number in spleens of mice. Germinal centerreduction is apparent at HED 6 mg/kg but not significantly reduced untilHED of 9 and 12 mg/kg doses.

For the rat, Dex HED between 3.23, 6.45 and 12.9 mg/kg (rat doses 20, 40and 80 mg/kg) was administered (IV or PO) to determine GC and marginalzone inhibition 48 hours later. In the rat, the HED Dex dose of 12.9mg/kg maximally inhibited both GC and marginal zone number and area asshown in FIG. 3 and FIG. 4. Formalin-fixed spleens were cross-sectionedin 5 pieces, trimmed and embedded in paraffin, sectioned and stainedwith hematoxylin and eosin (H&E). Measurements of the periarteriolarlymphoid sheath (PAL) diameter and the width of the marginal zone (MZ)in areas of white pulp that had PAL with the greatest diameter weremeasured using an ocular micrometer. BCL-6 immunohistochemical stainingin rat spleens was evaluated to determine GC area using automated imageanalysis methods.

Example 3: Immunosuppressant Lymphodepletion in Mice, Rats, and Humans36-48 Hours after Acute Administration of Dexamethasone, withNeutrophil, RBC, Platelet and Stem Cell Sparing Properties

As shown in FIG. 5, IV or PO administration of dexamethasone at 20 (3.2HED), 40 (6.5 HED) or 80 (12.9 HED) mg/kg to male Lewis rats weighing250-300 grams significantly reduced lymphocyte count at all dosescompared to Placebo 48 hours after administration. In contrast, as shownin FIG. 6, neutrophils were not reduced by acute high dosedexamethasone. Neutrophil number are actually increased by all doses ofdexamethasone, likely via a demargination effect. RBCs, platelets, Hct,HgB were not affected by the dexamethasone treatment.

Oral acute administration of dexamethasone to C57Bl male mice at HED of3 mg/kg (n=4), HED 6 mg/kg (n=6), 9 mg/kg (n=4) or 12 mg/kg (n=4)compared to placebo (n=7) reduced CD3+ T lymphocytes by 65% and CD4+ Tlymphocytes by 75% (FIG. 7), reduced CD8+ T lymphocytes by 56% and Tregsby 78% (FIG. 8), reduced natural killer cells (NK) by 87% and Blymphocytes by 83% (FIG. 9), reduced absolute lymphocyte count by 84%but spared neutrophils (FIG. 10), RBCs (FIG. 11) and platelets (FIG.11). Blood was drawn for CBC and flow cytometry 48 hours afterdexamethasone administration by oral gavage.

Oral acute administration of 3 mg/kg dexamethasone base equivalent (alldoses given are dexamethasone base equivalent in these examples) to fourhuman patients, three with knee osteoarthritis and one with aorticaneurysm, was administered. Blood was drawn before drug treatment and 48hours post-treatment for CBC analysis and flow cytometry to determinelymphocyte and other blood cell populations. Serum was analyzed forcytokine levels. For one patient, pre-treatment CBCs were not drawn andthus normalized flow cytometry data is shown for only 3 patients. Byun-normalized flow cytometry data only 2 of the 4 patients responded tothe dexamethasone with lymphodepletion (FIGS. 12, 13, and 14), while 2of 4 patients showed a lymphocytosis response in CD3 and CD4 lymphocytesand 1 of 4 patients showed a lymphocytosis response in CD8, Blymphocytes and NK cells, to this dose of dexamethasone. 3 of 4 patientsshowed elevated levels of IL-2 and 4 of 4 showed elevated levels ofIL-15 48 hours after acute oral dexamethasone abse (3 mg/kg) (FIG. 15).IL-6, a cytokine known to be the primary driver of potentially fatalcytokine release syndrome (CRS) was not elevated in any patient. Basedon the lymphocytosis response observed in 2 of 4 non cancer patients atthe 3 mg/kg dose, preferred lymphodepleting preconditioning doses priorto ACT will be 3 mg/kg or higher based on the increased sensitivity oftumor bearing mice to Dexamethasone where the lowest lethal dose was HED43 mg/kg in tumor bearing mice compared to HED 114 mg/kg in healthy mice(P. Scorza Barcellona, Arch. Toxicol., Supp!. 7, 90-93 (1984)).

Bone marrow was drawn 48 hours after dexamethasone administration andmesenchymal stem cell (MSC) number was determined by colony-formingassay fibroblast (CFU-F). Oral administration of dexamethasone base 3mg/kg increased ileac crest BM MSC almost two fold (FIG. 16). Trilineagedifferentiation capacity of the BM MSC was also determined in a study inhorses. A 6 mg/kg HED doubled sternal BM MSC stem cell number 48 hoursafter a one hour IV infusion administration to horses, but did not altertrilineage differentiation capacity of the MSC towards osteocytes,chondrocytes or adipocytes.

Example 4: Comparison of Acute 12 mg/kg Dexamethasone Base HED to aStandard Cy (Cyclophosphamide) Flu (Fludarabine) Preconditioning Regimen

Dexamethasone base was administered by oral gavage to adult male mice at12 mg/kg HED on day −2. To another group of mice Cy was administered IPat 166 mg/kg (HED 500 mg/m²) on day −5 and day −4 and Fludarabine 10mg/kg (HED 30 mg/m²) on days −5, −4, −3, −2. To a third group of mice Cywas administered IP at 166 mg/kg (HED 500 mg/m²) on day −5 andFludarabine 10 mg/kg (HED 30 mg/m²) on days −5, then 12 mg/kg HEDdexamethasone base was administered orally on day −2. CBC and flowcytometry results are shown in FIGS. 17-22, and body weights are shownin FIG. 23. Dexamethasone base 12 mg/kg HED given between 12-72 hoursbefore blood draw leads to a comparable lymphodepletion profile comparedto standard 2 day Cy with 4 day Flu, as does the combination of a singleCy on day −5 and a single Flu on day −5 with 12 mg/kg dexamethasone HEDon day −2. The single Cy and single Flu dose can be administered on day−6, day −4, or day-3 with equal effect. The lymphodepletion profile ofdexamethasone alone may be preferable because absolute lymphocytes arenot depleted as dramatically as with CyFlu, and the degree oflymphodepletion may be related to neuroedema when ACT is given afterCyFlu.

The standard repeat CyFlu preconditioning significantly reduced bodyweight as a general measure of toxicity, while 12 mg/kg dexamethasonebase HED did not impact body weight, and the combination of one Cy andone Flu dose on day −5 with 12 mg/kg dexamethasone HED impacted bodyweight significantly less than the standard CyFlu regimen.

Other standard preconditioning agents that can given as a single dose(s)on day −1 or day −2 or day −3 or day −4 or day −5 and be combined withDexamethasone between about 3 to about 12 mg/kg on day −2 include: Cy120 mg/kg and Flu 75 mg/m²; 30 mg/m² flu and 50 mg/kg Cy and 200 cGyTBI; Cy 1500 mg/m2 and Bendamustine 120 mg/m2; Cy between about 300mg/m² and about 2300 mg/m²; Flu between about 10 mg/m² and about 900mg/m²; Cy 600 mg/m² and

Flu 30 mg/m²; Busulfan and Melphalan and Flu; Busulfan (dose adjustedaccording to weight) and Thiotepa (10 mg/kg) and Fludarabine (160mg/m²); Flu 30 mg/m² and Cy 300 mg/m² and Mensa 300 mg/m²; Flu 30 mg/m²and Cy 60 mg/m² and Alemtuzumab 0.2 mg/kg.

Example 5: Immunocompetent Mouse Model of Multiple Myeloma

The mouse multiple myeloma MOPC315 cell line available from ATCC is tailvein inoculated to immunocompetent Balbc mice at 2×10⁶ cells.Approximately 21 days later symptoms begin to show which include hindlimb paralysis. Between day 21 and day 67 after inoculation greater than90% of inoculated mice will be affected with disease.

Mice are preconditioned with standard CyFlu (Cy 300 mg/m2 to 2100 mg/m2for 2 to 5 days on about days −6, −5, −4, −3, −2, or −1 before ACT andFlu 10 mg/m2 to 30 mg/m2 for 2 to 5 days on about days −6, −5, −4, −3,−2, or −1 before ACT); other mice are preconditioned with Dexamethasonebase HED between 3-12 mg/kg administered either orally or over a 15-60minute intravenous infusion; other mice are preconditioned with a singledose of Cy (300 mg/m2 to 2100 mg/m2 between day −6 to day −2 and Flu (10mg/m2 to 30 mg/m2 between day −6 to day −2) plus Dexamethasone base HEDbetween 3-12 mg/kg administered either orally or over a 15-60 minuteintravenous infusion between 12-72 hours before allogeneic HSCT orNatural Killer (NK) cell administration, which is considered day 0 forthe purpose of planning the timing of preconditioning.

Mice can also be preconditioned with: An agent containing hydrocortisoneis administered intravenously or orally about every 12 hours at a doseof about 75 to about 300 mg/kg between about 12 to about 72 hours beforeadministration of the cellular immunotherapy. An agent containingcortisone is administered intravenously or orally about every 12 hoursat a dose of about 93 to about 375 mg/kg between about 12 to about 72hours before administration of the cellular immunotherapy. An agentcontaining prednisolone is administered intravenously or orally aboutevery 24 hours at a dose of about 19 to about 75 mg/kg between about 12to about 60 hours before administration of the cellular immunotherapy.An agent containing methylprednisolone is administered intravenously ororally about every 24 hours at a dose of about 15 to about 60 mg/kgbetween about 12 to about 60 hours before administration of the cellularimmunotherapy. An agent containing triamcinolone is administeredintravenously or orally about every 24 hours at a dose of about 15 toabout 60 mg/kg between about 12 to about 60 hours before administrationof the cellular immunotherapy. An agent containing paramethasone isadministered in either a single acute dose or cumulative doses of about7.5 to about 30 mg/kg, given between about 12-72 hours prior to cellularimmunotherapy. An agent containing betamethasone is administered ineither a single acute dose or cumulative doses of about 2.5 to 10 mg/kg,given between about 12-72 hours prior to cellular immunotherapy.

Balb/cJ (H-2d) and B10.D2 (H-2d) mice were purchased from JacksonLaboratory (Bar Harbor, Me., USA). Mice were used when they were between10- to 14-wk-old. For allogeneic HSCT, spleens and bone marrows (femursand tibias) from donor B10.D2 mice are harvested and homogenized in RPMI1640 medium containing 10% FBS and 1% Penicillin/Streptomycin (5complete medium). Red blood cells are lysed using sterile filtered RBClysis buffer (eBioscience, San Diego, USA) and cells are washed,resuspended in phosphate buffered saline (PBS) containing 3% FBS, andfiltered through a 70 mM nylon membrane. For CD8 T-cell depletion, the“Mouse CD8a positive selection kit” (Stem Cell, Grenoble, France) areused according to the manufacturer's EASYSEP depletion protocol.Finally, cells are suspended in 200 ml PBS for i.v. injection. Balbcmice are transplanted by i.v. tail vein injection of 1×10⁷ bone marrowcells and 7×10⁷ splenocytes from donor B10.D2 mice between 10 and 30days after MOPC315 inoculation. 94% of the mice will show completeelimination of MOPC315 cells after alloHSCT. The group that receivedDexamethasone preconditioning will have a similar elimination of MOPC315cells after alloHSCT compared to standard CyFlu, but less toxicity asbody weights are reduced 20% by the CyFlu preconditioning, but notreduced by the Dex preconditioning. The combination of one dose CyFluplus Dex is also effective and has lower toxicity than standard repeatCyFlu preconditioning. The Dexa preconditioned group will have similaror better anti-tumor effect, improved progression-free survival, reducedDisease progression, enhanced duration of response, improved overallsurvival, reduced minimal residual disease compared to mice who werepreconditioned with CyFlu for 2 to 5 days.

For allogeneic NK cell administration, fully functional NK cells areisolated from donor B10.D2 mice using commercially available kits suchas the one from Miltenyi. Alternatively, mouse NK cells can be purchasedfrom ATCC (KIL cells). The NK Cell Isolation Kit was developed for theisolation of untouched NK cells from single-cell suspensions of murinespleen. Non-NK cells, i.e. T cells, dendritic cells, B cells,granulocytes, macrophages, and erythroid cells are magnetically labeledby using a cocktail of biotin-conjugated antibodies and Anti-BiotinMicroBeads. Isolation of highly pure unlabeled NK cells is achieved bydepletion of non-target cells. The kit has been optimized to giveoutstanding purities in C57BL/6J mice. 1×10⁷ isolated NK cells aretransplanted by IV tail vein injection between 10 and 30 days afterMOPC315 inoculation. NK cell eradication of MOPC315 cells is aseffective when Dexa preconditioning was used as when standard CyFlupreconditioning is used, with much less toxicity. The combination of onedose CyFlu plus Dex is also effective and has lower toxicity thanstandard repeat CyFlu preconditioning. The Dexa preconditioned groupwill have similar or better anti-tumor effect, improved progression-freesurvival, reduced Disease progression, enhanced duration of response,improved overall survival, reduced minimal residual disease compared tomice who were preconditioned with CyFlu for 2 to 5 days.

Example 6: A Patient with a Condition Selected from the Group Consistingof

Hemophagocytic lymphohistiocytosis, multiple myeloma, allergen specificimmunotherapy, autosomal dominant haploinsufficiency, anteriorinterosseous nerve syndrome, Churg-Strauss syndrome, Systemicvasculitis, chronic graft versus host disease, Opsoclonus-MyoclonusSyndrome, Necrotising Autoimmune Myopathy (NAM), Pulmonary Sarcomatoidcarcinomas, Waldenstrom's macroglobulinaemia (WM), fertility, BehcetsDisease, Alopecia areata (AA), Acute-on-chronic Liver Failure, melanoma,‘organizing bronchiolitis syndrome’, encephalitis, minimal changedisease, or a patient receiving Tumor flare reaction therapy orSublingual immunotherapy (SLIT) or subcutaneous immunotherapy (SCIT), orhaving:

Disease (Source of Disease)

Acinetobacter infections (Acinetobacter baumannii), Actinomycosis(Actinomyces israelii, Actinomyces gerencseriae and Propionibacteriumpropionicus) African sleeping sickness or African trypanosomiasis(Trypanosoma brucei), AIDS (Acquired immunodeficiency syndrome) (Humanimmunodeficiency virus), Amebiasis (Entamoeba histolytica), Anaplasmosis(Anaplasma species), Angiostrongyliasis (Angiostrongylus), Anisakiasis(Anisakis), Anthrax (Bacillus anthracis), Arcanobacterium haemolyticuminfection (Arcanobacterium haemolyticum), Argentine hemorrhagic fever(Junin virus), Ascariasis (Ascaris lumbricoides), Aspergillosis(Aspergillus species), Astrovirus infection (Astroviridae family),Babesiosis (Babesia species), Bacillus cereus infection (Bacilluscereus), Bacterial pneumonia (multiple bacteria), Bacterial vaginosis(List of bacterial vaginosis microbiota), Bacteroides infection(Bacteroides species), Balantidiasis (Balantidium coli), Bartonellosis(Bartonella), Baylisascaris infection (Baylisascaris species), BK virusinfection (BK virus), Black piedra (Piedraia hortae), Blastocystosis(Blastocystis species), Blastomycosis (Blastomyces dermatitidis),Bolivian hemorrhagic fever (Machupo virus), Botulism (and Infantbotulism) (Clostridium botulinum; Note: Botulism is not an infection byClostridium botulinum but caused by the intake of botulinum toxin),Brazilian hemorrhagic fever (Sabia virus), Brucellosis (Brucellaspecies), Bubonic plague (the bacterial family Enterobacteriaceae),Burkholderia infection, usually Burkholderia cepacia and otherBurkholderia species, Buruli ulcer (Mycobacterium ulcerans), Calicivirusinfection (Norovirus and Sapovirus) (Caliciviridae family),Campylobacteriosis (Campylobacter species), Candidiasis (Moniliasis;Thrush) (usually Candida albicans and other Candida species),Capillariasis (Intestinal disease by Capillaria philippinensis, hepaticdisease by Capillaria hepatica and pulmonary disease by Capillariaaerophila), Carrion's disease (Bartonella bacilliformis), Cat-scratchdisease (Bartonella henselae), Cellulitis (usually Group A Streptococcusand Staphylococcus), Chagas Disease (American trypanosomiasis)(Trypanosoma cruzi), Chancroid (Haemophilus ducreyi), Chickenpox(Varicella zoster virus (VZV)), Chikungunya (Alphavirus), Chlamydia(Chlamydia trachomatis), Chlamydophila pneumoniae infection (Taiwanacute respiratory agent or TWAR) (Chlamydophila pneumoniae), Cholera(Vibrio cholerae), Chromoblastomycosis (usually Fonsecaea pedrosoi),Chytridiomycosis (Batrachochytrium dendrabatidis), Clonorchiasis(Clonorchis sinensis), Clostridium difficile colitis (Clostridiumdifficile), Coccidioidomycosis (Coccidioides immitis and Coccidioidesposadasii), Colorado tick fever (CTF) (Colorado tick fever virus(CTFV)), Common cold (Acute viral rhinopharyngitis; Acute coryza)(usually rhinoviruses and coronaviruses), Creutzfeldt-Jakob disease(CJD) (PRNP), Crimean-Congo hemorrhagic fever (CCHF) (Crimean-Congohemorrhagic fever virus), Cryptococcosis (Cryptococcus neoformans),Cryptosporidiosis (Cryptosporidium species), Cutaneous larva migrans(CLM) (usually Ancylostoma braziliense; multiple other parasites),Cyclosporiasis (Cyclospora cayetanensis), Cysticercosis (Taenia solium),Cytomegalovirus infection (Cytomegalovirus), Dengue fever (Dengueviruses (DEN-1, DEN-2, DEN-3 and DEN-4)—Flaviviruses), Desmodesmusinfection (Green algae Desmodesmus armatus), Dientamoebiasis(Dientamoeba fragilis), Diphtheria (Corynebacterium diphtheriae),Diphyllobothriasis (Diphyllobothrium), Dracunculiasis (Dracunculusmedinensis), Ebola hemorrhagic fever (Ebolavirus (EBOV)), Echinococcosis(Echinococcus species), Ehrlichiosis (Ehrlichia species), Enterobiasis(Pinworm infection) (Enterobius vermicularis), Enterococcus infection(Enterococcus species), Enterovirus infection (Enterovirus species),Epidemic typhus (Rickettsia prowazekii), Erythema infectiosum (Fifthdisease) (Parvovirus B19), Exanthem subitum (Sixth disease) (Humanherpesvirus 6 (HHV-6) and Human herpesvirus 7 (HHV-7)), Fasciolasis(Fasciola hepatica and Fasciola gigantica), Fasciolopsiasis(Fasciolopsis buski), Fatal familial insomnia (FFI) (PRNP), Filariasis(Filarioidea superfamily), Food poisoning by Clostridium perfringens(Clostridium perfringens), Free-living amebic infection (multiple),Fusobacterium infection (Fusobacterium species), Gas gangrene(Clostridial myonecrosis) (usually Clostridiumperfringens; otherClostridium species), Geotrichosis (Geotrichum candidum),Gerstmann-Straussler-Scheinker syndrome (GSS) (PRNP), Giardiasis(Giardia lamblia) Glanders (Burkholderia mallei), Gnathostomiasis(Gnathostoma spinigerum and Gnathostoma hispidum), Gonorrhea (Neisseriagonorrhoeae), Granuloma inguinale (Donovanosis) (Klebsiellagranulomatis), Group A streptococcal infection (Streptococcus pyogenes),Group B streptococcal infection (Streptococcus agalactiae), Haemophilusinfluenzae infection (Haemophilus influenzae) Hand, foot and mouthdisease (HFMD) (Enteroviruses, mainly Coxsackie A virus and Enterovirus71 (EV71)), Hantavirus Pulmonary Syndrome (HPS) (Sin Nombre virus),Heartland virus disease (Heartland virus), Helicobacter pylori infection(Helicobacter pylori), Hemolytic-uremic syndrome (HUS), Escherichia coliO157:H7, O111 and O104:H4, Hemorrhagic fever with renal syndrome (HFRS)(Bunyaviridae family), Hepatitis A (Hepatitis A virus), Hepatitis B(Hepatitis B virus), Hepatitis C (Hepatitis C virus), Hepatitis D(Hepatitis D Virus), Hepatitis E (Hepatitis E virus), Herpes simplex(Herpes simplex virus 1 and 2 (HSV-1 and HSV-2)), Histoplasmosis(Histoplasma capsulatum), Hookworm infection (Ancylostoma duodenale andNecator americanus), Human bocavirus infection (Human bocavirus (HBoV)),Human ewingii ehrlichiosis (Ehrlichia ewingii), Human granulocyticanaplasmosis (HGA) (Anaplasma phagocytophilum), Human metapneumovirusinfection, Human metapneumovirus (hMPV), Human monocytic ehrlichiosis(Ehrlichia chaffeensis), Human papillomavirus (HPV) infection (Humanpapillomavirus (HPV)), Human parainfluenza virus infection (Humanparainfluenza viruses (HPIV)), Hymenolepiasis (Hymenolepis nana andHymenolepis diminuta), Epstein-Barr virus infectious mononucleosis(Mono) (Epstein-Barr virus (EBV)), Influenza (flu) (Orthomyxoviridaefamily) Isosporiasis (Isospora belli), Kawasaki disease (unknown;evidence supports that it is infectious) Keratitis (multiple), Kingellakingae infection (Kingella kingae), Kuru (PRNP), Lassa fever (Lassavirus), Legionellosis (Legionnaires' disease) (Legionella pneumophila),Legionellosis (Pontiac fever) (Legionella pneumophila), Leishmaniasis(Leishmania species), Leprosy (Mycobacterium leprae and Mycobacteriumlepromatosis), Leptospirosis (Leptospira species), Listeriosis (Listeriamonocytogenes), Lyme disease (Lyme borreliosis) (Borrelia burgdorferi,Borrelia garinii, and Borrelia afzelii), Lymphatic filariasis(Elephantiasis) (Wuchereria bancrofti and Brugia malayi), Lymphocyticchoriomeningitis (Lymphocytic choriomeningitis virus (LCMV)), Malaria(Plasmodium species), Marburg hemorrhagic fever (MHF) (Marburg virus),Measles (Measles virus), Middle East respiratory syndrome (MERS) (MiddleEast respiratory syndrome coronavirus), Melioidosis (Whitmore's disease)(Burkholderia pseudomallei), Meningitis (multiple), Meningococcaldisease (Neisseria meningitidis), Metagonimiasis (usually Metagonimusyokagawai), Microsporidiosis (Microsporidia phylum), Molluscumcontagiosum (MC) (Molluscum contagiosum virus (MCV)), Monkeypox(Monkeypox virus), Mumps (Mumps virus), Murine typhus (Endemic typhus)(Rickettsia typhi), Mycoplasma pneumonia (Mycoplasma pneumoniae),Mycetoma (disambiguation) (numerous species of bacteria (Actinomycetoma)and fungi (Eumycetoma)), Myiasis (parasitic dipterous fly larvae),Neonatal conjunctivitis (Ophthalmia neonatorum) (most commonly Chlamydiatrachomatis and Neisseria gonorrhoeae), Norovirus (children and babies)((New) Variant Creutzfeldt-Jakob disease (vCJD, nvCJD), PRNP),Nocardiosis (usually Nocardia asteroides and other Nocardia species),Onchocerciasis (River blindness) (Onchocerca volvulus), Opisthorchiasis(Opisthorchis viverrini and Opisthorchis felineus),Paracoccidioidomycosis (South American blastomycosis) (Paracoccidioidesbrasiliensis), Paragonimiasis (usually Paragonimus westermani and otherParagonimus species), Pasteurellosis (Pasteurella species), Pediculosiscapitis (Head lice) (Pediculus humanus capitis), Pediculosis corporis(Body lice) (Pediculus humanus corporis), Pediculosis pubis (Pubic lice,Crab lice) (Phthirus pubis), Pelvic inflammatory disease (PID)(multiple), Pertussis (Whooping cough) (Bordetella pertussis), Plague(Yersinia pestis), Pneumococcal infection (Streptococcus pneumoniae),Pneumocystis pneumonia (PCP) (Pneumocystis jirovecii), Pneumonia(multiple), Poliomyelitis (Poliovirus), Prevotella infection (Prevotellaspecies), Primary amoebic meningoencephalitis (PAM) (usually Naegleriafowleri), Progressive multifocal leukoencephalopathy (JC virus),Psittacosis (Chlamydophila psittaci), Q fever (Coxiella burnetii),Rabies (Rabies virus), Relapsing fever (Borrelia hermsii, Borreliarecurrentis, and other Borrelia species), Respiratory syncytial virusinfection (Respiratory syncytial virus (RSV)), Rhinosporidiosis(Rhinosporidium seeberi), Rhinovirus infection (Rhinovirus), Rickettsialinfection (Rickettsia species), Rickettsialpox (Rickettsia akari), RiftValley fever (RVF) (Rift Valley fever virus), Rocky Mountain spottedfever (RMSF) (Rickettsia rickettsii), Rotavirus infection (Rotavirus),Rubella (Rubella virus), Salmonellosis (Salmonella species), SARS(Severe Acute Respiratory Syndrome) (SARS coronavirus), Scabies(Sarcoptes scabiei), Schistosomiasis (Schistosoma species), Sepsis(multiple), Shigellosis (Bacillary dysentery) (Shigella species),Shingles (Herpes zoster) (Varicella zoster virus (VZV)), Smallpox(Variola) (Variola major or Variola minor), Sporotrichosis (Sporothrixschenckii), Staphylococcal food poisoning (Staphylococcus species),Staphylococcal infection (Staphylococcus species), Strongyloidiasis(Strongyloides stercoralis), Subacute sclerosing panencephalitis(Measles virus), Syphilis (Treponema pallidum), Taeniasis (Taeniaspecies), Tetanus (Lockjaw) (Clostridium tetani), Tinea barbae (Barber'sitch) (usually Trichophyton species), Tinea capitis (Ringworm of theScalp) (usually Trichophyton tonsurans), Tinea corporis (Ringworm of theBody) (usually Trichophyton species), Tinea cruris (Jock itch) (usuallyEpidermophyton floccosum, Trichophyton rubrum, and Trichophytonmentagrophytes), Tinea manum (Ringworm of the Hand) (Trichophytonrubrum), Tinea nigra (usually Hortaea werneckii), Tinea pedis (Athlete'sfoot) (usually Trichophyton species), Tinea unguium (Onychomycosis)(usually Trichophyton species), Tinea versicolor (Pityriasis versicolor)(Malassezia species), Toxocariasis (Ocular Larva Migrans (OLM))(Toxocara canis or Toxocara cati), Toxocariasis (Visceral Larva Migrans(VLM)) (Toxocara canis or Toxocara cati), Trachoma (Chlamydiatrachomatis), Toxoplasmosis (Toxoplasma gondii), Trichinosis(Trichinella spiralis), Trichomoniasis (Trichomonas vaginalis),Trichuriasis (Whipworm infection) (Trichuris trichiura),Tuberculosis(usually Mycobacterium tuberculosis), Tularemia (Francisellatularensis), Typhoid fever (Salmonella enterica subsp. enterica, serovartyphi), Typhus fever (Rickettsia), Ureaplasma urealyticum infection(Ureaplasma urealyticum), Valley fever (Coccidioides immitis orCoccidioides posadasii), Venezuelan equine encephalitis (Venezuelanequine encephalitis virus), Venezuelan hemorrhagic fever (Guanaritovirus), Vibrio vulnificus infection (Vibrio vulnificus), Vibrioparahaemolyticus enteritis (Vibrio parahaemolyticus), Viral pneumonia(multiple viruses), West Nile Fever (West Nile virus), White piedra(Tinea blanca) (Trichosporon beigelii), Yersinia pseudotuberculosisinfection (Yersinia pseudotuberculosis), Yersiniosis (Yersiniaenterocolitica), Yellow fever (Yellow fever virus), Zygomycosis(Mucorales order (Mucormycosis) and Entomophthorales order(Entomophthoramycosis)) Human immunodeficiency virus [HIV] disease, HIVdisease with infectious and parasitic diseases, HIV disease withmycobacterial infection, HIV disease with cytomegaloviral disease, HIVdisease with other viral infections, HIV disease with candidiasis, HIVdisease with other mycoses, HIV disease with Pneumocystic cariniipneumonia, HIV disease with malignant neoplasms, HIV disease withKaposi's sarcoma, HIV disease with Burkitt's lymphoma, HIV disease withother type's of non-Hodgkin's lymphoma, HIV disease with other malignantneoplasms of lymphoid, hematopoietic and related tissue, HIV diseasewith multiple malignant neoplasms, HIV disease with other malignantneoplasms, HIV disease with unspecified malignant neoplasm, HIV diseasewith encephalopathy, HIV disease with lymphoid interstitial pneumonitis,HIV disease with wasting syndrome, HIV disease with multiple diseasesclassified elsewhere, HIV disease with other conditions, HIV diseaseAcute HIV infection syndrome, HIV disease with (persistent) generalizedlymphadenopathy, HIV disease with hematological and immunologicalabnormalities, not elsewhere classified, HIV disease with otherspecified conditions, Unspecified HIV disease, Malignant neoplasm oflip, Malignant neoplasm of tonsil, Malignant neoplasm of tongue,Malignant neoplasm of gum, Malignant neoplasm of mouth, Malignantneoplasm of parotid gland, Malignant neoplasm of salivary glands,Malignant neoplasm of pharynx, Malignant neoplasm of esophagus,Malignant neoplasm of stomach, Malignant neoplasm of small intestine,Malignant neoplasm of colon, Malignant neoplasm of recto sigmoidjunction, Malignant neoplasm of rectum, Malignant neoplasm of anus,Malignant neoplasm of liver, Malignant neoplasm of gallbladder,Malignant neoplasm of biliary tract, Malignant neoplasm of pancreas,Malignant neoplasm of intestinal tract, Malignant neoplasm of spleen,Malignant neoplasm of nasal cavity and middle ear, Malignant neoplasm ofaccessory sinuses, Malignant neoplasm of larynx, Malignant neoplasm oftrachea, Malignant neoplasm of bronchus and lung, Malignant neoplasm ofthymus, Malignant neoplasm of heart, mediastinum and pleura, Malignantneoplasm of sites in the respiratory system and intrathoracic organs,Malignant neoplasm of bone and articular cartilage of limbs, Malignantneoplasm of bones of skull and face, Malignant neoplasm of vertebralcolumn, Malignant neoplasm of ribs, sternum and clavicle, Malignantneoplasm of pelvic bones, sacrum and coccyx, Malignant melanoma of skin,Malignant melanoma of lip, Malignant melanoma of eyelid, includingcanthus, Malignant melanoma of ear and external auricular canal,Malignant melanoma of face, Malignant melanoma of anal skin, Malignantmelanoma of skin of breast, Malignant melanoma of limbs, includingshoulder, Merkel cell carcinoma, Basal cell carcinoma of skin of lip,Squamous cell carcinoma of skin of lip, Other and unspecified malignantneoplasm skin/eyelid, including canthus, Malignant neoplasm skin/ear andexternal auric canal, Other and unspecified malignant neoplasm skin/andunspecified parts of face, Basal cell carcinoma of skin of other andunspecified parts of face, Squamous cell carcinoma of skin of andunspecified parts of face, Basal cell carcinoma of skin of scalp andneck, Squamous cell carcinoma of skin of scalp and neck, Basal cellcarcinoma of skin of trunk, Basal cell carcinoma of anal skin, Basalcell carcinoma of skin of breast, Squamous cell carcinoma of skin oftrunk, Squamous cell carcinoma of anal skin, Squamous cell carcinoma ofskin of breast, Squamous cell carcinoma of skin of other part of trunk,Other and unspecified malignant neoplasm skin/limbs including shoulder,Basal cell carcinoma skin/limbs, including shoulder, Squamous cellcarcinoma skin/limbs, including shoulder, Basal cell carcinoma of skinof limbs, including hip, Squamous cell carcinoma of skin of limbs,including hip, Mesothelioma, Kaposi's sarcoma, Malignant neoplasm ofperipheral nerves and autonomic nervous sys, Malignant neoplasm ofretroperitoneum and peritoneum, Malignant neoplasm of other connectiveand soft tissue, Malignant neoplasm of connective and soft tissue ofthorax, Malignant neoplasm of connective and soft tissue of abdomen,Malignant neoplasm of connective and soft tissue of pelvis, Malignantneoplasm of conn and soft tissue of trunk, unspecified, Malignantneoplasm of overlapping sites of connective and soft tissue, Malignantneoplasm of connective and soft tissue, unspecified, Gastrointestinalstromal tumor, Malignant neoplasm of breast, Malignant neoplasm ofvulva, Malignant neoplasm of vagina, Malignant neoplasm of cervix uteri,Malignant neoplasm of corpus uteri, Malignant neoplasm of uterus, partunspecified, Malignant neoplasm of ovary, Malignant neoplasm of otherand unspecified female genital organs, Malignant neoplasm of placenta,Malignant neoplasm of penis, Malignant neoplasm of prostate, Malignantneoplasm of testis, Malignant neoplasm of other and unspecified malegenital organs, Malignant neoplasm of kidney, Malignant neoplasm ofrenal pelvis, Malignant neoplasm of ureter, Malignant neoplasm ofbladder, Malignant neoplasm of other and unspecified urinary organs,Malignant neoplasm of eye and adnexa, Malignant neoplasm of meninges,Malignant neoplasm of brain, Malignant neoplm of spinal cord, cranialnerves, Malignant neoplasm of optic nerve, Malignant neoplasm of otherand unspecified cranial nerves, Malignant neoplasm of central nervoussystem, unspecified, Malignant neoplasm of thyroid gland, Malignantneoplasm of adrenal gland, Malignant neoplasm of endo glands and relatedstructures, Malignant neuroendocrine tumors, Malignant carcinoid tumors,Secondary neuroendocrine tumors, Malignant neoplasm of head, face andneck, Malignant neoplasm of thorax, Malignant neoplasm of abdomen,Malignant neoplasm of pelvis, Malignant neoplasm of limbs, Malignantneoplasm of lower limb, Secondary and unspecified malignant neoplasm oflymph nodes, Secondary malignant neoplasm of respiratory and digestiveorgans, Secondary malignant neoplasm of kidney and renal pelvis,Secondary malignant neoplm of bladder and other and unspecified urinaryorgans, Secondary malignant neoplasm of skin, Secondary malignantneoplasm of brain and cerebral meninges, Secondary malignant neoplasm ofand unspecified parts of nervous sys, Secondary malignant neoplasm ofbone and bone marrow, Secondary malignant neoplasm of ovary, Secondarymalignant neoplasm of adrenal gland, Hodgkin lymphoma, Follicularlymphoma, Non-follicular lymphoma, Small cell B-cell lymphoma, Mantlecell lymphoma, Diffuse large B-cell lymphoma, Lymphoblastic (diffuse)lymphoma, Burkitt lymphoma, Other non-follicular lymphoma,Non-follicular (diffuse) lymphoma, unspecified, Mature T/NK-celllymphomas, Sezary disease, Peripheral T-cell lymphoma, not classified,Anaplastic large cell lymphoma, ALK-positive, Anaplastic large celllymphoma, ALK-negative, Cutaneous T-cell lymphoma, unspecified, Othermature T/NK-cell lymphomas, Mature T/NK-cell lymphomas, unspecified,Other and unspecified types of non-Hodgkin lymphoma, Malignantimmunoproliferative dis and certain other B-cell lymph, Multiple myelomaand malignant plasma cell neoplasms, Lymphoid leukemia, Acutelymphoblastic leukemia [ALL], Chronic lymphocytic leukemia of B-celltype, Prolymphocytic leukemia of B-cell type, Hairy cell leukemia, AdultT-cell lymphoma/leukemia (HTLV-1-associated), Prolymphocytic leukemia ofT-cell type, Mature B-cell leukemia Burkitt-type, Other lymphoidleukemia, Lymphoid leukemia, unspecified, Myeloid leukemia, Acutemyeloblastic leukemia, Chronic myeloid leukemia, BCR/ABL-positive,Atypical chronic myeloid leukemia, BCR/ABL-negative, Myeloid sarcoma,Acute promyelocytic leukemia, Acute myelomonocytic leukemia, Acutemyeloid leukemia with 11q23-abnormality, Other myeloid leukemia, Myeloidleukemia, unspecified, Monocytic leukemia, Chronic myelomonocyticleukemia, Juvenile myelomonocytic leukemia, Other monocytic leukemia,Monocytic leukemia, unspecified, Other leukemias of specified cell type,Acute erythroid leukemia, Acute megakaryoblastic leukemia, Mast cellleukemia, Acute panmyelosis with myelofibrosis, Myelodysplastic disease,not classified, Other specified leukemias, Leukemia of unspecified celltype, Chronic leukemia of unspecified cell type, Leukemia, unspecified,Other & unspecified malignant neoplasm of lymphoid, hematopoietictissue, Carcinoma in situ of oral cavity, esophagus and stomach,Carcinoma in situ of colon, Carcinoma in situ of recto sigmoid junction,Carcinoma in situ of rectum, Carcinoma in situ of anus and anal canal,Carcinoma in situ of other and unspecified parts of intestine, Carcinomain situ of unspecified part of intestine, Carcinoma in situ of otherparts of intestine, Carcinoma in situ of liver, gallbladder and bileducts, Carcinoma in situ of other specified digestive organs, Carcinomain situ of digestive organ, unspecified, Carcinoma in situ of middle earand respiratory system, Carcinoma in situ of larynx, Carcinoma in situof trachea, Carcinoma in situ of bronchus and lung, Carcinoma in situ ofother parts of respiratory system, Melanoma in situ, Melanoma in situ oflip, Melanoma in situ of eyelid, including canthus, Melanoma in situ ofear and external auricular canal, Melanoma in situ of unspecified partof face, Melanoma in situ of scalp and neck, Melanoma in situ of trunk,Melanoma in situ of anal skin, Melanoma in situ of breast (skin) (softtissue), Melanoma in situ of upper limb, including shoulder, Melanoma insitu of lower limb, including hip, Melanoma in situ of other sites,Carcinoma in situ of skin, Carcinoma in situ of skin of lip, Carcinomain situ of skin of eyelid, including canthus, Carcinoma in situ skin ofear and external auricular canal, Carcinoma in situ of skin of other andunspecified parts of face, Carcinoma in situ of skin of scalp and neck,Carcinoma in situ of skin of trunk, Carcinoma in situ of skin of upperlimb, including shoulder, Carcinoma in situ of skin of lower limb,including hip, Carcinoma in situ of skin of other sites, Carcinoma insitu of breast, Lobular carcinoma in situ of breast, Intraductalcarcinoma in situ of breast, Other specified type of carcinoma in situof breast, Unspecified type of carcinoma in situ of breast, Carcinoma insitu of cervix uteri, Carcinoma in situ of other parts of cervix,Carcinoma in situ of cervix, unspecified, Carcinoma in situ of other andunspecified genital organs, Carcinoma in situ of endometrium, Carcinomain situ of vulva, Carcinoma in situ of vagina, Carcinoma in situ ofother and unspecified female genital organs, Carcinoma in situ of penis,Carcinoma in situ of prostate, Carcinoma in situ of unspecified malegenital organs, Carcinoma in situ of scrotum, Carcinoma in situ of othermale genital organs, Carcinoma in situ of bladder, Carcinoma in situ ofother and unspecified urinary organs, Carcinoma in situ of eye,Carcinoma in situ of thyroid and other endocrine glands, Benign neoplasmof mouth and pharynx, Benign neoplasm of major salivary glands, Benignneoplasm of colon, rectum, anus and anal canal, Benign neoplasm of andill-defined parts of digestive system, Benign neoplasm of esophagus,Benign neoplasm of stomach, Benign neoplasm of duodenum, Benign neoplasmof other and unspecified parts of small intestine, Benign neoplasm ofliver, Benign neoplasm of extrahepatic bile ducts, Benign neoplasm ofpancreas, Benign neoplasm of endocrine pancreas, Benign neoplasm ofill-defined sites within the digestive system, Benign neoplasm of middleear and respiratory system, Benign neoplasm of respiratory system,unspecified, Benign neoplasm of other and unspecified intrathoracicorgans, Benign neoplasm of thymus, Benign neoplasm of heart, Benignneoplasm of mediastinum, Benign neoplasm of other specifiedintrathoracic organs, Benign neoplasm of intrathoracic organ,unspecified, Benign neoplasm of bone and articular cartilage, Benignneoplasm of short bones of upper limb, Benign neoplasm of long bones oflower limb, Benign neoplasm of short bones of lower limb, Benignneoplasm of bones of skull and face, Benign neoplasm of lower jaw bone,Benign neoplasm of vertebral column, Benign neoplasm of ribs, sternumand clavicle, Benign neoplasm of pelvic bones, sacrum and coccyx, Benignneoplasm of bone and articular cartilage, unspecified, Benign lipomatousneoplasm, Ben lipomatous neoplm of skin, subcutaneous of head, face andneck, Benign lipomatous neoplasm of intrathoracic organs, Benignlipomatous neoplasm of intra-abdominal organs, Benign lipomatousneoplasm of spermatic cord, Benign lipomatous neoplasm of other sites,Benign lipomatous neoplasm of kidney, Benign lipomatous neoplasm ofother genitourinary organ, Hemangioma and lymphangioma, any site,Hemangioma, Hemangioma unspecified site, Hemangioma of skin andsubcutaneous tissue, Hemangioma of intracranial structures, Hemangiomaof intra-abdominal structures, Hemangioma of other sites, Lymphangioma,any site, Benign neoplasm of mesothelial tissue, Benign neoplm of softtissue of retroperitoneum and peritoneum, Other benign neoplasms ofconnective and other soft tissue, Melanocytic nevi, Melanocytic nevi oflip, Melanocytic nevi of eyelid, including canthus, Melanocytic nevi ofunspecified eyelid, including canthus, Melanocytic nevi of ear andexternal auricular canal, Melanocytic nevi of other and unspecifiedparts of face, Melanocytic nevi of scalp and neck, Melanocytic nevi oftrunk, Melanocytic nevi of upper limb, including shoulder, Melanocyticnevi of lower limb, including hip, Melanocytic nevi, unspecified, Otherbenign neoplasm of skin of eyelid, including canthus, Other benignneoplasm skin/ear and external auricular canal, Other benign neoplasmskin/left ear and external auric canal, Other benign neoplasm of skin ofother and unspecified parts of face, Other benign neoplasm of skin ofother parts of face, Other benign neoplasm of skin of scalp and neck,Other benign neoplasm of skin of trunk, Other benign neoplasm skin/upperlimb, including shoulder, Other benign neoplasm of skin of lower limb,including hip, Other benign neoplasm of skin, unspecified, Benignneoplasm of breast, Benign neoplasm of unspecified breast, Leiomyoma ofuterus, Other benign neoplasms of uterus, Benign neoplasm of ovary,Benign neoplasm of other and unspecified female genital organs, Benignneoplasm of male genital organs, Benign neoplasm of urinary organs,Benign neoplasm of kidney, Benign neoplasm of renal pelvis, Benignneoplasm of ureter, Benign neoplasm of bladder, Benign neoplasm ofurethra, Benign neoplasm of other specified urinary organs, Benignneoplasm of urinary organ, unspecified, Benign neoplasm of eye andadnexa, Benign neoplasm of conjunctiva, Benign neoplasm of cornea,Benign neoplasm of retina, Benign neoplasm of choroid, Benign neoplasmof ciliary body, Benign neoplasm of lacrimal gland and duct, Benignneoplasm of unspecified site of orbit, Benign neoplasm of unspecifiedpart of eye, Benign neoplasm of meninges, Benign neoplasm of brain andcentral nervous system, Benign neoplasm of thyroid gland, Benignneoplasm of other and unspecified endocrine glands, Benign neoplasm ofother and unspecified sites, Benign neoplasm of lymph nodes, Benignneoplasm of peripheral nerves and autonomic nervous sys, Benign neoplasmof other specified sites, Benign neuroendocrine tumors, Other benignneuroendocrine tumors, Neoplasm of uncertain behavior of oral cavity anddigestive organs, Neoplasm of uncertain behavior of the major salivaryglands, Neoplasm of uncertain behavior of pharynx, Neoplasm of uncertainbehavior of sites of the oral cavity, Neoplasm of uncertain behavior ofstomach, Neoplasm of uncertain behavior of small intestine, Neoplasm ofuncertain behavior of appendix, Neoplasm of uncertain behavior of colon,Neoplasm of uncertain behavior of rectum, Neoplasm of uncertain behaviorof liver, GB & bile duct, Neoplasm of uncertain behavior of otherdigestive organs, Neoplasm of uncertain behavior of digestive organ,Neoplm of mid ear and intrathoracic organs, Neoplasm of uncertainbehavior of larynx, Neoplasm of uncertain behavior of trachea, bronchusand lung, Neoplasm of uncertain behavior of pleura, Neoplasm ofuncertain behavior of mediastinum, Neoplasm of uncertain behavior ofthymus, Neoplasm of uncertain behavior of other respiratory organs,Neoplasm of uncertain behavior of respiratory organ, unspecified,Neoplasm of uncertain behavior of female genital organs, Neoplasm ofuncertain behavior of uterus, Neoplasm of uncertain behavior of ovary,Neoplasm of uncertain behavior of unspecified ovary, Neoplasm ofuncertain behavior of placenta, Neoplasm of uncertain behavior of malegenital organs, Neoplasm of uncertain behavior of urinary organs,Neoplasm of uncertain behavior of kidney, Neoplasm of uncertain behaviorof unspecified kidney, Neoplasm of uncertain behavior of renal pelvis,Neoplasm of uncertain behavior of ureter, Neoplasm of uncertain behaviorof bladder, Neoplasm of uncertain behavior of other urinary organs,Neoplasm of uncertain behavior of unspecified urinary organ, Neoplasm ofuncertain behavior of meninges, Neoplasm of uncertain behavior ofcerebral meninges, Neoplasm of uncertain behavior of spinal meninges,Neoplasm of uncertain behavior of meninges, unspecified, Neoplasm ofuncertain behavior of brain, Neoplasm of uncertain behavior of brain,Neoplasm of uncertain behavior of brain, infratentorial, Neoplasm ofuncertain behavior of brain, unspecified, Neoplasm of uncertain behaviorof cranial nerves, Neoplasm of uncertain behavior of spinal cord,Neoplasm of uncertain behavior of central nervous system, Neoplasm ofuncertain behavior of endocrine glands, Neoplasm of uncertain behaviorof thyroid gland, Neoplasm of uncertain behavior of adrenal gland,Neoplasm of uncertain behavior of unspecified adrenal gland, Neoplasm ofuncertain behavior of parathyroid gland, Neoplasm of uncertain behaviorof pituitary gland, Neoplasm of uncertain behavior of craniopharyngealduct, Neoplasm of uncertain behavior of pineal gland, Neoplasm ofuncertain behavior of carotid body, Neoplasm of uncertain behavior ofaortic body and other paraganglia, Neoplasm of uncertain behavior ofunspecified endocrine gland, Polycythemia vera, Myelodysplasticsyndromes, Refractory anemia without ring sideroblasts, so stated,Refractory anemia with ring sideroblasts, Refractory anemia with excessof blasts [RAEB], Myelodysplastic syndrome, unspecified, Other neoplm ofuncertain behavior of lymphoid, hematopoietic tissue, Histiocytic andmast cell tumors of uncertain behavior, Chronic myeloproliferativedisease, Monoclonal gammopathy, Essential (hemorrhagic) thrombocythemia,Osteomyelofibrosis, Other neoplasm of uncertain behavior of lymphoid,hematopoietic tissue, Neoplasm of uncertain behavior of lymphoid,hematopoietic & unspecified, Neoplasm of uncertain behavior of other andunspecified sites, Neoplasm of uncertain behavior of bone/articcartilage, Neoplasm of uncertain behavior of connective/soft tissue,Neoplasm of uncertain behavior of peripheral nerves and autonomousnervous sys, Neoplasm of uncertain behavior of retroperitoneum, Neoplasmof uncertain behavior of peritoneum, Neoplasm of uncertain behavior ofskin, Neoplasm of uncertain behavior of breast, Neoplasm of unspecifiedbehavior of digestive system, Neoplasm of unspecified behavior ofrespiratory system, Neoplasm of unspecified behavior of bone, softtissue, and skin, Neoplasm of unspecified behavior of breast, Neoplasmof unspecified behavior of bladder, Neoplasm of unspecified behavior ofother genitourinary organs, Neoplasm of unspecified behavior of kidney,Neoplasm of unspecified behavior of other GU organ, Neoplasm ofunspecified behavior of brain, Neoplasm of unspecified behavior of endoglands and other parts of nervous sys, Neoplasm of unspecified behaviorof retina and choroid, Neoplasm of unspecified behavior of unspecifiedsite, Iron deficiency anemia, Vitamin B12 deficiency anemia, Folatedeficiency anemia, Protein deficiency anemia, Other megaloblasticanemias, not elsewhere classified, Scorbutic anemia, Other specifiednutritional anemias, Nutritional anemia, unspecified, Anemia due toenzyme disorders, Anemia, Thalassemia, Hereditary persistence of fetalhemoglobin [HPFH], Hemoglobin E-beta thalassemia, Other thalassemia's,Thalassemia, unspecified, Sickle-cell disorders, Other hereditaryhemolytic anemias, Acquired hemolytic anemia, Acquired pure red cellaplasia [erythroblastopenia], Acquired pure red cell aplasia,unspecified, Other aplastic anemias and other bone marrow failuresyndromes, Drug-induced aplastic anemia, Aplastic anemia due to otherexternal agents, Idiopathic aplastic anemia, Other aplastic anemias andother bone marrow failure syndromes, Aplastic anemia, unspecified, Acuteposthemorrhagic anemia, Anemia, Disseminated intravascular coagulation,Hereditary factor VIII deficiency, Hereditary factor IX deficiency,Other coagulation defects, Acquired coagulation factor deficiency,Primary thrombophilia, Other thrombophilia, Purpura and otherhemorrhagic conditions, Secondary thrombocytopenia, Thrombocytopenia,unspecified, Other specified hemorrhagic conditions, Hemorrhagiccondition, unspecified, Neutropenia, Congenital agranulocytosis,Agranulocytosis secondary to cancer chemotherapy, Other drug-inducedagranulocytosis, Neutropenia due to infection, Cyclic neutropenia, Otherneutropenia, Other disorders of white blood cells, Genetic anomalies ofleukocytes, Eosinophilia, Other specified disorders of white bloodcells, Decreased white blood cell count, Lymphocytosis (symptomatic),Diseases of spleen, Methemoglobinemia, Congenital methemoglobinemia,Other methemoglobinemias, Methemoglobinemia, unspecified, Other andunspecified diseases of blood and blood-forming organs, Familialerythrocytosis, Secondary polycythemia, Other specified diseases ofblood and blood-forming organs, Myelofibrosis, Heparin inducedthrombocytopenia (HIT), Other specified diseases of blood andblood-forming organs, Other dis with lymphoreticular andreticulohistiocytic tissue, Intraoperative and postproceduralcomplications of the spleen, Immunodeficiency with predominantlyantibody defects, Hereditary hypogammaglobulinemia, Nonfamilialhypogammaglobulinemia, Selective deficiency of immunoglobulin A [IgA],Selective deficiency of immunoglobulin G [IgG] subclasses, Selectivedeficiency of immunoglobulin M [IgM], Immunodeficiency with increasedimmunoglobulin M [IgM], Antibody deficiency w near-norm immunoglobulinor w hyperimmunoglobulin, Transient hypogammaglobulinemia of infancy,Other immunodeficiencies with predominantly antibody defects,Immunodeficiency with predominantly antibody defects, unspecified,Combined immunodeficiencies, Severe combined immunodeficiency withreticular dysgenesis, Severe combined immunodeficiency w low T- andB-cell numbers, Severe combined immunodeficiencies w low or normalB-cell numbers, Adenosine deaminase [ADA] deficiency, Nezelofs syndrome,Purine nucleoside phosphorylase [PNP] deficiency, Majorhistocompatibility complex class I deficiency, Major histocompatibilitycomplex class II deficiency, Other combined immunodeficiencies, Combinedimmunodeficiency, unspecified, Immunodeficiency associated with othermajor defects, Wiskott-Aldrich syndrome, Di George's syndrome,Immunodeficiency with short-limbed stature, Immunodeficiency followingresponse to Epstein-Barr virus, Hyperimmunoglobulin E [IgE] syndrome,Immunodeficiency associated with other major defects, Immunodeficiencyassociated with major defect, unspecified, Common variableimmunodeficiency, Other immunodeficiencies, Lymphocyte functionantigen-1 [LFA-1] defect, Defects in the complement system, Otherspecified immunodeficiencies, Sarcoidosis, Other disorders involving theimmune mechanism, NEC, Polyclonal hypergammaglobulinemia,Cryoglobulinemia, Hypergammaglobulinemia, unspecified, Immunereconstitution syndrome, Mast cell activation syndrome and relateddisorders, Mast cell activation, unspecified, Monoclonal mast cellactivation syndrome, Idiopathic mast cell activation syndrome, Secondarymast cell activation, Other mast cell activation disorder, Otherdisorders involving the immune mechanism, NEC, Graft-versus-hostdisease, Acute graft-versus-host disease, Chronic graft-versus-hostdisease, Acute on chronic graft-versus-host disease, Graft-versus-hostdisease, unspecified, Autoimmune lymphoproliferative syndrome [ALPS],Other disorders involving the immune mechanism, NEC, Disorder involvingthe immune mechanism, unspecified, Autoimmune thyroiditis, Type 1diabetes mellitus, Other diabetes mellitus with other specifiedcomplication, Primary adrenocortical insufficiency, Autoimmunepolyglandabular failure, Dementia in human immunodeficiency virus [HIV]disease (B22.0), Multiple sclerosis, Guillain-Barre syndrome, Myastheniagravis without (acute) exacerbation, Myasthenia gravis with (acute)exacerbation, Cytotoxic myoneural disorders, Congenital anddevelopmental myasthenia, Lambert-Eaton syndrome, unspecified,Lambert-Eaton syndrome in disease classified elsewhere, Other specifiedmyoneural disorders, Myoneural disorder, unspecified, Unspecified acuteand subacute iridocyclitis, Crohn's disease, Ulcerative (chronic)pancolitis, Inflammatory polyps of colon, Left sided colitis, Otherulcerative colitis without/with complications, Chronic persistenthepatitis, Chronic lobular hepatitis, Chronic active hepatitis, Otherchronic hepatitis, Chronic hepatitis, unspecified, Primary biliarycirrhosis, Autoimmune hepatitis, Celiac disease, Pemphigus, Bullouspemphigoid, Cicatricial pemphigoid, Chronic bullous disease ofchildhood, Acquired epidermolysis bullosa, unspecified, Other acquiredepidermolysis bullosa, Other pemphigoid, Psoriasis vulgaris, Otherpsoriatic arthropathy, Alopecia (capitis) totalis, Alopecia universalis,Ophiasis, Other alopecia areata, Alopecia areata, unspecified, Vitiligo,Felty's syndrome, Rheumatoid lung disease w rheumatoid arthritis,Rheumatoid vasculitis with rheumatoid arthritis of unspecified site,Rheumatoid vasculitis w rheumatoid arthritis, Rheumatoid heart disease wrheumatoid arthritis, Rheumatoid myopathy with rheumatoid arthritis,Rheumatoid polyneurop w rheumatoid arthritis, rheumatoid arthritis,Rheumatoid arthritis with/without rheumatoid factor, Adult-onset Still'sdisease, Rheumatoid bursitis, Rheumatoid nodule, Inflammatorypolyarthropathy, Other specified rheumatoid arthritis, Juvenilerheumatoid arthritis, Juvenile ankylosing spondylitis, Juvenilearthritis, Wegener's granulomatosis without renal involvement, Wegener'sgranulomatosis with renal involvement, Juvenile dermatopolymyositis,Polymyositis, Dermatopolymyositis, Giant cell arteritis with polymyalgiarheumatica, Systemic lupus erythematosus, Endocarditis in systemic lupuserythematosus, Pericarditis in systemic lupus erythematosus, Lunginvolvement in systemic lupus erythematosus, Glomerular disease insystemic lupus erythematosus, Tubulo-interstitial neuropath in sys lupuserythematosus, Progressive systemic sclerosis, CR(E)ST syndrome,Systemic sclerosis, Sicca syndrome, Polymyalgia rheumatica, Systemicinvolvement of connective tissue, Ankylosing spondylitis, Laboratoryevidence of human immunodeficiency virus [HIV], Other abnormalimmunological findings in serum, Immunosuppressive agents,Immunoglobulin is treated with an NTLA immune suppressant, or anantagonist to CD26 prior to administration of a cellular immunotherapy.The NTLA can be chosen from the list consisting of: Dexamethasone baseHED between 3-12 mg/kg administered either orally or over a 15-60 minuteintravenous infusion between 12-72 hours before administration of acellular immunotherapy. Mice can also be preconditioned with: An agentcontaining hydrocortisone is administered intravenously or orally aboutevery 12 hours at a dose of about 75 to about 300 mg/kg between about 12to about 72 hours before administration of the cellular immunotherapy.An agent containing cortisone is administered intravenously or orallyabout every 12 hours at a dose of about 93 to about 375 mg/kg betweenabout 12 to about 72 hours before administration of the cellularimmunotherapy. An agent containing prednisolone is administeredintravenously or orally about every 24 hours at a dose of about 19 toabout 75 mg/kg between about 12 to about 60 hours before administrationof the cellular immunotherapy. An agent containing methylprednisolone isadministered intravenously or orally about every 24 hours at a dose ofabout 15 to about 60 mg/kg between about 12 to about 60 hours beforeadministration of the cellular immunotherapy. An agent containingtriamcinolone is administered intravenously or orally about every 24hours at a dose of about 15 to about 60 mg/kg between about 12 to about60 hours before administration of the cellular immunotherapy. An agentcontaining paramethasone is administered in either a single acute doseor cumulative doses of about 7.5 to about 30 mg/kg, given between about12-72 hours prior to cellular immunotherapy. An agent containingbetamethasone is administered in either a single acute dose orcumulative doses of about 2.5 to 10 mg/kg, given between about 12-72hours prior to cellular immunotherapy.

Cellular immunotherapy is administered on day 0 and can be chosen fromthe list of: toleragenic dendritic cells, tumor infiltratinglymphocytes, adoptive cell transfer, adoptive cell therapy, chimericantigen receptor cells, genetically engineered TCR cells, regulatory Tcell transfer, cellular adoptive immunotherapy, cellular immunotherapy,cellular immune-oncology, in vivo complex (IL-2C) consisting of IL-2 andanti-IL-2 monoclonal antibody (JES6-1) expanded Tregs, T-Cell receptor(TCR) immunogenicity for T-cell vaccinations, autological polyclonalT-cell vaccines (TCVs), adoptive transfer of Treg-of-B cells (B cellsinduced a particular subset of regulatory T), adoptive transfer ofGC-induced or ATF3-deficient G-MDSCs (myeloid derived suppressor cells),genetically engineered lymphocytes, RNA redirected autologous T cells,T-cell Natural Killer cells, Receptor NKG2D cells, CD4+ cells, CD8+cells, CD4+ T cells, CD8+ T cells, mixtures of CD4+ and CD8 T cells,MDSCs, CTLs, EBV-CTLs, virus specific cytocytotoxic T lymphocytes(CTLs), cytokine-induced killer cells, antigen pulsed dendritic cells,CMV-CTLs, natural dendritic cells, dendritic cells, third party donorderived CTL's, autologous γδ T lymphocyte therapy, CD45RA DepletedT-cell Infusion, Laboratory-treated T Cells, HER2Bi-armed activated Tcells, autologous tumor DC vaccine, Dendritic Cell (DC)-Based VaccinesLoaded with Allogeneic Prostate Cell Lines, Dendritic Cell/AML Vaccine,Dendritic Cell vaccines, gene-modified lymphocytes, dendritic celltherapy, ESO-1 Lymphocytes, Tumor-Pulsed Dendritic Cells, AutologousTumor Lysate-pulsed Dendritic Cell, gene-modified immune cells, MarrowInfiltrating Lymphocytes, Alpha-galactosylceramide-pulsed DendriticCells, Alpha-galactosylceramide-pulsed Natural Killer T (NKT) Cells,Alpha-galactosylceramide-pulsed Dendritic Cells and Natural Killer T(NKT) Cells, Autologous gamma/Delta T Cells, Activated Self-lymphocytes,Epstein-Barr Virus Immune T-Lymphocytes Derived From a NormalHLA-Compatible Or Partially-Matched Third-Party Donor, granulocytemacrophage colony-stimulating factor plus bi-shRNAi furin vectortransfected autologous tumor cells, Alpha-galactosylceramide PulsedDendritic Cells (Chiba-NKT), P53-Pulsed Dendritic Cells, PrimaryTransplant Donor Derived CMVpp65 Specific T-cells, mixed T- and naturalkiller (NK) cell-like phenotype (CIK Cells), Antigen Pulsed DendriticCells (APDC), DC-CTK, Alpha-galcer Pulsed APC, Zoledronate-ActivatedAutologous Killer Lymphocytes (Zak Cells), Chiba NKT cells, AutologousDendritic Cells Loaded with Autologous Tumor Lysate or Homogenate, ThirdParty Donor Derived CMVpp65 Specific T-cells, Autologous TumorLysate-pulsed D-CIK, Multi-epitope TARP Peptide Autologous DendriticCells, T-reg Adoptive Cell Transfer (TRACT), Modified DLI (Donor DoubleNegative T Cells), Type-1 Polarized Dendritic Cells (AlphaDC1),Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells, Peptide PulsedDendritic Cells, Dendritic Cytocytotoxic Lymphocyte (DC-CTL) Cells,MTCR-transduced Autologous Peripheral Blood Lymphocytes, CytokineInduced Memory-like NK Cells, LMP-specific T-cells, Modified DLI(Related-donor Double Negative T Cells), Autologous Dendritic CellsLoaded with Autologous Tumour Homogenate, Vigil® Engineered AutologousTumor Cell (EATC) therapy, New Antigen Reactive Immune Cell Therapy(NRT), Autologous Cytokine-induced Killer Cells, Fused AutologousDendritic Cells, Peptide Specific CTL, Allogeneic Cell ImmunotherapyACIT-1, PD-1 Knockout Engineered T Cells, DC/AML Fusion Cells, (DC/PC3),Laboratory-treated T Cells, Dendritic Cell Tumor Fusions, LethallyIrradiated, Autologous Breast Cancer Cells, CD4-ZETA Gene Modified TCells, EBV-specific Immune Effector Cell (EBV-IE), Herpes Virus (HHV)Specific Immune Effector (IE) Cell, mRNA-transfected Dendritic Cells,Allogeneic Dendritic Cell Therapy, Cytomegalovirus (CMV) Pp65-specificLyphocytes, Alpha-Galactosylceramide-Pulsed IL-2/GM-CSF-CulturedPeripheral Blood Mononuclear Cells, Depleted T Cells, Donor CellsDendritic Vaccination, DCs Vaccine Combined with Cytokine-induced KillerCells, DC Vaccine Combined with CIK Cells, HB-vac Activated-DCs,Haploidentical NK-cell Infusion, ZNK cell, WT1 and MUC1 Peptide-PulsedDendritic Cells, ONETreg1 cells, Alpha DC1, Autologous T Lymphocyteswith ADCC, Memory T-cell Infusion, HER-2/Neu Pulsed DC1, StimulatedAutologous CD4+ T Cells, Gamma delta T cell, irradiated allogeneic lungadenocarcinoma cells, CD40LGVAX, irradiated allogeneic lungadenocarcinoma cells combined with a bystander cell line transfectedwith hCD40L and hGM-CSF, EGFRBi-armed Autologous T Cells, MiHA-loadedPD-L-silenced DC, MyDC/pDC, ROR-1.taNK, PDL1.taNK, Adjuvant DendriticCell-immunotherapy, D-CIK, DOT-Cells, Autologous Tumor Lysate (TL) plusYeast Cell Wall Particles (YCWP) plus Dendritic Cells, AutologousEBV-specific Cytocytotoxic T Cells, Autologous TLPLDC vaccine (tumorlysate, particle loaded, dendritic cells), Regulatory T Cells,Personalized Cellular Vaccine (PERCELLVAC), CAR-pNK Cell, HER2.taNK,MUC16.taNK, DCIs-CTLs, (PERCELLVAC2), (PERCELLVAC3), MASCT, CAR-pNKCells, CD33.taNK, Post Cord Blood HCT Dendritic Cells, Umbilical CordBlood Regulatory T Cells, High-activity Natural Killer cells, PD-1Knockout EBV-CTLs, DC-CTL Combined with CIK, Antigen-Bearing DendriticCells, Dendritic Cell/Tumor Fusions, Transfected Dendritic Cell, Her2and TGFBeta CTLs, Blood T-cells and EBV Specific CTLs, Autologous BreastCancer Cells Engineered to Secrete Granulocyte-macrophageColony-Stimulating Factor (GM-CSF), Gene-modified White Blood Cells,Epitope-enhanced TARP Peptide and TARP Peptide-pulsed Dendritic Cells,Laboratory-treated Autologous Lymphocytes, Multi-virus CTLs,Cytomegalovirus-specific T-cell Adoptive Transfer (ERaDICATe), GM-K562Cells, Kappa-CD28 T Lymphocytes, TGFB2-Antisense-GMCSF Gene ModifiedAutologous Tumor Cell, Bi-shRNA-furin and Granulocyte Macrophage ColonyStimulating Factor (GMCSF) Augmented Autologous Tumor Cells, Donor TCells Sensitized with Pentadecapeptides of the CMV-PP65 Protein,Peptide-pulsed Monocyte-derived Dendritic Cell Vaccination to ExpandAdoptively Transferred CMV-specific Cytocytotoxic T Lymphocytes, CMVSpecific DLIs From 3-6/6 HLA Matched Family Member, CMV Specific DLIs,Autologous T-cells Combined With Autologous OC-DC, TAA-Specific CTLs,Autologous Lymphocytes, Autologous Tolerogenic Dendritic Cells,Langerhans-type Dendritic Cells, Langerhans-type Dendritic CellsElectroporated with mRNA Encoding a Tumor-associated Antigen, AutologousT Cells, Multi-virus Cytocytotoxic T-cells, Autologous IL2 and CD40Ligand-Expressing Tumor Cells, Multiple Antigen-Engineered DC. WT1And/Or Tumor Lysates-pulsed Dendritic Cells, Autologous HumanCytomegalovirus (HCMV)-specific T cell Therapy, Ad/HER2/Neu DendriticCell, WT1 Peptide (Peptivator)-pulsed Dendritic Cell, Donor Derived,Multi-virus-specific, Cytocytotoxic T-Lymphocytes, Ex-vivo ExpandedDonor Regulatory T Cells, Alpha-GalCer-Pulsed Antigen Presenting Cells(APCs), Cytokine-induced Memory-like NK Cells, “Re-stimulated”Tumor-infiltrating Lymphocytes, Autologous Langerhans-type DendriticCells, Memory Enriched T Cells, Expanded Multi-antigen SpecificallyOriented Lymphocytes, TAA-Specific CTLs, Regulatory Dendritic Cells,Closely Matched Third Party Rapidly Generated LMP, BARF1 and EBNA1Specific CTL, Activated Marrow Infiltrating Lymphocytes, AutologousTumor Lysate-loaded Dendritic Cells, Multi-Epitope TARP PeptideAutologous Dendritic Cells, HPV-16/18 E6/E7-specific T Lymphocytes,Autologous Epstein-barr Virus-specific T Cells, Activated T-cells, DonorMultitaa-specific T Cells, Multitaa-specific T Cells, Type I-PolarizedAutologous Dendritic Cells, Vaccine Enriched Autologous ActivatedT-cells, Multivirus-specific Cytocytotoxic T Lymphocytes (mCTL),Allogeneic Virus-specific T Cell Lines (VSTs), Donor Regulatory T Cells,TCR-modified T cells (TCRs), MIC Cell, Adoptive T Cell Therapy withActivated P53 Specific T Cells, MUC1-DC-CTL, T cell receptor-modified Tcells, “Negative” Dendritic Cell-based Vaccine, tolDC, CD22 RedirectedAutologous T Cells, Dendristim, Primary NK Cells, Lentiviral-basedCART-EGFRvIII Gene-modified Cellular Therapy Products, AutologousDendritic Cells Pulsed with Lysated Allegenic Tumor Lines, ExpandedMulti-antigen Specific Lymphocytes, PD-1 Knockout Engineered T Cells,GSC-loaded Dendritic Cells, Treg Adoptive Cell Transfer (TRACT), E7 TCRT Cells, PD-1 Knockout Engineered T Cells, CAR-Treg (ENTX-DN), ChimericSwitch Receptor Modified T Cells, Neoantigen-primed Dendritic Cells(DC), Pre-activated T (PreT) Cells, TSA-CTL (Tumor SpecificAntigen-induced Cytocytotoxic T Lymphocytes), Allogeneic CellImmunotherapy (ACIT-1), Autologous OC-DC, Mature Dendritic Cells,CD8+NKG2D+ AKT Cell, Natural Killer (NK) cells—oNKord®, antigenpresenting cells—sDCord®.

In comparison to administering the cellular immunotherapy withoutpretreatment with an NTLA immunosuppressant, with NTLA dexamethasonedoses, or an antagonist to CD26, when the patient is pretreated with anNTLA immunosuppressant, with NTLA dexamethasone doses, or an antagonistto CD26 the administered cellular immunotherapy remains in thecirculation or at the site of injection where it can find and kill itstarget, resulting in greater killing or slower growth of the cancer ortumor or autoimmune cell, or pathogen. The NTLA preconditioned patientswill have similar or better anti-tumor effect, improved progression-freesurvival, reduced Disease progression, enhanced duration of response,improved overall survival, or reduced minimal residual disease comparedto patients who are preconditioned with radiation or repetitive doses ofcytotoxic chemotherapy.

Example 7: Post-Surgical Treatment of Solid Tumors with NTLA andCellular Immunotherapy to Prevent Relapse

A patient with a solid tumor undergoes surgical removal or reduction,which can release cancer blasts and cause ultimate relapse. Relapse canoccur in the short term, for cancers such as pancreatic cancer, or inthe long term for cancers such as breast cancer, which may relapse aslong as 20 years following surgery. After recovery from surgery, betweenabout 1 to about 3 days to about 1 year after surgery, the patient ispreconditioned with NTLA as Tacrolimus delivered as an injection or oraldose of about 0.48 mg/kg/day to about 10 mgs/kg/day for about 1 to about4 weeks, or as Cyclosporine administered at about 15 to about 100mgs/kg/daily for about 7 to about 28 days (the daily dose is divided bytwo and administered every 12 hours), or as Dexamethasone base, or anequivalent dose of another glucocorticoid, between about 3 mg/kg andabout 26 mg/kg single acute dose about 12 to about 72 hours prior tocell immunotherapy administration or total dose of about 3 mg/kg toabout 26 mg/kg given between about 12 to about 72 hours prior to celltherapy administration (the single acute dose would most preferably begiven about 36 to about 48 hours prior to cell immunotherapyadministration), or as a TNF inhibitor administered for about 3 to about4 weeks, or as an immunotherapy of the class of Rituximab administeredbetween about 375 mg/m2 to about 500 mg/m2 administered about every 7days on about day −7 and day −1. After preconditioning, between about 1day to about 4 days after preconditioning, the patient is administered acellular immunotherapy between about 1×10⁵ cells/kg body weight to about1×10⁷ cells/kg body weight. The preferred cellular therapy is an NK cellproduct, a TCR cell product, a TAC cell product, or a CarT cell product.Relapse free survival is increased and overall survival time isenhanced. The NTLA preconditioned patients will have similar or betteranti-tumor effect, improved progression-free survival, reduced Diseaseprogression, enhanced duration of response, improved overall survival,or reduced minimal residual disease compared to patients who arepreconditioned with radiation or repetitive doses of cytotoxicchemotherapy.

Example 8: Treatment of Post-Surgical Breast Tumors in Mice

Eight groups of BALB/c mice each are injected with 4T1 cells into themammary fat pad for the generation of breast tumor mouse model. After9-11 days or until the tumor size reach a diameter of 3.5-5 mm, tumorswill be surgically removed. One day after primary tumor removal,preconditioning schedule will be followed according to Table I below.Either syngeneic (NK cells isolated from BALB/c mice; 3 groups) orallogenic (KIL cell; 3 groups) NK cells are transplanted by IV tail veininjection after preconditioning. Mice are sacrificed between day 30 andday 60. The groups in this study are found in Table I below.

TABLE I Preconditioning schedule for Example 8: Treatment ofpost-surgical breast tumors in mice Group Preconditioning NK cellProtocol 1 Cy/Flu* allogeneic Cyclophosphamide 166 mg/kg, dosing at days−5, −4, −3 Fludarabine Phosphate 10 mg/kg, dosing at days −5, −4, −3 2AVM0703 allogeneic AVM0703 148 mg/kg, dosing at day −2 3 CyFlu +allogeneic Cyclophosphamide 166 mg/kg, dosing at day −5 AVM0703Fludarabine Phosphate 10 mg/kg, dosing at day −5 AVM0703 148 mg/kg,dosing day −2 4 Cy/Flu* syngeneic Cyclophosphamide 166 mg/kg, dosing atdays −5, −4, −3 Fludarabine Phosphate 10 mg/kg, dosing at days −5, −4,−3 5 AVM0703 syngeneic AVM0703 148 mg/kg, dosing at day −2 6 CyFlu +syngeneic Cyclophosphamide 166 mg/kg, dosing at day −5 AVM0703Fludarabine Phosphate 10 mg/kg, dosing at day −5 AVM0703 148 mg/kg,dosing day −2 7 Vehicle allogeneic Vehicle only, dosing at day −2 (AVMPlacebo) 8 Vehicle syngeneic Vehicle only, dosing at day −2 (AVMPlacebo)

Method of investigation: Body weight, blood, and spleen collection forfurther analysis. Lungs are excised and perfused with India Ink forvisual counts of metastasis. Mice survival plot will be made to comparethe survival benefit between different treatments.

Expected outcome: Efficacy of NK-cell therapy after AVM0703preconditioning demonstrated to be equivalent or superior to therapyafter chemotherapy preconditioning in breast cancer mouse model.

Example 9: Treatment of Post-Surgical Solid Tumors in Mice

Mice are injected subcutaneously in the flank with solid tumor cells.C57Bl6 mice are injected with B16 or B16-F10 melanoma cells or LLC lungcancer cells; Balb/c mice are injected with RENCA renal cancer cells orCT26 colon cancer cells. When the tumor reaches a palpable size of 3.5-5mm the tumors are completely excised. One day after primary tumorremoval, preconditioning schedule is followed according to the table IIschedule. Either syngeneic (NK cells isolated from BALB/c mice orC57Bl6) or allogenic (NK cells isolated from BALB/c mice or C57Bl6 orthe KIL cell line) NK cells are transplanted by IV tail vein injectionafter preconditioning. Mice are sacrificed between day 30 and day 60.The groups in this study are found in Table II below.

TABLE II Preconditioning schedule for Example 9: Treatment ofpost-surgical solid tumors in mice Group Preconditioning NK cellProtocol 1 Cy/Flu* allogeneic Cyclophosphamide 166 mg/kg, dosing at days−5, −4, −3 Fludarabine Phosphate 10 mg/kg, dosing at days −5, −4, −3 2AVM0703 allogeneic AVM0703 148 mg/kg, dosing at day −2 3 CyFlu +allogeneic Cyclophosphamide 166 mg/kg, dosing at day −5 AVM0703Fludarabine Phosphate 10 mg/kg, dosing at day −5 AVM0703 148 mg/kg,dosing day −2 4 Cy/Flu* syngeneic Cyclophosphamide 166 mg/kg, dosing atdays −5, −4, −3 Fludarabine Phosphate 10 mg/kg, dosing at days −5, −4,−3 5 AVM0703 syngeneic AVM0703 148 mg/kg, dosing at day −2 6 CyFlu +syngeneic Cyclophosphamide 166 mg/kg, dosing at day −5 AVM0703Fludarabine Phosphate 10 mg/kg, dosing at day −5 AVM0703 148 mg/kg,dosing day −2 7 Vehicle allogeneic Vehicle only, dosing at day −2 (AVMPlacebo) 8 Vehicle syngeneic Vehicle only, dosing at day −2 (AVMPlacebo)

Method of investigation: Body weight, blood, and spleen collection forfurther analysis. Lungs are excised and perfused with India Ink forvisual counts of metastasis. Mice survival plot will be made to comparethe survival benefit between different treatments.

Expected outcome: Efficacy of NK-cell therapy after AVM0703preconditioning demonstrated to be equivalent or superior to therapyafter chemotherapy preconditioning in solid tumor mouse models.

Example 10: Treatment of Patients with Solid Tumors

A patient with a solid tumor including but not limited to prostatecancer, pancreatic cancer, colon cancer, breast cancer, a sarcoma, acarcinoma, a neuroblastoma, blastomas, fibromas, chondromas, lymphomas,adenomas, lung cancer, ependymomas, chromocytomas, histiocytomas,seminomas, uterine cancer, cervical cancer is identified. The patient ispreconditioned with NTLA as Tacrolimus delivered as an injection or oraldose of about 0.1 mg/kg/day to about 10 mgs/kg/day but preferably about0.48 mg/kg to about 10 mg/kg for about 1 to about 4 weeks, or asCyclosporine administered at about 15 to about 100 mgs/kg/daily forabout 7 to about 28 days (the daily dose is divided by two andadministered every 12 hours), or as Dexamethasone base, or an equivalentdose of another glucocorticoid, between about 3 mg/kg and about 26 mg/kgsingle acute dose about 12 to about 72 hours prior to cell immunotherapyadministration or total dose of about 3 mg/kg to about 26 mg/kg givenbetween about 12 to about 72 hours prior to cell therapy administration(the single acute dose would most preferably be given about 36 to about48 hours prior to cell immunotherapy administration), or as a TNFinhibitor administered for about 3 to about 4 weeks, or as animmunotherapy of the class of Rituximab administered between about 375mg/m2 to about 500 mg/m2 administered about every 7 days on about day −7and day −1. After preconditioning, between about 1 days to about 4 days,the patient is administered a cellular immunotherapy between about 1×10⁵cells/kg body weight to about 1×10⁷ cells/kg body weight. The preferredcellular therapy is an NK cell product, a TCR cell product, a TAC cellproduct, or a CarT cell product. Minimal residual disease (MRD) isreduced, complete remission rates are increased, partial remission ratesare increased, relapse free survival is increased and overall survivaltime is enhanced. The NTLA preconditioned patients will have similar orbetter anti-tumor effect, improved progression-free survival, reducedDisease progression, enhanced duration of response, improved overallsurvival, or reduced minimal residual disease compared to patients whoare preconditioned with radiation or repetitive doses of cytotoxicchemotherapy.

Example 11: Treatment of Patients with Leukemias or Lymphomas orMyelomas

A patient with multiple myeloma, acute lymphoblastic leukemia, chroniclymphoblastic leukemia, acute myelogenous leukemia or any leukemia orlymphoma or myeloma is preconditioned with NTLA as Tacrolimus deliveredas an injection or oral dose of about 0.1 mg/kg/day to about 10mgs/kg/day but preferably 0.48 mg/kg to about 10 mg/kg for about 1 toabout 4 weeks, or as Cyclosporine administered at about 15 to about 100mgs/kg/daily for about 7 to about 28 days (the daily dose is divided bytwo and administered every 12 hours), or as Dexamethasone base, or anequivalent dose of another glucocorticoid, between about 3 mg/kg andabout 26 mg/kg single acute dose about 12 to about 72 hours prior tocell immunotherapy administration or total dose of about 3 mg/kg toabout 26 mg/kg given between about 12 to about 72 hours prior to celltherapy administration (the single acute dose would most preferably begiven about 36 to about 48 hours prior to cell immunotherapyadministration), or as a TNF inhibitor administered for about 3 to about4 weeks, or as an immunotherapy of the class of Rituximab administeredbetween about 375 mg/m2 to about 500 mg/m2 administered about every 7days on about day −7 and day −1. After preconditioning, between about 1days to about 4 days after, the patient is administered a cellularimmunotherapy between about 1×10⁵ cells/kg body weight to about 1×10⁷cells/kg body weight. The preferred cellular therapy is an NK cellproduct, a TCR cell product, a TAC cell product, or a CarT cell product.Minimal residual disease (MRD) is reduced, complete remission rates areincreased, partial remission rates are increased, relapse free survivalis increased and overall survival time is enhanced. The NTLApreconditioned patients will have similar or better anti-tumor effect,improved progression-free survival, reduced Disease progression,enhanced duration of response, improved overall survival, or reducedminimal residual disease compared to patients who are preconditionedwith radiation or repetitive doses of cytotoxic chemotherapy.

Example 12: Treatment of Patients with Autoimmune Diseases

A patient with an autoimmune disease such as, but not limited to: SLE,psoriasis, rheumatoid arthritis, sporiatic arthritis, type I diabetes,multiple sclerosis, Sjogren's Syndrome, scleroderma, Grave's Disease,Hashimoto's thyroiditis, Celiac Disease, Addison's Disease, MyastheniaGravis, Autoimmune hepatitis, Antiphospholipid syndrome, biliarycholangitis, is treated with NTLA immune suppressant, with NTLAdexamethasone doses, or an antagonist to CD26. NTLA dexamethasone (asbase) doses range from about 3 mg/kg to about 12 mg/kg, with dosesbetween about 9 mg/kg and about 12 mg/kg being preferred.

B lymphocyte numbers are reduced by greater than 90% with the NTLAdexamethasone dose, and as memory B cells make up approximately 50% ofthe B cell compartment in people over age 20, memory B cell populationsare also reduced by greater than 90%. The patient's autoimmune attackingB cells have apoptosed and the patient ceases to have active self-immuneattacks. The patient's physical symptoms are improved or eliminated.Remission from the autoimmune disease lasts indefinitely in mostpatients, however, should the patient relapse then a repeat dose of theNTLA immune suppressant, with NTLA dexamethasone doses, or an antagonistto CD26. Repeat treatments can occur as often as once per month ifnecessary, but preferably not more than one a year, and most preferablynot more than once every 5 years.

Example 13: Treatment of Residual HIV

A patient with residual HIV is treated with NTLA immune suppressant,with NTLA dexamethasone doses, or an antagonist to CD26. NTLAdexamethasone (as base) doses range from about 3 mg/kg to about 12mg/kg, with doses between about 9 mg/kg and about 12 mg/kg beingpreferred. The treatment eliminates the nuches in the spleen where HIVhides and sends the infected T cells into the circulation where they canbe killed by standard HIV therapies that include anti-retroviral drugs,including but not limited to nucleoside reverse transcriptase inhibitors(NTRIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs),protease inhibitors (PIs), fusion and entry inhibitors, pharmacokineticenhances and integrase strand transfer inhibitors (INSTIs).

Example 14: Treatment of Germinal Center Lymphomas, for Example BurkittsLymphoma

A patient with a germinal center lymphoma such as but not limited toBurkitt's Lymphoma or diffuse large B-cell lymphoma (DLBCL) is treatedwith NTLA immune suppressant, with NTLA dexamethasone doses, or anantagonist to CD26. NTLA dexamethasone (as base) doses range from about3 mg/kg to about 12 mg/kg, with doses between about 9 mg/kg and about 12mg/kg being preferred. The treatment eliminates the nuches in the spleenwhere the germinal center lymphomas bind and sends the cells into thecirculation where they can be eliminated more completely, or with lowerdoses, of standard chemotherapy such as R-CHOP, or by antibodies to CD20such as Rituxan, Bexxar, or Zevalin, or by antibodies to CD22 or CD70such as Lymphocide or Vorsetuzumab mafodotin, or by Bcl-2 inhibitorssuch as Oblimersen sodium, ABT-737 (oral form navitoclax, ABT-263), orFenretinide, or by Syk inhibitors such as Fostamatinib or Tamatinib, orby proteasome inhibitors such as Bortezomib (Velcade), or COMPADME,CODOX-M/IVAC. Relapse rates are reduced and disease free survival ratesare increased.

Example 15: Conversion of a Dexamethasone Dose to an Equivalent Dose ofAnother Glucocorticoid

To calculate the equivalent dosing for another glucocorticoid, the doseof dexamethasone is entered into a publicly available glucocorticoidconversion calculator, preferably medcalc.com. Then the total dosing isdetermined based on the half-life of the glucocorticoid. For instance, 3to 12 mg/kg dexamethasone converts to 19 to 75 mg/kg prednisone. Sinceprednisone's biologic half-life is about 20 hours, while dexamethasone'sbiologic half-life is about 36 to 54 hours. Therefore, prednisone wouldbe dosed between 19 to 75 mg/kg every 24 hours for equivalent biologicdosing.

1-23. (canceled)
 24. A method of enhancing adoptive cellular therapy (ACT) in a patient suffering from an autoimmune disease or an infectious disease, the method comprising: administering to the patient dexamethasone or another glucocorticoid at a dose that is effective to cause substantial lymphodepletion and/or cause ablation of secondary lymphatic germinal centers, wherein the method does not include the administration of a chemotherapeutic agent for a duration of more than 1 day; and wherein the dose of dexamethasone or another glucocorticoid that is effective to cause lymphodepletion and/or cause ablation of secondary lymphatic germinal centers a human equivalent dose (HED) of at least 3 mg/kg dexamethasone or a dose of another glucocorticoid that is equivalent to at least 3 mg/kg dexamethasone.
 25. The method of claim 24, wherein the ACT comprises either a cell used to enhance the immune system in treating a disease in said patient or a cell derived from an immune lineage which directly treats said disease.
 26. The method of claim 24, wherein the dexamethasone or another glucocorticoid is selected from the group consisting of dexamethasone, dexamethasone base, prednisone, methylprednisolone, and a dexamethasone analogue.
 27. The method of claim 24, wherein the dexamethasone or another glucocorticoid is dexamethasone.
 28. The method of claim 24, wherein the dose of dexamethasone or another glucocorticoid that is effective to cause lymphodepletion and/or cause ablation of secondary lymphatic germinal centers is a human equivalent dose (HED) of at least about 4 mg/kg, at least about 5 mg/kg, at least about 6 mg/kg, at least about 7 mg/kg, at least about 8 mg/kg, at least about 9 mg/kg, at least about 10 mg/kg, at least about 11 mg/kg, or at least about 12 mg/kg of dexamethasone or a dose of another glucocorticoid that is equivalent to at least about 4 mg/kg, at least about 5 mg/kg, at least about 6 mg/kg, at least about 7 mg/kg, at least about 8 mg/kg, at least about 9 mg/kg, at least about 10 mg/kg, at least about 11 mg/kg, or at least about 12 mg/kg human equivalent dose (HED) of dexamethasone.
 29. The method of claim 24, wherein the dose of dexamethasone or another glucocorticoid that is effective to cause lymphodepletion and/or cause ablation of secondary lymphatic germinal centers is a human equivalent dose (HED) of up to about 26 mg/kg dexamethasone or a dose of another glucocorticoid that is equivalent to up to about 26 mg/kg human equivalent dose (HED) of dexamethasone.
 30. The method of claim 24, wherein the dose of dexamethasone or another glucocorticoid that is effective to cause lymphodepletion and/or cause ablation of secondary lymphatic germinal centers is a human equivalent dose (HED) of between about 9 mg/kg to about 12 mg/kg of dexamethasone, or a dose of another glucocorticoid that is equivalent to between about 9 mg/kg to about 12 mg/kg.
 31. The method of claim 24, wherein the dose of dexamethasone or another glucocorticoid that is effective to cause lymphodepletion and/or cause ablation of secondary lymphatic germinal centers is between 5-26 mg/kg human equivalent dose (HED) of dexamethasone or a dose of another glucocorticoid that is equivalent to between 5-26 mg/kg human equivalent dose (HED) of dexamethasone.
 32. The method of claim 24, wherein the patient is a human.
 33. The method of claim 24, wherein the enhanced ACT comprises reduced autoimmune causing cell count in a patient with an autoimmune disease, or reduced infectious agent load in a patient with an infectious disease.
 34. The method of claim 24, wherein the dexamethasone or another glucocorticoid is administered before ACT commences.
 35. The method of claim 24, wherein the dexamethasone or another glucocorticoid is administered at least 12 hours before ACT commences.
 36. The method of claim 24, wherein the dexamethasone or another glucocorticoid is administered at one or more time points between about 72 to about 12 hours prior to commencement of ACT.
 37. The method of claim 24, wherein the ACT comprises administration of T cells.
 38. The method of claim 24, wherein no chemotherapeutic agents are administered to the patient.
 39. A method of performing adoptive cellular therapy (ACT) in a patient suffering from an autoimmune disease or an infectious disease, said method comprising: administering to the patient dexamethasone or another glucocorticoid at a dose that is effective to cause substantial lymphodepletion and/or cause ablation of secondary lymphatic germinal centers; and administering ACT to the patient; wherein the method does not include the administration of a chemotherapeutic agent for a duration of more than 1 day or more; and wherein the dose of dexamethasone or another glucocorticoid that is effective to cause lymphodepletion and/or cause ablation of secondary lymphatic germinal centers a human equivalent dose (HED) of at least 3 mg/kg dexamethasone or a dose of another glucocorticoid that is equivalent to at least 3 mg/kg dexamethasone.
 40. The method of claim 39, wherein the ACT comprises either a cell used to enhance the immune system in treating a disease in said patient or a cell derived from an immune lineage which directly treats said disease.
 41. The method of claim 39, wherein the dose of dexamethasone or another glucocorticoid that is effective to cause lymphodepletion and/or cause ablation of secondary lymphatic germinal centers is between 5-26 mg/kg human equivalent dose (HED) of dexamethasone or a dose of another glucocorticoid that is equivalent to between 5-26 mg/kg human equivalent dose (HED) of dexamethasone.
 42. The method of claim 39, wherein the patient is a human.
 43. The method of claim 39, wherein the dexamethasone or another glucocorticoid is administered before ACT commences. 